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Abstract 
The high mortality from cardiovascular diseases is caused by atherosclerosis. Atherosclerosis 
develops due to multiple factors, including biomechanical factors, such as shear stress 
generated by the flow of blood on the inner lining of blood vessels. In order to tackle this 
serious life-threatening condition, we aimed to develop synthetic and systems biology tools 
for studying the effect of atherogenic shear stress regimes on vascular cells. Our tools could 
potentially also lead to the identification of drug targets and of drug candidates against 
cardiovascular disease.  
The first tool that we developed is a network of genes consisting of a shear stress sensor 
module, a reporter module and a linker module which signals from the sensor to the reporter 
module. This circuit is capable of processing the shear stress or ligand activation signal into a 
fluorescent readout, allowing screening for drug candidate compounds that modify the 
activity of the shear stress sensor. Instead of the reporter module, the gene network could be 
coupled to therapeutic genes in order to express these genes under atherogenic shear stress 
conditions.  
Our second developed tool is a flow chamber which facilitates exposure of vascular cells to 
linearly increasing shear stress along the length of the channel floor for in vitro cellular 
biomechanical studies. This device outperforms currently available linear shear stress 
inducing devices in terms of the magnitude of shear stress range, linearity of shear stress 
along the channel length, and the large sampling area granted by the uniformity of shear 
stress across the channel width.  
The third tool that we developed is an electroporation and flow device capable of inserting 
genetic material into primary vascular cells in their adherent state, exposing these cells to 
fluid flow. This device allows investigations into cardiovascular mechanotransduction 
pathways under relevant physiological flow conditions. 
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Synopsis 
 
Chapter 1 gives a general background for this thesis. It introduces cardiovascular diseases, 
biomechanical risk factors for atherosclerosis, and the concepts of systems and synthetic 
biology. At the end of this chapter the aims of the thesis are also outlined; the aims are to 
develop tools and devices for tackling multi-factorial cardiovascular diseases from different 
angles. 
 
In Chapter 2 we present a synthetic biology based gene network which is capable of 
monitoring the shear stress sensing activity of a G-protein coupled receptor which sits in the 
plasma membrane of endothelial cells. The gene network is inserted into endothelial cells at 
the DNA level, it is expressed and then it is activated by a ligand or by shear stress. This gene 
network can be applied to study mechano-transduction, to screen for compounds that modify 
the activity of the shear stress sensor, and for conditional gene therapy. 
 
Chapter 3 presents the design, manufacturing and implementation of a new flow chamber 
which yields linearly increasing shear stress at the floor of the channel along the axis of flow. 
This device provides sterility and it is compatible with standard microscopes to allow 
visualization of cells in real-time. Thus, cells seeded at the floor of this chamber can be 
exposed to a wide range of linearly increasing shear stress, exploring a variety of conditions 
in a single experiment. 
 
The development of a novel in-situ electroporation and flow device for mechanotransduction 
studies is described in Chapter 4. This device is capable of introducing genetic material into 
hard-to-transfect primary endothelial cells and to expose these cells to complex flow and 
chemical environments, mimicking physiological conditions. This tool should aid the 
investigation of complex biomechanical signalling pathways involved in the development of 
atherosclerosis.
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3a,4,5,9b-3H-cyclopenta[c]quinoline 
72 G-36 
(4S)-rel-4-(6-bromo-1,3-benzodioxol-5-yl)-3aR,4,5,9bS-
tetrahydro-8-(1-methylethyl)-3H-cyclopenta[c]quinoline 
73 GFP Green fluorescent protein 
74 
Gi1, Gi2, Gi3, Go, Gz, 
Gq, Gs 
G proteins 
75 GPCR G-protein coupled receptor 
76 
GPER1, CEPR, GPER,  
DRY12, FEG-1, 
LyGPR, GPR30, 
LERGU,  CMKRL2, 
LERGU2, GPCR-Br 
G-protein coupled estrogen receptor 1 
77 GPR1 G protein-coupled receptor 1 
78 GRKs G protein–coupled receptor kinases 
79 HB-EGF Heparin bound epidermal growth factor 
80 HBSS Hank’s Balanced Salt Solution 
81 HeLa Patient (Henrietta Lacks) derived immortal human epithelial 
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cell line 
82 HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
83 HF High-Fidelity 
84 HMEC-1 Immortalized human microvascular endothelial cell line 
85 HOE 140 
Selective B2 bradykinin receptor antagonist 
D-Arg-L-Arg-L-Pro-L-Hyp-Gly-L-(2-thienyl)Ala-L-Ser-D-
1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2α,3β,7aβ)-
octahydro-1H-indole-2-carbonyl-L-Arg, Icatibant acetate 
86 HSV Herpes simplex virus 
87 IP3 Inositol trisphosphate 
88 IPTG Isopropyl β-D-1-thiogalactopyranoside 
89 IRES Internal ribosome entry site 
90 ITO Indium tin oxide 
91 K
+ 
Potassium ion 
92 kbp Kilobase pairs 
93 kg Kilogram (10
-3
 gram) 
94 Kif3A Kinesin family member 3A 
95 Kir2.1 
Inward-rectifier potassium ion channel is encoded by the 
KCNJ2 gene, subfamily J, member 2. 
96 KKS Kinin-kallikrein system 
97 KLF2 Krüppel-like factor-2 
98 l Litre  
99 LacO Lactose operator 
100 LacR Lactose repressor 
101 LB Luria-Bertani 
102 LDL Low-density lipoprotein  
103 m Meter 
104 MAPK Mitogen-activated protein kinase 
105 MCS Multiple cloning site 
106 MGFP Monster green fluorescent protein 
107 MHz Megahertz (10
6 
hertz) 
108 min Minute 
109 miRNA Micro ribonucleic acid 
110 ml Millilitre (10
-3
 litre) 
111 mm Millimetre (10
-3
 meter) 
112 mM Millimolar (10
-3
 molar) 
113 MOPS 3-(N-morpholino)propanesulfonic acid 
114 mRNA Messenger ribonucleic acid 
115 ms Millisecond (10
-3
 second) 
116 MS1 
MILE SVEN 1, Immortalized mouse pancreatic endothelial 
cell line 
117 N Newton 
118 N Number of repetitions 
119 Na
+ 
Sodium ion 
120 NADPH Nicotinamide adenine dinucleotide phosphate 
121 NCBI National Center for Biotechnology Information 
122 NEB New England Biolabs 
123 NF-κB Nuclear factor kappa-light-chain-enhancer of activated B 
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cells 
124 nm Nanometre (10
-9 
meter) 
125 nM Nanomolar (10
-9 
molar) 
126 NO Nitric oxide 
127 OD600 Optical density at 600 nm wavelength 
128 p27
Kip1
 Cyclin-dependent kinase inhibitor 1 
129 P2X4 Purinergic receptor P2X, ligand-gated ion channel, 4 
130 Pa Pascal 
131 PAECs Primary porcine aortic endothelial cells 
132 PBS Phosphate buffer saline  
133 PC2 Polycystin-2 
134 PCR Polymerase chain reaction 
135 PDB Protein Data Bank 
136 PDF Probability Density Functions 
137 PDMS Polydimethylsiloxane 
138 PECAM-1 
Platelet endothelial cell – adhesion molecule, also known as 
CD31 
139 PFA Paraformaldehyde 
140 PI Propidium iodide 
141 PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
142 Pipet. Shear stress applied by pipetting for 1 minute 
143 PKA 
Cyclic adenosine monophosphate – dependent protein kinase 
A 
144 PLA2 Phospholipase A2 
145 pmol Picomol (10
-12
 mols) 
146 PP2A Protein phosphatase 2A 
147 Ptet 
Promoters responsive to tetracycline-controlled 
transactivator 
148 PTRE3G 3
rd
 generation Tet-responsive promoter 
149 qPCR Real-time (quantitative) polymerase chain reaction 
150 RAS Renin-angiotensin system 
151 RCSB Research Collaboratory for Structural Bioinformatics 
152 RISC Ribonucleic acid – induced silencing complex 
153 RNA Ribonucleic acid 
154 RNAi Ribonucleic acid interference 
155 ROI Region of interest 
156 RPM Rotations per minute 
157 RT Reverse transcription 
158 rtTA Reverse tetracycline-controlled transactivator 
159 s Second 
160 S.D. Standard deviation 
161 S/MAR 
Scaffold/matrix attached region from the 5’-region of the 
human interferon β-gene 
162 S1P Sphingosine 1-phosphate 
163 S1pr1 Sphingosine-1-phosphate receptor-1 
164 Sh. Str. Shear Stress 
165 shRNA short hairpin ribonucleic acid 
166 siKLF2 Short interfering ribonucleic acid targeted against the 
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Krüppel-like factor-2 messenger ribonucleic acid  
167 siRNA short interfering ribonucleic acid 
168 SOC Super optimal broth with catabolite repression 
169 SV40 Simian virus 40 
170 T Deoxythymidine 
171 TBE Tris-Borate-Ethylenediaminetetraacetic acid 
172 TCS Tobacco etch virus protease cleavage site 
173 temp Temperature 
174 Tet Tetracycline 
175 tetO Tetracycline operator 
176 TEV Tobacco etch virus 
177 TIE-2  
178 
TIE-2, TEK, hTIE2, 
p140 TEK, VMCM, 
VMCM1, 
CD_antigen=CD202b, 
Angiopoietin-1 receptor 
179 TKR, RTK Tyrosine kinase receptors 
180 TM Trans membrane 
181 Tm Melting temperature 
182 
TM 
Trade mark 
183 Tn10 Transposable element from Escherichia coli 
184 TPE Thermosetting polyester 
185 TRP Transient receptor potential 
186 tTA Tetracycline-controlled transactivator 
187 UV Ultra violet 
188 V Volt 
189 v/v Volume per volume 
190 VE-Cadherin Vascular endothelial 
191 VEGFR-2 Vascular endothelial growth factor receptor 2 
192 VP16 Virion protein 16 from herpes simplex virus 
193 w/v Weight per volume 
194 W146 
R-3-amino-4-(3-hexylphenylamino)-4-oxobutylphosphonic 
acid hydrate, [(3R)-3-amino-4-[(3-hexylphenyl)amino]-4-
oxobutyl]-phosphonic acid 
195 X Fold 
196 α2A-AR Human α2A-adrenergic receptor 
197 α2C-AR Human a2C-adrenergic receptor 
198 β1-AR Human b1-adrenergic receptor 
199 β2-AR Human b2-adrenergic receptor 
200 μPIV Micro particle image velocimetry 
201 Ω Ohm 
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electroporation the gene network was induced with bradykinin and cells were imaged 
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seeded either in µ-Slide I 
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control conditions). For cells seeded in ibidi flow channels, flow experiments were 
started 24 hours after electroporation, cells were subjected to 1.5–2 Pa of shear stress 
for a period of 24 hours and cells were imaged 48 hours after electroporation. To 
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Figure 2.17. Circular maps of redesigned gene network encoding plasmids. A. pZK13 
encodes the fusion protein consisting of the human bradykinin receptor B2 (BDK-B2) 
fused to the 29 C-terminus amino acids of the human arginine vasopressin receptor 2 
(AVPR2tail), tethered to the TEV protease cleavage site (TCS) followed by the 
transcriptional trans-activator (tTA) without the stop codon. After this fusion protein 
gene the nucleotide sequence of an internal ribosome entry site (IRES) is present, 
followed by the human β-arrestin2 (βArrestin2) gene fused to the catalytic domain of 
the tobacco etch virus NIa protease gene, amino acids 189-424 of the mature NIa 
protease (TEV) and stop codon. Transcription of this entire construct is facilitated by 
the human cytomegalovirus (CMV) constitutive immediate early promoter 
downstream of the CMV immediate early enhancer. This way, two gene constructs 
can be expressed from the same bicistronic mRNA transcript encoded on a single 
plasmid. The plasmid also contains a neomycin resistance gene to aid in the selection 
of transfected cells using the G418 antibiotic. B. pZK14 contains the enhanced green 
fluorescent protein (eGFP) gene downstream of the 3
rd
 generation Tet-responsive 
promoter (PTRE3G). PTRE3G consists of 7 repeats of a 19 bp long tet operator sequence 
located upstream of an improved minimal CMV promoter, providing very low basal 
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Figure 2.18. Images of agarose gels ran to analyse and separate BDK-B2-AVPR2tail-TCS-
tTA and βArrestin2-TEV PCR products for the Gibson Assembly®. A. The first 
attempt to PCR amplify the constructs of interest using Phusion
®
 High-Fidelity DNA 
Polymerase with reactions carried out at 3 different ATs failed, since no bands are 
visible. B. The Phusion
®
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and the range of ATs extended, resulting in the successful amplification of the BDK-
B2-AVPR2tail-TCS-tTA construct. C. The βArrestin2-TEV construct was amplified 
with two different DNA polymerases, the Phusion
®
 High-Fidelity and the Q5
®
 High-
Fidelity, with the addition of final concentrations of 3% DMSO to the Phusion
®
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and final concentration of 1X of Q5 High GC Enhancer to the Q5
®
 PCR. Both DNA 
polymerase systems yielded PCR products of interest. D. BDK-B2-AVPR2tail-TCS-
tTA and βArrestin2-TEV were PCR amplified using the Q5® High-Fidelity DNA 
Polymerase in the presence of final concentration of 1X of Q5 High GC Enhancer in 
order to obtain sufficient amounts of these fragments for subsequent Gibson 
Assembly
®
. ................................................................................................................ 153 
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Figure 2.19. Images of agarose gels ran to analyse and separate restriction digestion products 
of pZK12 for the Gibson Assembly
®
. A. Plasmid pZK12 was simultaneously digested 
with NheI-HF, NotI-HF and XbaI and then in a separate reaction with EcoRI. B. In 
order to generate higher quantity and clearer cut ends (avoiding steric hindrance of 
XbaI and NotI), 8 restriction reactions were carried out in parallel, first digesting 
together with NheI-HF and NotI-HF, in a seconds reaction digesting with XbaI and in 
a third reaction digesting with EcoRI. ....................................................................... 155 
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(with extensions to anneal in the XbaI and NotI sites) PCR products for the Gibson 
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®
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®
 High-Fidelity DNA 
Polymerase. A. To optimize the PCR, different ATs were used: 60 and 61.4 °C for 
BDK-B2-AVPR2tail-TCS-tTA and 67 and 68.7 °C for βArrestin2-TEV. Both ATs 
yielded bands with the expected size, thus the band obtained at the higher AT will be 
further processed. B. In parallel, a third AT was tried, 58.4°C for BDK-B2-
AVPR2tail-TCS-tTA and 65.2°C for βArrestin2-TEV. These also worked, however, 
since the AT was lower compared to the previous cases. These bands were not 
selected for further processing. C and D. PCR carried out the previously optimized 
ATs, in order to generate a sufficient quantity of DNA for the Gibson Assembly
®
. 158 
Figure 2.21. Images of agarose gels ran to analyse and separate restriction digestion products 
of pZK12 for the Gibson Assembly
®
. Plasmid pZK12 was simultaneously digested 
with NheI-HF and NotI-HF. XbaI and EcoRI digestions were carried out sequentially. 
A, B, C, D. Repeated digestions for generating the quantity of fragments required for 
the Gibson Assembly
®
. .............................................................................................. 159 
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obtained by overlap extension PCR and by restriction enzyme digestion. ................ 164 
Figure 2.23. Sanger sequencing chromatogram showing the mutation in the βArrestin2-TEV 
start codon. Screenshot of DNA Star Lasergene’s SeqMan ProTM sequence analyser 
aligning sequencing results with the expected sequence. The upper-most sequence is 
the consensus sequence. The second sequence from the top was the expected 
sequence indicating a mutated start codon (the non-mutated start codon is ATG). The 
following 4 chromatogram sequences are reads from our DNA samples. Comparing 
the read sequences with the expected sequence, revealed that the Adenosine 
monophosphate (A) of the start codon has been changed to Cytidine monophosphate 
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(C). Additionally, an A has been inserted in between the Thymidine monophosphate 
(T) and the Guanosine monophosphate (G) of the start codon. These mutations render 
the start codon dysfunctional, thus the entire βArrestin2-TEV became non-
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The forward primer binds to the BDK-B2-AVPR2tail-TCS-tTA construct and the 
reverse primer binds to the βArrestin2-TEV, the resulting PCR product in the 
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was present in low amounts. ...................................................................................... 178 
Figure 2.32. Images of agarose gels on which DNA fragments generated by PCR and by 
restriction enzyme digestion with EcoRI and NotI were separated for conventional 
cloning. A. The 8.3 kbp long pZK12 backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES 
fragment with cohesive ends for cloning was obtained by PCR followed by restriction 
enzyme digestion. The ≈2 kbp βArrestin2-TEV fragment was obtained by PCR and its 
ends were chopped off with restriction enzymes. B. Bands corresponding to the 
fragment of interest that were excised are marked in yellow rectangles. .................. 180 
Figure 2.33. Image of agarose gel ran for periodically assessing the quality of plasmid 
solutions. Plasmids were digested with single-cut restriction enzymes to avoid 
supercoiling and plasmid associations. 1 µg of plasmid DNA was loaded into each 
well of the gel. No signs of degrading of plasmid DNA molecules are visible. ........ 182 
Figure 2.34. Optimization of electroporation pulse voltages and cell electroporation densities 
for electroporating EA.h929 cells with plasmids pZK11 and pZK13, as model 
plasmids for the redesigned gene network (pZK13 and pZK14). Using plasmid pZK11 
(constitutive phMGFP), instead of pZK14 (eGFP reporter plasmid), simplified the 
procedure by eliminating potential gene expression and gene network activation 
problems as well as the need to induce the gene network in order to observe GFP 
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expression. Cells were stained with Hoechst 33342 and propidium iodide 24 hours 
after electroporation and were microscopy imaged. Obtained images were analysed in 
ImageJ to count cells and determine the percentage of green fluorescent cells and cell 
viabilities plotted on the left Y-axis of the graph. The number of total cells per image 
is plotted on the secondary right Y-axis. On the X-axis the electroporation pulses are 
shown. A. 50.000 cells were electroporated per reaction. B. 100.000 cells were 
electroporated per reaction. C. 200.000 cells were electroporated per reaction. N=2, 
error bars show standard deviation. ........................................................................... 187 
Figure 2.35. Comparison of the redesigned gene network (pZK13, pZK14) with the old 
version of the same gene network (pZK9, pZK5, pZk10). EA.hy926 cells were 
electroporated using 900 V 30 ms double pulses with either one of the two gene 
network versions (conditions 1–10) or with the pZK11 (constitutive phMGFP) 
together with pZK13 (condition 11) and treated as described in the table below the 
graph. Cells transfected with the gene network, conditions 1–10, were either seeded in 
ibidi µ-Slide I 
0.4
 Luer flow channels for 24 hour flow experiments at 1.5–2 Pa, 
commencing 24 hours after transfection (conditions 1 and 2) or were seeded in multi 
well plates and treated with shear stress induced by pipetting for 1 minute (conditions 
3 and 4), with 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt (conditions 5 
and 6), with 100 nM HOE 140 (conditions 9 and 10), or left untreated (conditions 7 
and 8). Cells were stained with Hoechst 33342 and propidium iodide and imaged 48 
hours transfection. Images were processed in imageJ, determined cell viabilities and 
transfection efficiencies are plotted on the left Y-axis and the total number of cells per 
image is plotted on the right Y-axis. Overall, the percentages of green fluorescent 
cells were low and the new version of the gene network seems to yield a higher 
percentage of green fluorescent cells compared to the old gene network version. 
Subsequently, it was noticed that the plasmid pZK10 (eGFP reporter from the old 
gene circuit version) contained suspended particles and also 10 fold drop in 
concentration. Error bars represent standard deviation, N=2. ................................... 190 
Figure 2.36. Comparison between the performances of the two gene circuit versions (old and 
new), between the performance of components (reporter plasmid and signalling 
cascade) of these two gene network versions, and also comparing relative transfection 
efficiencies and gene expression levels. 50,000 EA.hy926 cells were electroporated 
per reaction using 900 V 30 ms double pulses with plasmids specified in the table 
below the graph. Cells transfected with the gene network were treated with shear 
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stress induced by pipetting for 1 minute, with 2 µM [Hyp
3
]-bradykinin and 2 µM 
bradykinin acetate salt, with 100 nM HOE 140, or left untreated. Cells were stained 
with Hoechst 33342 and propidium iodide and imaged 48 hours transfection. Images 
were processed in imageJ, determined cell viabilities and transfection efficiencies are 
plotted on the left Y-axis and the total number of cells per image is plotted on the 
right Y-axis. Error bars represent standard deviation, N=3. ...................................... 192 
Figure 2.37. Mammalian selection antibiotic titration for EA.hy926 cells. Non-transfected 
cells were cultured under antibiotic concentrations specified on the X-axis for a period 
of 7 days. Cells were stained with Hoechst 33342 and propidium iodide and imaged. 
Images were processed in ImageJ to determine cell viabilities, plotted on the left Y-
axis; total number of cells per image is plotted on the right Y-axis. A. Cell viabilities 
in function of Hygromycin B concentrations B. Cell viabilities at various G418 
concentrations. Error bars show standard deviation, N=2. ........................................ 195 
Figure 2.38. Optimization of electroporation pulse voltages for electroporating HMEC-1 cells 
with the redesigned gene network (pZK13 and pZK14). The gene network was 
induced with bradykinin 12, 24 and 36 hours after electroporation. Cells were stained 
with Hoechst 33342 and propidium iodide 48 hours after electroporation and were 
microscopy imaged. Obtained fluorescent images were processed in ImageJ to count 
cells to determine the percentage of green fluorescent cells and cell viabilities, plotted 
on the left Y-axis of the graph. The number of total cells per image is plotted on the 
secondary, right Y-axis. On the X-axis the electroporation pulses are shown. N=2, 
error bars represent standard deviation. ..................................................................... 202 
Figure 2.39. Optimization of electroporation pulse duration and multiplicity for 
electroporating HMEC-1 cells with the redesigned gene network (pZK13 and 
pZK14). The gene network was induced with bradykinin 12, 24 and 36 hours after 
electroporation. Cells were stained with 2 µg/ml Hoechst 33342 and 0.5 µg/ml 
propidium iodide 48 hours after electroporation and were microscopy imaged. 
Obtained fluorescent images were analysed in ImageJ to count cells and resulting 
green fluorescent cell percentages and cell viabilities are plotted on the left Y-axis of 
the graph. The number of total cells per image is plotted on the secondary, right Y-
axis. On the X-axis the electroporation pulses are shown. N=2, error bars represent 
standard deviation. ..................................................................................................... 204 
Figure 2.40. Evaluating the leakiness of the redesigned gene network in HMEC-1 cells. Final 
concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt or of 100 
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nM HOE 140 were repeatedly added 6, 24 and 36 hours after electroporation. 
Alternatively, cells were cultured without adding bradykinin or HOE 140. 48 hours 
after electroporation cells were stained with 2 µg/ml Hoechst 33342 and 0.5 µg/ml 
propidium iodide and were microscopy imaged. Obtained fluorescent images were 
processed in ImageJ to count cells and resulting green fluorescent cell percentages 
and cell viabilities are plotted on the left Y-axis of the graph. The number of total 
cells per image is plotted on the secondary, right Y-axis. The higher-than-expected 
green fluorescent cell percentages in the negative control conditions are most 
probably due to activation of the gene network by shear stress caused by frequent 
opening and shutting of the incubator door. N=3, error bars represent standard 
deviation. .................................................................................................................... 205 
Figure 2.41. Optimizing HMEC-1 cell electroporation densities, culture media and comparing 
negative controls. A. Cells were electroporated with the gene network encoded on 
plasmid pZK13 and pZK14 and densities indicated on the X-axis. The gene network 
was either activated with final concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM 
bradykinin acetate salt or inhibited at the transcription level by 20 ng/ml doxycycline. 
48 hours after electroporation cells were stained with 2 µg/ml Hoechst 33342 and 0.5 
µg/ml propidium iodide and were microscopy imaged. Obtained fluorescent images 
were processed in ImageJ to count cells and resulting green fluorescent cell 
percentages and cell viabilities are plotted on the left Y-axis of the graph. The number 
of total cells per image is plotted on the secondary, right Y-axis. B. Cells 
electroporated with the gene network were seeded in 1 day old culture media 
collected from 80% confluent healthy growing cells, in 50% old 50% fresh culture 
media or in fresh culture media. The culture media was supplemented with 2 µM 
[Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt, 100 nM HOE, 10 ng/ml 
doxycycline or 20 ng/ml doxycycline. 48 hours after electroporation cells were 
stained with final concentrations of 2 µg/ml Hoechst 33342 and 0.5 µg/ml propidium 
iodide and were microscopy imaged. Obtained fluorescent images were processed in 
ImageJ to count cells and resulting green fluorescent cell percentages and cell 
viabilities are plotted on the left Y-axis of the graph. The number of total cells per 
image is plotted on the secondary, right Y-axis. N=3, error bars represent standard 
deviation. .................................................................................................................... 206 
Figure 2.42. Reagent transfection of HMEC-1 cells with the gene network encoded on 
plasmid pZK13 and pZK14. Cells were seeded 24 hours prior transfection to reach 
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70-80% confluency at the time of transfection. The transfection reagents were 
complexed with the plasmid DNA and were added to the cell culture. The gene 
network was activated 12, 24 and 36 hours after transfection with final concentrations 
of 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt 48 hours after 
electroporation cells were stained with 2 µg/ml Hoechst 33342 and 0.5 µg/ml 
propidium iodide and were microscopy imaged. Obtained fluorescent images were 
processed in ImageJ to count cells and resulting green fluorescent cell percentages 
and cell viabilities are plotted on the left Y-axis of the graph. The number of total 
cells per image is plotted on the secondary, right Y-axis. A. 60,000 HMEC-1 cells 
seeded per wells of 24 well plates 24 hours prior transfection, were either transfected 
in antibiotic and serum free MCDB 131 medium or in Opti-MEM
®
 I Reduced Serum 
Medium using the Lipofectamine
®
 Plus
TM
 Reagent. The DNA–PLUSTM–
Lipofectamine
®
 Reagent mixture was incubated with the cells for 24 hours. N=4. B. 
28,800 or 40,000 HMEC-1 cells seeded 24 hours prior transfection per well of 24 well 
plates. Cells were either transfected with Lipofectamine
®
 or TurboFect™ transfection 
reagents. In case of Lipofectamine
®
 transfection, the DNA–PLUSTM–Lipofectamine® 
Reagent mixture was incubated with cells either for 3 or 12 hours. In case of 
TurboFect™ transfection, various amounts of plasmid DNA were tried. N=2. Based 
on these results, it has been decided not to continue on using transfection reagents for 
the transfection of HMEC-1 cells since green fluorescent cell percentages seemed 
inferior to those obtained via electroporation. Error bars represent standard deviation.
.................................................................................................................................... 209 
Figure 2.43. Comparing performances of gene circuit components under various activating 
and inhibiting conditions and comparing transfection efficiencies. 100,000 HMEC-1 
cells were electroporated per reaction using 1200 V 30 ms double pulses with 
plasmids specified in the table below the graph. 6, 24 and 36 hours after transfection, 
the gene network was activated with 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin 
acetate salt, with shear stress induced by pipetting for 1 minute or it was inhibited 
with 100 nM HOE 140, or cells were left untreated. The gene network was also 
inhibited with 20 ng/ml doxycycline added before seeding electroporated cells and re-
added 24 and 36 hours after electroporation. Non-electroporated cells were also 
included as an additional negative control condition. Cells were stained with Hoechst 
33342 and propidium iodide and imaged 48 hours transfection. Images were 
processed in imageJ, determined cell viabilities and transfection efficiencies are 
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plotted on the left Y-axis and the total number of cells per image is plotted on the 
right Y-axis. Error bars represent standard deviation, N=4–6. .................................. 212 
Figure 2.44. Hygromycin B and G 418 antibiotic titration on HMEC-1 cells for 7 days 
selection. Non-transfected cells were cultured under antibiotic concentrations 
specified on the X-axis for a period of 7 days. Cells were stained with Hoechst 33342 
and propidium iodide and imaged. Images were processed in ImageJ to determine cell 
viabilities, plotted on the left Y-axis. The total number of cells per image is plotted on 
the right Y-axis. A. Cell viabilities under various Hygromycin B concentrations. B. 
Cell viabilities in function of G418 concentrations. Error bars represent standard 
deviation, N=2. .......................................................................................................... 215 
Figure 2.45. G 418 antibiotic titration on HMEC-1 cells for 2 days selection. Non-transfected 
cells were seeded in 24 well plates coated with 1% gelatine. Twenty-four hours after 
seeding, wells of the 24 well plates were supplemented with antibiotic concentrations 
specified on the X-axis and incubated for a period of 2 days. A. Cell viabilities in 
function of G418 concentrations. Cells were stained with Hoechst 33342 and 
propidium iodide, and imaged. Images were processed in ImageJ to determine cell 
viabilities, plotted on the left Y-axis. The total number of cells per image is plotted on 
the right Y-axis. Error bars represent standard deviation, N=2. B. Phase contrast 
microscopy images showing cell morphologies and the proportion of adherently 
growing cells, as an indicator of cell viability. According to these images cell viability 
decreased at G418 concentrations of above 200 µg/ml. ............................................ 216 
Figure 2.46. Selection of HMEC-1 cells electroporated with the gene network. HMEC-1 cells 
were electroporated with 1:1 molar ratio of pZK13 and pZK14 (redesigned gene 
network), using 1200 V 30 ms double pulses. 24 hours after electroporation, the 
culture media was supplemented with 400 µg/ml G 418 antibiotic and selection was 
carried out for two day, at the of which the gene network was induced with 2 µM 
[Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt. 24 hours after induction cells 
were stained with Hoechst 33342 and propidium iodide and cells were imaged. 
Recorded images were processed in imageJ to determine cell viabilities and 
transfection efficiencies. Error bars represent standard deviation, N=4. ................... 217 
Figure 2.47. Selection of HMEC-1 cells electroporated with pZK13 followed by a second 
electroporation and induction. HMEC-1 cells were electroporated with pZK13. 
Twenty-four hours after electroporation the culture media was supplemented with 200 
and 400 µg/ml G 418 and cells were incubated for two days at the end of which the 
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culture media was replaced with G 418 media. Twenty-four hours after ending the 
selection cells were electroporated with pZK14. Six and twenty-four hours after the 
second electroporation cells were induced with 2 µM [Hyp
3
]-bradykinin and 2 µM 
bradykinin acetate salt. As negative control, cells electroporated with pZK14 were 
seeded in culture media containing 20 ng/ml doxycycline, the same amount of 
doxycycline being added 24 hours after the second electroporation. Cells were stained 
with Hoechst 33342 and propidium iodide and were imaged 48 hours after the second 
electroporation. Recorded images were processed in imageJ to determine cell 
viabilities and transfection efficiencies, plotted on the left Y-axis alongside total cell 
numbers per images on the right Y-axis. Treatment conditions are shown on the X-
axis. Error bars represent standard deviation, N=3. ................................................... 219 
Figure 2.48. Flow experiment on non-transfected HMEC-1 cells. HMEC-1 cells were seeded 
in µ-Slide I 
0.2
 Luer, µ-Slide I 
0.4
 Luer, and µ-Slide I 
0.8
 Luer flow channels pre-coated 
with 1% fibronectin. After a priming period of 2 hours at low flow rate, the flow was 
increased to 3 ml/min, which yielded 3.2, 0.8 and 0.2 Pa shear stress in the µ-Slide I 
0.2
 Luer, µ-Slide I 
0.4
 Luer, and µ-Slide I 
0.8
 Luer flow channels, respectively. This 
flow rate was maintained for 48 hours. Images were recoded before starting the flow 
and after 24 and 48 hours of flow exposure using the 10x objective. ....................... 221 
Figure 2.49. Activation of the gene network by shear stress in the linear shear stress inducing 
flow channel. HMEC-1 cells were electroporated with 1:1 molar ration of pZK13 and 
pZK14 and seeded in the seeding well of the flow setup. Twenty-four hours after cell 
seeding, the well was replaced with the bottomless flow channel and following a 3 
hours priming period at low flow rates, cells have been exposed to 24 hours of 28 
ml/min flow which yielded a shear stress increasing from 0 to 5 Pa along the flow axis 
of the in-house designed flow channel. Cells on the glass slide were stained with 2 
µg/ml Hoechst 33342 and 0.5 µg/ml propidium iodide and then fixed with 4% (v/v) 
paraformaldehyde. The slide was imaged using tile acquisition and cells were counted 
from images where cells have been exposed to shear stress values of 0.2, 0.5, 1, 1.5, 2, 
2.5, 3.0, 3.5, 4.0, 4.5, and 5 Pa. Resulting green fluorescent cell percentages were 
plotted against shear stress. Error bars represent standard deviation, N=2. .............. 223 
Figure 2.50. Activation of the gene network in antibiotic selected HMEC-1 cells by shear 
stress in the linear shear stress inducing device. HMEC-1 cells were electroporated 
with pZK13 and 24 hours later, selection with 200 µg/ml of G 418 was started and 
was carried out for a period of 48 hours. 24 hours after stopping the selection, cells 
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were electroporated with pZK14 and seeded in the in-house designed flow device. 
Twenty-four hours after cell seeding cells were primed at low flow rates for 3 hours 
and then exposed to 24 hours of 28 ml/min flow which yielded a shear stress 
increasing from 0 to 5 Pa along the flow axis of the in-house designed flow channel. 
Cells on the glass slide were stained with 2 µg/ml Hoechst 33342 and 0.5 µg/ml 
propidium iodide and then fixed with 4% (v/v) paraformaldehyde. The slide was 
imaged using tile acquisition and cells were counted from images where cells have 
been exposed to shear stress values of 0.2, 0.5, 1, 1.5, 2, 2.5, 3.0, 3.5, 4.0, 4.5, and 5 
Pa. Resulting green fluorescent cell percentages were plotted against shear stress. 
Error bars represent standard deviation, N=3 for data points at 0.2 and 0.5 Pa and N=5 
for all other data points. ............................................................................................. 225 
Figure 2.51. Pilot flow experiment with reversed flow direction (high shear to low shear). 
HMEC-1 cells were electroporated with pZK13 and 24 hours later, selection with 200 
μg/ml of G 418 was started and was carried out for a period of 48 hours. 24 hours 
after stopping the selection, cells were electroporated with pZK14 and seeded in the 
in-house designed flow device. Twenty-four hours after cell seeding, the flow 
experiment was set up by flowing the culture media in the reversed direction in the 
flow channel: flow entering at high shear stress and exiting at low shear stress. In the 
initial phase, cells were primed at low flow rates for 4 hours and then exposed to 24 
hours of 28 ml/min flow which yielded a shear stress decreasing from 5 to 0 Pa along 
the flow axis of the in-house designed flow channel. Cells on the glass slide were 
stained with 2 μg/ml Hoechst 33342 and 0.5 μg/ml propidium iodide and then fixed 
with 4% (v/v) paraformaldehyde. The slide was imaged using tile acquisition and 
cells were counted from images where cells have been exposed to shear stress values 
of 1, 1.5, 2, 2.5, 3.0, 3.5, 4.0, 4.5, and 5 Pa. Resulting green fluorescent cell 
percentages were plotted against shear stress. Error bars represent standard deviation. 
N=1, number of technical replicates equals 4 since 4 images were recorded at each 
shear stress value within one experiment. .................................................................. 226 
Figure 3.1. The geometry of the flow channel for inducting linearly increasing shear stress, 
designed in SolidWorks. The lowest height of this channel (in the high shear stress 
region) is 200 µm. ...................................................................................................... 245 
Figure 3.2. Performance of the flow channel designed by Usami et. al. [642]. A. Illustration 
of the parallel plate flow channel. The width of the flow channel varies in order to 
modify flow velocities and consequently shear stress values. B. Variation of the shear 
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stress along the length of the channel, in the width-wise middle of the channel floor. 
Flow simulation results obtained in SolidWorks at 5 ml/min flow rate. C. Variation of 
shear stress across the width of the channel, in the length-wise middle of the channel. 
Flow simulation results obtained in SolidWorks at 5 ml/min flow rate. ................... 246 
Figure 3.3. Shear stress map at the floor of the flow channel with 200 µm minimal height 
computed using SolidWorks Flow Simulation Package. The flow entered with a flow 
rate of 10 ml/min at the high height end of the channel and the flow exited at the low 
height end of the channel. .......................................................................................... 247 
Figure 3.4. Shear stress computed in SolidWorks along the length and across the width of the 
floor of the channel with 200 µm minimal height, at 3 flow rates. A. Variation of 
shear stress along the length of the channel floor, in the width-wise centre of the 
channel floor, at 5 ml/min flow rate. B. Shear stress across the width of the channel 
floor, in the length-wise middle of the channel floor, at 5 ml/min flow rate. C. Shear 
stress along the length of the channel floor, in the width-wise centre of the channel 
floor, at 10 ml/min flow rate. D. Shear stress calculation across the width of the 
channel floor, in the length-wise centre of the channel floor, at 5 ml/min flow rate. E. 
Evolution of shear stress along the length of the channel floor, in the width-wise 
centre of the channel floor, at 20 ml/min flow rate. F. Shear stress across the channel 
floor width, in the length-wise centre of the channel floor, at 20 ml/min flow rate. . 249 
Figure 3.5. Shear stress mapped in SolidWorks at the channel floor of the flow channel with 
400 µm minimal height. The fluid flowed in at a rate of 40 ml/min at the high end of 
the channel and the fluid exited at the low end of the channel. ................................. 250 
Figure 3.6. Shear stress plotted along the length and across the width of the floor of the 400 
µm minimal height channel at 3 flow rates. A. Shear stress along the length of the 
channel floor, in the width-wise centre of the channel floor, at 20 ml/min flow rate. B. 
Shear stress across the width of the channel floor, in the length-wise middle of the 
channel floor, at 20 ml/min flow rate. C. Shear stress along the length of the channel 
floor, in the width-wise centre of the channel floor, at 40 ml/min flow rate. D. Shear 
stress computed across the width of the channel floor, in the length-wise centre of the 
channel floor, at 40 ml/min flow rate. E. Shear stress in function of the length of the 
channel floor, in the width-wise centre of the channel floor, at 80 ml/min flow rate. F. 
Shear stress across the channel floor width, in the length-wise centre of the channel 
floor, at 80 ml/min flow rate. ..................................................................................... 252 
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Figure 3.7. Shear stress map at the floor of the flow channel with 200 µm minimal height, 
reversed flow direction. The fluid flowed in with a rate of 10 ml/min at the low height 
end of the channel and the fluid exited at the high height end of the channel, where 
standard atmospheric pressure (101325 Pa) was applied. ......................................... 253 
Figure 3.8. Shear stress plotted along the length and across the width of the floor of the 200 
µm minimal height channel at 3 flow rates, when the flow entered at the high height 
end and exited at the low height end of the channel. A. Shear stress along the length 
of the channel floor, in the width-wise centre of the channel floor, at 5 ml/min flow 
rate. B. Shear stress across the width of the channel floor, in the length-wise middle of 
the channel floor, at 5 ml/min flow rate. C. Shear stress along the length of the 
channel floor, in the width-wise centre of the channel floor, at 10 ml/min flow rate. D. 
Shear stress computed across the width of the channel floor, in the length-wise centre 
of the channel floor, at 10 ml/min flow rate. E. Shear stress in function of the length 
of the channel floor, in the width-wise centre of the channel floor, at 20 ml/min flow 
rate. F. Shear stress across the channel floor width, in the length-wise centre of the 
channel floor, at 20 ml/min flow rate......................................................................... 255 
Figure 3.9. Shear stress map at the channel floor of the flow channel with 400 µm minimal 
height, reversed flow direction. The fluid flowed in with a rate of 40 ml/min at the 
low height end of the channel and the fluid exited at the high height end of the 
channel, where standard atmospheric pressure (101325 Pa) was considered. ........... 256 
Figure 3.10. Shear stress plotted along the length and across the width of the floor of the 400 
µm minimal height channel at 3 flow rates, when the flow entered at the high height 
end and exited at the low height end of the channel. A. Shear stress along the length 
of the channel floor, in the width-wise centre of the channel floor, at 20 ml/min flow 
rate. B. Shear stress across the width of the channel floor, in the length-wise middle of 
the channel floor, at 20 ml/min flow rate. C. Shear stress along the length of the 
channel floor, in the width-wise centre of the channel floor, at 40 ml/min flow rate. D. 
Shear stress computed across the width of the channel floor, in the length-wise centre 
of the channel floor, at 40 ml/min flow rate. E. Shear stress in function of the length 
of the channel floor, in the width-wise centre of the channel floor, at 80 ml/min flow 
rate. F. Shear stress across the channel floor width, in the length-wise centre of the 
channel floor, at 80 ml/min flow rate......................................................................... 258 
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Figure 3.11. Image of the 100 µm minimal height channel manufactured by 3 dimensional 
(D) printing (also known as rapid prototyping), using FullCure720 rapid prototype 
resin printed out on an Objet Eden250 Professional 3D Printer. ............................... 260 
Figure 3.12. Manufacturing of the negative mould for casting the bottomless channel. Top: a 
0.5 cm thick aluminium plate (W1) was cut to obtain the a wedge part (W2), which 
was then flipped 90° (W3), holes were drilled at its both ends into which aluminium 
cylinders were glued (W4). Bottom left: a 0.5 cm thick aluminium plate (B1) was cut 
a rectangular hole into to obtain the base part (B2). Bottom right: the wedged (W4) 
was assembled (M1 → M2) with the base part (B2), to obtain the final mould (M2) 
for casting................................................................................................................... 261 
Figure 3.13. Complementary equipment and the assembly of the flow device. A. Illustration 
of the device parts. From the bottom: microscope holder and bottom clamp plate; 
microscopy glass slide on which cell are seeded and which constitutes the bottom of 
the flow channel; bottomless flow channel; top clamp plate; screws which fit into the 
bottom plate. B. The manufactured and assembled flow device. .............................. 265 
Figure 3.14. Phase contrast microscopic images of PAECs exposed to linearly increasing 
shear stress along the length of the channel floor in our in-house designed flow 
device. Cells were seeded in the PDMS seeding well coated with 1 mg/ml fibronectin. 
24 hours after seeding, the PDMS seeding well was detached from the glass slide and 
was replaced with the PDMS bottomless flow channel. Next, the flow experiment was 
started with lower flow rate in the initial two hours and maintained at 0–10 Pa 
yielding flow rate thereafter for 24 hours. The presence of cells and flow alignment 
starting above 1.5 Pa confirmed the success of our in-house designed channel. ....... 267 
Figure 4.1. Scheme of the electroporation-flow device. A. Construction of the device. First an 
indium tin oxide (ITO) coated transparent and electrically conductive glass slide was 
placed in a Petri dish, and metal wires were soldered to metal connectors glued to 
corners of the glass slide, using electrically conductive glue. Next, the cell 
accommodating chamber was created by placing adhesive PCR tape double layer on 
top of the glass slide. After sterilization with UV light and coating with fibronectin, 
cells were seeded, left to reach confluence and electroporated in the chamber. Flow 
chambers were created by placing a bottomless flow channel on top of the cell 
containing chamber. B. Electroporation procedure. The glass slide on which cells 
adhered was connected to the negative outlet of the electrical pulse generator by 
wires. A gold plated solid aluminium block was wired to the positive outlet of the 
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same pulse generator. The metal block came on top of the adherent cell monolayer in 
contact with the electroporation solution, and the pulse was delivered. C. Flow 
experiment procedure. Following electroporation the wires and the top electrode were 
removed, and a bottomless self-adhesive ibidi flow channel was placed on top of the 
cell containing well. The obtained flow chamber was connected by tubes to the 
culture medium reservoir and the peristaltic pump, facilitating the suction of liquid 
from the reservoir through the flow chamber into the pump, and pushing the liquid 
back into the reservoir. ............................................................................................... 283 
Figure 4.2. Electrical square pulses applied for optimizing the electroporation parameters. A. 
Single pulses with magnitudes between 1 and 12 Volts (V), and with durations of 1ms 
to 1 s. B. Double pulses of 1 to 12 V lasting between 1 ms and 1 s, with a gap of 1 to 
100 ms in between pulses. C. Triple pulses with magnitudes between 1 and 12 V, with 
duration of 1 ms to 1 s and with pauses of 1 to 100 ms in between pulses. D. Multiple 
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 CARDIOVASCULAR DISEASE 1.1
1.1.1 Definition 
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels, that 
include: coronary heart disease (causing heart attacks), cerebrovascular disease (leading to 
stroke), raised blood pressure (hypertension), peripheral artery disease, rheumatic heart 
disease, congenital heart disease and heart failure [1]. 
CVDs are predominantly caused by atherosclerosis. Atherosclerosis involves the deposition 
of lipids and low-density lipoproteins in the walls of large and medium sized arteries (blood 
vessels that carry blood away from the heart). Once inside the arterial wall, lipids and 
lipoproteins are being oxidized and trigger an immune response. Next, a type of white blood 
cells, monocytes, enter the arterial wall. Monocytes transform into macrophages to engulf 
oxidized lipoproteins. Oxidized lipoprotein containing macrophages form foam cells. Foam 
cells, smooth muscle cells, calcium, cellular debris and extracellular matrix build up plaques, 
also known as atheroma [2-4]. This process leads to the sclerosis (or hardening) of the arterial 
wall, hence the name of the condition: atherosclerosis. 
Plaques can grow over time and reduce the inner diameter of the arteries, restricting blood 
flow, which leads to organ malfunction or damage. Moreover, plaques can rupture causing a 
blood clot downstream. When such a blood clot enters and blocks the coronary arteries 
(which supply blood with oxygen and nutrients to the hearth), the hearth muscle cells 
(myocardium) become depleted of oxygen and subsequently die, resulting in myocardial 
infarction (commonly known as heath attack). Similarly, if a blood clot blocks an artery 
which supplies oxygen and nutrients to the brain, brain tissue dies, causing stroke [5]. 
1.1.2 Mortality 
CVDs are the leading cause of human death and disability in the world [6-10]. According to 
the World Health Organization, CVDs were responsible for 17.3 million human deaths 
worldwide in 2008, which accounted for 30% of total global human deaths [10]. Out of the 
total 17.3 million CVDs-caused deaths, 7.3 million were due to heart attacks and 6.2 million 
were provoked by strokes. Atherosclerosis, being the underlying cause for hearth attack, 
stroke and other CVDs, accounts for the extremely high mortality rate caused by CVDs. 
Approximately 80% of CVDs related deaths in 2008 occurred in low- and middle- income 
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countries [11]. Over the past 2 decades, CVDs related death rates shrunk in high income 
countries but these rates have dramatically risen in low- and middle- income countries. It was 
predicted that in 2030, the number of people who die from CVDs, mainly from heart disease 
and stroke, will increase to 23.3 million [11, 12]. CVDs are projected to remain the single 
leading cause of global death [12]. 
1.1.3 Risk factors 
Factors that have been observed to promote the development of CVDs are known as risk 
factors for CVDs. These risk factors range from life style related to predetermined (e.g. 
genetic) factors. CVD risk factors are categorized in Table 1.1, based on the degree of control 
that individual persons have over modifying the magnitude and impact of these factors, into 3 
categories: directly controllable, indirectly controllable and non-controllable. The indirectly 
controllable risk factors are often heavily influenced by the directly controllable risk factors. 
The last column of Table 1.1 shows the estimated contribution of these risk factors to the 
global mortality in 2004 [13]. CVD risk factors also guide the diagnosis and treatment of the 
disease [14]. CVDs related mortality rates could be significantly decreased by reducing the 
magnitude and impact of the directly controllable risk factors. 
 Table 1.1. Cardiovascular disease risk factors 
Controllability
§
 Risk factor 
Global mortality 
contribution
¥ 
[%] 
Directly controllable 
Tobacco smoking 8.7 
Physical inactivity 5.5 
Excessive alcohol 
consumption 
3.8 
Low fruit and vegetable 
intake 
2.8 
Air pollution 2.7 
Indirectly controllable 
High blood pressure 12.8 
High blood cholesterol 4.5 
High blood glucose 5.8 
Overweight and obesity 4.8 
Poverty and low educational 
status 
N. A. 
Psychological factors (e.g. 
stress, depression) 
N. A. 
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Non-controllable 
Gender N. A. 
Age N. A. 
Ethnic background  N. A. 
Genetic predisposition N. A. 
§
The degree of control that individuals can exert over altering the magnitude and impact of 
cardiovascular risk factors. 
¥
The percentage by which individual risk factors were estimated to contribute on average 
to the global morality in 2004 [13]. 
 
 
 ATHEROGENIC BIOMECHANICAL FACTORS 1.2
1.2.1 Localization of atherosclerotic plaques 
Although the above mentioned risk factors act uniformly on the entire arterial system, a study 
[15] which examined the medical records of 13,827 patients hospitalized in Houston, Texas, 
USA for atherosclerotic related disease between 1948 and 1983, showed that atherosclerosis 
occurred at certain, well-defined areas of the arterial system. These atherosclerosis 
predilection sites were curved vessel segments, bifurcations and side branching locations. At 
these locations, blood flow patterns are different, disrupted, compared to straight, non-
branching arterial segments: on average flow velocities are lower, vortexes occur and the 
direction of flow alternates throughout the cardiac cycle [16, 17].  
1.2.2 Haemodynamic shear stress and atherosclerosis 
The flow of blood exerts a friction force on the stationary endothelial surface which lines the 
interior of blood vessels. This tangential force acting per unit area is termed haemodynamic 
shear stress and it is measured in dyne/cm
2
 or Newton/m
2
 (N/m
2
) or Pascal (Pa). 
Haemodynamic shear stress is the product of the blood flow rate at the vessel wall and the 
dynamic viscosity of blood [18]. Mean arterial hemodynamic shear stress values are 15 to 20 
dyne/cm
2
 that corresponds to 1.5 to 2 Pa [19-22].  
Haemodynamic shear stress was first shown to be correlated with atherosclerosis in humans 
in the late 1960s by Caro et al. [23]. Later, advanced computational fluid dynamics 
simulations performed in autopsy-based arterial models showed that at curved vessel 
segments, bifurcations and side branches, where atherosclerosis occurred, the endothelial 
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shear stress is low, 0.2 – 1 Pa, [24-26]. In vivo experiments in animal models also supported 
the role low endothelial shear stress in the development of atherosclerosis [27-29]. By placing 
a flow modifying cuff around the carotid artery of atheroprone mice, it was also observed that 
atherosclerosis occurred at areas where shear stress was low or oscillatory low [30]. Medical 
imaging techniques, such as ultrasound and magnetic resonance imaging, and computational 
fluid dynamics, performed on humans, in vivo, also confirmed the atherogenic role of low 
endothelial shear stress [31-33]. Besides these physiological studies at the organ and tissue 
level, vast research has been undertaken to unveil the cellular and molecular mechanism of 
atherosclerosis development under the influence of low endothelial shear stress, for a review 
see [18]. This review summarizes that, at the molecular level, low endothelial shear stress has 
the following atherogenic functions: lessens nitric oxide dependent atheroprotection; 
enhances low-density lipoprotein uptake, synthesis, and permeability; promotes oxidative 
stress and inflammation; promotes vascular smooth muscle cell migration, differentiation, 
and proliferation; promotes extra-cellular matrix degradation and inhibits its synthesis; 
increases plaque thrombogenecity. The same review also sums up the literature which shows 
that low endothelial shear stress plays a role in atherosclerotic wall remodelling. 
Additionally, it has also been shown that low endothelial shear stress influences the 
conversion of stable, non-rupture prone plaques into vulnerable, rupture prone plaques [34]. 
1.2.3 Tensile stress and atherosclerosis 
The pressure generated by the beating heart inside arteries, exerts a compressive and a 
circumferential force on the arterial wall [22]. Thus, blood pressure leads to the expansion of 
blood vessel circumference and the stress state causing this expansion is termed tensile stress. 
Arterial tensile stress is directly proportional with blood pressure and the radius of the vessel 
and it is inversely proportional with thickness of the arterial wall. Tensile stress has the units 
of force applied per unit area and it is commonly expressed in N/m
2 
or Pa. At blood vessel 
bends, bifurcations and side branching area, the effective radius of blood vessels is modified 
[35], and in plaque areas the wall thickness is modified, thus modifying the tensile stress. 
The effect of tensile stress on plaques and plaque rupture was studied in humans [36, 37]. 
Such studies showed that atherosclerotic arterial tissue is stiffer than healthy tissue [37, 38]. 
In general, it is accepted that calcified plaques rich in fibrous connective tissue, extracellular 
matrix and smooth muscle cells, containing a thick fibrous cap, having a small lipid core and 
with few inflammatory cells are stable and not prone to rupture [39-41]. On the other hand, a 
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thin fibrous cap on the atheroma, lack of calcification, a large lipid core infiltrated by 
immune cells renders the plaques vulnerable to rupture [40, 42].  
Plaques rupture at areas where higher mechanical stresses are applied and where thickness of 
fibrous cap is minimal [43-46]. Plaques were also shown to rupture at location where local 
calcification was high due to variation on the local stiffness of the plaque [47]. 
It is believed that endothelial shear stress plays a far more significant role in the development 
of atherosclerosis than tensile stress does [18]. 
1.2.4 Mass transport and atherosclerosis 
As previously described, atherosclerosis occurs at locations where blood flow patterns 
deviate from their normal spatial and temporal distribution patterns from straight, non-
branching arteries. These disrupted blood flow patterns could also affect the transfer of low 
density lipoproteins and other lipid-bearing material into the arterial wall [48, 49]. The 
transport of mass in the arterial system happens through convective and diffusive processes. 
Convection is the concrete and collective movement of groups of molecules within the fluid 
or the movement of the entire fluid body. Diffusion is the net movement of atoms, ions or 
molecules from a region of high concentration to a region of low concentration. Mass 
transport that occurs due to diffusion is often termed mass transfer [50]. 
Initially, the localization of atherosclerosis was thought to be due to the ﬂuid (blood) phase 
resistance to transport of low-density lipoprotein (LDL) and of other atherogens under the 
control of shear stress [51]. Subsequent studies in the field suggested that the accumulation of 
lipids in the arterial wall could not be correlated with the mass transport rates in the ﬂuid-
phase [52]. This led to the conclusion that instead of the fluid phase mass transport rates, the 
resistance to mass transport across the wall (endothelium) was limiting the uptake of lipids in 
arteries [52]. This inferred that blood flow affected the properties of the endothelium and the 
transport of atherogens across the endothelium as described in subsection 1.2.2 above. About 
a decade later, atheroma generation was thought to be influenced also by the resistance of 
materials to exit the arterial wall, besides the resistance of atherogens to enter the arterial wall 
[53, 54]. This way, attention was also drawn to the role of the layers of the arterial wall in the 
process of atherosclerosis development.  
To date, there are four mass transport mechanisms that could describe the localization of 
atherosclerosis. In the first mechanism, oxygen transport may be limited by the fluid phase, 
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leading to deprivation of the endothelium of adequate oxygen supply, condition known as 
hypoxia, which increases endothelial permeability of atherogens [55]. In the second mass 
transport mechanism, the uptake of atherogens is controlled by the endothelium and leaky 
endothelial junctions allow the accumulation of LDL in the arterial wall [56]. According to 
the third mechanism, adaptation of the endothelium to changes in blood flow causes the 
remodelling of the intracellular junctions which in turn increases the arterial uptake rate of 
macromolecules [57]. Finally, the fourth mechanism emphasizes the role of blood convection 
in clearing the sub-endothelial intimal and medial layers from atherogenic macromolecules 
[49, 58]. All of these four mass transport mechanisms appear to be influenced by shear stress 
[49]. 
In our study, out of the three atherogenic biomechanical factors, the focus will fall on shears 
stress, since this appears to be the most crucial biomechanical atherosclerosis initiation and 
localization factor. 
  
 
 SYSTEMS AND SYNTHETIC BIOLOGY OF THE 1.3
ARTERIAL WALL 
1.3.1 Systems biology 
The flow of blood regulates highly complex mechanotransduction pathways, which are 
connected to eight recognized transcription factors that control the expression of 
approximately 2000 known genes [59-65]. These complex signalling pathways are 
interconnected and they are not fully characterized [66]. In order to comprehend such 
complex signal transduction networks, a holistic (computational) mathematical modelling 
approach has been developed, giving rise to the interdisciplinary field of systems biology, 
particularly from year 2000 onwards [67, 68]. Systems biology requires experimental data for 
integration into mathematical models in order to map out signalling pathways and their 
properties [67, 68]. Systems biology also provides a framework for assembling models of 
biological systems form systematic experimental measurements. Currently, four applications 
of systems biology are considered to be of the greatest relevance: (1) pathway-based 
biomarkers, (2) global genetic interaction maps, (3) systems approaches to identify disease 
genes and drug targets, and (4) systems biology for stem cell research [69]. A great deal of 
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computational tools have been, are being and will be developed for the field of systems 
biology [70-73].  
1.3.2 Synthetic biology 
Following the genomic revolution and the rise of systems biology, rigorous engineering was 
applied to biology with the aim of creating biological entities with novel, controllable and 
predictable function, and with the aim of (re)-programming and controlling cellular behaviour 
[74]. This gave birth to one of the most rapidly developing and promising scientific fields of 
the XXI century: synthetic biology [74, 75]. Synthetic biology has already been applied in the 
areas of biosensing, therapeutics and pharmaceuticals, biofuels and biomaterials (for a review 
cf. [76]). Some of the specific synthetic biology applications include: engineering of bacteria 
to invade cancer cells [77], producing naturally replicating rubber for tires [78] and creating 
“smart” plants that sense and respond to multiple threats, such as pathogens, toxins, 
desiccation, and nutrient availability [79]. In order to aid the study of atherogenic 
mechanotransduction, gene networks can be developed to characterize the behaviour of 
various genes involved in the disease process. Furthermore, synthetic biology also offers the 
potential to develop gene networks for screening for drugs against atherosclerosis and gene 
networks for therapeutic purposes.  
 
 
 AIM OF THE THESIS 1.4
To tackle multifactorial cardiovascular disease, we aim to develop synthetic and systems 
biology tools for investigating and obviating the effect of atherogenic blood flow on vascular 
cells. Three different synthetic and systems biology tools were aimed to be developed, and 
the development of each of these will be presented separately in the following 3 chapters, 
Chapter 2–4. 
In Chapter 2, the design and implementation of a synthetic biology based gene network for 
monitoring shear stress sensor activity in endothelial cells (ECs) will be presented. Once 
developed, this gene network could be applied for screening for atherosclerosis drug 
candidates and for coupling synthetic shear stress sensing to the expression of therapeutic 
genes. Chapter 3 describes a project aiming to design and manufacture a flow chamber which 
will enable to expose endothelial cells to linearly increasing shear stress along the length of 
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the channel floor, permitting in vitro cellular biomechanical studies. The aim of Chapter 4 is 
to develop a device that is capable of electroporating primary vascular cells in their adherent 
state and allows the exposure of these cells to fluid flow to mimic physiological conditions. 
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Chapter 2  
 
 
2 Synthetic gene network for monitoring 
shear stress sensor activity in endothelial 
cells 
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 ABSTRACT 2.1
 
Shear stress, exerted by blood flow on the inner surface (endothelium) of arteries, plays a 
crucial role in initiating and progressing atherosclerosis. Low and/or oscillatory endothelial 
shear stress is considered particularly atherogenic and is sensed by specific membrane 
molecules (G protein-coupled receptors (GPCRs), ion channels, tyrosine kinases receptors, 
etc.) and the cytoskeleton, collectively known as shear stress sensors. To date, no techniques 
are available to monitor shear stress sensor activity. The aim of the project presented in this 
chapter is to design and evaluate a novel assay that monitors mechanosensor activity of B2 
Bradykinin GPCR, using a synthetic biology approach. 
 
Our synthetic gene network consists of a shear stress sensor, a reporter gene and a cascade 
which signals from the sensor to the reporter gene. The plasmids that encode the network 
were constructed and electroporated into HeLa cells and into the EA.hy926 endothelial cell 
line. The intracellular functionality of the gene network was evaluated by bradykinin 
activation and the shear stress response was subsequently tested in cells seeded in 
microfluidic flow chambers. Upon activation, the gene network expressed enhanced green 
fluorescent protein and cells were visualized using fluorescent microscopy. 
 
The synthetic gene network was proven functional in HeLa cells by bradykinin activation. 
Next, the gene network was transfected into the endothelial cell line EA.hy926 and activity of 
the network was confirmed by bradykinin activation. Subsequently, the cells were seeded in 
in-house developed flow chambers and it was shown that the gene network was activated by 
1.5-2 Pa shear stress, by 24 hours flow exposure. 
 
These results show - for the first time - that a synthetic gene network is capable of monitoring 
mechanosensor activity. This new assay enables to screen for compounds that modify the 
response of mechanosensors to low or oscillatory low shear stress.  
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 INTRODUCTION 2.2
The aim of this second chapter is to design and implement a synthetic gene network that 
monitors the activity of shear stress sensors in endothelial cells. This gene network would 
promote screening for compounds that modify the activity of the shear stress sensor. 
Knowing the link between shear stress and cardiovascular diseases, presented in the previous 
chapter, these compounds could then candidate as drugs against atherosclerosis in subsequent 
trials. Among other applications, this shear stress sensitive gene network could also be 
coupled to the expression of atheroprotective (therapeutic) genes under detrimental, 
atherogenic shear stress conditions. In order to establish such a gene network, in the 
following sections, mammalian synthetic biology will be reviewed in order to identify 
existing synthetic biology parts and tools which could be used to construct our shear stress 
sensitive gene network. Following that known endothelial shear stress sensors will be 
summarized and finally the design of our shear stress sensor monitoring gene network will be 
presented. 
2.2.1 Mammalian synthetic biology 
Synthetic biology, or the engineering of biological systems with novel functions, started in 
prokaryotic organisms, moved into lower eukaryotes (e.g. yeast) and then into mammalian 
cells [80-82]. Over the past years, mammalian synthetic biology has rapidly evolved from the 
development of simple gene switches and gene networks to complex, therapy-oriented 
circuits. Nowadays, mammalian synthetic biology provides strategies for gene- and cell-
based therapies with a wide range of applications, such as: artiﬁcial insemination, 
personalized medicine and the treatment of cancer and of metabolic and immune disorders. 
Besides, gene networks directly applied for treatment, gene network for the discovery of 
novel antibiotics and for anti-cancer drug screening have also been developed. In the 
following subsections, reviewed mammalian synthetic biological assemblies are categorized 
into mammalian synthetic biological gene switches and gene networks. 
2.2.1.1 Switches in mammalian synthetic biology 
In order to harvest the full potential of synthetic biology, biological parts should be re-
organized into controllable and well-defined switches, logical operators and other systems 
with predictable functions. Similar to electronic switches, synthetic biological switches 
should be able to switch a signal between two discrete states: ON and OFF. In the case of 
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electronic switches, the signal is electricity; in the case of biological switches, a biological 
signal propagates. A crucial difference between electronic and mammalian molecular 
switches lies in the complexity, spatial organization and mobility of constitutive parts and of 
interacting elements. Biological switches are part of systems that are far more complex, of 
fluid state and spatially mobile compared to the less-complex, well defined, solid state, 
spatially fixed and separated electronic circuits [74, 83]. Despite these tremendous 
detrimental differences, mammalian synthetic biological switches have been engineered to 
control, for example, artificial insemination in cows by hormones [84], T cell population in 
mice [85] and transgene expression in an oncolytic virus by theophylline [86]. In this study, 
ON-OFF switches in mammalian synthetic biology have been classified in 4 different 
categories based on the level where they intervene in the processing of the genetic signal; 
these 4 switch categories are illustrated below in Figure 2.1. 
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Figure 2.1. ON-OFF switches in synthetic biology and their regulatory location in genetic 
signal processing. ON-OFF switches can control either translation, post-translational, 
transcriptional or post-transcriptional events. 
 
A comprehensive list of ON-OFF switches is shown in Table 2.1 below. In the following 
subsections, mammalian synthetic biological switches will be presented that control the 
propagation and processing of biologicals signals from the DNA blueprint to the mature gene 
product. 
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Table 2.1. ON-OFF switches in mammalian synthetic biology. 
Switch 
Level
§
 
# Name 
ON 
Switch
¥
 
OFF 
Switch
£
 
Origin Effector
€
 Applications Ref 
T
ra
n
sc
ri
p
ti
o
n
al
 s
w
it
ch
es
 
1 ABA Yes No 
Arabidopsis 
thaliana, 
yeast 
Abscisic acid 
gene therapy, 
experimental tool to 
control diverse 
cellular activities in 
vivo 
[87] 
2 AIR Yes No 
Aspergillus 
nidulans 
Acetaldehyde 
gas-adjustable 
transgene expression, 
biopharmaceutical 
manufacturing 
[88] 
3 ART Yes No 
Chlamydia 
pneumoniae 
L-Arginine 
biopharmaceutical 
manufacturing, gene 
therapy 
[89] 
4 
BEARON, 
BEAROFF 
Yes Yes 
Campylobacte
r jejuni 
Bile acid 
gene and cell-based 
therapies 
[90] 
5 BirA-tTA No Yes 
Escherichia 
coli (E. coli) 
Biotin (vitamin H) 
biopharmaceutical 
manufacturing, cell 
therapy 
[91] 
6 BIT Yes No E. coli Biotin (vitamin H) 
gene therapy, tissue 
engineering, 
biopharmaceutical 
manufacturing 
[92] 
7 Cry2-CIB1 Yes No 
Arabidopsis 
thaliana, 
yeast 
Blue light 
protein translocation, 
transcription control, 
Cre-mediated DNA 
recombination using 
light 
[93] 
8 CTA, CTS Yes Yes 
Comamonas 
testosterone, 
Homo sapiens 
Food additives 
(benzoate, vanillate) 
gene- and cell-based 
therapy 
[94] 
9 cTA, rcTA Yes Yes 
Pseudomonas 
putida 
Cumate 
regulation of gene 
expression level and 
duration 
[95] 
10 Ecdysone Yes No 
Homo 
sapiens, 
Drosophila 
melanogaster 
Ecdysone 
transient inducible 
expression, gene 
therapy 
[96] 
11 EcR:RXR Yes No 
Homo 
sapiens, 
Locusta 
migratoria 
Ecdysone 
ligand-dependent 
induction of reporter 
gene, gene therapy 
[97] 
12 
Electro-
Genetic 
Yes No 
Aspergillus 
nidulans 
Electricity, 
Acetaldehyde 
electric power-
adjustable 
transcription control; 
mammalian cell-
based control of 
microelectronic 
[98] 
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circuits 
13 
ER- p65-
ZF 
Yes No 
Homo 
sapiens, yeast 
4,4'-dyhydroxybenzil 
generating a wide 
array of orthogonal 
gene switches 
[99] 
14 E.REX Yes Yes E. coli Erythromycin 
gene therapy, tissue 
engineering, in vivo 
gene-function 
analyses, drug 
discovery, 
biopharmaceutical 
manufacturing 
[100] 
15 EthR No  Yes 
Mycobacteriu
m 
tuberculosis 
2-Phenylethyl-butyrate drug discovery [101] 
16 GAL4-ER Yes Yes 
Yeast, 
Homo sapiens 
Estrogen, 4-
hydroxytamoxifen 
regulating 
heterologous genes, 
identifying Fos 
(oncogene) targets 
[102] 
17 GAL4-hPR Yes Yes 
Yeast, 
Homo sapiens 
Mifepristone 
positive and negative 
regulation of gene 
expression, also in 
vivo 
[103, 
104] 
18 
GAL4-
Raps 
Yes Yes 
Yeast, 
Homo sapiens 
Rapamycin and 
rapamycin derivatives 
targeted gene 
expression control 
[105] 
19 GAL4-TR Yes No 
Yeast, 
Homo sapiens 
Thyroid hormone 
study nuclear 
receptor signalling 
[106] 
20 GyrB Yes Yes E. coli 
Coumermycin, 
novobiocin 
rapid regulation of 
gene expression 
[107] 
21 HEA-3 Yes No Homo sapiens 4-hydroxytamoxifen gene therapy [108] 
22 Intramer No Yes 
Synthetic 
SELEX-
derived 
aptamers 
Theophylline 
controlling transgene 
expression, 
construction of 
complex gene 
networks 
[109] 
23 LacI Yes No E. coli 
Isopropyl-β-D- 
thiogalactopyranoside 
reversible regulation 
of gene expression, 
predictable levels of 
de-repressed gene 
expression 
[110-
114] 
24 LAD Yes No 
Arabidopsis 
thaliana, 
yeast 
Blue light 
light-controlled gene 
expression 
regulation; protein 
hetero- and homo-
dimerization induced 
by light 
[115] 
25 LightOn Yes No 
Neurospora 
crassa, 
yeast 
Blue light 
light-switchable 
transcription control 
[116] 
26 NICE Yes Yes Arthrobacter 6-Hydroxynicotine therapeutic cell [117] 
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nicotinovoran
s 
engineering, 
biopharmaceutical 
manufacturing 
27 PPAR* Yes No Homo sapiens Rosiglitazone gene therapy [118] 
28 PEACE No Yes 
Pseudomonas 
putida 
Flavonoids 
(e.g., phloretin) 
biopharmaceutical 
manufacturing, gene- 
and cell-based 
therapies 
[119] 
29 PIT Yes Yes 
Streptomyces 
coelicolor 
Pristinamycin I, 
virginiamycin 
compatible with the 
TetOFF system, thus 
two different gene 
activities can be 
controlled in the 
same cell 
[120] 
30 REDOX No Yes 
Streptomyces 
coelicolor 
NADH 
process development, 
biopharmaceutical 
manufacturing 
[121] 
31 QuoRex Yes Yes 
Streptomyces 
coelicolor, 
Streptomyces 
pristinaespira
lis 
Butyrolactones 
(e.g., SCB1) 
small molecule-
adjustable gene 
control systems for 
clinical application 
[122] 
32 ST-TA Yes Yes 
Streptomyces 
coelicolor, E. 
coli, Herpes 
simplex 
γ-butyrolactone, 
Tetracycline, 
Design of therapeutic 
gene circuits for gene 
and cell-based 
therapies 
[123] 
33 TIGR No Yes 
Streptomyces 
albus 
Temperature 
temperature-
inducible gene 
regulation 
[124] 
34 TraR Yes No 
Agrobacteriu
m 
tumefaciens 
N-(3-oxo-
octanoyl)homoserine 
lactone 
versatile gene 
expression control 
[125] 
35 
TET-OFF, 
TET-ON  
Yes  Yes 
E. coli, 
Herpes 
simplex 
Tetracycline, 
doxycycline 
reversible and tight 
gene expression 
control 
[126, 
127] 
36 TRT Yes No 
Chlamydia 
trachomatis 
L-Tryptophan 
synthetic 
bidirectional 
communication 
between mammalian 
cells 
[128] 
37 UREX Yes No 
Deinococcus 
radiodurans 
Uric acid 
self-sufficient control 
of pathologic 
metabolites, gene- 
and cell-based 
therapies 
[129] 
38 VAC Yes  Yes 
Caulobacter 
crescentus 
Vanillic acid 
biopharmaceutical 
manufacturing, gene- 
and cell-based 
therapies 
[130] 
39 ZF-ER, Yes Yes Mus 4-hydroxytamoxifen, spatiotemporal [131] 
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ZF-
RXR/EcR 
musculus, 
Homo 
sapiens, 
Drosophila 
melanogaster 
ponasterone-A control of gene 
expression, genomic 
and proteomic 
research, gene 
therapy 
40 ZF-Raps Yes No Homo sapiens Rapamycin 
gene expression 
control, gene therapy 
[132] 
41 
ZF 
switches 
Yes No 
Mus 
musculus, 
Homo 
sapiens, 
Drosophila 
melanogaster 
4-Hydroxytamoxifen, 
mifepristone 
study of gene 
function, alteration of 
phenotypes of cells 
or organisms 
[133] 
42 ZF(TF)s Yes No 
Xenopus 
laevis, Homo 
sapiens 
ethyl-4-
hydroxybenzoate, 
propyl-4-
hydroxybenzoate 
genomic and 
proteomic research, 
gene therapy 
[134] 
P
o
st
-t
ra
n
sc
ri
p
ti
o
n
al
 s
w
it
ch
es
 
1 
Aptamer 
RNAi 
Yes No 
Synthetic 
SELEX-
derived 
aptamer 
Theophylline 
Regulation of gene 
expression by small 
molecules without 
engineered proteins 
[135] 
2 
Aptamer 
RNAi 
No Yes 
Synthetic 
SELEX-
derived 
aptamer 
Theophylline 
construction of 
conditional RNAi 
systems 
[136] 
3 
Aptamer 
RNAi 
miRNA 
Yes No 
Synthetic 
SELEX-
derived 
aptamer 
Theophylline, 
tetracycline, 
hypoxanthine 
probing and 
programming of 
cellular function 
[137] 
4 
Aptamer 
Splicing 
Yes Yes 
Homo 
sapiens, MS2 
bacteriophage 
MS2, p65, p50, 
b-catenin 
programmable 
sensing-actuation 
devices for 
autonomous cell 
behaviour control 
[138] 
5 Aptazyme  No Yes 
Synthetic 
SELEX-
derived 
aptamer, 
Schistosoma 
mansoni 
theophylline 
regulation of 
therapeutic gene 
expression 
[86] 
6 
Replicon 
CytTS 
Yes No Sindbis virus Temperature 
expression of toxic 
proteins, bioprocess 
engineering 
[139] 
7 
TET-OFF-
shRNA, 
TET-ON-
shRNA 
Yes Yes 
E. coli, 
Herpes 
simplex, 
Homo sapiens 
doxycycline 
basic or translational 
research, 
development of 
gene-based 
therapeutics 
[140] 
8 
Theo 
Aptamer  
No Yes 
Synthetic 
SELEX-
Theophylline 
basic, 
biotechnological, and 
[141] 
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derived 
aptamer 
biomedical research 
9 
3’ UTR 
aptazyme 
Yes No 
Synthetic 
SELEX-
derived 
aptamers, 
tobacco 
ringspot virus 
Theophylline, 
tetracycline 
functional response 
regulation, gene and 
cellular therapy 
[85] 
10 
5’ UTR 
aptazyme 
No Yes 
Synthetic 
SELEX-
derived 
aptamer, 
Schistosoma 
mansoni 
Theophylline 
control of gene 
expression, gene 
therapy 
[142] 
T
ra
n
sl
at
io
n
al
 s
w
it
ch
es
 
1 
Hoechst 
Aptamer 
No Yes 
Synthetic 
RNA 
sequence 
Hoechst dyes 
Translational gene 
regulation, biology 
and medical research 
[143] 
2 
H23 
Aptamer 
No Yes 
Archaeoglobu
s fulgidus 
L7Ae, L7KK 
gene expression 
regulation, 
construction of a 
NOR gate 
[144] 
3 
L7Ae 
Aptamer 
Yes Yes 
Archaeoglobu
s fulgidus 
L7Ae 
detection, repair or 
rewiring of intrinsic 
cellular defects, 
characterization of 
complex circuits 
[145] 
4 
MS2 
Aptamer 
No Yes 
MS2 
bacteriophage 
MS2 
study RNA-protein 
interactions, clone 
RNA-binding 
proteins 
[146] 
P
o
st
-t
ra
n
sl
at
io
n
al
 s
w
it
ch
es
 
1 AID No Yes 
Arabidopsis 
thaliana, 
Oryza sativa, 
Gossypium 
hirsutum 
Auxins (e.g., IAA) 
control protein 
expression and study 
protein function 
[147] 
2 ER DD No Yes Homo sapiens 
CMP8, 4- 
Hydroxytamoxifen,  
regulate the 
intracellular 
concentration of any 
protein 
[148] 
3 FM Yes No Homo sapiens AP21998 
delivery of 
polypeptides that 
require rapid and 
regulated delivery 
[149] 
4 HaloTag No Yes 
Rhodococcus 
sp. RHA1 
HyT13 
validating potential 
drug targets in 
disease models 
[150, 
151] 
5 
HDV- 
aptazyme 
No Yes 
Hepatitis 
delta 
virus 
theophylline, guanine 
dynamic range of 
gene regulation 
[152] 
6 PROTAC No Yes Homo sapiens PROteolysis TArgeting chemical knockouts, [153] 
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Chimeric moleculeS 
(PROTACS) 
control of protein 
function  
7 Shield DD Yes No Homo sapiens Shields (e.g., Shld1) 
conditional control of 
proteins levels 
[154] 
8 Shield LID No Yes Homo sapiens Shields (e.g., Shld1) 
conditional control of 
proteins levels 
[155] 
9 TMP DD Yes No E. coli Trimethoprim (TMP) 
tuneable regulation 
of protein expression 
in the mammalian 
central nervous 
system 
[156] 
§ Level of gene expression where the switching occurs. 
¥ ON Switchability by an effector; other than removing the effector which confers the OFF state.  
£ OFF Switchability by an effector; other than removing the effector which confers the ON state. 
€ A ligand or other physical stimuli (e.g. temperature, electromagnetic radiation, electricity) which    
   stabilizes the switch either in its ON or OFF state. 
2.2.1.1.1 Transcriptional switches 
The first step towards a mammalian synthetic switch was the implementation of the lactose 
regulator, discovered in Escherichia coli in the early 1960s by Jacob and Monod [157], in 
mammalian cells in the late 1980s [110-113]. In this transcriptional control system, gene 
expression can be switched ON by adding the lactose analogue Isopropyl β-D-1-
thiogalactopyranoside (IPTG). When IPTG subsequently binds to the Lac repressor, it 
facilitates its dissociation from the lac operator DNA sequence in a dose dependent manner, 
and the expression of targeted genes downstream of the lac operator is switched ON [110].  
Following the inclusion of a prokaryotic transcriptional system into mammalian cells, the 
next step was the construction of the first mammalian synthetic transcription factor, the 
tetracycline-controlled transactivator (tTA), by Gossen and Bujard in 1992 [126]. This was 
achieved by fusing the prokaryotic tetracycline (Tet) repressor, TetR, with the C-terminal 
domain of virion protein 16 (VP16) from herpes simplex virus (HSV). Promoters responsive 
to tTA (Ptet) consist of heptamerized tetracycline operator (tetO) sequences and minimal 
promoters derived from viral or cellular RNA polymerase II promoters [126]. TetR and tetO 
sequences originate from the Tn10 transposon, natively present in Escherichia coli [126]. 
Consequently, genes downstream of Ptet are transcribed only in the presence of tTA. 
Doxycycline, a tetracycline analogue, binds to tTA with relatively high affinity. This 
promotes the dissociation of tTA from the heptamerized tetO DNA sequence, inhibiting the 
expression of the gene downstream of Ptet, setting the switch to the OFF state [158, 159]. A 
reverse tetracycline-controlled transactivator rtTA has also been created by point mutating 
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the tTA gene [127, 160]. These point mutations completely reverse the tetracycline 
responsiveness of rtTA: rtTA requires tetracyclines (or tetracycline derivatives) for binding to 
tetO sequences to set the switch to the ON state [127, 160]. The tTA dependent control circuit 
is also referred to as the Tet-Off System and the rtTA system is also known as the Tet-On 
System.  
Based on these developments and utilizing prokaryotic regulators, with DNA binding 
capacity controlled allosterically by small molecules, several mammalian transgene control 
switches have been developed [161, 162] (cf. Table 2.1). Switches controlled by antibiotics 
[95, 100, 163], hormones and hormone analogues [97, 108, 164], quorum-sensing substances 
[122], and immune suppressive and anti-diabetic drugs [118, 165] have recently been 
engineered expanding the arsenal of tools of synthetic biologists. 
The second generation of synthetic transcriptional switches are regulated by metabolites such 
as amino acids [89], vitamins [91], gaseous acetaldehyde [88], food and cosmetics additives 
[101, 166]. These second generation compounds may be used for regulating gene therapy 
more effectively than the previously mentioned small molecules, such as hormones, which 
have known and potent side effects. Moreover, mammalian transcriptional switches that 
respond to physical factors, such as electricity [98], temperature [167] and blue light [168-
170] have also been developed. Thus, synthetic biologists can already choose from a plethora 
of transcriptional switches to fulfil the requirements for various individual applications.  
2.2.1.1.2 Post-transcriptional switches 
The above mentioned transcriptional switches regulate the transcription of DNA into mRNA. 
Post-transcriptional switches control the stability or splicing of mRNA molecules. The innate 
molecular immune response to viruses and other foreign genetic material, RNA interference 
(RNAi), discovered in the 1990s and the subsequently developed RNAi technology allows 
control of the degradation of mRNA molecules (for a review on RNAi cf. [171]). RNAi 
involves the cleavage of double-stranded RNA molecules (normally occurring only in viruses 
[172]), such as short hairpin RNAs (shRNA), into 21–23 nucleotide long RNA duplexes by 
the endogenous enzyme Dicer. The obtained RNA duplexes are short interfering RNAs 
(siRNA) or micro RNAs (miRNA), if they fully or partially complement the sequence of a 
target RNA molecule, respectively. One of the two strands of these RNA duplexes is then 
incorporated into the RNA-induced silencing complex (RISC), which degrades 
complementary mRNA sequences to which the siRNA or miRNA of RISC binds to, leading 
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to mRNA degradation and post-transcriptional repression. Post transcriptional switches can in 
principle be engineered by switch-controlled generation of siRNA and miRNA molecules. A 
switch has been developed which regulates the expression of shRNA by doxycycline and the 
resulting shRNA controls the expression of a transgene in vitro and in vivo [173]. 
Post transcriptional switches can also be achieved by employing aptamers. Aptamers are 
small, single-stranded, highly-folded nucleic acids with high affinity and specificity for their 
target molecules (small molecules or protein ligands), which inhibit their biological functions 
[174]. By integrating aptamers into siRNA or miRNA, sophisticated switches have been 
obtained in which the RNAi function is ligand-controlled [135-137]. By integrating a 
theophylline-biding aptamer into an essential structural loop of a shRNA, the processing of 
the shRNA by Dicer could be inhibited by adding theophylline which modified the structure 
of the shRNA, thus the RNAi function was modulated by theophylline concentration [135]. 
Gene expression has also been regulated by controlling mRNA splicing using an aptamer. For 
this, the theophylline-biding aptamer was used to cloak an essential spicing element within 
the pre-mRNA, inhibiting splicing in the presence of theophylline [175]. Aptamers have also 
been applied to regulate transcription factor function in a ligand dependent manner [176].  
An aptamer (sensor) together with a ribozyme (actuator) forms an aptazyme (also called 
allosteric ribozymes). The ribozyme part is an RNA molecule with enzymatic function, 
capable of catalysing specific biochemical reactions. In the presence of a ligand that binds to 
the aptamer, the ribozyme part of the aptazyme self-cleaves and functionality is induced. 
Thus, aptazymes can also act as post-transcriptional switches. For instance, by incorporating 
an aptazyme into the 5’ or 3’ untranslated region (UTR) of an mRNA, the 5’ and 3’ UTR 
structural elements necessary for gene expression can be chopped off, in a ligand dependent 
manner, thereby inducing ligand-controlled silencing of gene expression [177-179].  
2.2.1.1.3 Translational switches 
Once the mature mRNA reaches the ribosomes, translation of the mRNA into amino acid 
chains or proteins begins. At the translational level, further control switches have been 
engineered to regulate the expression of genes into proteins. For this, RNA-binding proteins, 
such as the archaeal ribosomal protein L7Ae, can be switched on by an input protein to block 
translation, by binding to an RNA motif integrated in the 5’ untranslated region of an mRNA 
transcript [180, 181]. An aptamer controlled by the Hoechst 33258 dye has also been shown 
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to inhibit translation in the presence of Hoechst 33258, thus function as a translational switch 
[182]. 
2.2.1.1.4 Post-translational switches 
Following the translation of mRNA into proteins, at the post-translational level, switches 
have been developed to control the half-life of proteins or protein trafficking. To degrade a 
protein, the protein in question is tagged with a degradation signal and it reaches the 
endogenous ubiquitin-proteasome system, where it is degraded. As an example, an auxin-
inducible protein degradation system from plants was shown to degrade proteins of interest in 
mammalian cells under the control of auxin [183]. Destabilized or ligand induced degradation 
protein domains can be fused to a target protein to control the degradation of the entire fusion 
protein [184-188]. A noteworthy example is the HaloTag system [150, 151] which involves 
the fusion of a dehalogenase enzyme to the protein of interest. By adding small hydrophobic 
molecules that covalently bind to the HaloTag, the fusion protein unfolds and is efficiently 
degraded by the proteasome. Recently switches have also been developed to control protein 
secretion [189] (see also Figure 1). 
Another type of post-translational switch involves inteins. An intein (also known as protein 
intron) is a segment within a protein which is capable to excise itself, whilst the remaining 
protein segments (the exteins) are joined with a peptide bond in the process of protein 
splicing [190, 191]. Since inteins are transcribed and translated together with the target 
protein before they undergo autocatalytic self-excision and splicing, inteins increase the time 
it takes to transcribe, translate and post-translationally process a target gene. The intein 
domain can be transcribed and translated by two separate genes (known as split inteins) and 
the resulting precursor proteins splice each other, process termed trans-splicing, to yield a 
single functional protein [192, 193]. The protein splicing and trans-splicing processes can be 
triggered by small molecules or protein inputs to obtain intein based post-translational 
switches [194-197]. 
Most synthetic gene circuits developed to date employ digital logic. However, there has been 
rising interest in the design and implementation of analog synthetic gene circuits. These 
circuits allow for the construction of multi-signal integration and are able to execute complex 
computational functions in living cells, such as ratiometric operations, power-law 
implementations, logarithmically-linear sensing, amongst others [198, 199]. 
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2.2.1.2 Synthetic gene networks as standardized parts 
Synthetic biological ON-OFF switches and/or a set of genes can be rationally selected and 
combined, to interact in a predictable and controllable manner, forming a system with a pre-
set function, a synthetic gene network, also known as synthetic gene circuit, Figure 2.2. Thus, 
a gene network consist of a set of genes, rationally selected and combined, such that they 
interact in a predictable and controllable manner, forming a system with a distinct function. 
In order to rationally construct higher-order gene networks for advanced therapeutic 
applications, a toolbox of well-characterized and well-controllable standardized parts should 
be available. The following subsections present gene networks that were developed to 
function as standardized parts in a higher-order gene network. In some cases, these simple 
gene networks are also used as therapies. 
2.2.1.2.1 Boolean logic gates 
In order to perform logical operations in mammalian cells, in the same way as in computer 
sciences, programmable Boolean logic gates were constructed in 2004, by combining four 
heterogeneous transcription factors [200]. Topologies for AND, OR, NOT and NOR gates are 
shown in Figure 2.2A. Additionally to gating and similarly to electronic circuits, several 
multicomponent circuits with complex trigger-controlled topology have been designed with 
time-delay [201], band-pass [202] and hysteretic [203] properties. A gene network operated 
by a Boolean AND gate was applied for targeting cancer cells [204]. In this AND gate 
operated network, when both of the pre-set conditions are met, the death of targeted cell is 
promoted by the expression of apoptotic genes. 
Boolean logic gates have also been engineered based on synthetic transcription factor-
containing zinc finger motifs and Clustered Regularly Interspaced Short Palindromic Repeats 
( CRISPR)/Cas9 motifs [205]. These are attractive parts for engineering higher-order 
networks because (1) zinc fingers and CRISPR/Cas9 can be created to recognize virtually any 
DNA sequence, and (2) they can function without interfering with each other. Indeed, the 
bacterial CRISPR /Cas system has been shown to be particularly versatile and easy to use. 
Many bacteria use CRISPR-based immune systems to degrade genetic materials of invading 
phages [206, 207]. In these systems, short RNAs expressed from CRISPR loci are used to 
guide an endonuclease protein (Cas9) to recognize and cleave invading genetic material. 
Recently, Cas9 was used as a programmable tool for genome editing in mammalian cells 
[208-210]. In this context, small customizable guide RNAs (gRNAs) can be designed to 
program and target Cas9 endonuclease to specific loci in living cells to induce double (or 
Synthetic gene network for monitoring shear stress sensor activity in endothelial cells 
68 
 
single)-stranded breaks in DNA. Upon cleavage, error-prone or template-directed repair 
pathways are triggered, generating variants of the original target loci. Recently, Qi et al. [211] 
showed that an endonuclease-deficient Cas9 (dCas9, with D10A H841A mutations relative to 
the wild-type Cas9) can be used as a programmable “CRISPRi” tool for gene silencing in 
Escherichia coli. Several groups have shown that dCAS9/gRNA can be used to inhibit or 
partially stimulate synthetic or endogenous mammalian genes, when dCAS9 was fused to an 
actuator (VP64), depending on the position of gRNA binding with respect to the TATA 
box[212-214]. Inhibitory circuits in mammalian cells have recently been introduced using 
dCAS9 systems [209, 215, 216]. Recently, CRISPR regulatory devices were layered to obtain 
cascaded circuits [217], and the expression of functional gRNAs from RNA polymerase II 
promoters (normally expressed from RNA polymerase II promoters) and multiplexed 
production of proteins and gRNAs from a single transcript in human cells was made possible 
[218]. 
2.2.1.2.2 Synthetic mammalian toggle switch 
In the synthetic biological switches presented so far, the switching molecule should be 
continuously present in order to maintain the switch in either the ON or OFF state. In analogy 
with electrical switches, this means that one should keep holding on to the switch after having 
switched for example the light to ON or OFF. To reversibly set the switch to ON or OFF 
positions by transiently applying a trigger molecule, toggle switches have been developed 
[100, 120, 219, 220]. Toggle switches have been employed to monitor the environment of 
immune cells in lymph nodes or the presence of hormones or signalling molecules. A 
mammalian toggle switch is topologically represented in Figure 2.2B. 
2.2.1.2.3 Synthetic mammalian oscillators 
Although, more complex in network topology, synthetic mammalian oscillators, Figure 2.2C, 
constitute synthetic biological parts that can be integrated into higher order circuits or applied 
alone to reprogram circadian clocks [221, 222] in order to govern metabolic [223], repair 
[224] and signalling pathways [225] in mammalian cells. Such a synthetic mammalian 
oscillator has been developed using a positive feedback loop and a time-delayed negative 
feedback loop controlled at the transcription level to generate autonomous, self-sustained and 
tuneable oscillatory expression of reporter genes [226]. A low-frequency mammalian 
oscillator has also been developed by silencing of the tetracycline-controlled transactivator 
using siRNA encoded in the introns of the mRNA to facilitate robust and autonomous 
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expression of a fluorescent reporter protein with periods of 26 hours [227]. Currently, in our 
group, work in ongoing to engineer a synthetic mammalian oscillator with higher oscillatory 
period and amplitude uniformity, and with improved tunability and robustness (assessed by 
the percentage of cells exhibiting the expected oscillatory behaviour). 
All of these synthetic biological control circuits described in this subsection contribute to the 
development of mammalian cell biocomputers [199] and gene networks with advanced 
functions, described in the following subsections. 
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Figure 2.2. Gene networks in mammalian synthetic biology. A. Boolean logic gates. The 
exemplified AND gate consists of two gene expression activators, under the control of two 
input signals, to enable gene expression (output) only when both activators are switched on 
by the input signals. The OR gate is formed by two gene expression activators, regulated by 
two input signals, that output gene expression when wither one of the activators is switched 
ON. The NOT gate is composed of a repressor that shuts down the expression of a target gene 
in response to an input signal. Two repressors controlled by two input signals can form a 
NOR gate to inhibit gene expression when either one the two repressors is activated. B. 
Toggle switch. The exemplified network is formed by two trans-acting repressors that inhibit 
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each other’s expression in response to input signals. An input signal applied for a short period 
of time sets the toggle switch into one of its predetermined states. The reporter gene can be 
fused to either repressors or be under the control of these repressors. C. Oscillator. The 
exemplified system is composed of two activators and a repressor. The first activator is cis-
acting and is also trans-triggering expression of the second activator. The second activator 
then switches on the expression of the repressor. The repressor feeds back with a time-delay 
to inhibit expression of the first activator, generating oscillations in the concentrations of the 
first activator over time. In the exemplified network the reporter gene is fused to the first 
activator, but it could also be regulated by this activator. 
2.2.1.3 Synthetic gene networks for advanced medical applications 
One of the ultimate goals of mammalian synthetic biology is to improve human health. For 
this purpose, gene networks that contribute to the diagnosis and/or treatment of diseases are 
emerging and/or have been already developed. The application of these gene networks in 
health care is illustrated in Figure 2.3 below.  
2.2.1.3.1 Synthetic gene networks for cancer therapy 
Along these lines, a gene network has been created that enables the tracking of human cell 
fate by retaining memory of exposure to stimuli [228]. In these memory circuits, a brief 
doxycycline, UV and hypoxia stimuli up-regulates the expression of a synthetic transcription 
factor that subsequently induces the expression of a reporter gene and positive feedback loop 
which amplifies the generation of the reporter. This memory circuit can change gene 
expression, growth rates and cell viability for several generations after the initial stimulus. 
A slightly more elaborate circuit has been designed to detect cell line lineages [229]. This 
multi-input RNAi-based Boolean logic circuit identified the presence of HeLa cells by the 
expression levels of a customizable set of endogenous miRNAs. When these pre-determined 
conditions are met, a fluorescent signal or an apoptosis signal is triggered, leading to the 
diagnosis or death of the targeted cells. This offers unique capabilities to monitor complex 
miRNA dynamics in cells under a wide variety of conditions. Similarly, in order to target 
cancer cells, a tunable dual-promoter integrator has been developed, which expresses an 
effector gene when two internal input promoters show high activity levels [204]. Existing and 
potential synthetic biological applications for diagnosis are illustrated in Figure 2.3A. 
In order to control cellular behaviour, a synthetic gene network has been engineered which 
interfaces with native cellular pathways [138]. For this, a class of RNA controllers have been 
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constructed to perceive innate signalling through the nuclear factor κB and Wnt signalling 
pathways in human cells and rewire these signalling cascades to generate new behaviour by 
regulating alternative RNA splicing. This way, disease markers can be linked to non-invasive 
detection and re-programmed cell fates. Therapeutic applications of synthetic biology are 
illustrated in Figure 2.3D. 
2.2.1.3.2 Synthetic gene networks for diabetes and other metabolic disorders treatment 
A synthetic signalling cascade has been developed which controls blood glucose homeostasis 
by illumination with blue light [230] in order to threat type 2 diabetes which is characterized 
by high blood glucose due to insulin resistance or due to relative insulin deficiency [231]. To 
tackle insulin deficiency, an insulin expression mammalian gene network under the control of 
radio waves was also developed [232].  
A therapeutic gene network which is capable of sensing host metabolic parameters and 
respond to return parameters to normal levels, without external input, has been developed as 
well. This self-sufficient, sensor-effector gene network senses uric acid concentrations in 
blood and expresses urate oxidase in a uric acid dependent manner. Urate oxidase then 
restores urate homeostasis [129]. 
2.2.1.3.3 Synthetic gene networks for enhancing the mammalian immune system 
T cells (also known as T lymphocytes) are a type of white blood cells that play a crucial role 
in cell-mediated immunity, especially in the response to invading pathogens. Human T cells 
are important targets for synthetic biology because they can be extracted from patients, 
genetically engineered, and inserted back into patients to treat chronic infection or cancer 
[233]. A synthetic, drug-responsive, RNA-based switch has been implemented to control 
cytokine expression in mice, in turn governing T cell proliferation [179]. In this system the 
input ligands and regulatory targets can be modified to meet various therapeutic needs. T 
cells were also reprogrammed for tumour immunotherapy [234].  
2.2.1.3.4 Synthetic gene network for the treatment of cardiovascular disease 
In addition to the above described RNA-based switch, a synthetic signal cascade has been 
developed in order to confront multiple risk factors of cardiovascular disease simultaneously 
[235]. In this circuit, the chimeric trace-amine-associated receptor 1, activated by the 
clinically licensed antihypertensive drug guanabenz (Wytensin
®
), is coupled to cAMP and 
cAMP-dependent phosphokinase A (PKA)-mediated activation of the cAMP-response 
element binding protein (CREB1). After activation, CREB1 drives the expression of bi-
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functional therapeutic peptide hormone GLP-1-Fc-Leptin which attenuates hyperglycemia 
and dyslipidemia. Thus, this gene network adds to the antihypertensive effect of Wytensin
®
 
two other functions to create a three-in-one treatment strategy for cardiovascular diseases 
[235]. 
 
Figure 2.3. Synthetic biology enlightens the health care spectrum from diagnosis of diseases, 
to drug screening, biomanufacturing and to therapy. A Synthetic biology can be applied to 
diagnose diseases either by inserting gene circuits into the human body or into patient-
derived cells. Alternatively, viruses, bacteria or mammalian cells can be used as synthetic 
network carriers and added to patient-derived tissue or body fluids. In either case, the 
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diagnostic synthetic network should recognize diseased stated and generate a measurable 
readout in response to the disease. B. Following disease diagnosis, synthetic biology can also 
be applied to screen for pharmaceutical compounds to combat diseases. In this case, synthetic 
circuits inserted into various organisms should mimic disease related states and the alteration 
of these states by added compounds should yield a measurable readout. Synthetic gene 
networks can also be applied to monitor the activation or inactivation of trans-membrane 
receptor, which are potential drug targets. Additionally, synthetic biology holds great 
promises to screen for vaccines 199. C. After pharmaceuticals are identifies, synthetic 
biology can significantly enhance the manufacturing of these pharmaceuticals and other 
biologics. D. Last but not least, synthetic biology enhances state-of-the-art treatments such as 
gene therapy, cell therapy, Chimeric Antigen Receptor (CAR) T-Cell immunotherapy, 
bacterial based therapy for cancer and other diseases, and bacteriophage based therapy of 
infectious diseases. 
2.2.1.4 Synthetic gene networks for drug discovery 
For tackling diseases, besides applying synthetic biology to modify or reprogram genetic 
material, mammalian synthetic gene networks can be developed which can aid finding 
pharmaceutical compounds. This therapeutic approach has the advantage of not modifying 
the genetic material of the treatment subject, thus reducing the severity of controversial 
ethical issues [236-238]. Applications of synthetic biology for pharmaceutical compound 
screening are illustrated in Figure 2.3B. 
2.2.1.4.1 Synthetic gene networks for antibiotic screening 
An early example for this approach is the employment of a streptogramin-controlled 
transcriptional switch [120] for the identification of bioavailable, non-cytotoxic streptogramin 
antibiotics [239]. This streptogramin-controlled transcriptional switch contains a protein 
domain which is involved in conferring the antibiotic resistance. By adding libraries of 
metabolic compounds to cells that contained the streptogramin-controlled switch, new 
streptogramin antibiotics were identified which modified the transcription activity of the 
switch.  
Another example is the development of a drug discovery circuit that led to the identification 
of antituberculosis drugs [101]. In Mycobacterium tuberculosis, ethionamide activator (EthA) 
converts the pro-drug ethionamide into an antimycobacterial nicotinamide adenine 
dinucleotide derivative which is effective against Mycobacterium tuberculosis [240]. The 
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expression of the EthA is inhibited by the ethionamide repressor (EthR), increasing the 
resistance of this pathogen to ethionamide, the last-line-of-defence in treatment [240]. In the 
antituberculosis drug discovery gene network, the activity of EthR is monitored and a 
screening for compounds that inhibit EthR was carried out to identify the food additive 
‘‘strawberry ﬂavour’’ (2-phenyl ethyl butyrate) as a new line of defence against multidrug-
resistant Mycobacterium tuberculosis [101].  
2.2.1.4.2 Synthetic gene network for anti-cancer drug screening 
A gene network which allows screening for anticancer drugs has also been developed [241, 
242]. Cancer is characterized by uncontrollably proliferating cells in tissues where cells are 
arrested in the resting phase (G0) or growth 1 (also known as gap 1, G1) phases of their cell 
cycle. In order to treat cancer, proliferating cancer cells should be targeted and destroyed 
without adversely affecting healthy tissue. For this, a mammalian synthetic gene network was 
developed which expressed the cyclin-dependent kinase inhibitor (p27
Kip1
) under the control 
of tTA to arrest mammalian cells in their cell cycle in a tetracycline-dependent manner. 
Chinese hamster ovary cells containing this gene circuit grow normally in the presence of 
tetracycline, which inhibits tTA and thus, p27
Kip1
 expression is switched OFF. When 
tetracycline is removed, tTA promotes the expression of p27
Kip1
 and cells are arrested in the 
G1 phase. By maintaining p27
Kip1
 expression for prolonged periods, a fraction of cells escape 
the arrest in their G1 phase and resume growth. This way, similarly to cancer development, a 
mixed cell population is obtained which contains proliferating and proliferation-arrested 
cells. Approved cancer therapeutics killed proliferating cells, without affecting growth-
arrested cells. Therefore, cells with this gene network led into this mixed population could be 
used for the screening of compounds that selectively kill neoplastic cells [241, 242]. 
2.2.1.4.3 Synthetic gene network for assaying receptor activation 
In addition to screening for anti-cancer drugs and antibiotics, gene circuits for identifying 
compounds that modify the activity of cell membrane receptors are also are prioritized on 
being engineered. Cell membrane receptors are extremely important drug targets. In fact, one 
family of plasma membrane receptors, G protein-coupled receptors (GPCRs), represent the 
core drug target in modern medicine [243]; over 50% of all prescription drugs currently on 
the market act on GPCRs [244]. Only approximately 50 members out of the approximately 
1000 members of the large GPCR family are currently targeted by drugs [245]. Therefore, 
developing drugs that target GPCRs represents an important weapon in the fight against 
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diseases. A common approach for finding GPCR targeting drugs is to screen for compounds 
that modify the activity of GPCRs. Although receptor activation assays have already been 
developed [246], synthetic biology offers possibilities to improve the efficiency and 
controllability of receptor activation monitoring.  
A synthetic gene network has been established which records the activation of plasma 
membrane receptors such as G protein-coupled receptors (GPCRs), receptor tyrosine kinases 
and steroid hormone receptors [247]. The activation of these plasma membrane receptors is 
coupled to secondary messengers, which then promote the transcription of a firefly luciferase 
reporter gene. This circuit was used to identify a ligand for the orphan G protein-coupled 
receptor 1 (GPR1), suggesting that this receptor is involved in the regulation of inflammation 
[247]. 
2.2.1.5 Synthetic biology in biomanufacturing 
Another human health improving application of synthetic biology that does not modify the 
genetic material of patients, is the manufacturing of biotherapeutics. Although a large 
proportion of biomanufacturing is carried out in bacteria, some products need to be 
manufactured in mammalian cells, predominantly those from the area of biopharmaceuticals. 
A common example for biomanufacturing in mammalian cells is the production of 
monoclonal antibodies [248, 249]. In general, mammalian proteins that require mammalian-
specific post translational modifications such as glycosylation, carboxylation, hydroxylation, 
sulfation and amidation, etc. are needed to be expressed in mammalian cells. When 
expressing proteins in mammalian cells, the rate limiting step seems to be the folding and 
secretion of the protein of interest. Mammalian synthetic biology was also employed to 
engineer protein folding and secretion for the manufacturing of recombinant protein 
biopharmaceuticals [250, 251]. Synthetic biological applications for biomanufacturing are 
illustrated in Figure 2.3C. 
2.2.2 Mammalian endothelial shear stress sensors 
After having a clear view on mammalian synthetic biological parts and networks, the 
identification of a model shear stress sensor became the next objective. Numerous plasma 
membrane molecules and cellular micro-domains on the basal, junctional and luminal 
surfaces of endothelial cells have been proposed to detect and respond to shear stress. These 
include: G-proteins [252], G-protein coupled receptors [253], ion channels [254], receptor 
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tyrosine kinases [255, 256], xanthine oxidoreductase [257], nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase [258], platelet EC-adhesion molecule (PECAM-1) 
[259], vascular endothelial (VE)-Cadherin transmembrane proteins [260], integrins and focal 
adhesion proteins [261, 262], caveolae [263], primary cilia [264, 265], the apical glycocalyx 
[266-268], the cytoskeleton [269], and the cytoplasmic membrane [270, 271]. The molecular 
mechanisms by which these shear stress sensors are activated by shear stress are not fully 
understood. After shear stress sensing, these sensors activate complex and interconnected 
signalling cascades within the cell, which lead to modification in the activity of genes (i.e. 
up- or down-regulating gene expression). These complex signalling cascades are not well 
characterized either. In the following subsections, various types of shear stress sensors will be 
reviewed. 
2.2.2.1 G-protein coupled receptors (GPCRs) as shear stress sensors 
Shear stress generated by the flow of blood affects directly the luminal surface of endothelial 
cells. On this surface of endothelial cells, numerous receptor proteins, embedded in the 
plasma membrane, are found, including G-protein coupled receptors (GPCRs). GPCRs are 
also known as seven-transmembrane domain receptors, 7TM receptors, heptahelical 
receptors, serpentine receptor, and G protein-linked receptors. They are the largest family of 
membrane proteins in the human genome, with approximately 1000 members [272], and the 
most important source of targets for the pharmaceutical industry [273]. GPCRs regulate 
virtually all known physiological processes in humans [274]. The importance of the research 
performed on this protein family was also recognized by the Nobel committee and the 2012 
Nobel Prize in Chemistry was awarded jointly to Robert J. Lefkowitz and Brian K. Kobilka 
"for studies of G-protein-coupled receptors" [275].  
All GPCRs consist of 7 hydrophobic transmembrane (TM) segments, the amino terminus 
being extracellular and the carboxyl terminus is inside the cell. The highest homology among 
GPCRs can be found within their hydrophobic TM segments. The structural features with the 
highest variation between GPCRs are the intracellular carboxyl terminus, the intracellular 
loop spanning TM5 and TM6 and the extracellular amino terminus. The length of the amino 
terminus varies greatly in between GPCRs: it is 10–50 amino acids in case of monoamine and 
peptide receptors, 350–600 amino acids long for glycoprotein hormone receptors and the 
glutamate family receptors, and even larger in case of adhesion family receptors [273]. 
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The extracellular binding location of ligands that activate GPCRs has been determined for 
some GPCRs [276], however, the size of the ligands alone cannot be used to predict the 
binding site [273]. GPCRs are activated when an agonist (defined as ligands that fully 
activate the receptor) diffuses to into and binds to an unliganded receptor. Ligand-free 
receptors possess some basal activity, which can very drastically among GPCRs [277-279]. 
In general, upon GPCR activation, the most pronounced common structural change that 
occurs, is the rotation and tilting, also described as an outward “swinging”, of TM helix VI in 
the intracellular side relative to TM helix V [280-283]. TM helices III and VII also change 
location when GPCRs are activated [283, 284]. The movement of TM helix VI with respect 
to TM helix V seems to be essential for G protein binding and activation [285]. The 
conformational change resulting in the translocation of TM helices III and VII may play a 
role in G protein independent signalling (such as signalling mediated by arrestins and 
kinases) [286].  
Opposed to the occurrence of only two conformational states in GPCRs (one active and one 
inactive) as previously considered, evidence showing the existence of multiple 
conformational states in GPCRs is accumulating [287]. Vibrating GPCRs are stabilized in 
their active conformation by agonist binding and couple to heterotrimeric G-proteins. 
Activated G-proteins then initiate the generation of secondary messengers such as cyclic 
adenosine monophosphate (cAMP), calcium, or phosphoinositides. It is becoming clear that, 
rather than signalling through linear cascades, GPCRs activate complex and interconnected 
signal transduction pathways [288, 289], some GPCRs couple to several G-protein subtypes 
[290, 291], while others signal independently of G-proteins [292]. 
Besides heterotrimeric G proteins, two protein families specifically interact with the majority 
of GPCRs in their activated conformational state: G protein–coupled receptor kinases 
(GRKs) and arrestins [293]. There are 7 GRKs types in total [274]. There are 4 arrestins types 
in total, 3 dimensional crystal structures are available for all 4 of them [274]. All arrestins 
share the same fold, they all consist of two domains (amino and carboxyl terminal domains), 
made up almost entirely of antiparallel beta sheets, connected by a flexible hinge region and 
stabilized by a polar cord [274]. Until recently, the main function of GRKs and βArrestins 
was considered to be inactivation (known as desensitization), internalization, and recycling of 
GPCRs [294]. Over the past decade, accumulated new data placed GRKs and βArrestins 
under the light of G protein–independent signal transducers [293, 295, 296]. Particularly, 
βArrestins interact with multiple protein partners [297] and protein kinases, thereby causing 
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the phosphorylation of many intracellular targets [298]. βArrestin possesses a plethora of 
roles. βArrestin signalling mediates RhoA-dependent stress fibre formation [299]; inhibition 
of nuclear factor κB (NF-κB)-targeted gene expression [300]; protein phosphatase 2A 
(PP2A)-mediated dephosphorylation of AKT, which activates glycogen synthase kinase 3 
and dopaminergic behaviour [301]; extracellular signal-regulated kinase (ERK)-dependent 
initiation of protein translation [302] and antiapoptotic effects [303]; Kif3A-dependent 
trafficking and activation of the protein Smoothened in the primary cilium [304]; and 
phosphatidylinositol 3-kinase (PI3K)-mediated phospholipase A2 (PLA2) activation and 
increased vasodilation [305].  
GPCRs were classified into the following 5 families based on sequence similarity within their 
7 transmembrane segments: the rhodopsin family, the adhesion family, the frizzled/taste 
family, the glutamate family, and the secretin family [306]. GPCRs are versatile sensors for 
photons, lipids, neurotransmitters, hormones and sensory stimuli such as taste, smell, touch 
[285, 307]. Approximately half of all GPCRs are predicted to be olfactory sensors [306]. The 
physiologic function of a large fraction of GPCRs is unknown; these receptors are called 
orphan GPCRs. However, de-orphanization is ongoing, thus the number of orphan GPCRs is 
being reduced [282, 308]. 
At the moment, there is evidence that 6 GPCRs are sensitive to shear stress. These 6 GPCRs 
are summarized in Table 2.2 below, showing their name, organism and cell type in which 
they have been observed, G-proteins which they couple to, agonists, antagonist, whether they 
have known three-dimensional structures, as well their physiological function. Five of these 
six GPCRs, the B2 bradykinin receptor, six GPCRs, the B2 bradykinin receptor, formyl 
peptide receptor 1, dopamine receptor D5, sphingosine-1-Phosphate receptor 1 and G protein-
coupled estrogen receptor 1, are members of the rhodopsin GPCR family [306]. The sixth, 
the parathyroid hormone receptor 1, is a member of the secretin GPCR family [306].  
The B2 bradykinin receptor is a receptor for bradykinin. These 9 amino acid long peptides 
activate sensory fibres, induce the release of cytokines, contract venous smooth muscle, 
promote connective tissue proliferation and facilitate endothelium-dependent vasodilation 
[309, 310]. Inflammation, asthma, mild pain and endotoxic shock is treated with bradykinin 
antagonists. The B2 bradykinin receptor couples to Gq and Gi proteins. Gq stimulates 
phospholipase C to increase intracellular free calcium [311] and Gi inhibits adenylate cyclase 
[312-314]. This GPCR also stimulates the mitogen-activated protein kinase pathways 
(MAPK) [315]. The B2 bradykinin receptor forms a complex with angiotensin converting 
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enzyme (ACE) at the plasma membrane [316], and this is considered to link the renin-
angiotensin system (RAS) and the kinin-kallikrein system (KKS) [317]. The B2 bradykinin 
receptor also forms a complex and interacts with PECAM-1 [318]. The mitogen-activated 
protein kinase (MAPK) pathways are also induced by the B2 bradykinin receptor [315]. The 
B2 bradykinin receptor was proven to be activated by shear stress by time-resolved 
fluorescence microscopy and GPCR conformation-sensitive fluorescence resonance energy 
transfer (Förster resonance energy transfer, FRET) under stimulation of endothelial cells with 
fluid shear stress, hypotonic stress, or membrane fluidizing agents [319]. 
The formyl peptide receptor 1 is a high affinity receptor for N-formyl-methionyl peptides, 
which are powerful neutrophil chemotactic factors [320, 321]. Binding of formyl-methionyl-
leucyl phenylalanine to the formyl peptide receptor 1, triggers multiple signalling cascades by 
activating phospholipase A2, phospholipase C and phospholipase D. These signalling 
cascades couple to and control chemotaxis [322], phagocytosis [323], activation of 
transcription factors (such as the nuclear factor-κB) [324] and production of proinflammatory 
mediators [325]. Fluid shear stress caused the retraction of pseudopods in neutrophils 
mediated by the formyl peptide receptor 1, indicating that the formyl peptide receptor 1 acts 
as a shear stress sensor [326]. 
The parathyroid hormone receptor 1 senses parathyroid hormone and the parathyroid 
hormone-like peptide. The activity of this receptor is mediated by G proteins which activate 
adenylyl cyclase and also a phosphatidylinositol-calcium second messenger system [327, 
328]. The parathyroid hormone receptor 1 was shown to be ligand-independently activated by 
shear stress using time-resolved fluorescence microscopy and GPCR conformation-sensitive 
FRET when stimulating endothelial cells with fluid shear stress or membrane fluidizing 
agents [329]. 
The neurotransmitter and hormone dopamine is the primary endogenous ligand for dopamine 
receptors. Dysfunction of dopamine mediated neurotransmission has been linked with a 
variety of neuropsychiatric disorders, thus dopamine receptors are common drug targets [330, 
331]. The activity of dopamine receptor D5 is mediated by G proteins which in turn activate 
adenylyl cyclase [332]. It was shown that dopamine receptor D5 mediates the response of 
primary cilia to shear stress; activating this GPCR increases cilia length and restores cilia 
function in mutant cells, on the other hand, silencing dopamine receptor D5 completely 
abolishes the shear stress sensitive function of the cilia [333]. 
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Sphingosine-1-phosphate receptor-1 (S1pr1) senses sphingosine 1-phosphate (S1P). 
Activated platelets and other cell types release S1P in response to growth factors and 
cytokines [334]. S1P is involved in regulating inflammation, angiogenesis, heart-rate and 
tumour progression. S1pr1 could play a role in a number of disease states, such as 
atherosclerosis, and breast and ovarian cancer [334]. Sphingosine-1-phosphate receptor-1 is 
widely expressed in the brain, heart, lung, liver and spleen [335]. When activated by S1P, the 
receptor couples to Gi1, Gi2, Gi3, Go and Gz type G proteins, inhibiting adenylyl cyclase, 
phospholipase C activation and MAPK activation [334, 336]. Antagonism and shRNA-
induced down-regulation of sphingosine-1-phosphate receptor-1 block the effects of shear 
stress in endothelial cells, whereas overexpression of sphingosine-1-phosphate receptor-1 
restored the flow response in antagonised cells [337]. These data indicates that flow-mediated 
signalling and morphological changes require sphingosine-1-phosphate receptor-1 and that 
flow activates this GPCR in a ligand-independent manner [337]. 
G protein-coupled estrogen receptor 1 binds estrogen with high affinity and leads to the rapid 
and transient activation of numerous intracellular signalling pathways [338]. Promotes cAMP 
production, calcium mobilization and tyrosine kinase Src, stimulating the release of heparin-
bound epidermal growth factor (HB-EGF) and subsequent transactivation of the epidermal 
growth factor receptor (EGFR), inducing downstream signalling pathways such as 
PI3K/AKT and ERK/MAPK [338-341]. The expression of G protein-coupled estrogen 
receptor 1 from cDNA were up-regulated in response to shear stress in endothelial cells, 
indicating that this GPCR may play a role in regulating endothelial function under 
physiological blood flow conditions [342]. 
 
Table 2.2. Summary of shear stress sensitive GPCRs 
# Name Organism 
G-protein 
Coupling 
Cell type 
3.D. 
Struct.
¥
  
Activator 
ligand
§
 
Inhibitor 
ligand
§§
 
Function Ref. 
1 B2 
bradykinin 
receptor 
 
Human, 
mouse, 
rat, 
zebrafish, 
chicken, 
cattle, 
dog, pig, 
rainbow 
trout, etc. 
Gi, 
Gq/11 
Endothelial, 
smooth 
muscle cells 
and 
neurons. 
N.A. bradykinin HOE 140 vasodilation, 
oedema, 
smooth 
muscle spasm 
and pain fibre 
stimulation; 
Regulation of 
Actin 
Cytoskeleton 
[318
, 
343-
345] 
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2 Formyl 
peptide 
receptor 1 
Human, 
mouse, 
rat, etc. 
Gi/o Neutrophils 
monocytes 
N.A. N-Formyl-
Met-Leu-
Phe 
tert-
butyloxycarb
onyl-Met-
Leu-Phe; 
Boc-Met-
Leu-Phe 
Chemotaxis,  
cell migration, 
mediate immune 
response, 
suppress the 
immune system. 
[326
, 
346-
354] 
3 Parathyroid 
hormone  
receptor 1 
Humans, 
mouse, 
rat, 
zebrafish, 
cattle, etc. 
Gs / 
Gq/11 
bone 
(osteoblast) 
cells, 
kidney 
3H3G 
3C4M
3L2J 
1BL1 
parathyroid 
hormone, 
parathyroid 
hormone-
related 
protein 
Deg1,3,Bpa2,
M]PTH(1–
15) and 
[Deg1,3,Bpa2
,M]PTH(1–
21); 
benzoxazepin
one SW106 
 
Bone growth; 
regulates 
calcium ion 
homeostasis 
through 
activation of 
adenylate 
cyclase and 
phospholipase 
C; 
[329
, 
355-
360]  
 
4 Dopamine 
receptor D5 
(also 
known as 
D1B) 
Mice, 
humans, 
rat, 
monkey, 
etc. 
Gs Endothelial, 
neurons 
N.A. Dihydrexid
ine, 
Dopamine 
hexahydro-
dibenz[d,g]az
ecines lead to 
4-chloro-7-
methyl-
5,6,7,8,9,14-
hexahydrodib
enz[d,g]azeci
n-3-ol 
cardiovascula
r and renal 
effects, 
vasodilation, 
endothelium-
dependent 
relaxation 
[333
, 
361-
365] 
5 Sphingosin
e-1-
phosphate 
receptor-1 
(also 
known as 
Edg1, 
Lpb1) 
Mice, 
human, 
rat, 
zebrafish, 
frog, 
chicken, 
dog, 
horse, 
monkey, 
rabbit, etc. 
Gi1, Gi2, 
Gi3, Go 
and Gz 
endothelial 
cells, (lesser 
extent in: 
smooth 
muscle 
cells, 
fibroblasts, 
melanocytes 
and cells of 
epithelioid 
origin.) 
3V2W 
3V2Y 
sphingosin
e-1-
phosphate; 
CYM-5442 
W146 endothelial cells 
proliferation, 
differentiation, 
cell survival, 
adhesion, cell 
migration, 
aggregation, 
embryonic heart 
development 
and normal 
cardiac 
morphogenesis.   
[337
, 
366-
375] 
6 G protein-
coupled 
estrogen 
receptor 1, 
GPER1 
(Also 
known as: 
CEPR; 
GPER; 
DRY12; 
FEG-1; 
GPR30; 
LERGU; 
LyGPR; 
CMKRL2; 
LERGU2; 
Human, 
mice, rat, 
zebrafish, 
frog, dog, 
buffalo, 
pig, bat, 
sperm 
whale, 
tiger, 
turtle, 
mole, 
seal, 
alligator, 
etc. 
N.A. placenta, 
endothelial 
and 
epithelial 
cells, 
myometriu
m 
fibroblasts 
and cancer-
associated 
fibroblasts, 
prostate 
cancer cells 
and invasive 
adenocarcin
oma, brain. 
N.A. 17-beta-
estradiol 
(E2), G-1 
G-15, G-36 Mediates 
pleiotropic 
functions in the 
cardiovascular, 
endocrine, 
reproductive, 
immune and 
central nervous 
systems. 
Cardioprotectio
n, regulates 
arterial blood 
pressure,  
vasodilation. 
Reduces 
smooth 
[342
, 
376-
392] 
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GPCR-Br) muscle and 
endothelial 
cell 
proliferation. 
Blood glucose 
homeostasis. 
Regulates 
cancer 
progression. 
¥three-dimensional crystal structure identification code from the Research Collaboratory for 
Structural Bioinformatics (RCSB) Protein Data Bank (PDB). 
§§also known as agonist 
§§also known as inverse agonists or antagonist  
2.2.2.2 Shear stress sensing by the lipid bilayer membrane  
The plasma membrane is composed of a continuous lipid bilayer into which proteins are 
embedded. This membrane has a dynamic, ﬂuid structure, because the majority of the lipids 
and proteins seem to move freely in the plane of the membrane. The physical properties of 
the phospholipid bilayer change in function of lipid composition, density of lipid packing, 
relative water content, ion concentration, pH and temperature [393]. Knowing that the 
physical properties of the plasma membrane influences the conformational structure and 
function of membrane-linked molecules [394, 395], shear stress could alter the physical 
properties of the lipid bilayer, which in turn could activate proteins embedded in the 
membrane. In fact, shear stress was shown to increase membrane fluidity in endothelial cells 
by using the 9-(Dicyanovinyl)-julolidine fluorescent probe which integrates into the cell 
membrane and changes its quantum yield in function of the viscosity of the environment 
[396]. Additionally, measuring the diffusion coefficient by fluorescence recovery after 
photobleaching on endothelial cells, also showed that shear stress rapidly increases 
membrane fluidity [397]. Heterotrimeric G proteins have been demonstrated to be activated 
both by shear stress and by increase in membrane fluidity [252]. Lipid bilayer fluidity and 
tension can also alter the mechanosensitivity of ion channels, well studied 
mechanotransducers [398]. These evidences indicate that the lipid membrane bilayer may 
play a crucial role in shear stress sensing. 
2.2.2.3 Shear stress sensing by the glycocalyx 
On top of the phospholipid bilayer membrane, at the interface between the endothelium and 
blood flow, a dense glycocalyx layer covers the luminal surface of the endothelium. This 
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glycocalyx is composed of membrane-bound proteoglycans and glycoproteins (for a review 
on the composition and function of the glycocalyx c.f. [399]). The thickness of the 
glycocalyx layer ranges from 0.4 to 4.5 mm and varies proportionally with the lumen 
diameter [400, 401]. The flow of blood influences the conformation of the glycocalyx and 
this conformational change is transduced to the cytoskeleton through the intracellular domain 
of the glycocalyx. Alternatively, shear stress induced conformational change could be 
converted into biochemical signals which are then transmitted inside the cell through ions, 
amino acids and cell growth factors [266, 267, 402-405]. Degrading the hyaluronic acid (one 
of the five types of glycosaminoglycans of proteoglycans) in the glycocalyx by hyaluronidase 
treatment, reduced the flow-induced NO production to ≈20% in isolated canine femoral 
arteries [406]. Similarly, the NO production in response to shear stress was decreased in 
bovine aortic endothelial cells when heparan sulphate (another type of glycosaminoglycans of 
proteoglycans) of the glycocalyx was degraded by heparinise [407]. These findings indicate 
that the endothelial glycocalyx mediates NO production in response to shear stress. 
2.2.2.4 Shear stress sensing by ion channels 
Ion channels are pore-forming membrane proteins embedded in the plasma membrane. Ion 
channels regulate the flow of ions across this cell membrane. In the late 1980s, 
haemodynamic shear stress was shown to activate a K
+
 current in vascular endothelial cells 
[408], causing hyperpolarization of the endothelial cell membrane [409]. At the end of the 
1990s, a Cl
-
 current was show to occur in response to shear stress besides the K
+
 current, this 
Cl
- 
current depolarized the cell membrane [410]. Shear stress activates the inward-rectifying 
Kir2.1 K
+
 channels in the order milliseconds [254], ion channels being one of the most rapid 
shear responsive elements in endothelial cells [411]. Shear stress also activates transient 
receptor potential (TRP) Ca
2+
 channels [412]. By introducing the TRP cation channel 
subfamily V member 4 Ca
2+
 channel into human embryonic kidney cells, which present no 
shear dependent Ca
2+ 
influx, into these cells Ca
2+
 flow in in response to shear stress [413].  
Ion channels are considered to be the primary shear stress sensors due to their rapid response 
to shear stress. However, it still remains unclear whether these ion channels are activated 
directly by shear stress or through other intermediates. In fact, it was shown that the 
Adenosine-5'-triphosphate (ATP)-operated cation channel P2X purinoceptor 4 (P2X4) was 
activated indirectly by shear stress in an ATP-dependent manner [414-420]. 
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2.2.2.5 Shear stress sensing by other plasma membrane receptors 
Other plasma membrane receptors were also shown to respond to shear stress. Xanthine 
oxidoreductase and NADPH oxidase was shown to produce superoxide in response to 
oscillatory shear stress [258]. Flow was shown to facilitate ATP release by the cell surface 
ATP synthase [421]. Two tyrosine kinase receptors (TKR, also known as receptor tyrosine 
kinases, RTKs) were shown to be shear stress sensitive. The vascular endothelial growth 
factor receptor 2 (VEGFR-2, also known as foetal liver kinase 1, Flk-1) TKR was activated 
by shear stress ligand-independently to subsequently regulate activation of endothelial nitric 
oxide synthase [422-424]. The second shear sensitive RTK is the tyrosine kinase receptor 
TIE-2 [425, 426] which is also known as: Angiopoietin-1 receptor, endothelial tyrosine 
kinase, tunica interna endothelial cell kinase, tyrosine kinase with Ig and EGF homology 
domains-2, tyrosine-protein kinase receptor TEK, hTIE2, p140 TEK, CD_antigen=CD202b, 
TIE2, VMCM, VMCM1 and TEK. 
2.2.2.6 Shear stress sensing by the caveolae 
Flask-shaped membrane invagination, measuring 50-100 nm in diameter, called caveolae are 
densely populated by signal transducer molecules, such as receptors, ion channels and protein 
kinases [427]. It has been shown that caveolae have an important role in shear stress sensing 
[263, 428, 429]. At the onset of flow, Ca
2+ 
influx starts at caveolae and Ca
2+
 spreads 
throughout the cell [430]. Increased Ca
2+
 concentrations at the caveolae causes eNOS 
activation and subsequent NO production [430]. The activation of extracellular-signal-
regulated kinases (ERK) by shear stress was prevented when an anti caveolin-1 (caveolae 
constitutive protein) antibody was added to ECs [431]. Concentrated ATP release occurred at 
caveola-rich regions of the cell membrane [432]. Caveolae localized sphingomyelinase was 
also activated by shear stress, resulting in ceramide production which led to ERK activation 
and AKT dependent eNOS activation [433]. Experiments conducted in (caveolin-1 knock out 
and wild type) mice proved the crucial role of caveolin-1 and caveolae in 
mechanotransduction and blood vessels remodelling [434].  
2.2.2.7 Shear stress sensing by the primary cilia 
Primary, non-motile cilium (plural cilia) serves as a sensory organelle in eukaryotic cells. 
Primary cilia are membrane covered, microtubule containing rods that protrude out of the cell 
surface. Primary cilia were observed on the luminal surface of embryonic endothelial cells, 
human umbilical vein endothelial cells, and human aortic endothelial cells [435, 436]. 
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Primary cilia are physically linked to the cytoskeleton, thus their bending by flow is assumed 
to transmit shear stress signals into the cell [437]. A second mechanism of action has also 
been proposed, indicating that the bending of cilia by shear stress activates polycystin-2 
(PC2) Ca
2+
 channel localized in the cilia which yields a Ca
2+
 influx [264, 438]. Mutations or 
deletions of polycystin (cilia associated proteins) genes, in humans and mice, result in 
vascular defects [439]. Endothelial primary cilia rapidly disassemble under flow [435] and 
primary cilia were observed at atherosclerosis susceptible sites in vivo [440] foretelling a role 
of primary cilia in sensing low levels of shear stress in analogy with low shear sensing cilia in 
the kidney [441]. Primary cilia sensitize endothelial cells to shear stress: cells that possess 
cilia express the zinc-ﬁnger transcriptional factor Krüppel-like factor-2 (KLF2) significantly 
more in response to shear stress compared to cells that do not possess cilia [442]. However, 
the primary cilia does not appear to be the only endothelial shear stress sensor since cells that 
lack the primary cilia still sense shear stress [437]. 
2.2.2.8 Shear stress sensing by cell-cell adhesion molecules 
A large portion of cell-cell junctions in the endothelium consists of the protein called platelet 
endothelial cell adhesion molecule-1 (PECAM-1, also known as cluster of differentiation 31, 
CD31), which establishes homophilic interactions between neighbouring cells [443]. 
PECAM-1 was shown to interact with the cytoskeleton [444]. In a confluent monolayer of 
endothelial cells, shear stress caused tyrosine phosphorylation of PECAM-1, followed by the 
activation of the Ras signalling pathway, leading to ERK activation [445]. When PECAM-1 
expression was down-regulated with antisense oligonucleotides, ERK activation in response 
to shear stress was significantly reduced. It was also shown that mechanical force applied 
directly to PECAM-1 activated this protein. For this, magnetic beads were coated with 
antibodies that bind to the extracellular domains of PECAM-1. Pulling the PECAM-1 bound 
magnetic beads with a magnetic force caused PECAM-1 phosphorylation, whereas PECAM-
1 proteins not bound to magnetic beads were not phosphorylated. Moreover, PECAM-1 was 
modified by adding a 40 amino acid long elastic domain flanked by two fluorophores that 
underwent efficient fluorescence resonance energy transfer (FRET). The FRET signal 
decreased when the 40 amino acid long elastic domain was pulled and the distance between 
the two fluorophores increased [446, 447]. Using this FRET-based tension sensor revealed 
that flow triggered an increase in tension across junctional PECAM-1, while non-junctional 
PECAM-1 was not affected. 
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Vascular endothelial cell (VE-) cadherin is an endothelial specific adherence cell-cell 
junctional protein which connects the VE-cadherin of the neighbouring endothelial cell to the 
cytoskeleton [448]. VE-cadherin mediates the interaction between VEGFR-2 and PECAM-1 
[449]. PECAM-1 facilitates the transactivation of VEGFR-2 by active Src [422, 450, 451]. 
Activated VEGFR-2 activates phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) which 
mediates crucial downstream signals [260, 451, 452], such as the RAC(GTPase)-alpha 
serine/threonine-protein kinase (AKT) dependent phosphorylation of eNOS, resulting in NO 
synthesis and vessel relaxation [453]. 
2.2.2.9 Shear stress sensing by focal adhesion molecules 
Integrins are transmembrane glycoproteins that link the basal side of endothelial cells to the 
extracellular matrix. Integrins directly bind to the extracellular matrix proteins such as 
collagens, fibronectin and laminins and connect to the cytoskeleton by associating with other 
proteins to form focal adhesion complexes [454, 455]. Thus, integrins connect the 
cytoskeleton to the extracellular matrix. There is a significant body of evidence for the 
involvement of integrins in shear stress transduction [456, 457]. Activation of integrins by 
shear stress yields rapid focal adhesion kinase, paxillin, c-Src tyrosine kinase, Fyn tyrosine-
protein kinase, p130
CAS
 Cas Scaffolding Protein Family Member 4 and small GTPase (such 
as rac, rho and CDC42) activation [261, 458-460]. Therefore, integrins could function as 
mechanosensors [456, 461]. Moreover, there is evidence that integrins activate VEGFR-2 
tyrosine kinase receptor under the effect of shear stress [462]. 
2.2.2.10 The cytoskeleton as a shear stress sensor 
The cytoskeleton is the cellular scaffolding or skeleton within a cell’s cytoplasm. Eukaryotic 
cytoskeleton is composed of three main kinds of filaments: microfilaments (actin filaments), 
intermediate filaments, and microtubules. The cytoskeleton has a crucial role in endothelial 
responses to shear stress [426, 463]. Different regions of the cell are physically connected by 
microfilaments, intermediate filaments, and microtubules. Therefore, forces and shear stress 
applied to the luminal surface of endothelial cells are transmitted to basal and junctional 
surfaces where mechanotransduction events have also been observed [260, 464]. The 
intermediate filament protein vimentin, fused to green fluorescent protein (GFP), was shown 
to undergo nonhomogeneous changes under shear stress, regions of high strain being 
observed mostly at junctional and basal sides, suggesting the transmission of forces to these 
sites [465]. Furthermore, inhibition of actin, microtubules or intermediate filaments blocks 
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many endothelial responses to shear [466-468]. Endothelial cytoskeleton plays an important 
role in shear stress induced NO production and Inter-Cellular Adhesion Molecule 1 gene 
expression [269]. A cellular model has been proposed to explain the propagation of forces as 
cellular signals through the cytoskeleton, named the tensegrity cell model [469]. However, 
there is insufficient evidence supporting a direct role of the cytoskeleton in shear stress 
sensing. 
2.2.3 Design of a shear stress sensitive gene network 
The aim of the project presented in this second chapter is to design and implement a synthetic 
gene network for monitoring the activity of shear stress sensors in endothelial cells. Since I 
was the first person in our research group that entered the field of synthetic biology, we 
decided to build on previously proven-to-work techniques and approaches, instead of starting 
from zero, in order to minimize risks and increase the chances of successfully finalizing the 
project. 
We decided to build on the Tango assay, the gene network briefly presented in subsection 
2.2.1.4.3 that allows observing the activation of G protein-coupled receptors (GPCRs), 
receptor tyrosine kinases and steroid hormone receptors [247]. Given the tremendous 
importance of GPCRs in pharmacology and in sensing stimuli, as described in subsection 
2.2.2.1, it was decided to incorporate a shear stress sensitive GPCR in our gene network. The 
bradykinin B2 GPCR has been chosen because this GPCR was expressed in endothelial cells, 
it was shown to be present in caveolae [470] and the shear stress sensing ability of this GPCR 
was well documented and proven at the molecular level [253]. However the 3D crystal 
structure of this GPCR was not known (c.f. Table 2.2). The two shear stress sensitive GPCRs 
with known 3D structure are the parathyroid hormone receptor 1 and the sphingosine-1-
phosphate receptor 1. Parathyroid hormone receptor 1 was not chosen, because it is expressed 
predominantly in bone and kidney cells and not in endothelial cells [471]. The structure of 
Sphingosine-1-phosphate receptor 1 became available only in 2012 after our project was 
started [472]. Therefore, at the time, the bradykinin B2 GPCR seemed to be the best shear 
stress sensor choice. 
The design of our shear stress sensing synthetic gene network, which is based on the Tango 
assay [247], is presented in Figure 2.4. This gene network has 3 components. The first 
component consists of the shear stress sensitive bradykinin B2 GPCR linked to the 
tetracycline-controlled transcriptional trans-activator tTA. The linker between the bradykinin 
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B2 GPCR and tTA is a 7 amino acid long sequence that serves as a specific cleavage site for 
Tobacco etch virus (TEV) protease. The second component is the βArrestin2 signalling 
protein fused to the Tobacco Etch Virus (TEV) protease enzyme. The third component is the 
eGFP reporter gene under the control of the tTA dependent promoter. Activation of 
bradykinin B2 GPCR by an extracellular ligand or by shear stress causes a conformational 
change in the GPCR. This conformational change increases the binding affinity between the 
βArrestin2 and bradykinin B2 GPCR and leads to the binding of the βArrestin2 to the 
cytoplasmic domain of the GPCR. Upon the βArrestin2–TEV protease fusion binding, the 
TEV protease cleaves the linker between the GPCR and tTA which is a TEV protease 
specific cleavage site. This way, tTA is released and translocates to the nucleus to activate the 
transcription of the eGFP reporter gene. 
The tango assay for GPCRs was developed using the human arginine vasopressin receptor 2 
(AVPR2) GPCRS. It was shown that the binding specificity between AVPR2 and βArrestin2 
can be extended to multiple GPCRs by adding a 29 amino acid long fragment from the 
carboxyl-terminus (C-terminus) tail of AVPR2 to the C-terminus of other GPCRs. In our 
project, this 29 amino acid long fragment from the carboxyl-terminus (C-terminus) end of 
AVPR2 also follows after the last C-terminal amino acid of the bradykinin B2 GPCR. The 
luciferase reporter from the original tango assay will be replaced with the eGFP reporter gene 
for a faster and more convenient readout, without the need of performing the luciferase 
reporter assay. Moreover, the expression of the eGFP reporter gene can also be visualized in 
intact, living cells under a fluorescent microscope, acquiring other information (e.g. cell 
morphology, cell densities, cell viability upon propidium iodide staining) simultaneously. 
The Tango assay has been chosen because it is composed of robust, well characterized 
components. For example, compared to the LacR/O/IPTG system, tetR has a very high 
specificity for its operator sequence [473] and tetracycline has a very high affinity for tetR 
[474]. tTA is widely utilized in synthetic biology for controlling gene expression [475]. The 
TEV protease exhibits enhanced stability and high specific activity [476], being far more 
stringent than other proteases, such as activated blood coagulation factor X (factor Xa), 
enteropeptidase (enterokinase) and α-thrombin [476-479]. 
In order to obtain and implement our shear stress sensitive gene network in endothelial cells 
and study the shear stress response of the gene network, first, the gene network needs to be 
designed and constructed at the DNA level. Once the plasmids encoding the gene network are 
obtained, these plasmids will be inserted into endothelial cells. Insertion of plasmids into 
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mammalian cells is termed transfection. The transfection technique that was employed was 
electroporation. Electroporation involves the application of electrical pulses which cause 
temporary openings or pores in the cell membrane, through which plasmid DNA can enter 
the cell. Once the gene network is inserted and expressed in endothelial cells, the gene circuit 
will be activated by the bradykinin ligand and by shear stress. For shear stress activation, 
cells electroporated with the gene network will be seeded into flow chambers and exposed to 
controlled levels of shear stress. The amount of cells expressing eGFP due to shear stress will 
be quantified by analysing images acquired by fluorescent microscopy. The work aiming to 
obtain and implement the gene network will be presented in the Results section of the current 
chapter. 
 
Figure 2.4. Design of our shear stress sensitive gene network, based on the Tango assay 
[247]. The gene network has 3 modules: sensor module, linker module and reporter module. 
The sensor module consists of a shear stress sensitive GPCR (bradykinin B2 GPCR) linked 
(by protease cleavage site linker) to a transcription factor (tTA). The linker module is 
composed of a signalling protein (βArrestin2) fused to a protease enzyme (Tobacco Etch 
Virus (TEV) protease). The reporter module is a tTA dependent reporter gene (eGFP). 
Activation of bradykinin B2 GPCR by an extracellular ligand or by shear stress leads to the 
binding of the βArrestin2–TEV protease fusion to the cytoplasmic domain of the GPCR and 
the TEV protease cleaves the linker between the GPCR and tTA. This way, tTA is released 
and enters the nucleus to promote the transcription of the eGFP reporter gene.  
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 MATERIALS & METHODS 2.3
2.3.1 Bacterial growth conditions 
Bacterial cultures of JM109, NEB 5α F’Iq and DH5α Escherichia Coli (E. coli) strains were 
grown in Luria-Bertani (LB) broth (1% weight/volume (w/v) tryptone, 0.5% (w/v) yeast 
extract, 1% (w/v) sodium chloride) at 37°C at 180 RPM in a Labnet 311DS shaking 
incubator. Colonies were grown on LB-Agar containing Petri dishes (1% (w/v) tryptone, 
0.5% (w/v) yeast extract, 1% (w/v) sodium chloride, 1.5% (w/v) agar) supplemented with 
appropriate antibiotics. Ampicillin (Amp) was added at 50 µg/ml final concentration to both 
LB broth and LB-Agar, following autoclaving. High efficiency NEB 5α F’Iq competent E. 
coli cells (C2992H) were purchased from New England Biolabs Inc. (NEB), Ipswich, MA, 
USA. JM109 and DH5α competent E. coli cells were readily available in our laboratories. LB 
broth, (Miller BP1426500), LB-Agar, (Miller BP1425500) and ampicillin in form of sodium 
salt (BP17605) were procured from Fisher BioReagents, Hampton, NH, USA. Petri dishes 
(101R20, 101VR20 and 101VBLUE) were acquired from Sterilin Ltd., Cambridge, UK. For 
media, additives and reagent preparation, Milli-Q water with 18.2 MΩ⨯cm (at 25°C) 
resistivity produced using Pur1te Select EMD Millipore water purification systems was used. 
Liquids were sterilized at 121°C for 30 minutes and solids or instruments at 135°C for 5 
minutes in a MLS-3751L Sanyo autoclave. 
2.3.2 Preparation of competent E. coli cells 
A 2 ml pre-culture of E. coli strain JM109 or DH5α was prepared by incubation overnight at 
37°C at 180 RPM shaker speed. Next, 100 ml LB broth was inoculated with 1 ml of the pre-
culture and incubated at 37°C at 180 RPM. When the optical density at 600 nm wavelength 
(OD600) reached 0.3 absorbance units (AU), the bacterial culture was divided into two 50 ml 
polypropylene BD Falcon
TM
 centrifuge tubes with screw cap and placed on ice for 5 minutes. 
Afterwards the culture was centrifuged at 5,000 ⨯g for 10 minutes at 4°C. The pellet was re-
suspended in 20 ml TfbI per tube using a Fisher Scientific FB15012 vortex mixer or an IKA 
Lab Dancer S2 shaker, placed on ice for 5 minutes and centrifuged for 10 minutes at 5,000 
⨯g at 4°C. Pelleted cells were re-suspended in 2 ml of TfbII per tube using a Fisher Scientific 
FB15012 vortex mixer or an IKA Lab Dancer S2 shaker and placed on ice for 15 minutes. 
Following this, 100 µl of competent E. coli cells were quickly dispensed into separate 
autoclave-sterilized ice-cold 1.5 ml tubes, frozen quickly in liquid nitrogen and stored at -
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80°C in a New Brunswick Scientific ultra-low temperature U 725-86 lab freezer for 
subsequent transformations. TfbI was composed of Milli-Q water with final concentrations of 
30 mM potassium acetate, 100 mM RbCl, 10 mM CaCl2·2H2O, 50 mM MgCl2·4H2O and 
15% (volume/volume, (v/v)) glycerol with pH adjusted to 5.8 using 0.2 M acetic acid and 
sterile filtered. TfbII consisted of final concentrations of 10 mM 3-(N-
morpholino)propanesulfonic acid (MOPS), 75 mM CaCl2·2H2O, 10 mM RbCl and 15% (v/v) 
glycerol in Milli-Q water, pH adjusted to 6.5 with KOH and sterile filtered. Potassium acetate 
(60035), RbCl (R2252-50G), CaCl2·2H2O (C3306-100G), MOPS (69947-100G), acetic acid 
(A6283), KOH (38073) and MgCl2·4H2O (221279) were purchased from Sigma-Aldrich 
Corp., St. Louis, MO, US. Glycerol (G065017) was obtained from Thermo Fisher Scientific 
Inc. 50 ml polypropylene BD Falcon
TM
 conical, high-clarity centrifuge tubes with blue 
polyethylene flat-top screw caps (352070) were purchased from Thermo Fisher Scientific Inc. 
For filtration cellulose acetate syringe filters (28145-477) with 0.2 µm pore size have been 
used, from Sartorius Stedim Biotech, Aubagne, France. Ice was generated using the Scotsman 
AF20ASE Ice flaker. Milli-Q water with 18.2 MΩ⨯cm (at 25°C) resistivity was produced by 
Pur1te Select EMD Millipore water purification systems. 
2.3.3 In silico design of plasmid constructs and De novo DNA synthesis 
DNA sequences of the desired gene constructs were constructed in silico using SnapGene
®
 
Viewer and Microsoft Word 2010 using sequences from the National Center for 
Biotechnology Information (NCBI) GenBank and sequences provided by Dr Barnea. These 
sequences served as a template for DNA sequencing primer design and for DNA synthesis. 
De novo DNA synthesis of double stranded DNA was carried out at Eurofins NWG Operon, 
Ebersberg, Germany and synthesized genes were delivered in DNA plasmids. Obtained 
plasmids were transformed into competent E. coli for amplification and storage. 
2.3.4 E. coli transformations 
Competent JM109 and DH5α E. coli cells were transformed using the heat shock method. For 
this, 0.1 µl of 1 µg/ml of medium or high copy number plasmid solution was added to 100 µl 
of competent E. coli cell solution and placed on ice for 30 minutes. Afterwards, cells were 
heat shocked at 42°C for 1 minute and returned to ice for 2 minutes. 1 ml of LB broth 
containing 0.4% (w/v) D-glucose and 20 mM MgCl2 was added to cells and followed by 
incubation at 37°C, 180 RPM for 1 hour. Next, 100 µL of the transformed cell solution was 
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plated on Petri dishes containing LB-Agar supplemented with the appropriate selection 
antibiotic and 0.4% (w/v) D-glucose, and Petri dishes were incubated at 37°C overnight. The 
remaining transformed cell solution was centrifuged at 13,000 ⨯g for 10 minutes at 4°C, the 
pellet was re-suspended in 100 µL LB medium by pipetting and cells were plated on Petri 
dishes with LB-Agar supplemented with 50 µg/ml Amp and 0.4% (w/v) D-glucose, and Petri 
dishes were incubated at 37°C overnight. The following day successful transformants were 
isolated. Similarly, high efficiency NEB 5α F’Iq competent E. coli cells were also 
transformed using the heat shock method by adding 0.1 µl of 0.5 µg/ml of medium or high 
copy number plasmid solution to 50 µl of competent E. coli cell solution and placed on ice 
for 30 minutes. Next, cells were heat shocked at 42°C for 30 seconds and returned to ice for 5 
minutes, without mixing. For recovery, 950 µL of room temperature Super Optimal broth 
with Catabolite repression (SOC) outgrowth medium was added to cells and cells were 
incubated at 37°C, 180 RPM for 1 hour. Next, 100 µL of the transformed cell solution was 
plated on LB-Agar Petri dishes supplemented with 50 µg/ml Amp and 0.4% (w/v) D-glucose, 
and Petri dishes were incubated at 37°C overnight. The remaining transformed cell solution 
was centrifuged at 13,000 ⨯g for 10 minutes at 4°C, the pellet was re-suspended in 100 µL 
LB medium by pipetting and cells were plated on LB-Agar Petri dishes supplemented with 50 
µg/ml Amp and 0.4% (w/v) D-glucose, and Petri dishes were incubated at 37°C overnight. D-
glucose (G5500) and MgCl2·4H2O (221279) were purchased from Sigma-Aldrich Corp. SOC 
outgrowth medium (B9020S) was acquired from NEB. 
2.3.5 Plasmid preparation 
DNA plasmids were extracted and purified using the QIAprep Spin Miniprep Kit from 
Qiagen N.V., Venlo, Netherlands, following the manufacturer’s protocol. For this, E. coli 
from single colony from a freshly streaked selective plate was picked and inoculated in 5 ml 
LB culture containing the appropriate selective antibiotic, where applicable, in 14 ml 
polypropylene BD Falcon
TM
 tubes with snap cap. The liquid LB culture was incubated 
overnight (12–16 hours) at 37°C with shaking at 180 RPM. Bacterial cells were harvested by 
centrifugation at 4,000 x g for 10 min at 4 °C in a Hettich Rotanta 460R large bench 
centrifuge. The cell pellet was re-suspended using a Fisher Scientific FB15012 vortex mixer 
or an IKA Lab Dancer S2 shaker and lysed under alkaline conditions [480]. The lysate was 
subsequently neutralized and adjusted to high-salt binding conditions. The solution was 
applied and plasmid DNA was bound to a QIAprep spin column; the column was washed and 
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then the DNA was eluted in 50 µL of Milli-Q water to obtain the purified plasmid DNA. 
Plasmid DNA concentrations and quality were measured using a NanoDrop
TM
 2000c 
Spectrophotometer, Thermo Fisher Scientific Inc., Waltham, MA, USA. The NanoDrop
TM
 
2000c Spectrophotometer was blanked with 2 µl of Milli-Q water. 1.5 or 2 µl of plasmid 
DNA sample was loaded on the NanoDrop
TM
 2000c instrument and DNA concentrations 
were always measured 3 times and the average concentration was used. To evaluate the 
quality of plasmid DNA solution using the NanoDrop
TM
 2000c Spectrophotometer [481], the 
ratio of absorbance at 260 nm and 280 nm was confirmed to be above 1.8, indicating pure 
DNA (without protein, phenol or other contaminants that absorb strongly at or near 280 nm). 
Similarly, the absorbance ratio at 260 nm and 230 nm was also checked to be in the 2.0 – 2.2 
range, characteristic to pure DNA (free on contaminants that absorb at 230 nm). Milli-Q 
water with 18.2 MΩ⨯cm (at 25°C) resistivity was produced using Pur1te Select EMD 
Millipore water purification systems. 14 ml polypropylene BD Falcon
TM
 tubes (352059) with 
round bottom and dual-position snap cap were purchased from Thermo Fisher Scientific Inc. 
2.3.6 Primer design and DNA sequencing  
Plasmids (listed in Table 2.11 of the 2.4 RESULTS AND DISCUSSION section) were 
transformed into competent E. coli cells, prepared (as described above) and Sanger sequenced 
at GATC Biotech AG, Konstanz, Germany on Sanger ABI 3730xl instruments. GATC’s 
DNA sequencing technique from is ISO 9001 certified. Sanger sequencing is considered the 
“gold standard” with the longest read lengths, of up to 1,100 bases. The Sanger ABI 3730xl is 
a 96 capillary instrument with 50 cm capillaries for providing high throughput analysis and 
high resolution. Robust sequencing chemistry was assured by BigDye Terminator v3.1 and 
for GC-rich samples by dGTP BigDye Terminator Cycle Sequencing Kit. GATC’s laboratory 
information management system offered fast and secure data transfer. For DNA sequencing, 
primers (listed in Table 2.13 of the 2.4 RESULTS AND DISCUSSION section) were 
designed using SeqBuilder
TM
 Version 9.1.0 (109) from DNASTAR, Lasergene
®
 using 
sequences from National Center for Biotechnology Information (NCBI) GenBank as a 
template. The primers were generally designed 21 nucleotide long, with GC content of about 
40-60%, with melting temperatures between 52-58 °C (this range generally yields best 
results), with GC clamp at the 3’ end (for stronger binding at the 3’ synthesis end, though 
triple H-bonds between bases), avoiding mono- and di-nucleotide repeats and secondary 
structure artifacts such as hairpins, and self- and cross- dimerization products. Synthesized 
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primers received in powder state, were briefly centrifuged to collect the powder at the bottom 
of the tube, reconstituted to 100 µM stock solutions, mixed by vortexing to completely 
dissolve the powder and again briefly centrifuged to collect the solution at the bottom of the 
tube before freezing at -20°C. Twenty µl of 10 µM solutions were sent to GATC Biotech AG 
for up to 8 sequencing reactions. Volumes of 20 µL of plasmid DNA with concentration of 
80 ng/µL were sent for DNA sequencing for up to 8 sequencing reactions. The obtained DNA 
sequences were analysed using SeqMan Pro
TM
 Version 9.1.0 (109), 418 from DNASTAR, 
Lasergene
®
 by aligning with coding sequences from the online GenBank NCBI database. 
DNA sequences obtained through DNA sequencing were also aligned with sequences from 
the online GenBank NCBI database using SerialCloner 2 and the T-Coffee online alignment 
tool (available at http://tcoffee.crg.cat/apps/tcoffee/do:regular). To exclude codon usage 
biases in case of point mutations obtained from DNA sequencing, DNA sequences were 
converted into amino acid sequences using online converters from 
http://web.expasy.org/translate/, 
http://bioinformatics.picr.man.ac.uk/research/software/tools/sequenceconverter.html and 
http://www.fr33.net/translator.php and amino acid sequences from sequencing were 
compared with amino acid sequences from GenBank NCBI database. Antiparallel, 
complement and inverse DNA sequences were obtained using the sequence editor available at 
http://www.fr33.net/seqedit.php. Desired DNA sequences of our gene constructs were 
generated in silico by inserting or replacing the appropriate DNA sequences to or in the 
corresponding vectors, respectively.  
2.3.7 Freezing E. Coli cells  
Cells to be frozen were grown in 3 ml over-night culture. Approximately 1.4 ml of overnight 
culture was added to cryovials that contained 0.5 ml 80% (v/v) glycerol. Cryovials were 
stored in the -80°C New Brunswick Scientific ultra-low temperature U 725-86 lab freezer. 
Fisherbrand polypropylene 2 ml cryovials (12567501) were acquired from Thermo Fisher 
Scientific Inc. A list of stocked E. coli strains is given in Table 2.12 of the 2.4 RESULTS 
AND DISCUSSION section.  
2.3.8 Polymerase Chain Reaction 
For molecular cloning using conventional methods and Gibson Assembly
®
 (described 
below), DNA fragments were amplified from DNA plasmids using Polymerase Chain 
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Reaction (PCR). For PCR, Taq, Phusion
®
 High-Fidelity (HF), Q5
®
 High-Fidelity, Q5
®
 Hot 
Start High-Fidelity DNA polymerases and the KAPA 2G Robust HotStart Ready Mix PCR 
Kit were used. The composition of the PCR mixtures is shown in Table 2.3, Table 2.4, Table 
2.5 and Table 2.6 for Taq, Phusion HF, Q5 HF & Q5 Hot Start HF and KAPA 2G Robust 
HotStart PCRs, respectively. PCR was thermal cycled in Labnet MultiGene™ Gradient PCR 
Thermal Cycler (TC9600-G-230V) or in Eppendorf realplex
4
 epgradient S qPCR 
Mastercycler
®
 using programs shown in Table 2.7 for the five PCR types. For the 
amplification of long DNA fragments (> 6 kb), extension times were increased to 40–50 
seconds/kb. DNA primers for PCR were designed using SeqBuilder
TM
 Version 9.1.0 (109) 
from DNASTAR, Lasergene
®
 or using NEBuilder
TM
 (available at: http://nebuilder.neb.com/) 
or using In-Fusion
®
 primer design tool (available at: 
http://bioinfo.clontech.com/infusion/convertPcrPrimersInit.do). Primer synthesis was ordered 
from Sigma-Aldrich Corp. and from Life Technologies Inc., Carlsbad, CA, USA. Annealing 
temperatures (ATs) were calculated using NEB Tm Calculator [482] which used nearest-
neighbour thermodynamic parameter set from Santa Lucia [483] applying the salt correction 
algorithm outlined in Owczarzy et al. [484]. For Phusion DNA polymerases, the 
thermodynamic data were from Breslauer et al. [485]. If the PCR did not yield positive 
results, a gradient of ATs ranging ±10 °C (upper limit being 72 °C) of the estimated AT, in 
increments of 2 °C was used, and the enzyme system was replaced. If PCR was still 
unsuccessful, the above mentioned gradient PCR was repeated with increased DNA 
polymerase concentrations in increments of 20% of the initial concentration, to up 1 order of 
magnitude above the initial concentration. Taq (M0273S), Phusion
®
 High-Fidelity (M0530S), 
Q5
®
 High-Fidelity (M0491S) and Q5
®
 Hot Start High-Fidelity (M0493S) DNA polymerases 
were acquired from NEB. DNA polymerases were supplied with their corresponding reaction 
buffers, dimethyl sulfoxide (DMSO) and Q5
®
 High GC Enhancer solutions. 
Deoxyribonucleotide triphosphate (dNTP) Mix, 10 mM each, (R0191) was purchased from 
Thermo Fisher Scientific Inc. The KAPA2G Robust Hot Start Ready Mix PCR Kit (KK5702) 
was obtained from Kapa Biosystems, Inc. MA, USA. As nuclease free water both Milli-Q 
water generated by Pur1te Select EMD Millipore water purification systems and Nuclease-
Free Water (129114) from Qiagen N.V. was used. 
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Table 2.3. Taq PCR mixture composition 
Component Volume [µl] Final Concentration 
10X Standard Taq Reaction 
Buffer  
5 1X  
10 mM dNTPs (each) 1 200 µM 
10 µM Forward Primer 1 0.2 µM (0.05–1 µM) 
10 µM Reverse Primer 1 0.2 µM (0.05–1 µM) 
Template DNA 1 pg–1 ng* <20 ng/µl 
Taq DNA Polymerase 0.25 1.25 units/50 µl PCR 
Nuclease-free water to 50   
                       * The volume that contains this amount of DNA 
 
Table 2.4. Phusion
®
 High Fidelity PCR mixture composition 
Component Volume [µl] Final Concentration 
5X Phusion HF or GC Buffer 10 µl 1X 
10 mM dNTPs (each) 1 µl 200 µM 
10 µM Forward Primer 2.5 µl 0.5 µM 
10 µM Reverse Primer 2.5 µl 0.5 µM 
Template DNA 1 pg–1 ng* <5 ng/µl 
DMSO (optional) (1.5 µl) 3% 
Phusion DNA Polymerase 0.5 µl 1.0 units/50 µl PCR 
Nuclease-free water to 50 µl  
                    * The volume that contains this amount of DNA 
 
Table 2.5. Q5
®
 High-Fidelity and Q5
®
 Hot Start High-Fidelity PCR mixture composition 
Component 50 µl Reaction Final Concentration 
5X Q5 Reaction Buffer 10 µl 1X 
10 mM dNTPs (each) 1 µl 200 µM 
10 µM Forward Primer 2.5 µl 0.5 µM 
10 µM Reverse Primer 2.5 µl 0.5 µM 
Template DNA 1 pg–1 ng* < 20 ng/ µl 
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Q5 High-Fidelity DNA Polymerase 
or Q5 Hot Start High-Fidelity DNA Polymerase 
0.5 µl 0.02 U/µl 
5X Q5 High GC Enhancer (optional) (10 µl) (1X) 
Nuclease-Free Water to 50 µl 
 
              * The volume that contains this amount of DNA 
 
Table 2.6. KAPA 2G™ Robust HotStart ReadyMix (2X) 
Component Volume [µl] Final Concentration 
2X KAPA2G Robust HotStart 
ReadyMix 
12.5 1X 
10 µM Forward Primer 1.25 0.5 µM 
10 µM Reverse Primer 1.25 0.5 µM 
Template DNA 1-10 ng* <20 ng/µl 
DMSO 1.25 1.25 units/50 µl PCR 
Nuclease-free water to 25   
                * The volume that contains this amount of DNA 
 
Table 2.7. Thermocycling program for Taq, Phusion HF, Q5 HF and Q5 HF Hot Start PCR, 
and for KAPA 2G™ Robust HotStart ReadyMix (2X) PCR.  
Step 
Taq 
Phusion HF, Q5 HF 
and Q5 HF Hot Start 
KAPA 2G™ Robust 
HotStart ReadyMix 
(2X) 
Temp 
[°C] 
Time 
Temp 
[°C] 
Time 
Temp 
[°C] 
Time 
Initial 
Denaturation  
95 30 s 98 30 s 95 1-3 min 
25 – 40 Cycles  
95 
45-68 
68 
15-30 s 
15-60 s 
1 
min/kb 
98 
45-72 
72 
5-10 s 
10-30 s 
15-30 
s/kb 
95 
45-72 
72 
10-15 s 
10-15 s 
10-15 s 
Final Extension  68 5 min 72 2-10 m 72 0-10 min 
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Hold  4 ∞ 4 ∞ 4 ∞ 
 
2.3.9 Agarose Gel Electrophoresis 
DNA length and quality was assessed by 1% agarose gel electrophoresis (AGEP) using the 
Owl™ EasyCast™ B1 Mini Gel Electrophoresis System or the Owl™ EasyCast™ B2 Mini 
Gel Electrophoresis System from Thermo Fisher Scientific Inc. The 1% agarose solution was 
prepared by mixing 1 g or 1.5 g of agarose powder in 100 ml or 150 ml 0.5⨯ Tris-Borate-
EDTA (TBE) solution, respectively. This mixture was then heated in a Russell Hobbs GTS23 
microwave oven for approximately 4 min until the agarose was completely dissolved, 
resulting in a clear solution. The agarose solution was then kept at 55°C in a Grant 
Instruments GD120 stirred water bath for 20 min. Next, 1 μl of SYBR® Safe DNA Gel Stain 
was added per 10 ml agarose solution. The solution was mixed and poured on a gel tray 
placed in the casting position in the buffer chamber with combs in place and incubated at 
room temperature for 1 hour until the gel solidified. Alternately, for gel solidification, the 
gasket ends of the tray were also fixed and sealed with 4-5 layers of autoclave tape and the 
liquid gel was poured into this sealed tray without using the buffer chamber. The solidified 
gel was placed in the electrophoresis chamber in the Owl™ EasyCast™ Mini Gel 
Electrophoresis System and was poured onto with 0.5⨯TBE solution to the level indicated on 
the electrophoresis system. Ten μl of the 6x Orange DNA dye was added per 50 μl of DNA 
sample solution. Next, 20-60 μl of DNA sample – DNA loading dye mix was loaded into the 
wells of the gels, depending on the comb size used. Five μl and ten μl of the 1 kbp DNA 
ladder were also loaded in wells adjacent on both sides to wells containing the DNA sample – 
DNA loading dye mix. Next, the Owl™ EasyCast™ Mini Gel Electrophoresis Systems 
containing the gel was connected to the output jacks of a VWR 250 or Fisherbrand Power 
300 power supplies. The DNA was ran in the gel from the negative towards the positive 
electrode for about 40-120 minutes at constant voltage in the range of 120-200 V. Lower 
voltages were used in the case of Owl™ EasyCast™ B1 Mini Gel Electrophoresis System 
and in case of preparative AGEP when the DNA was subsequently extracted and used for 
subsequent enzymatic reactions (e.g. restriction digestion and ligation). For preparative 
AGEP TopVision low melting point agarose was used. The electrophoresis was stopped 
when the Orange G of the 6x Orange DNA dye reached the end of the gel, knowing that the 
speed at which Orange G migrates through the agarose gel is approximately equivalent to 50 
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bp DNA fragments. After stopping electrophoresis, the DNA containing gel was visualized 
under low intensity 254nm UV light using the UVP BioSpectrum 500 Imaging System. 
DNase and RNase free Agarose (BP1356-100) and TopVision Low Melting Point Agarose 
(R0801) was purchased from Thermo Fisher Scientific Inc., DNase and RNase free agarose 
(A9539-250G) was also acquired from Sigma-Aldrich Corp. Low electroendosmotic agarose 
(A0169-10G) and Tris-Borate-EDTA buffer powder blend (T3913) was purchased from 
Sigma-Aldrich Corp. SYBR safe DNA Gel Stain (S33102) was obtained from Life 
Technologies Inc., 1 kbp DNA ladder (N3232S) was provided by NEB and 6x Orange DNA 
loading Dye (RO631) was ordered from Thermo Fisher Scientific Inc. 
2.3.10 Extraction of DNA fragments from agarose gel  
After imaging the gel, gel bands containing DNA with the size of interest were cut from the 
using 0.13–0.17 mm thick microscopy cover slips. DNA from the excised bands was 
subsequently purified using the QIAquick
®
 Gel Extraction Kit (28706) from Qiagen N.V. 
together with an Eppendorf 5415R or a VWR Galaxy 1814 microcentrifuge, following 
Qiagen’s manual. For this, the gel was weighed on a MH-124 analytical balance from Fisher 
Scientific. Next, the gel was dissolved in 3 gel volumes of solubilisation Buffer QG, 
assuming a gel density of 1 g/ml, and the gel was heated at 50°C for 10 minutes using 
GRANT QBD1 or Techne Dri-block
®
 DB-2D heating blocks, vortexing every 3–5 minutes to 
enhance solubilisation. After solubilisation, the DNA solution was loaded onto the silica 
membrane containing spin column; high chaotropic salt concentrations [486] and a pH ≥7.5 
of Buffer QG ensured that the DNA remained bound to the column while contaminants 
passed through. Next, impurities were washed away by the ethanol-containing Buffer PE, 
then the ethanol was removed by an additional centrifugation step and the DNA was eluted in 
nuclease free water. Following elution, DNA concentrations were measured and DNA quality 
was assessed using a NanoDrop
TM
 2000c Spectrophotometer. As nuclease free water both 
Milli-Q water generated by Pur1te Select EMD Millipore water purification systems and 
Nuclease-Free Water (129114) from Qiagen N.V. was used. Microscopy cover slips (MNJ-
350-110G) were purchased from Gerhard Menzel GmbH. Brunswick, Germany. 
2.3.11 Purification of DNA from PCR or from other enzymatic reactions 
For salt sensitive applications (e.g. blunt end ligation) linear DNA fragments obtained from 
PCR or restriction enzyme digestions were purified using the QIAquick PCR Purification Kit 
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(28706) from Qiagen N.V. together with an Eppendorf 5415R or a VWR Galaxy 1814 
microcentrifuge, following Qiagen’s protocol. For this, the DNA solution was mixed with 5 
DNA solution volumes of Buffer PB which contains high chaotropic salt concentrations [486] 
and a pH ≥7.5, necessary for adsorption of DNA to the silica membrane of the spin columns. 
After DNA binding, impurities from the column were washed away by ethanol-containing 
Buffer PE, and then the ethanol was removed by an additional centrifugation step. Next, the 
DNA was eluted in nuclease free water and DNA concentrations and quality were assessed 
using a NanoDrop
TM
 2000c Spectrophotometer. Nuclease-Free Water (129114) was obtained 
from Qiagen N.V. or generated using Pur1te Select EMD Millipore water purification 
systems. 
2.3.12 Plasmid construction using conventional cloning 
Plasmids or PCR products (with restriction enzyme sites inserted by extensions in PCR 
primers) were digested using restriction enzymes listed in  
 
Table 2.8, following enzyme specific NEB protocols, using supplied buffers (NEBuffer 1, 
NEBuffer 2, NEBuffer 3, NEBuffer 4) and bovine serum albumin, as required. CutSmart™ 
Buffer (B7204S) was also purchased from NEB. Resulting linear DNA fragments were 
separated using Agarose Gel Electrophoresis (AGEP), as described above. DNA was purified 
from the gel using QIAquick
®
 Gel Extraction Kit, as described above. Linear DNA fragments 
with cohesive (sticky) ends were ligated overnight at 16°C or at room temperature for 10 
minutes using the T4 DNA ligase (M0202S) from NEB in 20 µL reaction volumes, following 
the manufacture’s protocol. For linear DNA fragments with blunt ends the room temperature 
ligation reaction was increased to 2 hours as recommended the by the T4 DNA ligase 
providing company. When ligating blunt ended DNA fragments, after digestion, the vector 
fragments were also treated with Thermosensitive Alkaline Phosphatase (M9910) from 
Promega Corp., WI, USA, by incubating for 15 minutes at 37°C to remove the 5’ phosphate 
groups. The Quick Ligation™ Kit (M2200S) from NEB was also used to ligate linear DNA 
fragments. After ligation, 4-10 µl of the solution was transformed into competent E. coli cells 
as described above. 
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Table 2.8. Restriction enzymes from NEB 
No. Enzyme name Recognition site 
Catalogue 
number 
1 EcoRI 
5' G
ᴠ
AATTC 
3' CTTAAᴧG 
R0101S 
2 EcoRV 
5' GAT
ᴠ
ATC 
3' CTAᴧTAG 
R0195S 
3 NheI-HF 
5' G
ᴠ
CTAGC 
3' CGATCᴧG 
R3131S 
4 NotI-HF 
5' GC
ᴠ
GGCCGC 
3' CGCCGGᴧCG 
R3189S 
5 PstI 
5' CTGCA
ᴠ
G 
3' GᴧACGTC 
R0140S 
6 Sal-HF 
5' G
ᴠ
TCGAC 
3' CAGCTᴧG 
R3138S 
7 Xbal 
5' T
ᴠ
CTAGA 
3' AGATCᴧT  
R0145S 
 
2.3.13 Gibson Assembly® plasmid construction 
To join multiple linearized DNA fragments, the Gibson Assembly
®
 was used following the 
manufactures’ instructions. For this, PCR primers with overhangs which were homologous to 
vector ends were designed and synthesized to amplify insert DNA fragments to be assembled. 
Using these primers, linear overlapping insert DNA fragments were amplified by PCR and 
linear vector DNA fragments were obtained by restriction enzyme digestion of circular 
plasmid vectors. Insert DNA fragments obtained by PCR were purified using the QIAquick 
PCR Purification Kit Protocol, the concentration was measured using a NanoDrop
TM
 2000c 
Spectrophotometer and aliquots of this solution were ran on AGEP to check the size of the 
DNA fragments. DNA fragments obtained by restriction digestion were ran on AGEP to 
separate the vector fragments. Fragments were excised and then extracted from the gel using 
the QIAquick
®
 Gel Extraction Kit, then purified using the QIAquick PCR Purification Kit. 
The concentration was determined using a NanoDrop
TM
 2000c Spectrophotometer. Once the 
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desired overlapping linear DNA fragments were obtained, these were mixed following the 
ratio described in Table 2.9 below. 
Table 2.9. Gibson Assembly
®
 reaction mix composition 
 
2–3 Fragment 
Assembly 
4–6 Fragment 
Assembly 
Positive Control** 
Total Amount 
of Fragments 
0.02–0.5 pmols*, X μl 0.2–1 pmols*, X μl 10 μl 
Gibson 
Assembly 
Master Mix 
(2X) 
10 μl 10 μl 10 μl 
Milli-Q H2O 10-X μl 10-X μl 0 
Total Volume 20 μl*** 20 μl*** 20 μl 
* Optimized cloning efficiency is 50–100 ng of vectors with 2–3 fold of excess inserts (If          
   insert size is less than 200 bps, use 5 times more inserts) 
** Control reagents were provided for two experiments. 
*** If greater numbers of fragments are assembled and if the DNA concentration is low and    
       larger volumes were needed, the volume of the Master Mix (2X) was increased to keep    
       the Master Mix (2X) : DNA fragment mix 1:1 ratio.  
 
The reaction mix described in Table 2.9 was incubated in a Labnet MultiGene™ Gradient 
PCR Thermal Cycler (TC9600-G-230V) or in an Eppendorf realplex
4
 epgradient S qPCR 
Mastercycler
®
 at 50°C for 60 minutes. During incubation, the 5’ exonuclease enzyme, 
chewed back 5’ ends of the double stranded DNA, creating single-stranded 3´ overhangs that 
facilitated the annealing of fragments that share complementarity due to extensions added to 
primers (homologous overlap region). Following annealing, the DNA polymerase filled in 
gaps and the DNA ligase sealed nicks in the assembled DNA. After the assembly incubation, 
samples were store on ice or at –20°C for subsequent transformation in competent E. coli 
cells. Transformation was carried out and obtained colonies were brought in liquid LB 
cultures, plasmids were isolated using the QIAprep Spin Miniprep Kit and were sent for 
DNA sequencing. Colonies that yielded the desired plasmids were again grown in liquid LB 
cultures and were stored in 20% glycerol in the -80 °C freezer New Brunswick Scientific 
ultra-low temperature U 725-86 lab freezer. Gibson Assembly
®
 Master Mix (E2611S) was 
ordered from NEB. The pIRES Vector (631605) was purchased from Clontech Laboratories, 
Inc. 
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2.3.14 In-Fusion® HD plasmid construction 
Besides Gibson Assembly
®
, the In-Fusion
®
 HD Cloning Kit (639648) from Clontech was 
also used to join multiple linearized DNA fragments following the manufactures’ 
instructions. Briefly, PCR primers for the gene of interest with 15 bp extensions that are 
complementary to the ends of the linearized vector were designed and synthesized. Using 
these primers, linear overlapping insert DNA fragments were amplified by PCR and linear 
vector DNA fragments were generated by digesting circular plasmid vectors with restriction 
enzymes. Insert DNA fragments obtained by PCR were purified using the QIAquick PCR 
Purification Kit Protocol, the concentration was measured using a NanoDrop
TM
 2000c 
Spectrophotometer and aliquots of this solution were ran on AGEP to check the integrity of 
the PCR product. DNA fragments obtained by restriction were ran on AGEP to separate the 
vector fragments, fragments were extracted from the gel using the QIAquick
®
 Gel Extraction 
Kit, then purified using the QIAquick PCR Purification Kit the concentration was determined 
using a NanoDrop
TM
 2000c Spectrophotometer. Once the desired overlapping linear DNA 
fragments were obtained, these were mixed following the ration described in Table 2.10 
below. 
Table 2.10. In-Fusion
®
 HD reaction mix composition 
Reaction 
Component 
Cloning Rxn Negative Control Rxn Positive Control Rxn 
Purified PCR 
fragment 
10–200 ng* – 
2 μl of 2 kb 
control insert 
Linearized 
vector 
50–200 ng* 1 μl 
1 μl of pUC19 
control vector 
5X In-Fusion 
HD Enzyme 
Premix 
2 μl 2 μl 2 μl 
Milli-Q water to 10 μl to 10 μl to 10 μl 
* For reactions with larger volumes of vector and PCR insert (> 7 μl of vector + insert), the 
amount of enzyme premix was doubled, and Milli-Q water up to a total volume of 20 μl was 
added. 
 
The reaction mix described in Table 2.10 was incubated in a Labnet MultiGene™ Gradient 
PCR Thermal Cycler (TC9600-G-230V) or in an Eppendorf realplex
4
 epgradient S qPCR 
Mastercycler
®
 for 15 minutes at 50°C. During incubation, the 3’ exonuclease enzyme, 
chewed back 3’ ends of the double stranded DNA, creating single-stranded 5´ overhangs that 
facilitate the annealing of fragments that share complementarity due to extensions added to 
primers (homologous overlap region). Following annealing, the DNA polymerase filled in 
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gaps and the DNA ligase seals nicks in the assembled DNA. After the cloning incubation, 
samples were store on ice or at –20°C for subsequent transformation in competent E. coli 
cells. Transformation was carried out and obtained colonies were brought in liquid LB 
cultures, plasmids were isolated using the QIAprep Spin Miniprep Kit and were sent for 
DNA sequencing. Colonies that yielded the desired plasmids were again grown in liquid LB 
cultures and were stored in 20% glycerol in the -80 °C freezer New Brunswick Scientific 
ultra-low temperature U 725-86 lab freezer.  
2.3.15 Production of endotoxin free DNA plasmids for mammalian cell 
culture use  
In order to purify large quantities of plasmids for transfections into mammalian cells, the 
EndoFree
®
 Plasmid Mega (12381) and Giga (12391) Kit from Qiagen N.V. were used 
following the manufacturer’s instruction manual. For this, 2-5 ml of LB medium (containing 
the corresponding selection antibiotic) was inoculated with the E. coli (that contained the 
plasmid to be purified) from freshly streaked selective plate or from frozen stocks. These pre-
cultures were grown over-nigh in 14 ml polypropylene BD Falcon
TM
 tubes with snap cap at 
37°C at 180 RPM in a Labnet 311DS shaking incubator. These starter-cultures were then 
diluted 1/500 to 1/1,000 to inoculate 500 ml of LB culture (containing the corresponding 
selection antibiotic) when high-copy number plasmid was purified using the EndoFree Mega 
kit or to inoculate 2.5 litres of LB culture (containing the corresponding selection antibiotic) 
when low copy number plasmid was purified using the EndoFree Mega kit. To purify high-
copy number plasmid with the EndoFree Giga kit, 2.5 litres of LB culture (containing the 
corresponding selection antibiotic) were inoculated with 1/500 to 1/1,000 dilutions of the pre-
culture. These main cultures were incubated overnight in an IOC400 Gallenkamp orbital 
shaker incubator in 2 l Erlenmeyer conical polycarbonate flasks (10410482) from Thermo 
Fisher Scientific Inc. Next day, bacterial cells were harvested by centrifugation in 50 ml 
polypropylene BD Falcon
TM
 tubes with screw cap at 4,000 x g for 15 min at 4 °C in a Hettich 
Rotanta 460R large bench centrifuge. The pellet was then re-suspended using a Fisher 
Scientific FB15012 vortex mixer or an IKA Lab Dancer S2 shaker and lysed under alkaline 
conditions. The lysate was cleared by filtration using QIAfilter Mega-Giga Cartridges 
connected to a Cole Parmer Instruments 35031-10 Aspirator Pump. Next, the endotoxin 
removal buffer was added to the clear lysate which was then applied to the QIAGEN Anion-
Exchange column for binding under appropriate low-salt and pH conditions. RNA, proteins, 
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dyes, and low-molecular weight impurities were removed by a medium-salt wash. Plasmid 
DNA was eluted in a high salt buffer. Next the DNA was concentrated and desalted by 
adding 0.7 volume of room-temperature (to prevent salt precipitation) isopropanol at 
centrifuged at 15,000 g for 30 minutes at 4°C (to prevent overheating of the sample). 
Alternatively, this isopropanol precipitation was also carried out by centrifugation at 4,500 g 
for 60 minutes at 4°C, without modifying the other parameters. The resulting DNA pellet was 
then washed with endotoxin free room-temperature 70% ethanol and centrifuged at 15,000 g 
for 10 minutes or at 4,500 g for 60 minutes at 4°C. The pellet was air-dried for 20 minutes 
under a Bioquell Class II safety cabinet and resuspended in endotoxin-free Buffer TE or 
endotoxin-free water. 
2.3.16 Mammalian cell culture 
The immortalized human umbilical vein endothelial cell line (EA.hy926) was kindly 
provided by Dr. Beata Wojciak-Stothard from the Department of Experimental Medicine and 
Toxicology, Imperial College London. EA.hy926 cells were cultured in Dulbecco's Modified 
Eagle's Medium (DMEM) supplemented with final concentrations of 5 mM L-Glutamine, 10 
mM 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 10% (v/v) foetal bovine 
serum (FBS) and, optionally, 100 units/ml penicillin with 100 μg/ml streptomycin.  
HeLa cells were provided by Dr. Jennifer Frueh, former PhD student in our group and these 
cells were grown in DMEM supplemented with final concentrations of 5 mM L-Glutamine, 
10 mM HEPES, 10% (v/v) foetal bovine serum (FBS) and, optionally, 100 units/ml penicillin 
with 100 μg/ml streptomycin. 
The immortalized human microvascular endothelial cell line (HMEC-1) was gifted by Ann 
Mccormack and Dr. Adrian H Chester from the National Heart & Lung Institute, Imperial 
College London. HMEC-1 cells were grown in MCDB 131 medium supplemented with final 
concentrations of 15% (v/v) FBS, 1 μg/ml hydrocortisone, 10 ng/ml endothelial cell growth 
factor (ECGF), 2 mM L-glutamine, and, optionally, 100 units/ml penicillin and 100 μg/ml 
streptomycin. 
The immortalized mouse pancreatic endothelial cell line (MS1, Cat. No. CRL-2279) was 
purchased from LGC Standards. The MS1 cell line was cultured in DMEM supplemented 
with 5 mM L-Glutamine, 10 mM HEPES, 20% (v/v) FBS and, optionally, 100 units/ml 
penicillin with 100 μg/ml streptomycin.  
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All cell types were cultured in MCO-18M, MCO-18AC or MCO-18AIC Sanyo incubators at 
37°C, saturated humidity and 5% (v/v) CO2 in Corning
®
 polystyrene cell culture flasks with 
25 cm
2
 or 75 cm
2
 CellBIND
®
 cell growth surface area. Cells were passaged and handled in 
Euroclone Bioair Top Safe 1.5 and Euroclone Bioair Top Safe 1.2 Class II safety cabinets. 
Prior passaging, the culture media, 1 x PBS and trypsin solution was pre-warmed to 37°C in a 
Thermo Fisher Scientific DMU19 Water Bath. For passaging, all cell types were washed 
twice with 1 ml of 1 x PBS solution per 10 cm
2
 of cell growth area and were detached by 
incubating at 37°C for 3-6 minutes in 0.4 ml of 0.25% (w/v) trypsin, 0.02% EDTA solution 
per 10 cm
2
 of cell growth area. Next, 10 ml of culture medium with serum was added per 1 
ml of cell-trypsin solution to neutralize the trypsin, and this solution was transferred to 15 or 
50 ml conical polypropylene CentriStar™ capped tubes to centrifuge for 5 minutes at 220 g 
in a MSE Mistral 2000 centrifuge. The resulting pellet was re-suspended in fresh culture 
medium, transferred to new cell culture flasks and placed back in the cell culture incubator. 
Liquid volumes in the order of millilitres were handled using 5 ml (734-1737), 10 ml (734-
1738) and 25 ml (734-1739) polystyrene Stripettes
®
 attached to Integra Pipetboys. For 
microliter volumes, 10 µl (S1120-3810), 200 µl (S1120-8810), 1,000 µl (S1126-7810) 
StartLab TipOne
®
 Filter Tips were used connected onto Eppendorf Research
®
 plus, 
adjustable-volume, single channel pipettes. For disposal, liquids were aspirated through 
autoclaved glass Pasteur pipettes (612-1701, VWR) and C-Flex tubing (190-947-001, Cole-
Parmer) into a Büchner flask to be neutralized by Klorsept 87 solution (CLE1490, Scientific 
Laboratory Supplies Ltd.). The Büchner flask was connected through Whatman™ Vacu-
Guard Filters (09-744-75, Thermo Fisher Scientific Inc.) to a vacuum line powered by a 
central vacuum pump. Surfaces were sterilized using 70% (v/v) ethanol solution in Milli-Q 
water with 18.2 MΩ⨯cm (at 25°C) resistivity. Ethanol absolute AnalaR NORMAPUR® 
(20821.321) was ordered from VWR BDH Prolabo. Conical 15 ml (734-1867) or conical-
skirted 50 ml (734-1876) polypropylene CentriStar™ tubes with high-density polyethylene 
caps were ordered from VWR. Rectangular Corning
®
 polystyrene cell culture flasks with 25 
cm
2
 (734-1712) and 75 cm
2
 (734-1713 T75) CellBIND
®
 cell growth area, with canted neck 
and with vented cap were purchased from VWR. L-Glutamine free DMEM (D5546), FBS 
(F7524), Hydrocortisone (H0888-1G), ECGF (E2759), L-Glutamine (G8540) and Penicillin-
Streptomycin solution (P4333), PBS (D8537) and Trypsin-EDTA solution (T4049) were 
acquired from Sigma-Aldrich Corp. MCDB 131 Medium (10372-019) was purchased from 
Life Technologies Inc.  
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2.3.17 Freezing of mammalian cells 
For storage, mammalian cells were frozen in liquid nitrogen. For this, cells were detached by 
washing twice with 1 x PBS, followed by trypsinization and cells were pelleted, as described 
above. The pellet was re-suspended in culture media with double the normal FBS 
concentration. A 10 µl aliquot of the cell suspension was mixed with 10 µl 0.4% (w/v) trypan 
blue solution and cells were counted using the Hawksley Improved Neubauer BS 748 
haemocytometer. To the mother solution, another solution, which besides the double to 
normal FBS concentration also contained 20 % dimethyl sulfoxide (DMSO), was added drop-
wise until the two solutions reached a volumetric ratio of 1:1. The final cell concentration 
was of 1 million cells per ml. One ml of this cell suspension was distributed per cryovial and 
cryovials were placed in the Thermo Fisher Scientific™ Mr. Frosty™ Freezing Container 
which contained 250 ml of isopropanol pre-chilled to 4°C. Mr. Frosty™ Freezing Container 
was then placed into the -80°C in a New Brunswick Scientific ultra-low temperature U 725-
86 lab freezer for 24 hours and subsequently cryovials were transferred to the gas phase of 
liquid nitrogen. Since the DMSO solution was not sterile, the culture medium which 
contained 20% DMSO, and had double the normal FBS concentration, was filtered through 
two cellulose acetate membrane VWR filters connected in a series. The first filter had a pore 
diameter of 0.45 µm (514-0063), whereas the pore diameter of the second filter was 0.2 µm 
(514-0061). The liquid was pushed through these filters using a 50 ml syringe (613-4902) 
from VWR. Isopropanol (20842.323) was ordered from VWR BDH Prolabo. DMSO (D8418) 
and 0.4% (w/v) trypan blue (T8154) solutions were supplied by Sigma-Aldrich Corp. 
Fisherbrand polypropylene 2 ml cryovials (12567501) were acquired from Thermo Fisher 
Scientific Inc. 
2.3.18 Thawing of mammalian cells 
Cryovials of cells were removed from the liquid nitrogen tank or from the -80°C New 
Brunswick Scientific ultra-low temperature U 725-86 lab freezer and were immediately 
placed in a 100 ml beaker containing 37°C water, avoiding the water to reach the cap area of 
the cryovial in order to prevent contamination. As soon as the cell solution melted, it was 
transferred into a 50 ml conical-skirted polypropylene CentriStar™ capped tube which 
contained 10 ml culture media pre-heated to 37°C in order to dilute the DMSO. Cells were 
then pelleted by centrifuging for 5 minutes at 250 g in a MSE Mistral 2000 centrifuge. The 
supernatant which contained the DMSO was removed using the vacuum line. Cells were re-
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suspended in culture media, pre-warmed at 37°C and placed in a Rectangular Corning
®
 
polystyrene cell culture flask with 25 cm
2
 CellBIND
®
 cell growth area in 6 ml culture media. 
Cells were placed in 20 ml of culture media when seeding in a cell culture flask with 75 cm
2
 
CellBIND
®
 cell growth area. The day after seeding, cells were visualized under a under Leica 
DM IL LED–DFC295 or Leica DM IL LED–DFC290 inverted phase contrast microscopes 
and checked whether cells were adhering and presenting the morphology characteristic for 
healthy cells. At this time, the culture media was refreshed by aspirating the old media with 
the vacuum line and adding the equivalent volume of fresh media pre-warmed at 37°C. Cells 
were placed back into cell culture incubator and cultured using the standard procedure from 
here onwards.  
2.3.19 Electroporation transfection 
For plasmid electroporation into mammalian cells, the Neon™ Transfection System from 
Life Technologies Inc. with 10 µl electroporation tips was used following the manufacturer’s 
instructions. Briefly, 24 hours prior electroporation, cells were sub-cultured or fed with fresh 
culture medium; to obtain 80-90% cell confluency at the time of electroporation. To 
electroporate, cells were washed twice with PBS, trypsinized, pelleted, re-suspended in PBS 
and counted using the Hawksley Improved Neubauer BS 748 haemocytometer. The 
appropriate amount of cells (50,000 – 300,000 cells per electroporation reaction) was pelleted 
and resuspended in Resuspension Buffer R (proprietary content, provided with the Neon™ 
Transfection System) and 1 µl of plasmid solution (3-15 µg/µl DNA concentration) was 
added for every 9 µl of Buffer R solution. Next, the 10 µl electroporation Neon
TM
 Tip was 
picked up with the Neon
TM
 Pipette. After mixing, this cell-DNA mixture was aspirated in the 
10 µl electroporation Neon
TM
 Tip, avoiding air bubbles, and the Neon
TM
 Tip – NeonTM 
Pipette assembly was inserted into the Neon
TM
 Tube. The Neon
TM
 Tube was pre-loaded with 
3 ml of proprietary Electrolytic Buffer E and was pre-mounted on the Neon
TM
 Pipette Station. 
Next, the cell type specific electroporation pulse was applied from the Neon
TM 
Device which 
was connected to the Neon
TM
 Pipette Station. The Neon
TM
 Pipette together with the cell-DNA 
solution containing Neon
TM
 Tip was removed from the Neon
TM
 Tube and the 10 µl content of 
the Neon
TM
 Tip was emptied and mixed into antibiotic-free culture medium pre-incubated in 
the cell culture incubator (to reach optimal temperature and CO2 content). The multi well 
plate or culture flask containing the electroporate cells was placed back into the cell culture 
incubator and 4-16 hours after electroporation the culture medium was renewed. The wells of 
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multi well plates were pre-coated with 1% gelatine solution by incubating 30 minutes in cell 
culture incubators prior usage for cell culturing purposes. The volume of cell culture solution 
and of the 1% (w/v) gelatine solution in wells of multi well plates was 2, 1, 0.5 and 0.25 ml 
for 6-well, 12-well, 24-well and 48-well plates, respectively.  
To electroporate cells for flow experiments, cells were seeded in a 0.5 x 5 cm well consisting 
of a glass slide clamped together with a Polydimethylsiloxane (PDMS) part as described in 
the Chapter 3. Prior seeding electroporated cells, this well was coated with 150 µL 1mg/ml 
fibronectin solution by incubating in the cell culture incubator for 1 hour and then 800 µl of 
culture media was placed in this well to incubate in the cell culture incubator for 2 hours. 
Pulse voltage (500 – 1500 V), pulse duration (5 – 500 ms), number of pulse (1 – 20) and cell 
electroporation density (50,000 – 300,000 cells per 10 µl) were optimized individually for 
each cell type. Six-well (734-1596), 12-well (734-1597), 24-well (734-1606) and 48-well 
(734-1607) Corning
®
 plates with surfaces treated for tissue culture were ordered from VWR. 
The Neon™ Transfection System 10 µL Kit (MPK1096) and Fibronectin from bovine plasma 
(33010-018) was ordered from Life Technologies Inc. Gelatin from bovine skin (G9382) and 
Fibronectin from bovine plasma (F1141) was ordered from Sigma-Aldrich Corp. Fibronectin 
from bovine plasma (341631) was also ordered from Merck Chemicals KGaA., Darmstadt, 
Germany. 
2.3.20 Mammalian antibiotic selection 
To determine the optimal neomycin (G 418) antibiotic concentration for selection, EA.hy926 
cells were seeded in 12-well plates, pre-coated with 1% (w/v) gelatine, at a density of 3,100 
cells/cm
2
. Twenty-four hours after seeding, the following G 418 concentrations were added to 
the wells of the 12-well plate: 0, 100, 200, 300, 400, 500, 600, 700, 800, 1,000, 1,200 and 
1,500 µg/ml. The media was replaced every 2-3 days with media containing the 
corresponding antibiotic concentrations and the selection was carried out for a period of 7 
days. A similar titration experiment was also carried out for the Hygromycin B antibiotic. 
The antibiotic concentration 100 µg/ml above the lowest mammalian selection antibiotic 
concentrations which killed all the EA.hy926 cells were used in subsequent selection 
experiments. To select EA.hy926 cells that contain pZK13 and pZK14 (Table 2.11), 
EA.hy926 cells were co-transfected with pZK13, pZK14 and the Linear Hygromycin Marker, 
the molar ration of the Linear Hygromycin Marker to plasmids was 1:20. Twenty-four hours 
after transfection, 400 µg/ml of Hygromycin B and 500 µg/ml of G 418 antibiotics were 
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added and re-added in fresh culture media every 2 – 3 days for a period of 6-7 days. 
Following the same procedure, 100 µg/ml of Hygromycin B and G 418 antibiotic 
concentrations were also used for selection. 
G 418 antibiotic was also titrated on HMEC-1 cells to determine the optimal G 418 
concentration for a 2 days selection. For this titration, HMEC-1 cells were seeded in a 24-
well plate, pre-coated with 1% (w/v) gelatine, at a density of 5,200 cells/cm
2
 and 24 hours 
after seeding, G 418 antibiotic was added in the 0 – 2,000 µg/ml concentration range. The 
antibiotic concentration 100 µg/ml above the lowest G 418 concentration that killed the cells 
was used to select HMEC-1 cells transfected with the pZK13 plasmid in a 2 days selection 
experiment.  
Optimizing the mammalian antibiotic selection procedure revealed that the highest 
percentage of cells with responsive gene network was achieved when HMEC-1 cells were 
electroporated with the pZK13 plasmid, 24 hours later 200 µg/ml of G 418 was added, 48 
hours after G 418 addition the selection pressure was removed, 24 hours after this cells were 
electroporated with the pZK14 plasmid and 24 hours after the second electroporation the 
gene network was induced. Ten minutes after the second electroporation, the gene network 
was inhibited with doxycycline and doxycycline was removed 2 minutes before inducting the 
gene network. Linear Hygromycin Marker (631625), comprising of the marker gene, an 
SV40 promoter, and the SV40 polyadenylation signal, were ordered from Clontech. G 418 
disulfate salt (A1720-1G) was ordered from Sigma Aldrich Corp. Hygromycin B (10687-
010) purchased from Life Technologies Inc.  
2.3.21 Induction and inhibition of the gene network  
To induce the expressed gene network, 4 – 24 hours after electroporation, 2 µM of [Hyp3]-
Bradykinin and 2 µM of Bradykinin [487-490] was added to the culture and the following 
day the cells were imaged. To enhance the induction, the same amount of [Hyp
3
]-Bradykinin 
and Bradykinin was re-added every 6 – 12 hours after the first addition, knowing that 
Bradykinin has a half-life in the order of seconds to minutes [491-495]. For induction, shear 
stress was also applied by pipetting using a 1,000 µl Eppendorf Research
®
 plus, adjustable-
volume, single channel pipette with 1,000 µl StartLab TipOne
®
 Filter Tips. 
To induce the gene network by applying well controlled shear stress, flow experiments were 
carried out using both conventional and in-house developed flow setups (see below). 
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To inhibit the gene network at the shear stress sensor level, 20–100 nM of the HOE 140 
selective B2 Bradykinin receptor antagonist was added 1 – 24 hours after electroporation 
[496-498]. To inhibit the gene network at the transcription factor (tTA) level, 20 ng/ml 
doxycycline was used [499, 500].  
Bradykinin acetate salt (B3259-1MG), [Hyp
3
]-Bradykinin (B7775-1MG), HOE 140 (H157-
250UG) and Doxycycline hyclate (D9891-1G) were purchased from Sigma-Aldrich Corp. 
2.3.22 Flow experiments  
To expose cells to well controlled levels of shear stress, flow experiments were carried out. 
The flow setup consisted of a peristaltic pump, a bubble catcher media reservoir, platinum-
cured silicone tubing and a flow channel. The peristaltic pump was either a Cobe precision 
peristaltic pump (03600-001) from COBE Laboratories, Inc., Lakewoor, CO. USA or a 
Perista Pump (SJ-1220) with 4 channels from Atto Bioinstrument Corp., Japan. Two different 
high temperature resistant, inert media reservoirs were used. The first one was a 150 ml glass 
chamber with a loosely fitted lid modified with a media inlet and with an outlet at the bottom 
of the chamber. The second reservoir was a 500 mL Schott glass bottle with a modified cap. 
The screw-on polypropylene cap was perforated to fit three tubes: media inlet, media outlet 
and gas exchange (fitted with a 0.22 μm hydrophobic filter). The flow channel was either a 
conventional µ-Slide I 
0.2
 Luer (80166 or 80161), µ-Slide I 
0.4
 Luer (80176 or 80171), µ-Slide 
I 
0.6
 Luer (80186), µ-Slide I 
0.8
 Luer (80196 or 80191) channel from ibidi GmbH., 
Martinsried, Germany or the in-house designed flow channel (as described in Chapter 3). For 
the pump head, a 36 cm long platinum-cured silicone tubing (WZ-95802-04) of 3 mm inner 
diameter and 4.8 mm outer diameter from Cole Parmer was used. The rest of the components 
of the flow setup were connected by platinum-cured silicone tubing (WZ-95802-03) of 2.29 
mm inner diameter and 4 mm outer diameter from Cole Parmer. The tubing was connected to 
the flow channel using Luer to 200 series barb elbow connectors with 3.2 mm inner diameter 
from The West Group Ltd., Waterlooville, UK. The pump head tubing was connected to the 
rest of the tubing using straight through connector with classic series barbs with 3.2 mm inner 
diameter from The West Group Ltd. The flow setup was sterilized by autoclaving at 135 °C 
for 5 minutes in a MLS-3751L Sanyo autoclave. Seventy ml of culture media was added to 
the media reservoir and the flow setup was placed in a cell culture incubator for 2 hours to 
equilibrate the gas concentrations and temperature before starting the flow experiment. For 
flow experiments using ibidi µ-Slide I Luer Family channels, channels were coated with 1 
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mg/ml fibronectin or 1% (w/v) gelatine. In case of channels with tissue culture treated 
ibiTreat hydrophilic surfaces, no further coating was applied. Next, cells were seeded at a 
density of 40000 cells/cm
2
. Twenty-two hours after cell seeding, 60–80 ml culture media was 
placed in the bubble-catcher media reservoir of the flow setup and this setup was placed 
inside the cell culture incubator for two hours in order to allow the culture medium to reach 
the temperature and gas content optimal for cell experiments. Twenty-four hours after cell 
seeding, the tubing of the pre-equilibrated flow setup was connected to the cell containing 
flow channel, avoiding air bubbles. The pump head tubing was coupled to the pump and the 
flow experiment was started by priming cells for 2 hours at 0.2–0.5 Pa. Over the course of the 
following hour, the flow rate was gradually increased to yield the experimental 1.5-2 Pa shear 
stress for 24 hours. When the Atto Perista Pump was used the entire setup, including the 
pump was placed inside the cell culture incubator. In case of the Cobe pump, the flow setup 
was placed inside the incubator but the pump stayed outside the incubator. The culture media 
was circulating from the media reservoir, through the flow channel to the pump and back to 
the media reservoir. 
Flow experiments carried out in the in-house designed flow device are described in Chapter 
3. 
2.3.23 Cell staining and fixation  
At the end of the flow experiments, the flow setup was disassembled. In case of the in-house 
designed flow channel, the glass slide with the cell monolayer was placed in a round petri 
dish (101VBLUE) with a diameter of 9 cm from Sterilin Ltd., Newport, UK. To assess cell 
viability, propidium iodide (P3566) from Life Technologies Inc. was used to stain the DNA 
of dead cells. The nuclei of all cells (dead and alive) were stained with Hoechst 33342 
(H3570) from Life Technologies Inc. EA.hy926 cells were stained with 0.5 µg/ml propidium 
iodide in DMEM solution by incubating at room temperature for 30 minutes. HeLa and 
EA.hy926 cells were stained with 2 µg/ml Hoechst 33342 DMEM solution by incubating at 
room temperature for 5 minutes. HMEC-1 cells were stained with final concentration of 1 
µg/ml propidium iodide and 2 µg/ml Hoechst 33342 solutions in DMEM by 10 minutes 
incubation. Following staining, cells were washed twice with PBS and fixed with 4% 
(paraformaldehyde) PFA by incubation at room temperature in a fume hood for 15 minutes, 
then cells were washed twice again with PBS and stored at 4°C for subsequent imaging. 
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2.3.24 Microscopy imaging 
Cells were visualized under Leica DM IL LED–DFC295 or Leica DM IL LED–DFC290 
inverted phase contrast microscopes. Cells were imaged using a Hamamatsu ORCA-ER 
camera coupled to a Zeiss Axiovert 200 inverted fluorescent microscope with a fully 
motorised stage, controlled by Improvision Volocity acquisition software. For imaging, the 
brightfield Köhler illumination was first adjusted and the Zeiss EC Plan-Neofluar 10x 0.30 
Ph1 objective was used with the phase contrast 1 channel (Ph1), Zeiss Filter Set 01 (DAPI), 
Zeiss Filter Set 15 (TRITC) and Zeiss Filter Set 10 (FITC) in combination with a mercury 
fluorescence lamp. To capture the surface of the entire cell monolayer or slide, the 
microscope was programmed for tile acquisition. For this, the microscope stage was first 
calibrated, the region of interest (ROI) was defined, a focus map was created using 5-10 
randomly selected points per cm
2
 of the ROI, and finally the tile acquisition protocol was 
stared using 10-20% overlap between tiles and following the created focus map to keep the 
specimen in focus.  
2.3.25 Image processing for determining cell viability and transfection 
efficiency 
To count cells, the acquired microscopy images were processed in ImageJ 1.47 [501, 502] . 
As a first step, images were calibrated (by correlating pixels to micrometres) by drawing a 
line (measured in pixels) that had the same length as the scale-bar (measured in µm). Then, 
the pixel/µm ratio was determined using the Set Scale function in imageJ. Next, the size 
(area) range of cells to be counted was determined by measuring a very small cell and setting 
its dimensions as the lower limit of the range, the upper limit was set to infinity. For the 
actual cell counting, the colour threshold was adjusted until the background noise 
disappeared, images were converted to binary, touching cells were separated using the 
watershed segmentation algorithm, and finally cells were counted with analyse particles 
command. In the analyse particles function, the circularity was set from 0.10 – 1.00 and the 
size of the cells to be counted was set to the predefined value range. To automate the process, 
a macro script was created and applied for the steps following colour thresholding.  
Counting Hoechst 33342 stained blue fluorescent nuclei gave the total number of cells, 
propidium iodide stained red fluorescent cells showed the number of dead cells, and cells 
turned green fluorescent due to eGFP or MGFP expression represented the positive cells. The 
percentage of green fluorescent cells and cell viability was calculated from fluorescent 
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images recorded on the same cell population using Equation 2.1 and Equation 2.2, 
respectively.  
 
𝐺𝑝 =
Gn
Bn
 × 100  [%] 
Equation 2.1. Calculation of the percentage of green fluorescent cells from fluorescent 
microscopy images.  
Where:  
Gp: Percentage of green fluorescent cells. 
Gn: Number of green fluorescent cells (eGFP or GFP expressing cells) 
Bn: Number of blue fluorescent cells; total number of cells, including dead and living     
       cells (Hoechst 33342 stained cells). 
 
Cv = 100 −
Rn
Bn
 × 100  [%] 
Equation 2.2 Calculation of cell viability from fluorescent microscopy images. 
Where:  
Cv: Cell viability, in percentage. 
Rn: Number of red fluorescent cells; number of dead cells (propidium iodide stained     
cells) 
Bn: Number of blue fluorescent cells; total number of cells, including dead and live     
       cells (Hoechst 33342 stained cells). 
2.3.26 Lipofectamine® transfection 
Cells were also transfected with the Lipofectamine
®
 Transfection Reagent (18324-012) in 
combination with the PLUS
TM
 Reagent (11514-015) from Life Technologies Inc., following 
the manufacturer’s protocol. For this, the day before transfection, cells were seeded in 500 μl 
of antibiotic free culture medium in 24 well plates so that the cells become 50-80% confluent 
at the time of transfection. For transfection, 0.4 µg of DNA in 25 µl of Opti-MEM
®
 I 
Reduced Serum Medium per well was pre-complexed with 4 µl of PLUS
TM
 Reagent per well 
by incubating at room temperature for 15 minutes. One µl of Lipofectamine
®
 Reagent per 
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well was diluted into 25 µl of Opti-MEM
®
 I Reduced Serum Medium per well, was mixed 
with the pre-complexed DNA–PLUSTM Reagent solution and was incubated at room 
temperature for 15 minutes. The medium on cells was replaced with 0.2 ml of serum free 
growth medium per well and 50 µl of DNA–PLUSTM–Lipofectamine® Reagent mixture was 
added per well to the cells. Complexes were gently mixed into the medium and cells were 
placed back in the incubator. Three hours later, the volume of the culture media in wells was 
increased by 250 µl using double than normal serum concentration medium, bringing the 
volume and serum concentration to normal levels. To maximize cell growth, 12-24 hours 
after transfection, the medium containing the complexes was replaced with fresh, complete 
culture medium. In case of transfection with the phMGFP constitutive GFP plasmid, cells 
were visualized 24-36 hours after transfection. When transfected with plasmids encoding the 
gene network, the gene network was induced with 2 µM of [Hyp
3
]-Bradykinin 24 hours after 
transfection and cells were visualized 48 hours after transfection. Phenol Red free Opti-
MEM
®
 I Reduced Serum Medium (11058-021) was ordered from Life Technologies Inc. 
2.3.27 TurboFectTM transfection 
TurboFect
TM
 Transfection Reagent (R0531) from Thermo Fisher Scientific Inc. was also used 
as an alternative reagent, following the manufacturer’s instruction. Cells were seeded in 500 
µl culture medium, in 24 well plates, 24 hours prior transfection to reach 70-80% confluency 
at the time of transfection. For each well, 1 µg of DNA and 2 µl of transfection reagent was 
added to 100 µl of serum-free growth medium. This solution was incubated a room 
temperature for 20 minutes and 100 µl of the transfection reagent – DNA mixture was added 
drop-wise to each well. The plate was gently rocked to evenly distribute the complexes and 
was placed back into the cell culture incubator. For optimization purposes, the volume of the 
transfection reagent solution was varied between 1 and 3.5 µl and the amount of DNA 
between 0.5 and 2 µg. Cells were visualized 24-36 hours after transfection in case of 
transfection with the phMGFP constitutive GFP plasmid. When transfected with the gene 
network, the gene network was induced with 2 µM of [Hyp
3
]-Bradykinin 24 hours after 
transfection and cells were visualized 48 hours after transfection. 
2.3.28 Reverse transfection using Lipofectamine® 
As an alternative transfection method, reverse transfection using Lipofectamine
®
 
Transfection Reagent was also employed, as described before [503]. First, 834 ng of plasmids 
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in Opti-MEM
®
 I Reduced Serum Medium were pre-complexed with 1.4 µl PLUS
TM
 Reagent 
or complemented with 1.4 µl of Opti-MEM
®
 I Reduced Serum Medium (without PLUS
TM
 
Reagent condition). After 15 minutes of incubation at room temperature, 1 µl of 
Lipofectamine
®
 Reagent containing 0 or 0.189 M sucrose was added to the pre-complexed 
DNA–PLUSTM Reagent solution. Following further 20 minutes incubation at room 
temperature, 5 µl of 1 mg/ml of fibronectin or 7.63 µl of 0.2% w/v gelatine was added to the 
pre-complexed DNA–PLUSTM–Lipofectamine® Reagent mixture, bringing the total up to 20 
µl for each of the 24 different mixtures. This solution was then spotted onto 0.1 % (w/v) 
poly-L-lysine coated and uncoated Corning
®
 plain microscopy glass slides using a GeSIM 
robotic Nano-Plotter
TM
 NP2.1 systems with the piezoelectric Pico-Tip J. The glass slides 
were contained in 128 x 86 mm rectangular wells of a Polystyrene, lidded, Nunclon
TM
 Delta 
surface treated flat bottom Nunc
TM
 Multidish (12-565-494) from Thermo Fisher Scientific 
Inc. After spotting, the slides were dried for 24 hours in a desiccator under vacuum. For 
transfection, 35,000 of HMEC-1 cells were gently seeded per cm
2
 of these slides in 5 ml of 
culture media per 128 x 86 mm rectangular Nunc
TM
 Multidish well. The gene network was 
induced with 2 µM of [Hyp
3
]-Bradykinin 24 hours after cell seeding and cells were imaged 
48 hours after transfection. Poly-L-lysine solution (P4707) and Sucrose (S0389) was 
purchased from Sigma-Aldrich Corp. 
 
 
 RESULTS AND DISCUSSION 2.4
2.4.1 Plasmid construction 
Original Tango assay plasmids, pZK1-pZK6, Table 2.11, were transformed into competent E. 
coli cells for amplification and storage. Obtained E. coli strains, ZK_S1-ZK_S3 are listed in 
Table 2.12. Plasmids pZK1, pZK5 and pZK6, isolated from these E. coli strains, were DNA 
sequenced with primers number 1 – 18, 44 – 52 and 53 – 67, respectively, listed in Table 2.13 
below. DNA sequencing primers were designed using gene sequences from National Center 
for Biotechnology Information (NCBI) GenBank as a template; template NCBI gene 
sequences are shown in Appendix 1. DNA sequences obtained by sequencing are shown in 
Appendix2.  
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Table 2.11. Mammalian expression DNA plasmids 
Plasmid 
name 
Gene content 
Plasmid 
backbone 
Plasmid 
size [kbp]  
Antibiotic 
marker 
Source 
pZK1 α2A-AR-AVPR2tail-
TCS-tTA 
pCI (Promega) 
6.5 
Ampicillin Dr. Barnea* 
pZK2 α2C-AR-AVPR2tail-
TCS-tTA 
pCI (Promega) 
6.5 
Ampicillin Dr. Barnea* 
pZK3 β1-AR-AVPR2tail-
TCS-tTA 
pCI (Promega) 
6.6 
Ampicillin Dr. Barnea* 
pZK4 β2-AR-AVPR2tail-
TCS-tTA 
pcDNA3 
7.8 
Ampicillin Dr. Barnea* 
pZK5 βArrestin2-TEV pcDNA3 7.4 Ampicillin Dr. Barnea* 
pZK6 Luciferase tango 
reporter 
pUHC 13-3 
5.5 
Ampicillin Dr. Barnea* 
pZK7 BDK-B2 pBSII SK(+) 4 Ampicillin Eurofins 
pZK8 eGFP pCR2.1 4.7 Ampicillin Eurofins 
pZK9 BDK-B2-AVPR2tail-
TCS-tTA 
pCI (Promega) 
6.2 
Ampicillin In-house 
pZK10 eGFP reporter pUHC 13-3 4.9 Ampicillin In-house 
pZK11 Constitutive Monster 
GFP 
phMGFP 
4.7 
Ampicillin Promega 
pZK12 Bicistronic plasmid pIRES 6.1 Ampicillin Clontech 
pZK13 
BDK-B2-AVPR2tail-
TCS-tTA-IRES-
βArrestin2-TEV 
pIRES 10.3 
Ampicillin, 
neomycin 
(G 418) 
In-house 
pZK14 eGFP reporter pTRE3G 4.1 Ampicillin Dr. Wilson
$ 
pZK15 hKLF2 
pBRYCAG-
floxStop 
dsRED-IresPuro 
9.8 
Ampicillin, 
Puromycin 
Addgene 
pZK16 hKLF2 reporter pTRE3G 4.4 Ampicillin In-house 
Legend: α2A-AR - human α2A-adrenergic receptor; AVPR2tail - last 29 amino acids of 
human arginine vasopressin receptor 2; TCS - tobacco etch virus protease (TEV) cleavage 
site; tTA - transcription factor; α2C-AR - human a2C-adrenergic receptor; β1-AR - human 
b1-adrenergic receptor; β2-AR - human b2-adrenergic receptor; βArrestin2 - human b-
arrestin2; TEV - catalytic domain tobacco etch virus NIa protease (amino acids 189-424 of 
the mature NIa protease); Luciferase – firefly luciferase, BDK-B2 – human bradykinin 
receptor B2; eGFP – enhanced green fluorescent protein; Monster GFP – monster green 
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fluorescent protein; IRES – Internal ribosome entry site; hKLF2 – human Krüppel-like 
factor 2. 
* Courtesy of Dr. Gilad Barnea from Brown University, USA, tango assay developer 
$
 Courtesy of Dr. Miranda SC Wilson and Dr. Adolfo Saiardi from the MRC 
Laboratory for Molecular Cell Biology, University College London, UK. 
 
Table 2.12. E. coli strains created 
Name strain 
Plasmid 
content 
Antibiotic 
marker 
ZK_S1 JM109* pZK1 Ampicillin 
ZK_S2 JM109* pZK5 Ampicillin 
ZK_S3 JM109* pZK6 Ampicillin 
ZK_S4 JM109* pZK7 Ampicillin 
ZK_S5 JM109* pZK8 Ampicillin 
ZK_S6 JM109* pZK9 Ampicillin 
ZK_S7 JM109* pZK10 Ampicillin 
ZK_S8 JM109* pZK11 Ampicillin 
ZK_S9 JM109* pZK12 
Ampicillin, 
neomycin (G 
418) 
ZK_S10 DH5α** pZK13 
Ampicillin, 
neomycin (G 
418) 
ZK_S11 JM109* pZK14 Ampicillin 
ZK_S12 DH5α** pZK16 Ampicillin 
*Genotype: endA1, recA1, gyrA96, thi, hsdR17 (rk
–
, 
mk
+
), relA1, supE44, Δ( lac-proAB), [F´ traD36, proAB, 
laqI
qZΔM15]. From Promega. 
**Genotype: F
–
, Φ80lacZΔM15, Δ(lacZYA-argF), 
U169, recA1, endA1, hsdR17 (rK
–
, mK
+
), phoA, supE44, 
λ–, thi-1, gyrA96, relA1. From Life Technologies Inc. 
 
Within pZK1 and pZK6 sequences obtained by DNA sequencing, coding regions of interest 
(α2A-AR-AVPR2tail-TCS-tTA and Luciferase) were mapped by aligning with coding 
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sequences of the same genes (Appendix 1), from NCBI GenBank. Sequences were aligned 
using SerialCloner2.1 and T-coffee [3]. These results confirmed that pZK1 encodes for the 
human α2A-adrenergic receptor (α2A-AR) fused to the last 29 amino acids of human 
arginine vasopressin receptor 2 (AVPR2tail), tethered to the tobacco etch virus, TEV, 
protease cleavage site (TCS) followed by the transcription factor tTA, as expected. According 
to these sequencing results, the human βArrestin2 gene fused to the tobacco etch virus NIa 
protease catalytic domain (amino acids 189-424 of the mature NIa protease) and the firefly 
luciferase reporter gene were encoded on plasmids pZK5 and pZK6, respectively. Primers 
19-43 from Table 2.13 were designed to sequence plasmids pZK2-pZK4 as a backup, in case 
that sequencing of pZK1 was not giving expected results. 
 
Table 2.13. DNA sequencing primers 
No. Primer name Primer Sequence (5’→3’) 
1 pZK1_seq_F_01 GTCATCTCGTCGTGCATCGGC 
2 pZK1_seq_F_02 CCGAGAACCTGTACTTCCAGC 
3 pZK1_seq_F_03 CACGCGCAGACTGTCGACGGC 
4 pZK1_seq_R_01 CCCGTTCCAGCTCGCGTTGCC 
5 pZK1_seq_R_02 TTGATGCGGCGCGGCGTGCGC 
6 pZK1_seq_R_03 CAGCACACCACGAACACTCCG 
7 pZK1_seq_R_04 GCTTGTCGTAATAATGGCGGC 
8 pZK1_seq_F_-01 GCTATTACCATGGTGATGCGG 
9 pZK1_seq_F_01a GCAAGGCCCGAGCGAGCCAGG 
10 pZK1_seq_F_02a TGCATTATATGCACTCAGCGC 
11 pZK1_seq_F_02b CTACCATCGAGGGCCTGCTCG 
12 pZK1_seq_R_03a CCGATGCACGACGAGATGACG 
13 pZK1_seq_R_04a ACATGCCAATACAATGTAGGC 
14 pZK1_seq_R_05 TCGGCCATATCCAGAGCGCCG 
15 pZK1_seq_R_06 TGGCAAGTGTAGCGGTCACGC 
16 pZK1_seq_R_07 CTGAGAGTGCACCATATGCGG 
17 pZK1_seq_T7 TAATACGACTCACTATAGGG 
18 pZK1_seq_BGH-
Reverse 
TAGAAGGCACAGTCGAGG 
19 pZK2_seq_F_01 GCTGGGCGCGGCGGCAGGCGC 
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20 pZK2_seq_F_02 CCGAGAACCTGTACTTCCAGC 
21 pZK2_seq_F_03 CTCCGCGCCTGTCCTTTCTCC 
22 pZK2_seq_R_01 CCTCTCGCCCGCGCCGCTCGC 
23 pZK2_seq_R_02 TTGACGCGGCGTGGTGTGCGC 
24 pZK2_seq_R_03 CGGAGCGCGAGCTGGCGCGCG 
25 pZK2_seq_R_04 ATCTCAATGGCTAAGGCGTCG 
26 pZK2_seq_R_05 AAATAATTCGATAGCTTGTCG 
27 pZK3_seq_F_01 GGCGGAGAGCGACGAGGCGCG 
28 pZK3_seq_F_02 CCGCCTCGGACGACGACGACG 
29 pZK3_seq_F_03 AGTACATTTAGGTACACGGCC 
30 pZK3_seq_F_04 CGCATGCCGACGCGCTAGACG 
31 pZK3_seq_R_01 TGGCGGGAGGCAGCAACGAGG 
32 pZK3_seq_R_02 GTCAGCAGGCTCTGGTAGCGG 
33 pZK3_seq_R_03 GCAGAGCAGTCCCTGGAAGGCC 
34 pZK3_seq_R_04 CATTAAGCAGCTCTAATGCGC 
35 pZK3_seq_R_05 CGACAGTCTGCGCGTGTGTCC 
36 pZK4_seq_F_01 CATGGACTCCGCAGATCTTCC 
37 pZK4_seq_F_02 AGAGCTGCTTAATGAGGTCGG 
38 pZK4_seq_F_03 CGCATGCCGACGCGCTAGACG 
39 pZK4_seq_R_01 GATGAGAGACATGACGATGCC 
40 pZK4_seq_R_02 TCGTGAAGAAGTCACAGCAGG 
41 pZK4_seq_R_03 GCCCACAAAGTCTTCCGTGCC 
42 pZK4_seq_R_04 ATGTACTTTTGCTCCATCGCG 
43 pZK4_seq_R_06 TCGTCGTCCGGGAGATCGAGC 
44 pZK5_seq_F_01 TGGACAAGGAGCTGTACTACC 
45 pZK5_seq_F_02 GCGGATCTAGCTTGTTTAAGG 
46 pZK5_seq_F_03 CATGAGCAAACCTGAAGAGCC 
47 pZK5_seq_R_01 AAGCACCACGCCATCTACAGG 
48 pZK5_seq_R_02 ACCTTTCGGATCACCAGCCGC 
49 pZK5_seq_R_03 CCACAGGGACATCTGTCTCCG 
50 pZK5_seq_R_04 GGTGTTGTTGCAAAGTCGTGG 
51 pZK5_seq_T7 TAATACGACTCACTATAGGG 
52 pZK5_seq_ BGH-
Reverse 
TAGAAGGCACAGTCGAGG 
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53 pZK6_seq_F_01 TTGACCTCCATAGAAGACACC 
54 pZK6_seq_F_02 CGAGGTGAACATCACGTACGC 
55 pZK6_seq_F_03 TCAACAGTATGAACATTTCGC 
56 pZK6_seq_F_04 ACTCGGATATTTGATATGTGG 
57 pZK6_seq_F_05 TTGATTGACAAGGATGGATGG 
58 pZK6_seq_F_06 TCTTACCGGAAAACTCGACGC 
59 pZK6_seq_F_07 GCTATTGTAATGACTCTAGAGG 
60 pZK6_seq_R_01 ACCGTACACGCCTACTCGACC 
61 pZK6_seq_R_02 GCGTACGTGATGTTCACCTCG 
62 pZK6_seq_R_03 AGAGGAATTCATTATCAGTGC 
63 pZK6_seq_R_04 AATCCACATATCAAATATCCG 
64 pZK6_seq_R_05 TCCTCTGACACATAATTCGCC 
65 pZK6_seq_R_06 GTCGAGTTTTCCGGTAAGACC 
66 pZK6_seq_T7 TAATACGACTCACTATAGGG 
67 pZK6_seq_ BGH-
Reverse 
TAGAAGGCACAGTCGAGG 
68 pZK7_ seq_M13-FP TGTAAAACGACGGCCAGT 
69 pZK7_ seq_M13-RP CAGGAAACAGCTATGACC 
70 pZK8_seq_ M13-FP TGTAAAACGACGGCCAGT 
71 pZK8_seq_ M13-RP CAGGAAACAGCTATGACC 
72 pZK9_ seq_R_04 GCTTGTCGTAATAATGGCGGC 
73 pZK9_ seq_ R_04A ACATGCCAATACAATGTAGGC 
74 pZK9_ seq_ F_-01 GCTATTACCATGGTGATGCGG 
75 pZK9_F1_22Jan2013 GGTGTACGCTGCTCCTGAGC 
76 pZK9_R1_22Jan2013 TGTTGAGCCAGCCCAGCC 
77 pZK9_R2_22Jan2013 GCCCACGACATTCAGGAGC 
78 pZK9_R3_22Jan2013 TGAATCTGGCGTTCCACGG 
79 pZK10_ seq_F_01 TTGACCTCCATAGAAGACACC 
80 pZK10_ seq_R_06 GTCGAGTTTTCCGGTAAGACC 
81 pZK10_06Nov2012_R1 AAACAAGTTAACAACAATTGC 
82 pZK10_06Nov2012_F1 TGTCAGCTTTGCACAAGGGCC 
83 pZK10_06Nov2012_F2 GATACGCCTATTTTTATAGGG 
84 pZK10_21Nov2012_F1 AGCACGGAAAGACGATGACGG 
85 pZK10_21Nov2012_F2 AATATCTGGGAAGTCCCTTCC 
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86 pZK10_21Nov2012_F3 CAGAAGTGTTGGTAAACAGCC 
87 pZK10_21Nov2012_R1 CTTTTGAGAGGGAGTACTCACC 
88 pZK10_21Nov2012_R2 TAGCGCAGAAGTCATGCCCGC 
89 pZK10_21Nov2012_R3 TCGCCGTCCAGCTCGACCAGG 
90 pZK10_21Nov2012_R4 ACACCACAGAAGTAAGGTTCC 
91 pZK10_21Nov2012_R5 TATGATTATAACTGTTATGCC 
92 pZK10_21Nov2012_R6 GACAAACCACAACTAGAATGC 
93 pZK10_21Nov2012_R7 GCTGTTTACCAACACTTCTGG 
94 pZK11_seq_T7 TAATACGACTCACTATAGGG 
95 pZK11_seq_T7-981079 TAATACGACTCACTATAG 
96 pZK11_seq_T7minus1 AATACGACTCACTATAGGG 
97  pZK13_R1_8March2013 GTCAGACATGAGGAAGTGGCG 
98 pZK13_F1_8March2013 CTAGGGCGGCCAATTCCG 
99 pZK13_F2_8march2013 GGAATAAGGCCGGTGTGCG 
100 pZK15_28Jan2013_F1 CGTCCTTCTCCACTTTCGCC 
101 pZK15_28Jan2013_F2 TCGGTGGCCCTGGTTTCG 
102 pZK15_28Jan2013_F3 TGAAACGGCACATGTAGCCG 
103 pZK15_28Jan2013_F4 TTTTTGGGCTACCTGGTTCG 
104 pZK15_28Jan2013_R1 GGCGAAAGTGGAGAAGGACG 
 
The identified α2A-AR gene sequence was replaced in silico with the human bradykinin 
receptor B2 (BDK-B2) coding sequence, whereas the Luciferase genes sequence was 
changed in silico to the enhanced green fluorescent protein (eGFP) coding sequence. Inserted 
BDK-B2 and eGFP coding sequences and neighbouring regions from the plasmid upstream 
and downstream, until the nearest unique restriction endonuclease site, were sent for 
synthesis to Eurofins NWG Operon, Ebersberg, Germany. Sequences sent for synthesis are 
shown in Appendix 3. Synthesized DNA sequences were received on plasmids pZK7 and 
pZK8, Table 2.11. Plasmids pZK7 and pZK8 were sequenced with primers 68-69 and 70-71 
from Table 2.13, respectively, to confirm the identity of DNA sequences. Resulting DNA 
sequences are shown in Appendix 4. E. coli stains ZK_S4 and ZK_S5 were created to store 
and amplify plasmids pZK7 and pZK8, respectively. 
Both plasmids pZK1 and pZK7 were sequentially digested with restriction endonucleases 
EcoRI and Xbal and resulting fragments were separated by electrophoresis on 1% agarose 
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gel, Figure 2.5. The first lane on these figures contains 5 µl of the 1 kb DNA ladder loaded 
per well, whereas in the last lane 10 µl of the same ladder solution from NEB was include as 
size reference. Two different amounts of the same ladder were loaded to both ends of the gel 
to match the intensity of the DNA sample band during imaging: in case the intensity of the 
sample DNA bands was very low, the ladder from the 5 µl lane was used as a reference since 
the 10 µl ladder lane became overexposed under these imaging conditions; in case the 
intensity of the sample bands was very high, the 10 µl ladder lane was used since the 5 µl 
ladder lane became underexposed in these imaging conditions. The second lane of Figure 
2.5A (pZK7) is the uncut plasmid; the third lane (pZK7+EcoRI) contains pZK7 digested with 
EcoRI, whereas the fourth lane (pZK7+XbaI) shows pZK7 digested with the restriction 
enzyme XbaI. DNA fragments resulting from the sequential double digestion of pZK7 first 
with EcoRI and then with XbaI, were run on the fifth lane of the gel (pZK7+EcoRI+XbaI). 
Sequential double digestion products of pZK7, first with XbaI and then with EcoRI, are 
visible on the sixth lane (pZK7+XbaI+ EcoRI) of the same gel. The seventh lane (pZK1) 
contains the undigested pZK1 plasmid; the eight lane (pZK1+EcoRI) shows pZK1 after 
digestion with EcoRI; the ninth lane (pZK1+XbaI) contains pZK1 digested with Xbal. 
Plasmid pZK1 after sequential digestion, first with EcoRI and then with XbaI were loaded on 
the tenth lane (pZK1+EcoRI+XbaI) of the electrophoretic gel, whereas the sequential double 
digestion in the reversed order, first XbaI and then EcoRI, of same pZK1 plasmid ran on the 
eleventh lane (pZK1+XbaI+ EcoRI) of the agarose gel.  
Figure 2.5B is an image of the agarose gel on which plasmids pZK6 and pZK8 single and 
sequentially double digested with restriction enzymes Pstl and EcoRV were separated. 
Similarly to Figure 2.5A, between the 1 kb DNA ladders (lane one and twelve) of Figure 
2.5B, the undigested plasmids (lane two and seven), then single cut plasmids with both Pstl 
and EcoRV (lane three, four, eight and nine), followed by sequential double digestions with 
Pstl and EcoRV (lane five and ten) and then with EcoRV and Pstl (lane six and eleven) are 
shown for plasmids pZK8 and pZK6, respectively. Figure 2.5B also proves that pZK8 
contains three Pstl sites, since three different DNA bands are visible in lane three where 
pZK8 was digested with PstI alone. When pZK8 was double digested with Pstl and EcoRV or 
with EcoRV and Pstl, three DNA bands of similar size as in case of single digestion with Pstl 
alone are obtained. This indicates that the unique EcoRV site is located in close proximity to 
one of the three Pstl sites. The close proximity of EcoRV to one of the Pstl sites was also 
confirmed by the sequencing data (shown in Appendix 4). Plasmids were digested with both 
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enzymes separately and sequentially (in both order) together, in order to better comprehend 
their digestion characteristics and in order to overcome problems that might occur. 
 
Figure 2.5. Images of agarose gels that separated digested pZK1, pZk7, pZK6 and pZK8 
plasmids. A. pZK7 and pZK1 were loaded on the gel undigested, single digested and 
sequentially double digested with EcoRI and Xbal. B. pZK8 and pZK6 ran on the gel 
undigested, single digested and sequentially double digested with PstI and EcoRV.  
The DNA sequence that encodes the bradykinin B2 receptor (BDK-B2, insert), low molecular 
weight band (1101 bp) from lanes five and six from Figure 2.5A were cut out from the gel 
and DNA was purified. The tango assay plasmid backbone in which the BDK-B2 gene was 
pasted, high molecular weight band (around 7 kbp, vector) from lanes tenth and eleventh of 
Figure 2.5A were cut out from the gel and DNA was purified. Next, the BDK-B2 coding 
sequence (insert) was ligated with the tango assay plasmid backbone (vector) to obtain pZK9, 
Table 2.11, that contains the BDK-B2 coding sequence fused to the 29 amino acids tail of 
human arginine vasopressin receptor 2 (AVPR2tail), tethered to the TEV protease cleavage 
site (TCS) followed by the transcription factor tTA. To check the sequence quality of pZK9, 
this plasmid was sequenced with primers 72-74 from Table 2.13 and the obtained sequence is 
shown in Appendix 5. For storage and amplification, pZK9 was transformed into E. coli to 
obtain strain ZK_S6, Table 2.12. 
In order to replace the tango assay reporter gene (luciferase) with eGFP, the eGFP gene from 
plasmid pZK8, band with the lowest molecular weight (0.8 kbp) from lane five and six from 
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Figure 2.5B was cut out from the gel and the DNA was extracted. From the tango assay 
reporter plasmid, the luciferase coding sequence was cut out. The vector backbone, high 
molecular weight band (around 7 kbp, vector) from lanes ten and eleven of Figure 2.5B, were 
excised and the DNA was extracted. After extraction and purification of insert and vector 
DNA fragments, the ligation of the eGFP gene with the tango reporter vector was carried out 
and the resulting solution was transformed into competent E. coli. However, the following 
day no colonies were obtained and for two months this cloning procedure did not yield the 
expected plasmid. The amount of ligation solution used for transformation was increased to 
up to 10% of the volume of the comment cell solution, but still no colonies were obtained. 
Besides transforming with the ligation solution, competent E. coli were also transformed with 
the intact plasmids pZK6 and pZK8. This transformation positive control revealed that the 
transformation procedure was working, since colonies appeared when transformed with intact 
plasmids pZK6 and pZK8. To reduce the chance of potential toxicity caused by the 
expression of the insert gene (eGFP) from the ligated plasmids in certain E. coli strains, three 
different E. coli strains were used, including the high efficiency 5α F’Iq strain from NEB. 
Using various E. coli strains should have had increased the transformation efficiency, 
knowing that different strains can be transformed with different efficiencies. To reduce 
expression of potentially toxic gene products, 0.4% D-glucose was also included in the agar 
on which the transformants were plated. These did not lead to any success either. The 
plasmids were re-sequenced to obtain more complete and higher quality sequencing data. The 
restriction enzyme digestion procedure was also altered from simultaneous digestion with 
enzymes PstI and EcoRV to semi-sequential and sequential digestion, to avoid spatial 
hindrance between enzymes due to close proximity of restriction enzyme sites, shown in the 
sequencing data in Appendix 3 and in the agarose gel image from Figure 2.5B. For the semi-
sequential digestion, digestion was started with either the EcoRV or PstI enzymes and after 
30 minutes of incubation, the other enzyme was added to incubate for further 1 hour. In case 
of sequential digestions, plasmids were treated with one enzyme for 1 hour, this enzyme was 
then heat inactivated and digestion with the second enzyme followed. Altering the digestion 
protocol alone did not lead to colonies that contained the desired plasmid. In parallel, the 
ligation procedure was also modified, altering rations of insert and vector fragments. Ligation 
was carried out at 16°C overnight or at room temperature (at 20, 22, 25 °C and their 
combination was programed in the thermal cycler) for 2-3 hours. Fresh buffer sets were tried 
and besides the conventional T4 DNA ligase the Quick Ligation™ Kit from NEB was also 
used. As negative controls, insert only and vector only ligation and transformation 
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experiments were performed. Knowing that EcoRV generates blunt ends, vector DNA 
fragments were treated with alkaline phosphatase to remove their 5´ phosphate groups. New 
primer sets were designed and ordered to sequence the digested DNA fragments. DNA 
fragments extracted from the agarose gel were extra purified, by applying an additional 
washing step when DNA was bound to the silica spin column during the QIAquick Gel 
Extraction procedure. To further purify the DNA after this gel extraction procedure, the 
QIAquick PCR Purification Kit was also used. In the end, ligation worked when DNA 
fragments were sequentially digested, extra-purified, treated with alkaline phosphatase and 
ligation was carried out at 16°C overnight. The obtained plasmid pZK10 was also sequenced, 
with primers 79-80 from Table 2.13. Sequencing results are available in Appendix 5. 
Transformation of pZK10 into E. coli yielded strain ZK_S7, Table 2.12.  
The obtained plasmids are schematically represented using circular maps shown in 
Figure 2.6 below. GFP expression was constitutively active from plasmid pZK11 and this 
was plasmid was included as a positive control for transfections into mammalian cells. 
Plasmid pZK11 was also stored and amplified in E. coli, yielding stain ZK_S8, Table 2.12. 
Next, these plasmids were produced at large scale and ultra-purified from endotoxins for cell 
culture use (using the Qiagen EndoFree
®
 Mega or Giga Kits). For this, as shown in Figure 
2.7A, bacterial cells were lysed; the lysate was cleared by filtration and treated with the 
endotoxin removal buffer. The resulting solution was applied to the QIAGEN Anion-
Exchange column, impurities were washed away and the plasmid DNA was eluted from the 
column. The plasmid DNA was then desalted and concentrated by isopropanol precipitation, 
washed with ethanol, air dried and resuspended to obtain ultra-pure endotoxin free DNA. 
Fractions S1, S2, S3 and S4 were collected from the cleared lysate, from the flow through 
upon applying the solution to the QIAGEN Anion-Exchange column, from the combined 
wash and from the eluate, respectively. Collected fractions were precipitated with 1 volume 
of isopropanol, DNA pellet was rinsed with 70% ethanol, drain well, resuspend in 10 μl 
Buffer TE with pH=8.0 and subjected to agarose gel electrophoresis. The resulting agarose 
gel image in Figure 2.7B shows that the only minimal amounts of DNA were lost during the 
purification process and that most DNA was successfully eluted from the column. In the 
same agarose gel image a clear, well defined DNA migration front is visible for the DNA in 
each lane of the S4 elution fraction, without any smear below this front, indicating that DNA 
molecules did not degrade to smaller molecules that could migrate faster and further than this 
front. The smear in the area above the front and the fact that the front is not straight line is 
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most probably due to DNA molecules tangling together and resulting in larger complexes that 
migrate slower. 
 
Figure 2.6. Circular maps of plasmids encoding the gene network and the constitutive GFP 
plasmid. A. pZK9 encodes the fusion protein consisting of the human bradykinin receptor B2 
(BDK-B2) fused to the 29 C-terminus amino acids of the human arginine vasopressin 
receptor 2 (AVPR2tail), tethered to the TEV protease cleavage site (TCS) followed by the 
transcriptional trans-activator (tTA). Transcription of this fusion protein was facilitated by the 
human cytomegalovirus (CMV) constitutively active immediate early promoter downstream 
of the CMV immediate early enhancer. B. pZK5 encodes the human β-arrestin2 (βArrestin2) 
fused to the catalytic domain of the tobacco etch virus NIa protease, amino acids 189-424 of 
the mature NIa protease (TEV). This gene construct was transcribed under the control of the 
CMV constitutive immediate early promoter accompanied upstream by the CMV immediate 
early enhancer. C. pZK10 contains the enhanced green fluorescent protein (eGFP) gene 
downstream of the tetracycline responsive element (seven copies of the tetracycline operator 
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(tetO)) where tTA binds. D. pZK11 encodes the monster green fluorescent protein (MGFP) 
under the control of the CMV constitutive immediate early promoter downstream of the 
CMV immediate early enhancer. 
 
 
Figure 2.7. Diagram of endotoxin free Giga-Prep purification process and the image of 
agarose gel resulting from the analysis of this purification process. A. During the purification 
process, bacteria was lysed, resulting solution was filtration cleared, applied to the QIAGEN 
Anion-Exchange column, washed, eluted, isopropanol precipitated, ethanol washed, air-dried 
and resuspended to obtain ultra-pure endotoxin free DNA plasmid solution. Fraction S1 was 
collected after the bacterial pellet was lysed and after this lysate has been cleared using the 
QIAfilters. Fraction S2 was the flow-through upon applying the plasmid DNA solution to the 
QIAGEN Anion-Exchange Resin. S3 represents the combined wash fractions. Fraction S4 
was an aliquot from the eluate. B. In order to analyse the efficiency of the process and the 
quality of the resulting DNA plasmids, these purification fractions were isopropanol 
precipitated, DNA pellet was rinsed with 70% ethanol, drained, resuspend and ran on agarose 
gel. The purification process was successful and DNA plasmids did not degrade.  
 
The quality of the produced plasmid DNA solution was evaluated using a NanoDrop
TM
 2000c 
Spectrophotometer [481]. It was confirmed that the ratio of absorbance at 260 nm and 280 
nm was above 1.8, indicating pure DNA (without protein, phenol or other contaminants that 
absorb strongly at or near 280 nm). Similarly, the absorbance ratio at 260 nm and 230 nm 
was also confirmed to be in the 2.0 – 2.2 range, characteristic to pure DNA (free on 
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contaminants that absorb at 230 nm). For identity and quality check, these cell culture grade 
plasmids were also sequenced using primers 44-50 for pZK5, 72-74 for pZK9, 79-80 for 
pZK10 and 94-96 for pZK11.  
If these endotoxin free ultra-pure DNA solutions were used for longer periods, the DNA 
quality was assed every three months to detect any deterioration in plasmid DNA quality (due 
to repeated freezing, thawing cycles). Results from such a periodic DNA quality assessment 
are shown in Figure 2.8 and  
 
Table 2.14 below. On the gel shown in Figure 2.8, a clear, well defined front is visible 
without any smaller molecule degradation product running in front of this front line. The 
smear behind the front is due to DNA-to-DNA association products which have a larger 
molecular weight and thus migrate slower. The non-straight line of the front is most probably 
also caused by this tangling up and association of DNA molecules with each other. 
 
Figure 2.8. Image of agarose gel ran for assessing the quality of plasmid solutions used a 
longer period of time. 1 µg of plasmid DNA was loaded into each well of the gel. No signs of 
degrading of plasmid DNA molecules are visible. 
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Table 2.14. Evaluation of the spectral properties of plasmid DNA solutions used for longer 
time periods. 
Plasmid name A260/A280
£ 
A260/A230
$ 
Measured 
Concentration
%
  
[µg/µl] 
Expected 
Concentration
# 
[µg/µl] 
pZK9 1.87 2.23 3.26 3.4 
pZK5 1.9 2.24 4.23 5.9 
pZK10 1.89 2.27 3.49 5.7 
Mix* 1.89 2.23 3.8 5.8 
pZK11 1.92 2.29 2.93 3.8 
* Equimolar mixture (1:1:1) of pZK9, pZK5 and pZK10. 
£
 Absorbance at 260 nm wavelength divided by the absorbance at 280 nm wavelength. 
$
 Absorbance at 260 nm wavelength divided by the absorbance at 230 nm wavelength. 
%
 Concentration measured during the quality check 
#
 Concentration measured when plasmids were initially Giga-Prepped 
  
The quality assessment from  
 
Table 2.14 shows that DNA remained pure, free of contaminants, retaining a ratio of 
absorbance at 260 nm and 280 nm of above 1.8 and a ratio of absorbance at 260 nm and 230 
nm of 2.2. However, after a few months the concentration slightly decreased from its initial 
value (measured after Giga-Prepping), but this concentration decrease is still in the 
acceptable range, knowing that no degradation products were visible on the agarose gel. 
2.4.2 Testing the gene network in the HeLa cell line 
Once the plasmids that encode the gene network (pZK9, pZK5 and pZK10) have been 
obtained free of endotoxins in large quantities, the gene network was inserted in HeLa cells, 
to test the functionality of the gene network. HeLa cells had been used because these cells 
were readily available in our laboratory and they were easy to transfect. HeLa cells have been 
electroporated with the Neon
®
 Transfection System with the 10 µl tip using 1,005 V, 30 ms, 
double pulses, following the cell line specific protocol from Life Technology’s Neon® 
Transfection System database. 200,000 cells have been electroporated per electroporation 
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reaction in the 10 µl Neon tip. Following electroporation, cells were seeded in 12 or 24 well 
plates pre-coated with 1% gelatine solution. A representative image from these experiments 
is shown below in Figure 2.9. Phase contrast, green fluorescent and superimposed (of phase 
contrast with green fluorescent) microscopy images are shown in the columns. The first row 
shows HeLa cells electroporated with the constitutive GFP expressing plasmid pZK11. Here, 
about 80% of cells appear green fluorescent indicating that the electroporation protocol 
worked successfully. Cells shown in the second row were electroporated with the gene 
network and 24 hours after electroporation the gene network was activated with final 
concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt. In this 
condition, on average, about 10% of cells show green fluorescence. The third row shows cells 
electroporated with the gene network and cultured without the addition of bradykinin. These 
cells do not present green fluorescence. These results confirm that the gene network can be 
transfected into HeLa cells, that the gene network was functional in HeLa cells and that the 
gene network can be switched on by adding bradykinin.  
Various molar ratios of the 3 plasmids that encode the gene network were transfected into 
HeLa cells and ratio of 1 : 1 : 1 of pZK9 : pZK5 : pZK10 yielded the highest green 
fluorescent cell percentages. Cells were visualized every day between day one and day four 
after plasmid electrotransfer and maximum GFP expression was observed the second day 
after electroporation, the first day after inducing the gene network.  
In order to observe the activation of the gene network by shear stress, flow experiments were 
performed on HeLa cells electroporated with the gene network but the HeLa cells were 
washed away by the flow. Flow experiments were also carried out on non-electroporated 
HeLa cells and these cells were also washed away by the flow, indicating that HeLa cells 
cannot be subjected to endothelial-magnitude flow with our flow setup. 
After proving that the gene network was functional in HeLa cells, the question was whether 
the gene network works in endothelial cells and whether the gene network can be induced by 
shear stress. Thus, experiments in HeLa were stopped, without further optimizing 
electroporation (e.g. seeding densities, electroporation efficiencies for the gene network 
encoded on 3 plasmids) and flow conditions and endothelial cells were started to culture.  
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Figure 2.9. Evaluating the functionality of the gene network in HeLa cells. The first column 
shows phase contrast microscopy images, the second column shown green fluorescent, GFP 
expressing cells and the third column shows a superimposition of the previous two columns. 
Cells from the first row were electroporated with the constitutively active GFP expressing 
pZK11 plasmid, whereas row 2 and 3 shows cells after electroporation with the gene 
network. In row 2, the gene network has been induced with bradykinin and in row 3 no 
bradykinin was added. N=3, S.D.≈8%, 10X magnification. 
2.4.3 Evaluating the functionality of the gene network in the EA.hy926 
endothelial cell line  
After the gene network has been proven functional in HeLa cells, the EA.hy926 endothelial 
cell line was also transfected with the 3 plasmids that encode the gene network. The 
EA.hy926 cell line was not present in Neon’s transfection database, consequently the 
electroporation conditions needed to be optimized for this cell line. For the optimization of 
the electroporation conditions, cells were electroporated with the 3 plasmids simultaneously 
which encode the gene network. Optimizing the electroporation conditions for 
electroporation with the constitutive GFP expressing plasmid pZK11, would have had been 
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technically simpler and quicker, since no induction of expression would have had been 
required, however the optimized electroporation conditions for electroporation with a single 
smaller plasmid most probably would have not provided the highest possible electroporation 
efficiency and cell viability for the 3 plasmids circuit. Thus, electroporation conditions were 
optimized upon electroporation with the 3 plasmid system. 
First the pulse voltage has been optimized. Results from experiments where EA.hy926 
endothelial cells have been electroporated with the gene network using pulses at different 
voltages are shown in Figure 2.10. Following electrotransfer of molar rations of 1 : 1 : 1 of 
plasmids pZK9 : pZK5 : pZK10, cells have been seeded in 1% gelatine coated 12 or 24 well 
plates. Six hours after the electroporation the gene network has been induced with final 
concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt. Cells were 
evaluated under the fluorescent microscope day 1, 2 and 3 after electroporation and cells 
were imaged 24 hours after electroporation, when eGFP expression was the highest. Inducing 
the gene network at 4 – 6 hours after electroporation and imaging at 24 hours after 
electroporation resulted in a higher percentage of green fluorescent cells, compared to the 
case when induction took place 24 hours and imaging at 48 hours post electroporation. 
Except the pulse voltages specified in the rows of the Figure 2.10, all other conditions were 
kept identical for all the cells from all the experimental conditions. Pulse voltage was varied 
in the range of 500 V to 1,500 V. As it can be seen Figure 2.10, at 800 V (and below 800 V, 
data not shown) a large number of adherent and viable cells are present, but the percentage of 
green fluorescent cells was rather low. At pulse voltages of 1,000 and above, very few 
adherent and viable cells are present and as the pulse voltage increases, the number of green 
fluorescent cells decreases. The 900 V pulses give the highest percentage of green fluorescent 
cells, keeping the viability of the cells at a relatively high level. 
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Figure 2.10. Optimization of the electroporation pulse voltage. EA.hy926 cells were 
electroporated with the 3 plasmids encoding the gene network, 6 hours after electroporation 
the gene network was induced with bradykinin and cells were imaged 24 hours after 
electroporation. The columns show phase contrast, green fluorescent and superimposed (of 
phase contrast and green fluorescent) microscopy images. In the rows results from 
electroporation experiments with different pulse voltages are shown. A. The pulse length was 
35 ms and the number of pulses applied was two. B. the pulse length was set to 40 ms and 
single pulses were applied. N=2, S.D.≈10%, 10X magnification. 
 
After the pulse voltage which yielded the best outcome was determined, the pulse duration 
was optimized, Figure 2.11. For this, cells were grown, electroporated and cultured under 
identical conditions in 12 or 24 well plates coated with 1% gelatine solution. The gene 
network was induced with 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt (unless 
otherwise specified) 6 hours after electroporation. The only parameter that was modified 
between electroporation experiments was the pulse duration or other conditions specified on 
the rows of Figure 2.11. Pulse length was varied in the 5 ms to 200 ms range. Shown 
microscopy images were recorded 24 hours after electroporation. In experiments summarized 
in Figure 2.11A, single pulses of 800 V with varying pulse durations have been applied. 
Upon applying pulses shorter than 30 ms the transfection efficiency was low. Transfection 
efficiency was the highest when the 30 ms pulses were applied. Transfection efficiency and 
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cell viability decreases when pulse length exceeds 40 ms. Cell densities are not indicative of 
cell viabilities, because cell densities in these experiments were not uniform across the 
surface of the well, due to insufficient mixing of the solution following the seeding of 
electroporated cells in the wells. This, together with the fact that images were acquired at 
random locations of the well was responsible for the unexpectedly high cell density at 800V 
40 ms single pulses, compared to the other conditions of Figure 2.11A. However, a similar 
cell density can be observed in the first row of Figure 2.10B. Figure 2.11B shows images of 
cells electroporated at 900 V, single pulses with various lengths. From this experiment it can 
be seen that transfection efficiencies are increasing until the pulse duration reaches 30 – 40 
ms, and then the percentage of green fluorescent cells decreases. Results from experiments 
where double pulses have been applied using the, so far, best pulse voltage and duration 
ranges are shown in Figure 2.11C. These electroporation experiments told us that the 800 V, 
40 ms double pulse and the 900 V, 30 ms double pulse gives the highest transfection 
efficiency without dramatically lowering the cell viability. Figure 2.11D summarizes results 
from experiments where double pulses of 1000 V with varying duration were applied. The 
bottom row in Figure 2.11D shows cells electroporated with the gene network, but the gene 
network was not activated by bradykinin addition 6 hours after electroporation. This negative 
control indicated that green fluorescence seen in these experiments was due to the induction 
of the gene network. In these experiments, again, pulses of 30 – 40 ms yield the highest 
transfection efficiency, however these transfection efficiencies as lower than those obtained 
when 800 V, 40 ms double pulses or 900 V, 30 ms double pulses were delivered. 
Furthermore, the total number of cells per well and the cell viability was also lower in case of 
1000 V double pulses compared with the 800 and 900 V double pulses of similar duration.          
In summary, this set of experiments showed us that transfection efficiency was the highest 
when pulses of 800 V, 30 ms were delivered. Additionally, double pulses tend to yield higher 
transfection efficiencies than single pulses. The percentage of green fluorescence cells 
reached 10 – 12% of the total cells. The next question was whether increasing the number of 
pulses would increase transfection efficiencies without significantly lowering cell viabilities. 
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Figure 2.11. Optimization of the electroporation pulse duration. EA.hy926 cells were 
electroporated with the gene network coded on 3 plasmids, the gene network was induced 
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with bradykinin (unless otherwise specified) 6 hours after electroporation and 24 hours after 
electroporation cells were imaged. The columns show phase contrast, green fluorescent and 
superimposed (of phase contrast and green fluorescent) images. In the rows, results from 
electroporation experiments with different pulse durations are shown. A. Single pulses of 800 
V with various durations had been applied. B. Single pulses of 900 V with varying length 
were applied. C. Double pulses of 800 and 900 V with different durations were used. D. Trial 
of 1,000 V double pulses with different pulse lengths. N=2, S.D.≈8%, 10X magnification. 
 
Therefore, Figure 2.12 shows results from an experiment where the number of 
electroporation pulses was varied in order to determine which pulse multiplicity gives the 
highest transfection efficiency. Increasing the number of pulses slightly increases the 
transfection efficiencies, at the same time, decreasing cell viabilities. At pulse numbers above 
4, electroporation sometimes failed due to the occurrence of sparks in the Neon 
electroporation tip. This arching occurred because after repeated pulsing, gas bubbles started 
to appear at the electrode in the top part of the Neon tip. These gas bubbles have a very low 
electrical conductivity compared to the liquid, thus an electrical discharge in the form of a 
spark appears in the vicinity of the gas bubble. To avoid sparks, we decided to use double 
pulses.  
 
Figure 2.12. Optimization of the electroporation pulse multiplicity. EA.hy926 cells were 
electroporated with the gene network coded on 3 plasmids, the gene network was induced 
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with bradykinin 6 hours after electroporation and cells were imaged 24 hours after 
electroporation. The columns show phase contrast, green fluorescent and superimposed (of 
phase contrast and green fluorescent) images. In the rows results from electroporation 
experiments with various pulse numbers are shown. N=2, S.D.≈5%, 10X magnification. 
 
In order to better characterize the gene network, control experiments from which results are 
shown in Figure 2.13 were carried out. In these experiments EA.hy926 cells were 
electroporated using 800 V, 30 ms, double pulses and cultured under identical conditions 
with the exception of the parameters specified on the rows of Figure 2.13. The success of the 
protocol was evaluated under the fluorescent microscope 24 and 48 hours after 
electroporation and microscopy images were recorded at 24 hours post electroporation, which 
was 18 hours after adding gene network activating or inhibiting ligands. Cells shown in the 
first row were electroporated only with plasmid pZK9, which encodes the B2 bradykinin 
GPCR shear stress sensor and tTA fusion protein. Six hours after electroporation the culture 
media was supplemented with final concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM 
bradykinin acetate salt. No green fluorescent cells could be seen under these conditions. The 
second row shows cells that were electroporated with plasmid pZK5 alone, which codes for 
the βArrestin-TEV protease construct. Final concentrations of 2 µM [Hyp3]-bradykinin and 2 
µM bradykinin acetate salt were added 6 hours post electroporation. No green fluorescent 
cells resulted from this experimental condition. Cells electroporated only with the eGFP 
encoding reporter plasmid pZK10 and treated with 2 µM [Hyp
3
]-bradykinin and 2 µM 
bradykinin acetate salt 6 hours after electroporation are shown in the third row of the same 
figure. From this experimental condition a few green cells emerged, around 2–4% of the total 
cells, indicating that the transcriptional promoter of the reporter plasmid was “leaky”, since 
this low level of eGFP expression occurred in the absence of the other parts of the gene 
network. Subsequently, cells were electroporated solely with plasmid pZK10 without adding 
bradykinin after electroporation, this did not modify the outcome; a similar low “leakiness” 
level of 2–4% was observed. Results from row 1 – 3 indicate that fluorescence was due to 
eGFP expressed from the reporter plasmid pZK10. Row 4 shows cells electroporated with the 
three plasmids encoding the entire gene network. The gene network in these cells was also 
induced with final concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate 
salt. As expected, about 10-12% of cells became green fluorescent. The 2–4% leakiness level 
shown in row 3 is not directly comparable with the 10-12% gene network activation level 
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from row 4 and from previous experiments since in the experimental condition shown in row 
4 cells were electroporated with only one plasmid, pZK10 instead of the 3 plasmids that 
encode the complete gene network. In case of electroporation with a single plasmid, more 
copies of the single plasmid can enter the nucleus of cells, resulting in a higher background 
expression level. Thus, the leakiness of the reporter plasmid pZK10 is most probably lower 
than the 2–4% shown from row 3 of Figure 2.13. Cells electroporated with the 3 plasmids 
that encode the gene network but without subsequent bradykinin induction are shown in the 
fifth row of the same image. Here, 1–2% of cells became green fluorescent. These green cells 
can be a result of the leakiness of the reporter plasmid pZK10 transcriptional promoter or 
eGFP expression can also be due to activation of the gene network (e.g. by shear stress 
caused by media renewal or transportation) or a combination of the previous two factors. A 
final concentration of 20 nM of the selective B2 bradykinin receptor antagonist peptide 
ligand, HOE 140, was added to cells instead of bradykinin 6 hours after electroporation. 
Images of these cells are shown in the sixth row of Figure 2.13. At times, under these 
conditions, around 1% of cells showed green fluorescence as well. The shear stress 
membrane sensor being blocked, this 1% of green fluorescent cells might represent the 
leakiness of reporter plasmid pZK10 transcriptional promoter in the presence of the 
transcriptional transactivator tTA in EA.hy926 cells. Thus, the slightly higher level of 
expression showed in row 5 is most probably due to the combination of plasmid promoter 
leakiness in the presence of tTA and activation of the gene network. The final row of Figure 
2.13, shows cells 24 hours after electroporation with the constitutively active GFP expressing 
pZK11. The percentage of green fluorescent cells under this condition did not exceed 30%. 
This could be due to several reasons: (1) the used 800 V, 30 ms double pulse optimized for 
transfecting simultaneously with the 3 large plasmid might not be the best possible 
electroporation pulse for electroporating with one smaller plasmid; (2) the expression of 
monster GFP is not maximal in this cell line; (3) this cell line, similarly to other endothelial 
cells, is known to be hard to transfect [504-507], thus, the obtained percentages of green 
fluorescent cells remained low. In summary, the network proved to be on-switchable by 
bradykinin in the EA.hy926 endothelial cell line, the fluorescence being due to eGFP 
expression from the reporter plasmid and eGFP expression “leaked” in around 1% of cells. 
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Figure 2.13. Control experiments for characterizing the gene network. EA.hy926 cells were 
electroporated with the plasmids indicated on the rows using the previously optimized 800 V, 
30 ms double pulses. Gene network activating or inhibiting compounds, as specified on the 
rows, were added 6 hours after electroporation and cells were microscopy imaged 24 hours 
after electroporation. The columns show phase contrast, green fluorescent and superimposed 
(of phase contrast and green fluorescent) images. N=2, S.D.≈5%, 10X magnification. 
The next question was whether shear stress could increase the percentage of green fluorescent 
cells. To tackle this, EA.hy926 endothelial cells were electroporated with the gene network 
using 800 V, 30 ms double pulses and cells were seeded in µ-Slide I 
0.4
 Luer ibidi flow 
channels or in multi well plates for control experiments. The flow experiment was started on 
cells seeded in µ-Slide I 
0.4
 Luer ibidi flow channels 24 hours after electroporation to expose 
cells to 1.5–2 Pa of shear stress for a period of 24 hours. Phase contrast, fluorescent and 
superimposed microscopy images from such flow experiments are shown in Figure 2.14 
below. Cells shown in the first row were kept in static culture; with 2 µM [Hyp
3
]-bradykinin 
and 2 µM bradykinin acetate salt added 6 hours post electroporation, and imaged 24 hours 
after electroporation. This experiment yielded the usual 10 – 12% green fluorescent cells. The 
second row shows cells electroporated with the gene network, exposed to 1.5–2 Pa of shear 
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stress 24 hours after electroporation for a period of 24 hours and imaged 48 hours after 
electroporation. The percentage of green fluorescent cells out of the total cells was still 10–
12%. Therefore, the gene network can be switched on by shear stress but the activation level 
by shear stress was similar to the level of activation by bradykinin. To find out whether by 
applying both shear stress and bradykinin inducing stimulus to the gene network at the same 
time, a higher percentage of green fluorescent cells could be achieved, and experiment 
similar to the one presented in row 2 was carried out but with the addition of 2 µM [Hyp
3
]-
bradykinin and 2 µM bradykinin acetate salt in the culture media when the flow experiment 
was started. Microscopy images recorded 48 hours after electroporation from such an 
experiment are shown in row 3 of Figure 2.14. The percentage of green fluorescent cells from 
such an experiment was around 10%, proving that the combined bradykinin plus shear stress 
gene network activating stimulus did not increase the percentage of green fluorescent cells, 
compared to the condition when only one of the inducing stimuli, either bradykinin or shear 
stress, was present. The final row of Figure 2.14 shows results from a static experiment where 
neither bradykinin, nor shear stress was applied. Here, only background level of eGFP 
expression occurred. In summary, this set of experiments proves that the gene network can be 
switched on by shear stress. However, the percentage of cells exhibiting green fluorescence 
following activation remains rather low, far from the desired 60% that would be necessary in 
order to apply the gene network for reliably studying shear stress sensing in vascular cells, by 
generating dose-response curves and by screening for compounds that modify the shear stress 
sensing ability of the shear stress sensor. 
The low percentage of green fluorescent cells was most probably due to low transfection 
efficiencies since endothelial cells are known to be hard to transfect [504-507] and for our 
applications a simultaneous transfection of 3 different plasmids was carried out. There was a 
lower probability for the low percentage of green fluorescent cells being caused by low 
expression levels or inefficient induction of the gene network. The probability of inefficient 
induction was further lowered by the fact the combined shear stress and bradykinin induction 
did not increase the percentage of green fluorescent cells. 
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Figure 2.14. Activation of the gene network by shear stress. EA.hy926 cells were 
electroporated with the gene network using 800 V, 30 ms double pulses. Cells were seeded 
either in µ-Slide I 
0.4
 Luer ibidi flow channels or in multi well plates (static control 
conditions). For cells seeded in ibidi flow channels, flow experiments were started 24 hours 
after electroporation, cells were subjected to 1.5–2 Pa of shear stress for a period of 24 hours 
and cells were imaged 48 hours after electroporation. To electroporated cells kept in static 
culture, bradykinin was added 6 hours after electroporation and cells were microscopy 
imaged 24 hours after electroporation. The columns show phase contrast, green fluorescent 
and superimposed (of phase contrast and green fluorescent) images. N=3, S.D.≈10%, 10X 
magnification. 
 
To increase electroporation efficiencies sequential transfections were also carried out. For 
this, a large number of cells were transfected with one plasmid at a time cultured for 12 – 24 
hours, then transfected with the second plasmid, again cultured for 12 – 24 hours and finally 
transfected with the third plasmid, induced and imaged. The first plasmid to transfect with 
was either pZK9 or pZK5, the second plasmid was the complementary pZK5 or pZK9 and 
pZK11 was the third plasmid to transfect with. From these experiments the percentage of 
green fluorescent cells at the end of the experiment was significantly lower (around 2%) than 
in case of simultaneous transfection with the 3 plasmids. Next, cells were electroporated in 
two steps, first with all possible paired combination of three plasmids (pZK9 with pZK5, 
pZK5 with pZK10, pZK9 with pZK10), and in the second electroporation with the remaining 
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of plasmid out of the 3. The percentage of green fluorescent cells from these experiments was 
below 5%, still lower than in case of electroporation in one step with the mix of the three 
plasmids. 
In these experiments, 200,000 cells have been electroporated per electroporation reaction in 
the 10 µl Neon tip. The electroporation cell density has been varied between 50,000 and 
300,000 without observing a noticeable improvement in the percentage of green fluorescent 
cells. Cells were electroporated with molar ratios of 1 : 1 : 1 of pZK9 : pZK5 : pZK10. 
Modifying this ratio decreased the percentage of green fluorescent cells and the 
responsiveness of the gene network.  
Up to this moment, no automated image analysis procedure for cell quantification has been 
employed because the primary goal was to increase transfection efficiencies up to at least 
60%. To better comprehend the outcome of electroporation experiments quantification of 
results was needed. For this, microscopy images were analysed in ImageJ to determine the 
percentage of green fluorescent cells and cell viability.  
Image analysis was preferred instead of flow cytometry because flow cytometry methods 
were not commonly used in our group and department, thus setting up this technique would 
have had taken a relatively long period of time and investing our limited time into this 
seemed unfeasible. Furthermore, capturing images with the microscope gives cell 
morphology information as well; this information is missing in flow cytometry data. 
In order to be able to count cells from images using ImageJ, cells were stained with final 
concentrations of 2 µg/ml Hoechst 33342 and with 0.5 µg/ml propidium iodide. Hoechst 
33342 is a cell-permeant nuclear stain which emits blue fluorescence (emission peak at 461 
nm) when exposed UV light (excitation maximum at 350 nm), when bound to dsDNA [508]. 
Thus, Hoechst 33342 stains all cells (dead and alive). To optimize the staining concentration, 
cells were stained with Hoechst 33342 stain in the range of 2–5 µg/ml of final concentrations, 
range recommended by the manufacturer. There was no notable difference in staining 
intensity between the lower and higher end of this range, thus the lower concentration, 2 
µg/ml was used with a staining incubation time of 10 minutes. Propidium iodide (PI) is red-
fluorescent nuclear stain that can penetrate exclusively dead cells, thus it is used to stain dead 
cells without staining living cells. When bound to nucleic acids, the fluorescence excitation 
maximum of PI is 535 nm and the emission maximum is at 617 nm [509], in the near red 
domain of the electromagnetic spectrum. PI staining final concentrations were optimized in 
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the 0.1–10 µg/ml range and the optimal concentration which produced a clear nuclear stain 
without high level of background noise proved to be 0.5 µg/ml. 
Using these staining methods, further control and optimization experiments, from which 
quantified results shown in Figure 2.15 and Figure 2.16, respectively, were carried out. 
Figure 2.15 shows results from an experiment similar to the one represented in Figure 2.13, 
where EA.hy926 cells were electroporated with individual or combined plasmids of gene 
network and 6 hours after electroporation were treated with 2 µM [Hyp
3
]-bradykinin and 2 
µM bradykinin acetate salt, with HOE 140 or with neither. Cells from all conditions were 
electroporated with the 800 V, 30 ms double pulses. Twenty-four after plasmid 
electrotransfer cells were stained with Hoechst 33342 and propidium iodide and were imaged 
under the fluorescent microscope. Columns of Figure 2.15A show an example of the obtained 
phase contrast, green (GFP), red (PI, dead), blue (Hoechst 33342, total) fluorescent and 
superimposed images. Rows 1–6 of this figure represent different conditions for plasmids 
used for electroporation and for ligands added, similarly to Figure 2.13. These images were 
imported to ImageJ and the threshold was adjusted until the background noise disappeared. 
Next, images were converted into binary, merged cells were separated using the watershed 
segmentation algorithm, and finally cells were counted with analyse particles function to 
obtain the number of cells in each image. To determine the percentage of green fluorescent 
cells, the number of eGFP or GFP expressing green fluorescent cells was divided by the 
number of blue fluorescent (total) cells and multiplied by 100. The number of red fluorescent 
(dead) cells divided by the number of blue fluorescent (total) cells was subtracted from 100 
and the resulting number was multiplied by 100 to obtain cell viabilities in percentage. 
Obtained percentages of green fluorescent cells and cell viabilities were plotted and the 
resulting graph is given in Figure 2.15B. On the left Y-axis of the graph, the cell viability 
(bars marked with diagonal lines) and percentage of green fluorescent relative to the total 
number of cells (grey bars) cells are plotted. As a second indicator of cell viability, the total 
number of cells per recorded microscopy image (black bar) is also plotted on a secondary, 
right Y-axis. Although the number of cells is not uniform across the cell containing well, 
hence the large error bars, this measure can also be indicative of cell viabilities, showing, at 
large, how many cells are still present at the time of imaging, since cells can disintegrate and 
disappear after electroporation. Conditions 1–6 plotted on the X-axis are described by the 
table below the graph. Similarly from what is shown in Figure 2.13, conditions 1 and 2 of 
Figure 2.15, where cells have only been electroporated with one plasmid, pZK9 and pZK5, 
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respectively, yield no fluorescence. Approximately 2% of cells become green fluorescent 
when electroporated only with the reporter pZK10 plasmid which encodes for eGFP. Cells 
electroporated with the entire gene network and not treated with bradykinin are shown under 
condition 4. This condition yielded less than 1% of cells to fluoresce in green. Upon 
electrotransfer of the 3 plasmids encoding the gene network and treatment with the selective 
B2 bradykinin receptor antagonist, HOE 140, about 1% of cells become fluorescent, slightly 
(non-significantly) more than in condition 4. As a positive control, EA.hy926 cells were also 
electroporated with the constitutive GFP plasmid pZK11, resulting in just below 30% of 
green fluorescent cells. Also worth noticing, is that cell viabilities tend to be lower when 
electroporating with the combination of 3 plasmids versus electroporation with single 
plasmids. This trend is followed to some extent by the total number of cells per image. The 
number of images counted for each condition (n) is shown in the bottom row of the table 
below the graph. Cell viability calculated with this method does not take into account the 
cells that were present before electroporation but disintegrated and disappeared after 
electroporation, or cells that detached and were washed away when the media was changed 
4–16 hours after electroporation. 
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Figure 2.15. Quantification of control experiments. EA.hy926 cells were electroporated with 
the plasmids indicated in the figure, using the previously optimized 800 V, 30 ms double 
pulses. Gene network activating or inhibiting compounds, as specified, were added 6 hours 
after plasmid electrotransfer. 24 hours after electroporation, cells were stained with Hoechst 
33342 and propidium iodide and then imaged. A. Recorded phase contrast, green (GFP), red 
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(propidium iodide, dead), blue (Hoechst 33342, total) fluorescent and superimposed images 
are shown in the columns. Electroporated plasmids and added ligands are specified for each 
row, and these conditions are numbered 1-6 on the right hand side of the images. 10X 
magnification. B. Images were processed in ImageJ to count cells and determine the 
percentage of green fluorescent cells and cell viabilities. Percentages of green fluorescent 
cells and cell viabilities are plotted on the left Y-axis and the total number of cells per images 
is plotted on the right Y-axis. The conditions of the X-axis are described in the table below 
the graph and they correspond to conditions numbered 1–6 on the right hand side of the 
microscopy images (from part A). The number of analysed images (n) is shown in the bottom 
row of the table. Error bars represent standard deviation. 
 
In the attempt of improving the electroporation outcome, cells were electroporated with 
various pulses and results from these experiments were quantified, Figure 2.16. For this, 6 
hours following the electroporation with equimolar ratio of the 3 plasmid which encode the 
gene network and cells were treated with 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin 
acetate salt. Twenty-four hours after plasmid electrotransfer, cell were stained with final 
concentrations of 2 µg/ml Hoechst 33342 and with 0.5 µg/ml propidium iodide and cells 
were imaged with the fluorescent microscope. Recorded green, red and blue fluorescent 
images were processed in ImageJ to count cells. Obtained percentages of green fluorescent 
cells and cell viabilities are plotted on the left Y-axis of Figure 2.16. The total number of 
cells is plotted on the right Y-axis of the same graph. Used electroporation pulses are shown 
on the X-axis. The 800 V, 300 ms double pulse yields on average 12.1% of cells to fluoresce 
in green with a standard deviation of 4.3%. The 800 V, 300 ms triple pulse gave 9.7% green 
fluorescent cells with a very low standard deviation. 28.9% of cells become green fluorescent 
after DNA electrotransfer with 6 pulses of 800 V and 30 ms duration, the standard deviation 
being 5.04%. This condition yielded high percentage of green fluorescent cells, however 
there is high risk of technical failure during electroporation pulse delivery due to the potential 
occurrence of electrical discharges in form of sparks. High transfection efficiencies have been 
reported when a high voltage, short duration pulse was followed by a low voltage, longer 
duration pulse [510, 511]. To try such a pulse combination, immediately after the 800 V 30 
ms double pulse was delivered, pulse generator was reprogramed and a 100 V 100 ms single 
pulse was delivered. However, the resulting percentage of green fluorescent cells was only 
13.7% with a standard deviation of 2.84%. Subsequently, 800 V 30 ms single pulses were 
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also followed by 100 V 100 ms single pulses but the percentage of green fluorescent cells did 
not increase. All the electroporation pulses showed in Figure 2.16 yielded cell viabilities of 
above 70% and the cell number per recorded image was higher in case of the combined 800 
V 30 ms double pulses followed by 100 V 100 ms single pulse. 
The maximum percentage of green fluorescent cells achieved so far upon transfecting 
EA.hy926 cells with the gene network was around 30%, which was only half of the 60% that 
was aimed for in order to be able to use our gene network to reliably studying shear stress 
sensing in vascular cells. The low percentage of green fluorescent cells was attributed to low 
transfection efficiencies, since endothelial cells are known to be hard to transfect [504-507] 
and the challenging task of transfecting with 3 plasmids simultaneously was faced. In order to 
increase transfection efficiencies, viral vectors have been considered, since transfection 
efficiencies of 99% have been reported in endothelial cells using lentiviral vectors [512-514]. 
However, lentiviral vectors are relatively difficult to produce, and setting up the technique is 
time consuming requiring investments in facilities and serious and safety considerations. 
Moreover, it seemed to be rather challenging to include the entire gene network into the 
virus. Mostly due to the limited time available for the completion of the PhD, it was decided 
not to develop lentiviral methods.  
Instead, modifying our plasmids and applying mammalian antibiotic selection in order to 
enrich the cell population in cells that contain the gene network was aimed.  
 
Figure 2.16. Quantification of electroporation optimization experiments. EA.hy926 cells were 
electroporated with the gene network coded on 3 plasmids, the gene network was induced 
with bradykinin 6 hours after electroporation. Cells were stained with Hoechst 33342 and 
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propidium iodide 24 hours after electroporation and microscopy imaged. Obtained images 
were analysed in ImageJ to count cells and determine the percentage of green fluorescent 
cells and cell viabilities plotted on the left Y-axis of the graph. The number of total cells per 
image is plotted on the right Y-axis. The various electroporation pulses are represented on the 
X-axis. The number of analysed images (n) is shown in brackets on the X-axis label. Error 
bars show standard deviation. 
2.4.4 Redesigning the gene network 
Graphical maps of the plasmid that were aimed to be obtained are shown in Figure 2.17. 
Thus, the goal was to reduce the number of plasmids from 3 to 2 and to include a mammalian 
antibiotic selection marker to the plasmids, for selecting cells that contain the plasmids. For 
this, plasmid pIRES from Clontech Laboratories, Inc. was used, which was catalogued as 
pZK12 in our project and was transformed into competent E. coli for storage. Plasmid pZK12 
is capable of encoding two genes (or gene constructs) of interest [515]. These two gene 
constructs of interest are transcribed into the same bicistronic mRNA. In between the gene 
constructs, the Encephalomyocarditis virus (ECMV) internal ribosome entry site (IRES) is 
present, allowing 5’ cap-independent translation of the gene construct downstream of the 
IRES sequence [515-517] . The entire bicistronic mRNA is transcribed under the control of 
the constitutively active cytomegalovirus immediate early promoter. Between the 
cytomegalovirus immediate early promoter and the start codon of the first upstream gene, an 
intervening sequence is located, which enhances the stability of the mRNA [518]. At the 3’ 
end of the bicistronic mRNA, the Simian virus 40 (SV40) polyadenylation signal can be 
found. The pZK12 vector also contains the neomycin resistance gene, transcribed from the 
SV40 enhancer/promoter to select cells transfected with this plasmid using the G418 
mammalian selection antibiotic.  
In order to obtain plasmid pZK13, shown in Figure 2.17A, the fusion protein genes from 
pZK9 and pZK5 needed to be cloned into pZK12. The circular map of pZK12 is shown in 
Appendix 7. Plasmid pZK12 was mini-prepped from E. coli, it was sent for DNA sequencing 
and the sequence was confirmed, shown in Appendix 7. 
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Figure 2.17. Circular maps of redesigned gene network encoding plasmids. A. pZK13 
encodes the fusion protein consisting of the human bradykinin receptor B2 (BDK-B2) fused 
to the 29 C-terminus amino acids of the human arginine vasopressin receptor 2 (AVPR2tail), 
tethered to the TEV protease cleavage site (TCS) followed by the transcriptional trans-
activator (tTA) without the stop codon. After this fusion protein gene the nucleotide sequence 
of an internal ribosome entry site (IRES) is present, followed by the human β-arrestin2 
(βArrestin2) gene fused to the catalytic domain of the tobacco etch virus NIa protease gene, 
amino acids 189-424 of the mature NIa protease (TEV) and stop codon. Transcription of this 
entire construct is facilitated by the human cytomegalovirus (CMV) constitutive immediate 
early promoter downstream of the CMV immediate early enhancer. This way, two gene 
constructs can be expressed from the same bicistronic mRNA transcript encoded on a single 
plasmid. The plasmid also contains a neomycin resistance gene to aid in the selection of 
transfected cells using the G418 antibiotic. B. pZK14 contains the enhanced green fluorescent 
protein (eGFP) gene downstream of the 3
rd
 generation Tet-responsive promoter (PTRE3G). 
PTRE3G consists of 7 repeats of a 19 bp long tet operator sequence located upstream of an 
improved minimal CMV promoter, providing very low basal expression and high maximal 
expression in the presence of tTA [519, 520]. 
 
To clone the BDK-B2-AVPR2tail-TCS-tTA into multiple cloning site (MCS) A, upstream of 
the IRES sequence, and βArrestin2-TEV into MCS B, downstream of the IRES sequence, of 
pZK12, the Gibson Assembly
®
 Kit was employed. This DNA assembly technique was 
supposedly capable of joining multiple overlapping linearized DNA fragments in a single, 
isothermal reaction. For this, primers with overhangs were designed, No. 1-4 from Table 
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2.15. These overhangs were homologous to neighbouring end sequences on the plasmid 
backbone from the desired final assembly, in order for the DNA fragments to anneal together 
based on classical Watson & Crick DNA complementarity. The BDK-B2-AVPR2tail-TCS-
tTA construct was PCR amplified from pZK9 using overhang primers 1 and 2 from Table 
2.15, whereas overhang primers 3 and 4 from the same table were used to PCR amplify the 
βArrestin2-TEV fusion gene from pZK5. DNA fragments resulting from PCR were separated 
using AGEP, gels were imaged and obtained images are shown in Figure 2.18 below. The 
first attempts to PCR amplify constructs BDK-B2-AVPR2tail-TCS-tTA and βArrestin2-TEV 
using the Phusion
®
 High-Fidelity DNA Polymerase, at 3 different ATs (67, 69, 71°C) for 
both constructs, as shown in Figure 2.18A, failed since no DNA bands of the desired sizes 
were obtained on the gel. Next, this PCR was repeated with double Phusion
®
 High-Fidelity 
DNA Polymerase concentration and with extended range of ATs (60.4–71.2 °C). PCR 
products were run on AGEP and the image of the gel is shown Figure 2.18B. Using these 
conditions, the BDK-B2-AVPR2tail-TCS-tTA was successfully amplified but the βArrestin2-
TEV construct exhibited only very low intensity bands. In order to successfully amplify the 
βArrestin2-TEV construct, besides the Phusion® High-Fidelity DNA Polymerase, the Q5® 
High-Fidelity DNA Polymerase was also used. To PCR reactions carried out with the 
Phusion
®
 High-Fidelity DNA Polymerase, were supplemented with a final concentration of 
3% DMSO, whereas to PCR reactions carried out with the Q5
®
 High-Fidelity DNA 
Polymerase, the Q5 High GC Enhancer (1X final concentration) was added. Solutions 
resulting from this PCR were run on AGEP and the recorded image is shown in Figure 2.18C. 
Under these conditions the βArrestin2-TEV construct was successfully amplified. In order to 
obtain a sufficient amount of these PCR fragments for subsequent assembly reactions, both 
BDK-B2-AVPR2tail-TCS-tTA and βArrestin2-TEV constructs were amplified using the Q5® 
High-Fidelity DNA Polymerase with Q5 High GC Enhancer at 1X final concentration. DNA 
bands from these PCRs after AGEP and imaging are visible in Figure 2.18D. Once the 
desired DNA fragments were successfully PCRed, bands at higher ATs (most specific 
annealing, resulting in highest quality products) were excised from the gel. This way, from 
the gel shown in Figure 2.18B, BDK-B2-AVPR2tail-TCS-tTA bands at 68.7 and 71.2 °C AT 
and the βArrestin2-TEV band at 68.7 °C AT were cut out. From Figure 2.18C gel, the 
Phusion
®
 amplified βArrestin2-TEV bands at 68.7 and 71.3 °C AT and Q5® amplified 
βArrestin2-TEV bands at 66.4 and 68.7 °C AT were excised from the gel. The excised bands 
from Figure 2.18D gel were the BDK-B2-AVPR2tail-TCS-tTA bands at 69.8 and 71.2 °C AT 
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and the βArrestin2-TEV bands at 64.8, 67.8, 69.8 and 71.2°C AT. From here onwards, all 
PCRs were carried out with the Q5
®
 High-Fidelity DNA Polymerase. 
 
Figure 2.18. Images of agarose gels ran to analyse and separate BDK-B2-AVPR2tail-TCS-
tTA and βArrestin2-TEV PCR products for the Gibson Assembly®. A. The first attempt to 
PCR amplify the constructs of interest using Phusion
®
 High-Fidelity DNA Polymerase with 
reactions carried out at 3 different ATs failed, since no bands are visible. B. The Phusion
®
 
High-Fidelity DNA Polymerase concentration was doubled and the range of ATs extended, 
resulting in the successful amplification of the BDK-B2-AVPR2tail-TCS-tTA construct. C. 
The βArrestin2-TEV construct was amplified with two different DNA polymerases, the 
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Phusion
®
 High-Fidelity and the Q5
®
 High-Fidelity, with the addition of final concentrations 
of 3% DMSO to the Phusion
®
 PCR and final concentration of 1X of Q5 High GC Enhancer 
to the Q5
®
 PCR. Both DNA polymerase systems yielded PCR products of interest. D. BDK-
B2-AVPR2tail-TCS-tTA and βArrestin2-TEV were PCR amplified using the Q5® High-
Fidelity DNA Polymerase in the presence of final concentration of 1X of Q5 High GC 
Enhancer in order to obtain sufficient amounts of these fragments for subsequent Gibson 
Assembly
®
. 
Plasmid pZK12 was digested at multiple cloning sites using restriction enzymes NheI-HF, 
EcoRI, XbaI and NotI-HF, cleaving the IRES fragment away from the rest of the pZK12 
backbone. The digested plasmid pZK12 was loaded on AGEP and images recorded of these 
gels are shown in Figure 2.19 below. One µg of plasmid DNA was digested in 50 µl reaction 
volumes. For results presented in Figure 2.19A, digestion of plasmid DNA with 4 enzymes 
was carried out in two steps. In the first step of simultaneous digestion with NheI-HF, NotI-
HF and XbaI in buffer NEBuffer 4 was performed by incubating at 37°C for 1 hour in the 
presence of 100 µg/ml (bovine serum albumin) BSA. Enzymes were heat inactivation at 80°C 
for 20 minutes. Next, DNA fragments were spin column purified using the QIAquick PCR 
Purification Kit and DNA concentrations were measured using the NanoDrop
TM
 2000c 
Spectrophotometer. In the second digestion step, 1 µg of plasmid DNA per reaction was 
digested with EcoRI in NEBuffer EcoRI by incubating at 37°C for 1 hour. Fragments 
digested with these 4 enzymes were run on AGEP and the recorded image is presented in 
Figure 2.19A. This experiment was repeated with larger starting quantities to obtain larger 
amounts of the digested fragments and digestion was carried out in three steps to ensure a 
better cut (avoiding potential spatial hindrance between enzymes due to the close proximity 
of restriction sites). This way, plasmid pZK12 was first simultaneously digested with NheI-
HF and NotI-HF in buffer NEBuffer 4 by incubating at 37°C for 1 hour in the presence of 
100 µg/ml BSA. Next, enzymes NheI-HF and NotI-HF were heat inactivated at 80°C for 20 
minutes and the second digestion step was performed with XbaI in buffer NEBuffer 4 by 
incubation at 37°C for 1 hour. Following that, XbaI was heat inactivated at 65°C for 20 
minutes and the DNA fragments were spin column purified using the QIAquick PCR 
Purification Kit and DNA concentrations were measured using the NanoDrop
TM
 2000c 
Spectrophotometer. The third digestion step was carried out with EcoRI in NEBuffer EcoRI 
by incubating at 37°C for 1 hour. After this third digestion, DNA fragments from 8 reactions 
were separated by AGEP and the recorded image of this gel is shown in Figure 2.19B. All 
Synthetic gene network for monitoring shear stress sensor activity in endothelial cells 
155 
 
sample band for both IRES sequence (around 0.6 kbp) and pZK12 vector backbone (about 
5.5 kbp) were excised from the gel shown in Figure 2.19 A and B.  
 
Figure 2.19. Images of agarose gels ran to analyse and separate restriction digestion products 
of pZK12 for the Gibson Assembly
®
. A. Plasmid pZK12 was simultaneously digested with 
NheI-HF, NotI-HF and XbaI and then in a separate reaction with EcoRI. B. In order to 
generate higher quantity and clearer cut ends (avoiding steric hindrance of XbaI and NotI), 8 
restriction reactions were carried out in parallel, first digesting together with NheI-HF and 
NotI-HF, in a seconds reaction digesting with XbaI and in a third reaction digesting with 
EcoRI.  
 
The DNA fragments of interest both from PCR and restriction digestion were extracted from 
gel excised pieces using the QIAquick
®
 Gel Extraction Kit. DNA concentrations were 
measured using the NanoDrop
TM
 2000c Spectrophotometer. Next, the Gibson Assembly was 
carried out to ligate BDK-B2-AVPR2tail-TCS-tTA into MCS A, downstream of NheI and 
upstream of EcoRI sites of pZK12 and to ligate βArrestin2-TEV in MCS B, downstream of 
XbaI and upstream of NotI sites of pZK12. Gibson Assembly was performed at 50°C for 60 
minutes, following the kit manufacturer’s instructions. The assembled plasmid was 
transformed into competent JM109 E. coli and plated overnight on LB-Agar Petri dishes 
containing 50 µg/ml final ampicillin (Amp) concentrations. Next day, 8 colonies were 
randomly selected and inoculated into liquid LB culture for overnight growing. The 
following day, plasmids were extracted from these 8 cultures and plasmids were sent for 
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DNA sequencing. Sequencing results revealed that the assembly did not work. It was 
observed that the colonies on the LB-Agar plates had a mucous consistency. Repeated the 
Gibson Assembly and transformed the assembled plasmid solution into the NEB 5α F’Iq 
competent E. coli strain and plated E. coli on freshly poured LB-Agar plates supplemented 
with 50 µg/ml final concentrations of Amp. No colonies were obtained the following day.  
Repeated the entire procedure, starting from PCR and restriction enzyme digestion to obtain 
DNA fragments at higher concentrations. These DNA fragments were separated using AGEP, 
were excised and extracted from the gel. After gel extraction, all DNA fragments were 
purified using the QIAquick PCR Purification Kit and DNA concentrations were measured 
using the NanoDrop
TM
 2000c Spectrophotometer. Ran the Gibson Assembly
®
 with various 
molar ratios of the inserts and vector backbone fragments. For Gibson Assembly
®
, besides 
our DNA fragments of interest (BDK-B2-AVPR2tail-TCS-tTA, βArrestin2-TEV, IRES and 
pZK12 backbone DNA fragments), the positive control DNA fragments provided by NEB for 
the Gibson Assembly were also included in a separate reaction. Resulting assembly solutions 
were transformed into the NEB 5α F’Iq competent E. coli strain and plated overnight. As a 
positive control for transformation the intact pZK12 was also included. Colonies were 
obtained both from Gibson Assembly positive control reaction and from transformation 
positive control reaction, but the assembly of our DNA fragments did not yield any colonies. 
Repeated the entire procedure from the beginning once again and identical results were 
obtained.  
Since the positive control experiments worked and the assembly of the fragments of interest 
did not, it was considered that the primers that were designed must have had failed to work. 
Thus, a second generational two new primer sets were designed using the NEBuilder
TM
 
online application, plasmids No. 5–12 from Table 2.15. Forward and reverse primers 5 and 6 
were designed to PCR amplify the BDK-B2-AVPR2tail-TCS-tTA construct with an overlap 
extension on its 5’ end that is complementary to the region upstream of EcoRI site on MCS A 
of PZK12 and with an overhang on the 3’ end of BDK-B2-AVPR2tail-TCS-tTA which is 
complementary to the region downstream of the EcoRI site on MCS A of pZK12. Similarly, 
PCR forward primer 7 for the amplification of βArrestin2-TEV contains a 5’ extension which 
is complementary to region upstream of the XbaI site on MCS B of pZK12. Reverse primer 8 
is meant to PCR amplify βArrestin2-TEV, placing an overlap extension to its 3’ end which is 
complementary to the region downstream of the XbaI site on MCS B of pZK12. As a backup, 
primer pairs 9 and 10 were similarly designed to amplify BDK-B2-AVPR2tail-TCS-tTA with 
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extensions on 5’ and 3’ ends that overlap regions upstream and downstream of the NheI site 
on MCS A of pZK12. The other backup primer pair, 11 and 12, was designed to integrate the 
βArrestin2-TEV construct into the NotI site on MCS B of pZK12.  
Using primer pairs 5&6 (EcoRI) and 9&10 (NheI) PCR amplified BDK-B2-AVPR2tail-TCS-
tTA. βArrestin2-TEV was PCR amplified using primer pairs 7&8 (XbaI) and 11&12 (NotI). 
Resulting PCR solutions were loaded on AGEP and images of the gels are given in Figure 
2.20. Initially, PCR was carried out at 3 different ATs for each of the constructs. The range of 
ATs differs between the two constructs because their corresponding primer length and GC 
content is different. Images of gels after AGEP of all four DNA fragment types at two AT are 
shown in Figure 2.20A. The image of all four PCR fragments separated on gel at the third AT 
is presented in Figure 2.20B. All of these three ATs yielded DNA bands of the expected size. 
The bands obtained at the highest AT of the three used (61.4 °C for BDK-B2-AVPR2tail-
TCS-tTA and 68.7 °C for βArrestin2-TEV) were cut out from the gel. Subsequent PCRs were 
carried out at these ATs to generate larger quantities of these 4 DNA fragments, which were 
then run on AGEP and recorded images are given in Figure 2.20 C and D. The DNA bands 
around 2 kbp which contain our fragments of interested were excised from the gel and stored 
for subsequent DNA extraction and Gibson Assembly
®
. 
Plasmid pZK12 was digested with two different enzyme sets: EcoRI&XbaI and NheI-
HF&NotI-HF. Images recorded of agarose gels on which these digestion fragments were 
separated and analysed are displayed in Figure 2.21. NheI-HF and NotI-HF double digestions 
were carried out simultaneously as previously described. XbaI and EcoRI digestions were 
carried out sequentially, with a spin column purification step in between, as previously 
described. Since the starting amount of total DNA per restriction enzyme reaction is only 1 
µg, hence the low intensity of the bands, many reactions had to be carried out in parallel to 
generate sufficient amounts of DNA fragments for the Gibson Assembly
®
. Thus, four gel 
images are shown within Figure 2.21: A, B, C and D. All of these images exhibit the bands of 
interest, for the IRES fragment (around 0.6 kbp) and the pZK12 backbone (around 5.5 kbp). 
As it can be seen from Figure 2.21B, the IRES fragment (around 0.6 kbp) did not migrate 
uniform distances in the agarose gel. The reason for this non-uniform migration was not 
known, however among the explanations for this rather unusual phenomena are the 
followings. Firstly, the DNA degraded, its size decreased, thus it migrated faster. Secondly, 
the distribution of the electrical field which was driving the electrophoresis was not uniform, 
a higher intensity field being applied to the lanes from the middle part of the gel. Thirdly, the 
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agarose gel was not uniformly mixed and a lower agarose concentration was present in the 
area around the middle of the gel and the agarose concentration gradually increased towards 
the exterior of the gel. To minimize the risk of failure, the DNA bands from Figure 2.21B 
were not excised for further processing. All the other IRES (around 0.6 kbp) and pZK12 
backbone (around 5.5 kbp) bands were cut out from the gel and stored. 
 
Figure 2.20. Images of agarose gels ran to analyse and separate BDK-B2-AVPR2tail-TCS-
tTA (with extensions to anneal in the EcoRI and NheI sites) and βArrestin2-TEV (with 
extensions to anneal in the XbaI and NotI sites) PCR products for the Gibson Assembly
®
. All 
reactions were carried out using the Q5
®
 High-Fidelity DNA Polymerase. A. To optimize the 
PCR, different ATs were used: 60 and 61.4 °C for BDK-B2-AVPR2tail-TCS-tTA and 67 and 
68.7 °C for βArrestin2-TEV. Both ATs yielded bands with the expected size, thus the band 
obtained at the higher AT will be further processed. B. In parallel, a third AT was tried, 
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58.4°C for BDK-B2-AVPR2tail-TCS-tTA and 65.2°C for βArrestin2-TEV. These also 
worked, however, since the AT was lower compared to the previous cases. These bands were 
not selected for further processing. C and D. PCR carried out the previously optimized ATs, 
in order to generate a sufficient quantity of DNA for the Gibson Assembly
®
.  
 
 
 
Figure 2.21. Images of agarose gels ran to analyse and separate restriction digestion products 
of pZK12 for the Gibson Assembly
®
. Plasmid pZK12 was simultaneously digested with 
NheI-HF and NotI-HF. XbaI and EcoRI digestions were carried out sequentially. A, B, C, D. 
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Repeated digestions for generating the quantity of fragments required for the Gibson 
Assembly
®
. 
 
Next, the QIAquick
®
 Gel Extraction Kit was used to isolate PCRed and digested DNA 
fragments from gel pieces. Following gel extraction, all DNA fragments were spin column 
purified with the QIAquick PCR Purification Kit and DNA concentrations were measured 
using the NanoDrop
TM
 2000c Spectrophotometer. The Gibson Assembly was carried out to 
assemble BDK-B2-AVPR2tail-TCS-tTA fragment obtained with primers 5&6 (EcoRI) and 
βArrestin2-TEV PCRed with primers 7&8 (XbaI) with pZK12 fragments digested with 
EcoRI and XbaI. In parallel, BDK-B2-AVPR2tail-TCS-tTA fragment generated using 
primers 9&10 (NheI) and βArrestin2-TEV PCRed with primers 11&12 (NotI) were also 
Gibson Assembled with linear DNA fragments obtained upon the digestion of pZK12 with 
restriction enzymes NheI-HF and NotI-HF. The resulting assembly solutions were 
transformed into both competent JM109 and NEB 5α F’Iq E. coli cells, which were plated 
overnight. No colonies appeared the next day.  
Generated new PCR fragments of BDK-B2-AVPR2tail-TCS-tTA using primer pairs 5&6 
(EcoRI) and 9&10 (NheI) and of βArrestin2-TEV using primer pairs 7&8 (XbaI) and 11&12 
(NotI). Double digested pZK12 with EcoRI&XbaI, NheI-HF&NotI-HF, with EcoRI&NotI-
HF and with Nhel-HF&XbaI in 4 separate reactions. PCRed and restriction digested DNA 
fragments were ran on AGEP, were excised and extracted from the gel. DNA fragments were 
purified using the QIAquick PCR Purification Kit and DNA concentrations were measured 
using the NanoDrop
TM
 2000c Spectrophotometer. In order to minimize the probability of 
having had used a faulty batch of the Gibson Assembly
®
 Kit, a newly ordered kit was used in 
parallel with the older kit. The Gibson Assembly was performed to assemble BDK-B2-
AVPR2tail-TCS-tTA fragment obtained with primers 5&6 (EcoRI) and βArrestin2-TEV 
PCRed with primers 7&8 (XbaI) with pZK12 fragments digested with EcoRI and XbaI. 
BDK-B2-AVPR2tail-TCS-tTA fragment generated using primers 9&10 (NheI) and 
βArrestin2-TEV PCRed with primers 11&12 (NotI) were also Gibson Assembled with DNA 
fragments obtained upon the digestion of pZK12 with NheI-HF and NotI-HF. Plasmid pZK12 
digested with EcoRI and NotI-HF was assembled with BDK-B2-AVPR2tail-TCS-tTA 
obtained with primers 5 and 6 (EcoRI) and with βArrestin2-TEV PCRed with primers 11 and 
12 (NotI). Plasmid pZK12 digested with Nhel and XbaI was also assembled with BDK-B2-
AVPR2tail-TCS-tTA obtained with primers 9 and 10 (NheI) and with βArrestin2-TEV 
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PCRed with primers 7 and 8 (XbaI). These resulting assembly solutions were transformed 
into both competent DH5α and NEB 5α F’Iq E. coli cells, which were plated overnight. No 
colonies appeared the next day. 
 
Table 2.15. PCR primers to generate DNA fragments for conventional cloning, for Gibson 
Assembly
®
 and for In-Fusion
®
 HD Cloning.  
No
. 
Primer Name Primer Sequence (5’→3’) 
1 pIRES-GPCR-F_wOH 
CGACTCACTATAGGCTAGCCTCGCCATGCTCAATGTC
ACCTTGC 
2 pIRES-GPCR-R_wOH 
GCATGCTCGACGCGTGAATTCTCGCCTACCCACCGTA
CTCGTCAATTCC 
3 pIRES-TEV-F_wOH 
CCACAACCCGGGATCCTCTAGAGTCGGGAATGGGGG
AGAAACCCGG 
4 pIRES-TEV-R_wOH 
CCCTCACTAAAGGGAAGCGGCCGCCCCATTCATGAGT
TGAGTCGCTTCC 
5 
pIRES_Gibson-
Assem_GPCR_EcoRI_F 
cactataggctagcctcgagATGCTCAATGTCACCTTG 
6 
pIRES_Gibson-
Assem_GPCR_EcoRI_R 
agatgcatgctcgacgcgtgCTACCCACCGTACTCGTC 
7 
pIRES_Gibson-
Assem_TEV_XbaI_F 
ttgccacaacccgggatcctATGGGGGAGAAACCCGGG 
8 
pIRES_Gibson-
Assem_TEV_XbaI_R 
agcggccgcccgggtcgactTCAAGCGTAATCTGGAACATCATA
TGG 
9 
pIRES_Gibson-
Assem_GPCR_NheI_F 
ttaatacgactcactataggATGCTCAATGTCACCTTG 
10 
pIRES_Gibson-
Assem_GPCR_NheI_R 
cgacgcgtgaattctcgaggCTACCCACCGTACTCGTC 
11 
pIRES_Gibson-
Assem_TEV_NotI_F 
cctctagagtcgacccgggcATGGGGGAGAAACCCGGG 
12 
pIRES_Gibson-
Assem_TEV_NotI_R 
aaccctcactaaagggaagcTCAAGCGTAATCTGGAACATCATA
TGG 
13 
pIRES_In-
Fusion_GPCR_EcoRI_F 
ctagcctcgagaattATGCTCAATGTCACCTTG   
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14 
pIRES_In-
Fusion_GPCR_EcoRI_R 
ctcgacgcgtgaattCTACCCACCGTACTCGTC 
15 
pIRES_In-
Fusion_TEV_XbaI_F 
cccgggatcctctagATGGGGGAGAAACCCGGG 
16 
pIRES_In-
Fusion_TEV_XbaI_R 
ccgggtcgactctagTCAAGCGTAATCTGGAACATCATATGG 
17 G_PCR_FW_11Feb2013 cactataggctagcctcgagATGCTCAATGTCACCTTG 
18 G_PCR_RW_11Feb2013 cgcgtgaattCTACCCACCGTACTCGTC 
19 I_ PCR_FW_11Feb2013 cggtgggtagAATTCACGCGTCGAGCATG 
20 I_ PCR_RW_11Feb2013 tctcccccatAGGATCCCGGGTTGTGGC 
21 T_ PCR_FW_11Feb2013 ccgggatcctATGGGGGAGAAACCCGGG 
22 T_ PCR_RW_11Feb2013 
agcggccgcccgggtcgactTCAAGCGTAATCTGGAACATCATA
TGG 
23 
pIRES_PCR_FW_11Feb2
013 
AGTCGACCCGGGCGG 
24 
pIRES_PCR_RW_11Feb2
013 
CTCGAGGCTAGCCTATAGTGAGTCG 
25 G_ext_FW_11Feb2013 
cactataggctagcctcgagCGGAATTCACCATGCTCAATGTCA
CCTTGC 
26 G_ext_RW_11Feb2013 cgcgtgaattCGCGCCCCCTACCCACCG 
27 I_ext_FW_11Feb2013 agggggcgcgAATTCACGCGTCGAGCATG 
28 I_ext_RW_11Feb2013 attccagaggAGGATCCCGGGTTGTGGC 
29 T_ext_FW_11Feb2013 ccgggatcctCCTCTGGAATGGGGGAGAAACC 
30 T_ext_RW_11Feb2013 agcggccgcccgggtcgactGCTCGAGCGGCCGCTCAA 
31 TEV_14Mar2013_FW ttgccacaacccgggatcctATGGGGGAGAAACCCGGG 
32 
pIRES_G_I_14Mar2013_
RW 
AGGATCCCGGGTTGTGGC 
33 Arr-TEV_conv_F1 GCCACAACCCGGAATTCTATGGGGGAGAAACCCGG 
34 Arr-TEV_conv_R1 
AAAGGGAAGCGGCCGCCCGGGTCGACTTCAAGCGTA
ATCTGGAACATC 
35 pIRES-t_conv_F1 GTCGACCCGGGCGGCCGC 
36 pIRES-t_conv_R1 GATCAGTCTAGAATTCCGGGTTGTGGCAAGCTTATCA
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TCG 
37 hKLF2_F1 
CGTAAAGTCGACAACGCCACCATGGCGCTGAGTGAA
CCC 
38 hKLF2_R1 
TTTCGTCATCGCTGAATACAGCTACATGTGCCGTTTC
ATGTGC 
39 pTRE3G_F1_27Sep2013 
GCACATGTAGGCTAGCCTGTATTCAGCGATGACGAAA
TTCTTAGC 
40 hKLF2_R2_27Sep2013 
GCTGAATACAGGCTAGCCTACATGTGCCGTTTCATGT
GC 
41 pTRE3G_R1_27Sep2013 
GGGTTCACTCAGCGCCATGGTGGCGTTGTCGACTTTA
CG 
 
NEB, the company which provided the Gibson Assembly
®
 Kit was contacted for technical 
support. They confirmed that our primers with overhangs are suitable for our purposes. They 
also recommended to spin column purify DNA fragments using the QIAquick PCR 
Purification Kit instead of carrying out AGEP, gel excision, gel extraction and purification. 
Thus, the above described procedure was repeated once more, overlap extension PCR was 
carried out and pZK12 was digested with restriction enzymes. Resulting DNA fragments 
were spin column purified using the QIAquick PCR Purification Kit and DNA concentrations 
were measured using the NanoDrop
TM
 2000c Spectrophotometer. Small aliquots of each 
DNA fragment were run on AGEP to check DNA fragment sizes, without excising and 
extracting the DNA from the gel; bands with the adequate sizes were obtained, Figure 2.22. 
The last two lanes to the right in this gel picture contain DNA fragments obtained in older 
PCR reaction. Since one of these two lanes did not contain the DNA band with the expected 
size, both of these two older PCR solutions were excluded from further processing. Using 
solution from which the other bands were aliquoted, the Gibson Assembly was carried out to 
assemble BDK-B2-AVPR2tail-TCS-tTA fragment PCRed with primers 5&6 (EcoRI) and 
βArrestin2-TEV generated with PCR primers 7&8 (XbaI) with pZK12 fragments (IRES and 
pZK12 backbone) digested with EcoRI and XbaI. In parallel, BDK-B2-AVPR2tail-TCS-tTA 
fragment obtained using PCR primers 9&10 (NheI) and βArrestin2-TEV PCRed with primers 
11&12 (NotI) were also Gibson Assembled with linear DNA fragments obtained upon the 
digestion of pZK12 with restriction enzymes NheI-HF and NotI-HF (IRES and pZK12 
backbone). Resulting Gibson Assembled solutions were transformed into competent E. coli 
and E. Coli were plated overnight. Next day, colonies appeared on all LB-Agar plates. 8 
colonies were randomly selected grown overnight in liquid LB cultures containing 50 µg/ml 
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final Amp concentrations. Next day, isolated the plasmids and sent plasmids for DNA 
sequencing. Analysed the sequencing results and only two of the 8 plasmids contained all 
four sequences: BDK-B2-AVPR2tail-TCS-tTA, IRES, βArrestin2-TEV and pIRES 
backbone. In the remaining 6 plasmids at least one of the DNA fragments that was supposed 
to be assembled, was missing. Further detailed sequencing of the two plasmids which 
contained all four DNA fragments of interest revealed a mutation in the βArrestin2-TEV start 
codon, Figure 2.23. 
 
 
Figure 2.22. Image of agarose gel after AGEP for analysing the sizes of DNA fragments 
obtained by overlap extension PCR and by restriction enzyme digestion.  
 
 
Synthetic gene network for monitoring shear stress sensor activity in endothelial cells 
165 
 
Figure 2.23. Sanger sequencing chromatogram showing the mutation in the βArrestin2-TEV 
start codon. Screenshot of DNA Star Lasergene’s SeqMan ProTM sequence analyser aligning 
sequencing results with the expected sequence. The upper-most sequence is the consensus 
sequence. The second sequence from the top was the expected sequence indicating a mutated 
start codon (the non-mutated start codon is ATG). The following 4 chromatogram sequences 
are reads from our DNA samples. Comparing the read sequences with the expected sequence, 
revealed that the Adenosine monophosphate (A) of the start codon has been changed to 
Cytidine monophosphate (C). Additionally, an A has been inserted in between the Thymidine 
monophosphate (T) and the Guanosine monophosphate (G) of the start codon. These 
mutations render the start codon dysfunctional, thus the entire βArrestin2-TEV became non-
expressible. 
 
Randomly selected further 12 colonies from LB-Agar plates, and 12 liquid LB culture 
containing 50 µg/ml final Amp concentrations were inoculated with these colonies. Next day, 
the plasmids were mini-prepped from the 12 cultures and sent for DNA sequencing. Only one 
out of the 12 plasmids seemed to contain all four DNA fragments: BDK-B2-AVPR2tail-TCS-
tTA, IRES, βArrestin2-TEV and pIRES backbone. This plasmid was further sequenced and 
the exact same mutation in the βArrestin2-TEV start codon was observed as in the previous 
experiment.  
Next, further 16 colonies were randomly selected from the LB-Agar plate and inoculated into 
liquid LB culture, grown overnight and plasmids were mini-prepped. In order to determine 
the presence of all inserts in the assembled plasmid, KAPA 2G™ Robust HotStart PCR was 
carried out with forward primer pZK1_seq_F_02 (No. 2 from Table 2.13) that anneals to the 
BDK-B2-AVPR2tail-TCS-tTA construct and with reverse primer pZK5_seq_R_04 (No. 50 
from Table 2.13) that anneals to the βArrestin2-TEV construct. If all sequences were 
correctly assembles, PCR would amplify parts of the BDK-B2-AVPR2tail-TCS-tTA, the 
entire IRES fragment and parts of βArrestin2-TEV, the length of the obtained PCR product 
being 3.15 kbp. To determine the size of PCR products, PCR solution were run on AGEP; 
images of the gel is shown below in Figure 2.24. PCR was carried out at two different ATs, 
60 and 68 °C, at both ATs similar results were obtained: out of the 16 PCR screened plasmids 
only one plasmid, number 35 seems to contain the right insert size. However, at the lower 
AT, besides the 3.15 kbp band of plasmid 35, another band containing DNA fragments of 
approximately 0.5 kbp length could also be seen in the same lane. This low molecular weight 
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band was most probably caused by unspecific binding of the PCR primers at this lower AT. 
In the case of the other 15 plasmids, PCR products with lower molecular weight have been 
obtained, indicating that one of the fragments was missing. The one plasmid that yielded the 
PCR product with the correct size, plasmid 35, was sequenced to determine whether 
βArrestin2-TEV start codon mutation was present or not. Sequencing revealed the presence 
of the exact same mutation in the βArrestin2-TEV start codon.  
 
 
Figure 2.24. PCR screening for determining the presence of all inserts: BDK-B2-AVPR2tail-
TCS-tTA, IRES fragment and βArrestin2-TEV, in the Gibson Assembled plasmid. The 
forward primer binds to the BDK-B2-AVPR2tail-TCS-tTA construct and the reverse primer 
binds to the βArrestin2-TEV, the resulting PCR product in the correctly assembled plasmid 
should be 3.15 kbp. Only plasmid number 35 yielded a PCR product with the correct size. 
 
Number of total colonies screened with DNA sequencing and PCR obtained with the second 
generational primers (No. 5–12 from Table 2.15) was 36. Out of 36 colonies only 4 seemed 
to contain all four DNA fragments: BDK-B2-AVPR2tail-TCS-tTA, IRES, βArrestin2-TEV 
and pIRES backbone. Out of these four, all four had the exact same mutation in the 
βArrestin2-TEV start codon. The reason why these start codon mutations occurred 
consistently and their origin was not clear to us. These could have had been caused during 
PCR by faulty primers or unsuccessful DNA polymerases, or caused during the Gibson 
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Assembly
®
 due to error-prone DNA polymerase enzymes, or the plasmid could have had 
been mutated by the host E. coli in which it had been transformed for replication.  
Since Gibson assembly did not work properly, in parallel, the In-Fusion
®
 HD Cloning Kit 
from Clontech was also employed to construct the plasmid pZK13. This kit serves the same 
purpose as the Gibson Assembly
®
 Kit, the only difference being that the ends of liner double 
stranded DNA fragments are chewed back by a 3’ exonuclease enzyme instead of Gibson 
Assembly’s 5’ exonuclease. Chewing back 3’ ends of the double stranded DNA by In-
Fusion’s 3’ exonuclease, creates single-stranded 5´ overhangs that facilitate the annealing of 
fragments that share complementarity due to extensions added to primers (homologous 
overlap region). Due to this difference in the exonuclease, the primers are not interchangeable 
between the In-Fusion
®
 HD Cloning Kit and Gibson Assembly
®
 kits. Thus, for the In-
Fusion
®
 HD Cloning Kit, primers 13 and 14 from Table 2.15 were designed to PCR amplify 
BDK-B2-AVPR2tail-TCS-tTA with extensions for cloning into the EcoRI site on MCS A of 
pZK12. Similarly, to clone βArrestin2-TEV construct into the XbaI site of MCS B of pZK12, 
primers 15 and 16 from Table 2.15 were designed. Using these primers, construct BDK-B2-
AVPR2tail-TCS-tTA and βArrestin2-TEV were amplified using overlap extension PCR. 
Plasmid pZK1 was sequentially digested with XbaI and EcoRI to obtain the IRES fragment 
(around 0.6 kbp) and the backbone fragment (about 5.5 kbp). DNA fragments were spin 
column purified using the QIAquick PCR Purification Kit and DNA concentrations were 
measured using the NanoDrop
TM
 2000c Spectrophotometer. Next, the In-Fusion
®
 cloning 
was performed by incubating BDK-B2-AVPR2tail-TCS-tTA, βArrestin2-TEV, IRES and 
pZK12 backbone DNA fragments together with the In-Fusion HD Enzyme Premix for 15 
minutes at 50°C, following the kit manufacturer’s instructions. The resulting solution was 
transformed in competent DH5α and NEB 5α F’Iq E. coli cells. E. coli cells were plated 
overnight on selective LB-Agar plates containing 50 µg/ml final Amp concentrations. The 
following day no colonies were obtained. Since the In-Fusion
®
 HD Cloning Kit wasn’t able 
to assemble pZK13 either and since at this stage we were more familiar with the Gibson 
Assembly
®
 Kit and because technical support from Clontech replied significantly slower to 
our enquiries than the technical support from NEB, it was decided to stop using the In-
Fusion
®
 HD Cloning Kit and focus solely on using the Gibson Assembly
®
 Kit in the future. 
In order to prevent mutations in the βArrestin2-TEV start codon from occurring, all 4 DNA 
fragments (BDK-B2-AVPR2tail-TCS-tTA, βArrestin2-TEV, IRES and pZK12 backbone) 
were planned to be amplified using extension PCR. For this a third generation of primers for 
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the Gibson Assembly were designed, No. 17–30 from Table 2.15. Generating all DNA 
fragments by overlap extension PCR, allows for the start codon to be contained within the 
overlap extension of the DNA fragment to be assembled upstream of the start codon as well. 
Thus, the start codon will be present both in the extension of the upstream sequence (e.g. 
IRES sequence, in case of βArrestin2-TEV start codon) and in the actual coding construct 
(e.g. βArrestin2-TEV). Having the start codon present in the overlap extensions of both 
neighbouring sequences to be assembled, should reduce the probability of mutation in the 
start codon, compared to the situation when DNA fragment upstream of the start codon (e.g. 
IRES sequence, in case of βArrestin2-TEV start codon) was generated by restriction enzyme 
digestion and the start codon was present only on the actual coding sequence (e.g. 
βArrestin2-TEV). For this purpose, primers 17–24 form Table 2.15 were designed. The 
second set of primers, 23–30 was designed with the same concept in mind; however, an 
additional measure was taken in order to prevent mutation in the βArrestin2-TEV start codon 
from occurring. This additional measure consisted of the inclusion of an 8–14 nucleotide long 
non-coding sequence right before the start codon on the primers designed for overlap 
extension PCR. This 8–14 nucleotide long non-coding sequence was in fact the sequence 
upstream of the start codon on the template plasmid, plasmid pZK9 from which BDK-B2-
AVPR2tail-TCS-tTA was amplified and plasmid pZK5 for the amplification of βArrestin2-
TEV. This way, the first set of BDK-B2-AVPR2tail-TCS-tTA, IRES, βArrestin2-TEV and 
pZK12 backbone DNA fragments were PCR amplified using primer pairs 17&18, 19&20, 
21&22 and 23&24 from Table 2.15, respectively. Similarly, the second set of pZK12 
backbone, BDK-B2-AVPR2tail-TCS-tTA, IRES and βArrestin2-TEV DNA fragments were 
PCRed using primer pairs 23&24, 25&26, 27&28 and 29&30 from Table 2.15, respectively. 
Aliquots of these fragments were run on AGEP to check the presentence and size of 
generated PCR products, picture of the agarose gel is visible in Figure 2.25. According to 
Figure 2.25A gel image, all fragments of interest were successfully generated except the 
βArrestin2-TEV with non-coding extensions. To generate the missing βArrestin2-TEV with 
non-coding extensions, PCR was repeated using a gradient of AT (68–72°C). Aliquots from 
this PCR were run on AGEP and the image of the gel is given in Figure 2.25B, showing that 
PCR worked under ATs of 70°C. 
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Figure 2.25. Image of agarose gel on which PCR generated DNA fragments were analysed. 
A. All four DNA fragments (BDK-B2-AVPR2tail-TCS-tTA, βArrestin2-TEV, IRES and 
pZK12 backbone), with and without non-coding extensions were PCR amplified and their 
aliquots were analysed by AGEP. No band was visible on the gel for the βArrestin2-TEV 
fragment with non-coding extension, meaning that PCR of this fragment was unsuccessful. B. 
PCR was repeated at various ATs (68–72°C) for the βArrestin2-TEV fragment with non-
coding extension. This fragment was successfully amplified at ATs below 70°C. 
  
All DNA fragments successfully amplified by PCR were spin column purified, Gibson 
Assembled, transformed into competent E. coli and plated overnight on selective LB-Agar 
plates. All 8 LB-Agar selection plates contained colonies the following day. 8 randomly 
selected colonies were inoculated into 8 overnight liquid LB-cultures supplemented with 50 
µg/ml ampicillin. Next day mini-prepped the plasmids and sent plasmids for sequencing. 
Analysed the sequencing results and found two promising plasmid clones with right insert 
size. Further sequencing analysis revealed that sequences of about 20 nucleotides was 
missing from the beginning of βArrestin2-TEV. Next, randomly selected further 16 colonies, 
inoculated liquid LB cultures containing 50 µg/ml ampicillin with these 16 colonies for 
plasmid isolation. These 16 isolated plasmids became PCR templates to amplify the 3.15 kbp 
sequence that should contain the second part of the BDK-B2-AVPR2tail-TCS-tTA construct, 
the entire IRES and the first region of the βArrestin2-TEV construct from the assembled 
plasmids. To amplify this 3.15 kbp DNA fragment, similarly to previous PCR screenings, 
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primers pZK1_seq_F_02 (No. 2 from Table 2.13) and pZK5_seq_R_04 (No. 50 from Table 
2.15) were used. The solution resulting from the PCR was run on AGEP and image of this gel 
is shown in Figure 2.26 below. Only plasmid number 23 contained an insert with a length of 
around 3.15 kbp. As positive controls for PCR and insert size, the last two lanes to the right 
on the gel were loaded with PCR products where the previously obtained assembly with the 
correct size and with the mutation in the βArrestin2-TEV start codon was used as PCR 
template. Both of the positive control PCR reactions yielded bands on the gel with the 
expected size, indicating the PCR worked successfully. The size of the positive control bands 
was the same as the size of band generated from plasmid 23. Next plasmid 23 was sequenced 
and a sequence of 10 nucleotides was missing from the beginning of the IRES sequence, 
rendering the assembly unsuccessful. 
 
Figure 2.26. PCR screening for determining the presence of all inserts BDK-B2-AVPR2tail-
TCS-tTA, IRES fragment and βArrestin2-TEV in Gibson Assembled plasmids. The forward 
primer binds to the BDK-B2-AVPR2tail-TCS-tTA construct and the reverse primer binds to 
the βArrestin2-TEV, the amplified PCR product in the correctly assembled plasmid should be 
3.15 kbp. Only plasmid number 23 yielded a PCR product with the correct size, similar to the 
positive control bands (5 old and 6 old). 
 
To repair the mutation in the start codon of the βArrestin2-TEV gene fusion in the previously 
obtained plasmid, which otherwise contained the correct sequence, the site directed 
mutagenesis kit was considered. However, this meant learning and establishing another new 
Synthetic gene network for monitoring shear stress sensor activity in endothelial cells 
171 
 
technique in our labs and after further consideration the site directed mutagenesis technique 
was not employed. 
The Gibson Assembly
®
 probably failed because of the high number of DNA fragments that 
need to be assembled in one step. To reduce the number of DNA fragments to be assembled, 
the already assembled entire pZK12 backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES 
construct was amplified as one DNA fragment from the assembled plasmid which contained 
the βArrestin2-TEV start codon mutation. Next, the βArrestin2-TEV fragment from pZK5 
was PCR amplified and was Gibson assembled with the construct amplified from pZK12, to 
obtain the desired pZK13 without any mutation. For this, primers 31 and 32 from Table 2.15 
were ordered to PCR amplify the βArrestin2-TEV fragment. The pZK12 backbone–BDK-B2-
AVPR2tail-TCS-tTA–IRES construct was PCR amplified using primers 31 and 23 from 
Table 2.15. Following the PCR, DNA concentrations were measured with the NanoDrop
TM
 
2000c Spectrophotometer and the concentration for the pZK12 backbone–BDK-B2-
AVPR2tail-TCS-tTA–IRES construct was very low (below 4 ng/µl), meaning that the PCR of 
this fragments was not successful. Repeated the PCR of the pZK12 backbone–BDK-B2-
AVPR2tail-TCS-tTA–IRES fragment with a gradient of ATs and ran aliquots of the resulting 
solution on AGEP to check the presence and size of resulting DNA fragments. Image of the 
gel is shown below in Figure 2.27. This image showed that PCR amplification of the 8.3 kbp 
pZK12 backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES fragment was still unsuccessful. The 
first lane to the left shows two low intensity bands for the amplification of the βArrestin2-
TEV fragment. It can be observed that the signal intensity in this gel image is very low (also 
for the ladder DNA fragments), most probably due to the fact that this was a gel piece left 
over from an older agarose gel that was used two weeks before, and the SYBR
®
 Safe DNA 
Gel Stain might have had been degraded since. 
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Figure 2.27. Image of agarose gel after electrophoresis of DNA fragments PCRed for the 
Gibson Assembly
®
. The first lane to the left contains the βArrestin2-TEV PCR product, 
where weak bands are visible. On the following 5 lanes, the PCR product of the pZK12 
backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES fragment amplification was loaded. In these 
lanes no DNA bands around the expected 8.3 kbp were visible, rendering the PCR 
unsuccessful. 
  
The PCR and AGEP were repeated once more but without any positive outcome for the 
amplification of the pZK12 backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES fragment. PCR 
amplification of DNA fragments longer than 5 kbp is known to be challenging [521]. The 
PCR was again repeated with double DNA polymerase concentration. DNA concentrations of 
below 4 ng/µl measured with the NanoDrop
TM
 2000c Spectrophotometer revealed that the 
PCR amplification of the pZK12 backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES fragment 
was unsuccessful. Repeated the PCR using a larger gradient (10°C) of ATs, loaded the 
resulting solution on agarose gel for electrophoresis, image of the resulting gel is shown in 
Figure 2.28 below. The gel image showed the absence of all the expected DNA fragments. 
The βArrestin2-TEV fragment was not visible either and the DNA ladder fragments had a 
very low intensity as well.  
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Figure 2.28. Image of agarose gel on which PCR products of the βArrestin2-TEV fragment 
and pZK12 backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES fragment were analysed. None 
of the PCR reactions yielded the DNA bands of interest.  
 
It was noticed that the Owl™ EasyCast™ B1 Mini Gel Electrophoresis Systems was reaching 
high temperature during AGEP ran at 200 V. Therefore, repeated the PCR and ran the AGEP 
at lower voltages (120 V) in the larger Owl™ EasyCast™ B2 Mini Gel Electrophoresis 
Systems, to prevent excessive heat generation. Image of the resulting gel is shown in Figure 
2.29 below. All DNA bands of interest were visible on the agarose gel.   
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Figure 2.29. Image of agarose gel for the analysis of the βArrestin2-TEV and pZK12 
backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES fragments. All DNA bands of the correct 
size were obtained.  
Using the obtained DNA fragments ran the Gibson Assembly protocol. The resulting solution 
was transformed in competent DH5α and NEB 5α F’Iq E. coli cells. E. coli cells were plated 
overnight on selective LB-Agar plates containing 50 µg/ml final Amp concentrations. From 
the obtained colonies selected 16 and prepared overnight liquid cultures in LB medium 
supplemented with 50 µg/ml final Amp concentrations, to isolate the plasmid. The following 
day, mini-prepped the plasmids, measured concentration using the NanoDrop
TM
 2000c 
Spectrophotometer and ran a PCR using insert-specific primers (No. 2 and 50 from Table 
2.13) to screen for the presence of the insert. Ran AGEP of the obtained PCR solutions to 
identify plasmids with the correct (3.15 kbp) insert size. According to the gel image, Figure 
2.30, 12 out 16 plasmids contained band with the expected insert DNA fragment sizes. Sent 
all 12 plasmids for DNA sequencing and analysing the sequencing results showed that all 12 
plasmids contained the exact same mutation in the βArrestin2-TEV start codon. The reason 
for the high consistency of the βArrestin2-TEV start codon mutation in this experiment could 
well be due to the presence of the initial plasmid with βArrestin2-TEV start codon mutation 
from which the pZK12 backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES fragment was 
amplified. This occurred because, following NEB’s instructions, after PCR of the fragments, 
the DNA was spin column purified using the QIAquick PCR Purification Kit. This 
purification method retains the total DNA with sizes between 100 bp – 10 kbp, thus the initial 
PCR template plasmid might have had been present after purification in the Gibson 
assembled solution which was transformed into competent E. coli. Thus, the obtained 
colonies could have contained the initial template plasmid with the mutation in the 
βArrestin2-TEV start codon.  
Synthetic gene network for monitoring shear stress sensor activity in endothelial cells 
175 
 
 
Figure 2.30. Image of PCR products ran on AGEP to identify assembled plasmids that 
contain the insert with the correct size. Plasmids number 2, 4, 5, 8-16 contain the insert with 
the desired size, identical with positive control plasmids (5 old and 6 old).  
 
Due to over 6 months of failures in obtaining pZK13 using the Gibson Assembly, the Gibson 
Assembly method was given up on and cloning was continued with conventional methods. It 
had been insisted on optimizing the Gibson Assembly procedure as a fast and convenient 
cloning method in our group. For conventional cloning of the pZK12 backbone–BDK-B2-
AVPR2tail-TCS-tTA–IRES fragment with the βArrestin2-TEV fragment, primers No. 33–36 
from Table 2.15 were designed and ordered. These PCR primers contained overhangs with 
restriction enzyme sites for conventional cloning. The βArrestin2-TEV fragment was PCR 
amplified using primers 33 and 34 and the pZK12 backbone–BDK-B2-AVPR2tail-TCS-tTA–
IRES fragment was PCR amplified using primers 35 and 36 from Table 2.15. For 
conventional cloning the NotI site was present on primer 34 and 35 and the EcoRI site was 
introduced to primers 33 and 36. The PCR was performed and PCR products were spin 
column purified. Concentration measurements using the nano-drop spectrophotometer 
revealed that the 8.3 kbp pZK12 backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES fragment 
was not present (concentrations were below 5 ng/µl). The PCR was repeated using a gradient 
of 10°C of ATs to PCR amplify the two fragments for conventional cloning. The spin column 
purification of PCR products was repeated, however, measured concentrations of the pZK12 
backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES fragment were very low (≈5 ng/µl), 
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indicating that the PCR did not work. Measured DNA concentrations revealed that the 
amplification of the βArrestin2-TEV fragment was successful. In order to get the PCR 
amplification of pZK12 backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES fragment working, 
the DNA template (two DNA templates which contained the βArrestin2-TEV start codon 
mutations were used, “5 old” and “6 old”), the amount of DNA template and the amount of 
DNA polymerase were systematically varied. The conditions and the outcome (DNA 
concentration measured with NanoDrop
TM
) from this experiment is shown in Table 2.16 
below. This experiment showed that increasing the Q5
®
 High-Fidelity DNA polymerase 
concentration resulted in higher amount of PCR products. Thus, the PCR products from 
samples number 4, 8, 12, 16, 20 and 24 were spin column purified and digested with 
restriction enzymes EcoRI and NotI-HF to generate cohesive ends for cloning. Digested 
fragments were run on AGEP and gel images are shown in Figure 2.31 below. Figure 2.31A 
shows that bands with the expected size were obtained for all of the pZK12 backbone–BDK-
B2-AVPR2tail-TCS-tTA–IRES fragments. In Figure 2.31B, bands which were excised from 
the same gel are marked in yellow rectangles. The PCR amplified βArrestin2-TEV fragment 
was also digested with EcoRI and NotI-HF restriction enzymes. Resulting fragments were 
also subjected to AGEP, Figure 2.31C. Among other bands, the bands of interested were also 
obtained. The bands of interested which were excised from the gel are shown in yellow 
rectangle. Gel extracted and purified both the βArrestin2-TEV and the pZK12 backbone–
BDK-B2-AVPR2tail-TCS-tTA–IRES fragments. Concentration of these fragments measured 
on NanoDrop
TM
 turned out to be very low (10-20 ng/µl); these amounts were insufficient for 
ligation.  
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Table 2.16. Optimization of the PCR protocol for the 8.3 kbp long pZK12 backbone–BDK-
B2-AVPR2tail-TCS-tTA–IRES fragment 
Sample 
# 
Name of 
DNA 
template 
Amount of DNA 
template added [ng] 
Amount of DNA 
polymerase added [U] 
PCR product 
concentration [ng/µl] 
1 5 old 2.5 0.25 30 
2 5 old 2.5 0.5 48 
3 5 old 2.5 1 66 
4 5 old 2.5 1.8 105 
5 6 old 2.5 0.25 38 
6 6 old 2.5 0.5 60 
7 6 old 2.5 1 88 
8 6 old 2.5 1.8 121 
9 5 old 5 0.25 35 
10 5 old 5 0.5 60 
11 5 old 5 1 69 
12 5 old 5 1.8 110 
13 6 old 5 0.25 51 
14 6 old 5 0.5 57 
15 6 5 1 93 
16 6 5 1.8 133 
17 5 300 0.25 52 
18 5 300 0.5 56 
19 5 300 1 88 
20 5 300 1.8 125 
21 6 300 0.25 70 
22 6 300 0.5 65 
23 6 300 1 88 
24 6 300 1.8 119 
 
    
Synthetic gene network for monitoring shear stress sensor activity in endothelial cells 
178 
 
 
Figure 2.31. Images of agarose gels on which DNA fragments generated by PCR and by 
digestion with restriction enzymes EcoRI and NotI were separated for conventional cloning. 
A. The 8.3 kbp long pZK12 backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES fragment with 
sticky ends for cloning was obtained by PCR followed by restriction enzyme digestion. B. 
Bands corresponding to fragment pZK12 backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES to 
be excised are marked in yellow rectangles. C. The ≈2 kbp βArrestin2-TEV fragment was 
obtained by PCR and its ends were chopped off with restriction enzymes. D. Bands 
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corresponding to the βArrestin2-TEV fragment that were excised are highlighted in yellow 
rectangles. The DNA fragment of interest was present in low amounts. 
The procedure was repeated from the beginning. Thus, generated PCR products (both for 
βArrestin2-TEV and the pZK12 backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES fragment) 
with overhangs that contain restriction enzyme sites for conventional cloning. Spin column 
purified the PCR products, measured concentrations using the NanoDrop
TM
 2000c 
Spectrophotometer. Digested both fragments with restriction enzymes EcoRI and NotI-HF to 
generate sticky ends for cloning. Resulting DNA fragments were separated by AGEP, Figure 
2.32A. Figure 2.32B shows the bands of the fragments of interest in yellow rectangles which 
were excised from the gel. The DNA was extracted from the gel using the QIAquick
®
 Gel 
Extraction Kit and the DNA spin column purified with the QIAquick PCR Purification Kit. 
DNA ligation was performed overnight at 16°C with the T4 DNA ligase. Transformed the 
ligation products into competent DH5α E. coli and which as then plated overnight on LB-
Agar supplemented with 50 µg/ml final Amp concentrations. The next day, inoculated 6 
overnight liquid cultures containing 50 µg/ml final Amp concentrations with 6 randomly 
picked colonies. The following day the 6 plasmids were mini-prepped and sent for DNA 
sequencing with primers to check the βArrestin2-TEV start codon mutation. Analysis of the 
sequencing results showed no mutations in the βArrestin2-TEV start codon. One of the 
plasmids was sent for complete sequencing with all the available relevant primers. The 
sequencing data showed that plasmid pZK13 was finally constructed, after 7 months, without 
any mutation in the coding region of this plasmid. The DH5α colony from which pZK13 
originated was inoculated into liquid LB culture containing 50 µg/ml final concentrations of 
Amp. The following day these cells were stored in glycerol stocks at -80°C for future 
amplification as ZK_S10, listed in Table 2.12. 
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Figure 2.32. Images of agarose gels on which DNA fragments generated by PCR and by 
restriction enzyme digestion with EcoRI and NotI were separated for conventional cloning. 
A. The 8.3 kbp long pZK12 backbone–BDK-B2-AVPR2tail-TCS-tTA–IRES fragment with 
cohesive ends for cloning was obtained by PCR followed by restriction enzyme digestion. 
The ≈2 kbp βArrestin2-TEV fragment was obtained by PCR and its ends were chopped off 
with restriction enzymes. B. Bands corresponding to the fragment of interest that were 
excised are marked in yellow rectangles. 
 
After re-configuring the BDK-B2-AVPR2tail-TCS-tTA and βArrestin2-TEV constructs into 
a single plasmid, the reporter plasmid was intended to be improved to reduce the background 
expression levels from this plasmid. The best performing tTA inducible plasmid was the 
pTRE3G from Clotech Inc. This 3
rd
 generation Tet-responsive promoter (PTRE3G) consists of 
7 copied of the tetracycline operator (DNA sequence: TCCCTATCAGTGATAGAGA) with 
17 nucleotide long spacer sequences in between, followed by a modified Cytomegalovirus 
(CMV) minimal promoter. The minimal CMV promoter has been designed to lack binding 
sites for endogenous mammalian transcription factors, thus, further minimizing background 
expression, but allowing high induction levels [519]. The PTRE3G is followed by a multiple 
cloning site into which the eGFP gene has been cloned. Plasmid pTRE3G with eGFP cloned 
into its multiple cloning site, pTRE3G-eGFP, pZK14, has been generously provided by Dr. 
Miranda SC Wilson and Dr. Adolfo Saiardi from the MRC Laboratory for Molecular Cell 
Biology, University College London, UK. For mammalian antibiotic selection, the linear 
hygromycin selection marker from Clontech Laboratories, Inc. was intended to being used in 
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combination with pZK14. Plasmid pZK14 was transformed in JM109 competent E. coli strain 
and cells were stored in glycerol at -80°C as ZK_S11, listed in Table 2.12. 
Sterile endotoxin free plasmids were produced at large scale using the EndoFree
®
 Plasmid 
Mega Kit from Qiagen N.V. For this, two overnight pre-cultures containing 50 µg/ml final 
Amp concentrations were prepared of E. coli strains ZK_S10 and ZK_S11. Using these pre-
cultures, a 2.5 litre LB cultures supplemented with Amp at 50 µg/ml final concentration was 
inoculated with the ZK_S10 pre-culture and a 500 ml LB culture containing 50 µg/ml final 
Amp concentration was inoculated with the ZK_S11 pre-culture. The following day, both 
cultures were pelleted and the EndoFree
®
 Plasmid Mega protocol was followed to isolate and 
sterilize large quantities of the two plasmids for insertion into endothelial cells. The 
efficiency of the Mega-Prep process and the quality of the obtained plasmids were confirmed 
by AGEP. The quality of the produced plasmid DNA solution was evaluated using a 
NanoDrop
TM
 2000c Spectrophotometer, a ratio of absorbance at 260 nm and 280 nm above 
1.8, indicated purity of the DNA (without protein, phenol or other contaminants that absorb 
strongly at or near 280 nm). Similarly, the absorbance ratio at 260 nm and 230 nm was also 
confirmed to be in the 2.0 – 2.2 range, characteristic to pure DNA (free on contaminants that 
absorb at 230 nm). The identity and quality of plasmid was further assessed by DNA 
sequencing, obtaining positive results. The DNA sequences of pZK12, pZK13 and pZK14 are 
shown in Appendix 8.  
The quality of endotoxin free ultra-pure DNA solutions was tested every three months to 
detect any plasmid DNA degradation caused by (repeated freezing, thawing cycles). Plasmid 
concentrations and spectral properties of DNA evaluated with the NanoDrop
TM
 2000c 
Spectrophotometer are shown below in Table 2.17. Measured DNA concentrations and 
spectral properties are in the appropriate range. Plasmids were digested with restriction 
enzymes with unique sites on the plasmid and single-cut plasmids were subjected to AGEP. 
Results from such a periodic DNA quality assessment are shown in Figure 2.33 below. On 
this gel image, clear, well defined DNA bands are visible without any smaller molecule 
degradation product running in front of this front line. The smear running behind the band 
(due to DNA-to-DNA association products) was also insignificant, since plasmids were 
linearized by digestion. This AGEP image indicates that plasmids did not degrade and that 
they are of high quality.  
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Table 2.17. UV-vis spectral and concentration measurement of plasmid DNA solutions used 
for longer time periods. 
Plasmid 
name 
Restriction 
Enzyme1 
Expected 
conc. [µg/µl] 
Measured 
conc. [µg/µl] 
A260/A2802 A260/A2303 
pZK9 EcoRI 3.4 3.15 1.88 2.08 
pZK5 EcoRI 3.8 2.95 1.9 2.08 
pZK10 EcoRV 2.4 1.84 1.88 2.12 
pZK13 EcoRI 7.77 6.19 1.82 2.2 
pZK14 BamHI 12.2 1.72 1.80 2.01 
pZK11 EcoRV 0.836 0.99 1.89 1.93 
1 Restriction endonuclease site that occurs only once on the plasmid. 
2 Absorbance at 260 nm wavelenght divided by the absorbance value at 280 nm wavelenght. 
The A260/A280 ratio should be ≈1.8. Lower ratios indicate contamination with molecules 
that abosrb at 280 nm (e.g. phenol and proteins). 
3 Absorbance at 260 nm wavelenght divided by the absorbance value at 230 nm wavelenght. 
The A260/A230 ratio should be between 2.0-2.2. Lower ratios indicate contamination with 
molecules that abosrb at 230 nm (e.g. phenol or other compounds used during purification). 
 
 
Figure 2.33. Image of agarose gel ran for periodically assessing the quality of plasmid 
solutions. Plasmids were digested with single-cut restriction enzymes to avoid supercoiling 
and plasmid associations. 1 µg of plasmid DNA was loaded into each well of the gel. No 
signs of degrading of plasmid DNA molecules are visible. 
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2.4.5 Evaluating the redesigned gene network in the EA.hy926 endothelial 
cell line 
Once the plasmids pZK13 and pZK14 were obtained, culturing of the EA.hy926 endothelial 
cell line was restarted. At this time, other group members were facing problems with the 
Neon™ Transfection procedure. Electrical arching (sparks) appeared seemingly due to the 
presence of (micro) bubbles in the transfection solution (containing the cells, nucleic acids 
and buffer R).At that stage, electroporation carried out by me yielded sparks in some of the 
electroporation reactions. When sparks appeared, electroporation of cells was unsuccessful. 
Our supervisor recommended us to place cells under vacuum prior electroporation in order to 
remove the gas bubbles. For cell degassing, a hole was punched using a hot needle through 
the lid of the 1.5 ml eppendorf tubes and vacuum was applied through this hole using the 
vacuum line of the Euroclone Bioair Top Safe 1.5 Class II safety cabinets. Thus, cells were 
degassed right before electroporation and imaged 24 hours after electroporation. 
Unfortunately, all cells that were subjected to degassing died, whereas non-degassed 
electroporated cells remained viable. This most probably occurred due to the removal of gas 
molecules (O2 and CO2), which are necessary for keeping cells viable. The sparks were 
eventually avoided by replacing Electroporation Buffer E and Resuspension Buffer R with 
fresh buffer batches.  
In parallel to overcoming electroporation problems, the TurboFect
TM
 Transfection Reagent 
was also used to transfect both HeLa and EA.hy926 cell with the redesigned gene network 
encoded on two plasmids. To find the best TurboFection condition, 24 different transfection 
conditions, shown in Table 2.18, were applied to both cell lines separately.  
Table 2.18. Optimization of TurboFect transfection for HeLa and EA.hy926 cell lines 
Well 
# 
Plasmids 
Amount of 
plasmid [µg] 
Volume of 
TurboFect 
[µl] 
Treatment* Observation 
1 
pZK13, 
pZK14 
0.5 1.2 2 µM BD 
experimental 
condition 
2 
pZK13, 
pZK14 
0.5 1.5 2 µM BD 
experimental 
condition 
3 
pZK13, 
pZK14 
0.5 1.8 2 µM BD 
experimental 
condition 
4 
pZK13, 
pZK14 
0.5 2 2 µM BD 
experimental 
condition 
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5 
pZK13, 
pZK14 
0.5 2.2 2 µM BD 
experimental 
condition 
6 
pZK13, 
pZK14 
0.5 2.5 2 µM BD 
experimental 
condition 
7 
pZK13, 
pZK14 
0.7 1.8 2 µM BD 
experimental 
condition 
8 
pZK13, 
pZK14 
0.7 2 2 µM BD 
experimental 
condition 
9 
pZK13, 
pZK14 
0.7 2.2 2 µM BD 
experimental 
condition 
10 
pZK13, 
pZK14 
0.7 2.5 2 µM BD 
experimental 
condition 
11 
pZK13, 
pZK14 
0.7 2.8 2 µM BD 
experimental 
condition 
12 
pZK13, 
pZK14 
0.7 3 2 µM BD 
experimental 
condition 
13 
pZK13, 
pZK14 
0.7 3.5 2 µM BD 
experimental 
condition 
14 
pZK13, 
pZK14 
0.7 2.8 
2 µM BD + sh 
str (pipetting) 
experimental 
condition 
15 
pZK13, 
pZK14 
0.7 2.8 
3 µM BD + sh 
str (pipetting) 
experimental 
condition 
16 
pZK13, 
pZK14 
0.7 2.8 2 µM BD 
experimental 
condition 
17 
pZK13, 
pZK14 
0.7 2.8 10 µM BD 
experimental 
condition 
18 
pZK13, 
pZK14 
0.7 2.8 20 µM BD 
experimental 
condition 
19 
pZK13, 
pZK14 
0.7 2.8 50nM HOE 140 negative control 
20 
pZK13, 
pZK14 
0.7 2.8 1 µM HOE 140 negative control 
21 
pZK13, 
pZK14 
0.7 2.8 
 
negative control 
22 
pZK12, 
pZK14 
0.7 2.8 
 
testing promoter 
leakiness 
23 pZK11 1 2 
 
positive control 
for transfection 
24 
    
negative control 
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* Final concentrations of each [Hyp
3
]-bradykinin and bradykinin acetate salt (BD), of the B2 
bradykinin receptor antagonist HOE 140, and BD in combination with shear stress stimulus 
applied by pipetting for 1 minute (using the 1,000 µl Eppendorf Research
®
 plus pipette) were 
added 24 hours after TurboFection. 
24 hours after transfection the gene network both in HeLa and EA.hy926 cells was induced 
by [Hyp
3
]-bradykinin and bradykinin acetate salt (BD), at concentrations indicated in Table 
2.18 also in combination with shear stress applied by pipetting for 1 minute; or the gene 
network was inhibited by indicated concentrations of HOE 140, or was left without activation 
and inhibition. 48 hours after transfection cells were stained with final concentrations of 2 
µg/ml Hoechst 33342 stain and imaged under the fluorescent microscope. Up to 10% of 
HeLa cells were transfected, however, most EA.hy926 cells were rounded up and dead at the 
time of imaging, the percentages of green fluorescent cells were below 1%. TurboFection 
didn’t seem to yield higher green fluorescent cell percentages than electroporation, thus 
electroporation remained our core transfection method. 
EA.hy926 endothelial cells were electroporated simultaneously with plasmid pZK13 and 
pZK14 using the Neon™ Transfection System using 800 V, 30 ms double pulses. Six and 
twenty-four hours after electroporation the gene network was induced with 2 µM [Hyp
3
]-
bradykinin and 2 µM bradykinin acetate salt. Twenty-four hours after electroporation, the 
vast majority of cells were rounded up, floating and dying. Cells were imaged 36 hours after 
electroporation, which was 12 hours after the second induction, but cell viabilities and 
percentages of green fluorescent cells were very low. 
The electroporation optimization was continued, taking a series of measured to ensure high 
cell viability. Thus, the day before electroporation, cells were fed with freshly prepared 
culture media and cells were sub-cultured if needed in order to reach 80% confluency at the 
time of electroporation. When preparing cells for electroporation, cells were handled with 
care, reducing exposure times to non-optimal conditions (e.g. trypsin, suspension in buffers, 
temperatures below 37°C and non-optimal gas concentrations, etc.). In this set of 
electroporation optimization experiment, EA.hy926 were electroporated with 1:1 molar ratio 
of pZK11 and pZK13, systematically varying the pulse voltage and cell electroporation 
densities. Following electroporation, cells were seeded in multi-well plates, pre-coated with 
1% (w/v) gelatine solution. The pZK11 (phMGFP constitutively active GFP plasmid) and 
pZK13 (pIRES with our gene constructs) plasmid combination was used in order to simplify 
the electroporation optimization procedure for electroporation with our gene network (pZK13 
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and pZK14). Plasmid pZK11 has a similar size to pZK14, but does not need activation in 
order to express GFP. This way, problems related to gene expression and activation of the 
gene network could be separated from transfection efficiencies, thus simplifying our 
optimization task, allowing focusing solely on transfection efficiencies. Plasmid pZK11 was 
used in combination with plasmid pZK13, instead of being used alone, in order to optimize 
electroporation condition for electroporating simultaneously with two plasmids. Since no 
induction of the gene network was needed, EA.hy926 cells were stained with 2 µg/ml 
Hoechst 33342 and 0.5 µg/ml propidium iodide 24 hours after electroporation and 30 minutes 
later cells were imaged under a fluorescent microscope. Phase contrast, red, green and blue 
fluorescent images were recorded. Cells were counted in ImageJ from these fluorescent 
images to determine cell viabilities and transfection efficiencies. Cell viabilities and 
transfection efficiencies along with the total number of cells were plotted in function of 
electroporation pulses for each of the three cell electroporation densities, Figure 2.34. The 
highest electroporation efficiency (37.7%) was obtained when 50.000 cells were 
electroporated per reaction using 800 V 30 ms double pulses. At 200.000 cells per 
electroporation reaction the 900 V 30 ms double pulse yielded the highest transfection 
efficiencies (19.6%).  
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Figure 2.34. Optimization of electroporation pulse voltages and cell electroporation densities 
for electroporating EA.h929 cells with plasmids pZK11 and pZK13, as model plasmids for 
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the redesigned gene network (pZK13 and pZK14). Using plasmid pZK11 (constitutive 
phMGFP), instead of pZK14 (eGFP reporter plasmid), simplified the procedure by 
eliminating potential gene expression and gene network activation problems as well as the 
need to induce the gene network in order to observe GFP expression. Cells were stained with 
Hoechst 33342 and propidium iodide 24 hours after electroporation and were microscopy 
imaged. Obtained images were analysed in ImageJ to count cells and determine the 
percentage of green fluorescent cells and cell viabilities plotted on the left Y-axis of the 
graph. The number of total cells per image is plotted on the secondary right Y-axis. On the X-
axis the electroporation pulses are shown. A. 50.000 cells were electroporated per reaction. B. 
100.000 cells were electroporated per reaction. C. 200.000 cells were electroporated per 
reaction. N=2, error bars show standard deviation. 
 
When electroporating with the combination of pZK11 and pZK13, it can happen that only 
pZK11 enters the cells, the absence of pZK13 was not detected. Thus, the seemingly optimal 
electroporation pulse could in fact be non-optimal since it might only bring the smaller 
pZK11 into the cells. To test this hypothesis, the exact same electroporation optimization 
experiment was repeated with the exception that plasmid pZK11 was replaced with plasmid 
pZK14, thus electroporating cells with the redesigned gene network encoded on plasmids 
pZK13 and pZK14. Six and twenty-two hours after electroporation the gene network was 
induced by 10 µM bradykinin. Twenty-four hours after electroporation cells were stained 
with 2 µg/ml Hoechst 33342 and 0.5 µg/ml propidium iodide and images were recorded 
under a fluorescent microscope. Hoechst 33342 staining did not work properly, most 
probably because of insufficient incubation time (due to reduced microscopy time available). 
Visual microscopy inspection of the cells confirmed that the 800 V, 30 ms double pulse 
yielded the highest green fluorescent cell percentages when 50.000 cells were electroporated 
per reaction, and the 900 V 30 ms double pulse when 200.000 cells were electroporated per 
reaction. 
As part of the troubleshooting process, to compare the newly constructed version of the gene 
network (encoded on plasmids pZK13 and pZK14) with the old version of the gene network 
(on plasmid pZK5, pZK9 and pZK10), an experiment from which results are summarized in 
Figure 2.35 was carried out. For this, eleven different experimental conditions were set up as 
depicted on the X-axis and the table in Figure 2.35. In experimental conditions 1–10, 200.000 
cells were electroporated per reaction either with the new version or the old version of the 
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gene network using 900 V 30 ms double pulses. After transfection, cells from conditions 1 
and 2 were seeded in ibidi µ-Slide I 
0.4
 Luer flow channels to start flow experiments 24 hours 
later, exposing cells to 1.5–2 Pa of shear stress for a period of 24 hours. Cells from conditions 
3–8, 24 hours after electrotransfer of plasmids were treated with either with 2 µM [Hyp3]-
bradykinin and 2 µM bradykinin acetate salt (BD), or 100 nM HOE 140, or shear stress 
applied by pipetting for 1 minute (Pipet.) using the 1,000 µl Eppendorf Research
®
 plus 
pipette, or were left untreated. Cells from condition 11 were electroporated with the pZK11 
(constitutive phMGFP) and pZK13 (pIRES with gene constructs) plasmid combination using 
900 V 30 ms double pulses at the same cell density as in the other conditions, 200.000 cells 
per reaction. Forty-eight hours after transfection cells were stained with 2 µg/ml Hoechst 
33342 and 0.5 µg/ml propidium iodide and imaged. Cells were counted from recorded 
fluorescent images using ImageJ and the calculated transfection efficiencies and cell 
viabilities are plotted on the left Y-axis of Figure 2.35, whereas the total number of cells per 
image is plotted on the right Y-axis of the same graph. This experiment shows that the new 
version of the gene network yields higher green fluorescent cell percentages compared to the 
old version of the gene network under all conditions. The percentage of green fluorescent 
cells upon activation of the redesigned gene network reaches only 7-8%. The old version of 
the gene network under activating conditions yields unexpectedly low 1.8% green fluorescent 
cells. Under inhibitory (HOE 140) or non-activating conditions, the background expression of 
the redesigned gene network was also higher than the background expression of the old 
version of gene network, this was also somewhat unexpected. The percentage of green 
fluorescent cells yielded by electrotransfer of pZK11 (constitutive phMGFP) in combination 
with pZK13 (pIRES with gene constructs) was only 13.2%, lower than the expected 20%, 
shown in Figure 2.34C, obtained under the same conditions. Later, it was discovered that 
plasmid pZK10 (eGFP reporter for the old gene network) solution contained suspended 
particles and the concentration of this plasmid was around 400 ng/µl, considerably lower than 
the expected 3.4 µg/µl. This drop in concentration might be responsible for the unexpectedly 
low green fluorescent cell percentages upon transfection with the old gene network version. 
Cell viabilities are the highest in the flow experiment condition, when dead cells are washed 
away. The second highest cell viabilities are visible when cells were stimulated with shear 
stress by pipetting, and cell viabilities tend to drop from the bradykinin activation condition 
to the no activation to HOE activation.    
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Figure 2.35. Comparison of the redesigned gene network (pZK13, pZK14) with the old 
version of the same gene network (pZK9, pZK5, pZk10). EA.hy926 cells were electroporated 
using 900 V 30 ms double pulses with either one of the two gene network versions 
(conditions 1–10) or with the pZK11 (constitutive phMGFP) together with pZK13 (condition 
11) and treated as described in the table below the graph. Cells transfected with the gene 
network, conditions 1–10, were either seeded in ibidi µ-Slide I 0.4 Luer flow channels for 24 
hour flow experiments at 1.5–2 Pa, commencing 24 hours after transfection (conditions 1 and 
2) or were seeded in multi well plates and treated with shear stress induced by pipetting for 1 
minute (conditions 3 and 4), with 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt 
(conditions 5 and 6), with 100 nM HOE 140 (conditions 9 and 10), or left untreated 
(conditions 7 and 8). Cells were stained with Hoechst 33342 and propidium iodide and 
imaged 48 hours transfection. Images were processed in imageJ, determined cell viabilities 
and transfection efficiencies are plotted on the left Y-axis and the total number of cells per 
image is plotted on the right Y-axis. Overall, the percentages of green fluorescent cells were 
low and the new version of the gene network seems to yield a higher percentage of green 
fluorescent cells compared to the old gene network version. Subsequently, it was noticed that 
the plasmid pZK10 (eGFP reporter from the old gene circuit version) contained suspended 
particles and also 10 fold drop in concentration. Error bars represent standard deviation, N=2.  
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In our continuous attempt to better understand the cause of low green fluorescent percentages 
and to better characterize the gene network, an experiment similar to the one described above 
was carried out with the addition of a few experimental conditions, Figure 2.36. All 
experimental conditions (including plasmid molar concentrations, plasmid molar ratios, cell 
densities, pulses, cell handling etc.) were kept strictly identical between the 18 conditions, 
only the parameters depicted in the table below the graph differed, in order to obtain inter-
comparable results. Cells were electroporated with 6 different plasmid sets. Four out of these 
six plasmid sets were composed of various combinations of the new and old versions of the 
gene network and were either repeatedly induced 6, 24 and 36 hours after transfection with 2 
µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt, or with shear stress applied by 
pipetting for one minute using a 1,000 µl Eppendorf Research
®
 plus pipette, or were inhibited 
by 100 nM HOE 140, or were left untreated. The other two out of these six plasmid sets, 
consisted of plasmid pZK11 (constitutive phMGFP) in combination with the reporter 
plasmid-less old version (pZK9 and pZK5) and new version (pZK13) of the gene network. 
Cells were stained with 2 µg/ml Hoechst 33342 and 0.5 µg/ml propidium iodide and imaged 
48 hours after electroporation. Cells were counted from recorded images and resulting cell 
viabilities and transfection efficiencies are plotted on the left Y-axis of Figure 2.36 along 
with the total number of cells on the right Y-axis. According to these results, the new 
(redesigned) version of the gene network produces a lower percentage of green fluorescent 
cells than the old version of the gene network. Conditions 17 and 18 yielded 32.6 and 21.9 
green fluorescent cell percentages, respectively. These values are significantly larger than 
those obtained by activating the gene network. This could be due to the fact the gene network 
was not entirely present, expressed or activated in these cells. The absence of gene network 
plasmids could be explained by the considerable size difference between, on one hand the 
reporter and constitutive GFP pZK11 plasmids and on the other hand the other plasmid 
(pZK9, pZK5 and pZK13) which are about double the size. Since larger plasmids are 
transfected at lower efficiencies, reporter plasmids cannot be activated due to absence of the 
larger plasmids but the constitutive GFP plasmid pZK11 expressed GFP in the absence of any 
other plasmid. This might account, at least partially, for the fact that the percentage of green 
fluorescent cells was significantly larger in conditions 17 and 18 compared to the other 
conditions. It could also well be that the lower percentage of green fluorescent cells in case of 
the gene network was due to that fact that a series of event have to occur in order for the gene 
network to produce green fluorescence. These events include: transfection, expression of the 
gene network, activation of the gene network by shear stress of bradykinin, cleavage of tTA 
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from the GPCR, migration of tTA into the nucleus, activation of eGFP transcription by tTA, 
expression of eGFP. If these events occur at probabilities below 1 (as they most probably do) 
the overall efficiency will be the product of the probabilities of these events, which was 
expected to be low. The green fluorescence from condition 17 was somewhat higher than the 
green fluorescence from condition 18. This might be caused by the fact that pZK13 being the 
largest plasmid, tends to block most pores opened during electroporation, causing lower 
transfection efficiencies and lower cell viabilities as it can be seen in Figure 2.36. It is also 
worth noticing, that cell viabilities tend to be the highest in conditions where cells were 
exposed to shear stress for 1 minute by pipetting. This might be explained by the preference 
of endothelial cells to be exposed to fluid flow and shear stress or by the fact that shearing 
might contribute to disintegrating dead cells.    
 
 
Figure 2.36. Comparison between the performances of the two gene circuit versions (old and 
new), between the performance of components (reporter plasmid and signalling cascade) of 
these two gene network versions, and also comparing relative transfection efficiencies and 
gene expression levels. 50,000 EA.hy926 cells were electroporated per reaction using 900 V 
30 ms double pulses with plasmids specified in the table below the graph. Cells transfected 
with the gene network were treated with shear stress induced by pipetting for 1 minute, with 
2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt, with 100 nM HOE 140, or left 
untreated. Cells were stained with Hoechst 33342 and propidium iodide and imaged 48 hours 
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transfection. Images were processed in imageJ, determined cell viabilities and transfection 
efficiencies are plotted on the left Y-axis and the total number of cells per image is plotted on 
the right Y-axis. Error bars represent standard deviation, N=3. 
In order to better characterize the gene network versions and their components, green 
fluorescent cell percentages from no treatment, HOE 140 and shear stress treatment have 
been normalized to green fluorescent cell percentages from the bradykinin activation 
condition, using Equation 2.3: 
Gpn =
GpI
GpBD
 × 100 
Equation 2.3. Normalization of percentages of green fluorescent cells to green fluorescent 
cell percentages from the bradykinin activation condition. 
Where:  
Gpn: green fluorescent cell percentages normalized to green fluorescent cell  
         percentages from the bradykinin activation condition. 
GpI: percentage of green fluorescent cells from conditions of interest, such as 2 or 3   
        or 4 from Figure 2.36. 
GpBD: percentages of green fluorescent cells from bradykinin activation condition;   
            such as condition 1 from Figure 2.36. 
 
Obtained values are summarized in Table 2.19 below. Normalizing no treatment and HOE 
140 treatment conditions show the leakiness of the gene network. The leakiness calculated 
this way corresponds to the inverse of fold activation (responsiveness), which shows by what 
percentage did green fluorescent cell percentages increase from the lack of activation or from 
inhibition to full bradykinin activation. Table 2.19 shows that the leakiness of the redesigned 
gene network (pZK13 and pZK14) was lower than the leakiness of the old version of the gene 
network (pZK9, pZK5, pZK10), both in case of no treatment leakiness and HOE 140 
inhibition leakiness. The leakiness of the old gene network (pZK9, pZK5, pZK10) decreases 
when the reporter plasmid was replaced by new reporter plasmid (c.f. pZK9, pZK5, pZK14), 
indicating that the new reporter plasmid (pZK14) was less leaky than the old one (pZK10) in 
EA.hy926 cells. Upon replacing the reporter plasmid of the redesigned gene network with the 
reporter plasmid of the old gene network, leakiness increases to values exceeding those of the 
old gene network (c.f. pZK13, pZK14 vs. pZK13, pZK10 vs. pZK9, pZK5, pZK10). This 
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again indicates that the new reporter plasmid (pZK14) was less leaky than the old one 
(pZK10), but also suggests that replacing pZK9 and pZK5 with pZK13, increases the 
leakiness of the system. Out of these four gene network versions the redesigned gene network 
(pZK13, pZK14) was the least leaky, as expected. It is also worth noticing that leakiness of 
the HOE 140 inhibition was higher than the leakiness of the no treatment condition for all 
plasmid combinations. This might be explained by the eventual stabilization of the GPCR in 
a conformation (out of a multitude of conformations) by HOE 140, which conformation has a 
higher affinity to βArrestin2 compared to the no treatment conformation. Green fluorescent 
cell percentages obtained following shear stress application by pipetting normalized to green 
fluorescent cell percentages obtained by bradykinin induction show that the new version of 
the gene network was somewhat more responsive to shear stress than the old version of the 
gene network. The gene network consisting of plasmids pZK9, pZK5, pZK14 seems to be far 
less responsive to shear stress activation, whereas the gene network composed of pZK13 and 
pZK10 has an unexpectedly high responsiveness to shear stress compared to the bradykinin 
response. 
 
Table 2.19. Green fluorescent cell percentages from no treatment, HOE 140 and shear stress 
treatment conditions normalized to green fluorescent cell percentages from the bradykinin 
treatment condition (values from Figure 2.36).  
No. 
Condition normalized to 
bradykinin treatment 
Percentages normalized to bradykinin 
treatment 
pZK9, 
pZK5, 
pZK10 
pZK13, 
pZK14 
pZK9, 
pZK5, 
pZK14 
pZK13, 
pZK10 
1 no treatment 21.6% 0% 21.1% 26.8% 
2 HOE 140 treatment 25.8% 21.9% 22.9% 29.6% 
3 
Shear stress (Pipetting) 
treatment 
97.4% 106.2% 69.1% 198.6% 
 
After seeing that the redesigned gene network (pZK13 and pZK14) had the lowest leakiness 
and highest fold of induction, green fluorescent cell percentages were set out to be increased 
by selecting cells that contain the gene network, using mammalian selection antibiotics. For 
this, initially the antibiotics were needed to be titrated on non-transfected cells in order to 
determine the lowest antibiotic concentration that kills all non-transfected cells, in order to 
subsequently select transfected cells. Thus, cells were seeded in 12 well plated pre-coated 
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with 1% (w/v) gelatine and 24 hours later the culture media was supplemented with 
Hygromycin B and Neomycin (G 418) antibiotics at final concentrations depicted on the X-
axis of Figure 2.37 in each well. Culture media with the corresponding antibiotic 
concentration was refreshed every 2-3 days for a period of 7 days at the end of which cells 
were stained with nuclear stains 2 µg/ml Hoechst 33342 (total cells) and 0.5 µg/ml propidium 
iodide (dead cells) and cells were imaged. Cells were counted in the recorded blue and red 
fluorescent images to determine cell viabilities which were plotted on the left Y-axis of 
Figure 2.37 along with the total number of cells per image plotted on the right Y-axis. 
Hygromycin B seems to be more effective in killing EA.hy926 cells than the G 418 
antibiotic, decreasing both cell viabilities and the total number of cells more drastically. 
Figure 2.37B shows that as the G 418 antibiotic concentrations increases, cell viabilities 
decrease reaching 0% at 400 µg/ml, and further increasing the G 418 antibiotic concentration, 
cell viabilities become higher than zero at and above 800 µg/ml G 418, which was rather 
unexpected. The reason for this could be that exposure of EA.hy926 cells to G 418 
concentration higher than 800 µg/ml shocks the cells, some cells entering into a latent state or 
they die but their cell and/or nuclear membrane remains intact. Cells in these states might 
have their membranes impermeable to propidium iodide, thus appearing viable when stained 
with this nuclear stain. The phase contrast microscopy images show that all cells are rounded 
up and appear to be dead at these G 418 concentrations above 800 µg/ml, thus, cells under 
these conditions had been considered dead. The final antibiotic concentrations used for 
selection are usually 100–200 µg/ml above the concentration that reduced cell viabilities to 
zero in the titration experiment [522]. Thus, transfectants in our experiments will be selected 
with 400 µg/ml Hygromycin B and 500 µg/ml G 418 antibiotic final concentrations. 
 
Figure 2.37. Mammalian selection antibiotic titration for EA.hy926 cells. Non-transfected 
cells were cultured under antibiotic concentrations specified on the X-axis for a period of 7 
days. Cells were stained with Hoechst 33342 and propidium iodide and imaged. Images were 
processed in ImageJ to determine cell viabilities, plotted on the left Y-axis; total number of 
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cells per image is plotted on the right Y-axis. A. Cell viabilities in function of Hygromycin B 
concentrations B. Cell viabilities at various G418 concentrations. Error bars show standard 
deviation, N=2. 
 
Once the selection Hygromycin B and G 418 concentrations have been determined, 
electroporation of EA.hy926 cells with the redesigned gene network for selection was 
planned, but the touchscreen of the Neon
TM
 Transfection System became dysfunctional. After 
the touchscreen was replaced, experiments were resumed and EA.hy926 cells were 
electroporated with the pZK13, pZK14 and linear hygromycin selection marker at molar 
ratios of 10:10:1 and at ratios of 20:20:1. Twenty-four hours after electroporation final 
concentrations of 400 µg/ml Hygromycin B and 500 µg/ml G 418 mammalian selection 
antibiotics were added. Culture media was refreshed every 2-3 days to maintain the selection 
pressure for a period of 7 days. On the last day of the selection the gene network was induced 
with bradykinin, with shear stress applied by pipetting, was inhibited with HOE140 or was 
left unaltered. Twenty-four hours after induction or inhibition of the gene network, cells were 
stained with 2 µg/ml Hoechst 33342 and 0.5 µg/ml propidium iodide and were visualized 
under the fluorescent microscope. Unfortunately, the percentage of green fluorescent cells 
was extremely low, below 1%. The selection experiment was repeated but the outcome did 
not improve. Cell viabilities in both experiments were very low, most probably due to the 
combined effect of both hygromycin and G 418 antibiotics, since these antibiotics were 
titrated separately.  
Thus, the antibiotic selection experiment was repeated with lower antibiotic concentrations, 
as described in Table 2.20. Cells in all wells were induced with 2 µM [Hyp
3
]-bradykinin and 
2 µM bradykinin acetate salt on the last day of selection and 24 hours cells were imaged. Out 
of these experiments, conditions number 3 (100 µg/ml and 0 µg/ml Hygromycin B) produced 
the highest percentage of green fluorescent cells, however this percentage was below 2%. 
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Table 2.20. Mammalian selection antibiotic concentrations used to select EA.hy926 cells that 
contain the redesigned gene network. 
Condition 
# 
Hygromycin B 
concentration 
[µg/ml] 
G 418 concentration 
[µg/ml] 
1 0 0 
2 100 0 
3 0 100 
4 100 100 
5 200 200 
6 300 300 
7 400 400 
  
A new antibiotic selection experiment was started in which the G 418 concentration was 
varied from 0 to 500 µg/ml, and the hygromycin concentration was kept at 0. On the 7th day 
after electroporation the selection antibiotic was removed from the culture media and the 
gene network was induced. The following morning, the gene network was induced again and 
in the evening of the same day cells were visualized under a fluorescent microscope, but no 
green fluorescent cells could be observed. The following day the culture media was renewed 
and the gene network was induced again. The day after, cells were imaged, without seeing 
any green fluorescent cells. In these antibiotic selection experiments only ≈0.2% of cells 
remaining alive after antibiotic selection, out of these cells only 0-3 cells becoming green 
fluorescent. Without selection approximately 10% of cells showed green fluorescence under 
identical transfection conditions 24 hours after transfection. Therefore, antibiotic selection 
experiments proved to be unsuitable for enriching the EA.hy926 cell population in cells that 
contain the gene network.  
In order to determine the cause of failing to select EA.hy926 cells transfected with the gene 
network and in order to solve this problem, a literature study was conducted. It became 
evident that transfection of DNA plasmids and gene expression from these plasmids is not 
well understood and efficiencies seem to depend on the plasmid and cell types used [523]. 
Secondly, as expected there are numerous barriers to effective DNA delivery into cells and to 
gene expression from this transfected DNA. These barriers could be summarized in two 
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categories, transfection barriers and gene expression barriers. Transfection barriers (in case of 
non-viral transfections) [524-530] depend on the transfection method used and these barriers 
include (for review c.f. [523, 531]): (a) physical and biochemical degradation of DNA 
plasmids in the extracellular space, (b) the extracellular matrix and cell surface interactions, 
(c) internalization, (d) trafficking from endosomes to lysosomes and subsequent degradation, 
(e) escape from endosomes into the cytoplasm, (f) dissociation of DNA from its carrier, (g) 
degradation in the cytoplasm mediated by nucleases [528, 529] and (h) transfer into the 
nucleus. 
There might be problems related to the expression of our gene network in the EA.hy926 cell 
line. Synthetic transactivator systems [100] such as Tet-On/Off system (tTA dependent) [127] 
are widely utilized in synthetic biology for controlling gene expression [475]. The hybrid 
transactivator from our gene network, tTA was obtained by fusing the prokaryotic 
tetracycline repressor (tetR) with the C-terminal domain of virion protein 16 (VP16) from 
herpes simplex virus (HSV) [126]. Due to the viral origin of transactivator parts [532], these 
transactivators can present toxicity to mammalian cells [533], affecting normal cell 
physiology, and compromising gene function [534]. There is evidence for suboptimal tetR 
expression in mammalian cells [535], [536].  
Another parameter worth considering was the degradation rate of plasmids, expressed in half-
life values. Measured half-lives of plasmids in cytoplasmic solutions of Chinese Hamster 
Ovary (CHO) cells was 3-11 min [529]. In the cytoplasm of HeLa and COS cells, at single 
cell level, DNA plasmids seem to have a half-life of 50–90 min, this rapid degradation was 
most probably being caused by cytoplasmic nucleases [528]. Other reports show that plasmid 
copy numbers per cell decreased sharply after transfection from approximately 30,000 
present at 24 h to 5000 copies at 72 h after transfection, the plasmid half-life in the period 
between 24 and 48 hours after transfection being 19.5 hours [537], consistent with values 
reported elsewhere [538]. Thus, in the absence of plasmid synthesis in mammalian cells, 
during a selection that takes 7 days, the number of plasmid molecules would be reduced to 
extremely low values. 
Replication of plasmids in mammalian cells should inevitably increase plasmid half-lives and 
the scale of gene expression from these plasmids [539]. In case of the simian virus 40 (SV40) 
plasmid replication system, two features are essential in order for the plasmid to replicate: the 
presence of the SV40 origin of replication on the plasmid and the expression of the SV40 
large T antigen by the mammalian host cell [539-541]. The simian virus 40 (SV40) derived 
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plasmids replication was uncoupled from the regulatory mechanisms of the host cell, 
replicating many times within each cell cycle. Thus, transfection with recombinant SV40 
plasmids can cause cell death due to the excessively high plasmid replication activity [542]. 
To solve this potentially toxicity caused by high plasmid replication rates, the large T antigen 
SV40 replication system could be replaced with the scaffold/matrix attached region (S/MAR) 
from the 5’-region of the human interferon β-gene, resulting in the replication of the SV40 ori 
containing plasmid at very low copy numbers and stable maintenance of the plasmid without 
selection for more than 100 generations in CHO cells. Alternatively, plasmids containing 
viral replication origins that are coupled to cell cycle and copy number regulation such as the 
Epstein-Barr virus (EBV) [543-545] and the bovine papillomavirus [546-548] could be 
employed. 
To the best of our knowledge, the EA.hy926 endothelial cell line does not express the SV40 
large T antigen and it is not capable of replicating plasmids. Since pZK13 contains an SV40 
origin of replication, endothelial cell lines which express the SV40 large T antigen were 
searched for, in order to replicate pZK13. The cell lines that were found and their relevant 
characteristics are summarized in Table 2.21.  
Out of these 15 cell lines, only 5 express the large T antigen. Out of these 5, the 2 most 
commonly used cell lines are HMEC-1 and MS1, according to the number of hits when the 
name of the cell line followed by the “cell line” syntax was searched in PubMed. Out of the 
remaining 3 cell lines, two are immortalized HUVEC’s (HUV-ST and EVLC2) and the third 
one (MS1 VEGF) is a derivative of the commonly used MS1 cell line. The two immortalized 
HUVEC cell lines were not considered further due to their low popularity and due to the fact 
that an immortalized HUCEV cell line (EA.hy926) has already been employed in this project. 
The MS1 VEGF cell line was less common compared to the MS1 cell line, thus the MS1 
VEGF cell line was not investigated further either. The HMEC-1 cell line was established by 
transfecting human dermal microvascular endothelial cells with a plasmid containing the 
coding region for the simian virus 40 A gene product, the large T antigen. The HMEC-1 cell 
line presents cobblestone morphology, characteristic to endothelial cells. Furthermore, the 
HMEC-1 cell line was transfected at high efficiencies, up to 87%, and the expression of 
transgenes has been reported in this cell line. However, it was unknown whether HMEC-1 
cells can withstand flow regimes that generate wall shear stresses above 0.4 Pa. The MS1 cell 
line was obtained by transducing primary islet endothelial cells with a temperature sensitive 
SV40 large T antigen (tsA-58-3). Information on transfection efficiencies, flow compatibility, 
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morphology and transgene expression levels for this cell line was not available. Based on 
these, both HMEC-1 and MS1 cell lines were ordered. MS1 was ordered from LGC 
Standards, partner of American Type Culture Collection (ATCC). The HMEC-1 cell line was 
not available at ATCC or LGC Standards, thus a literature search was carried out to identify 
research groups that possess this cell line. This way, the group of Dr. Adrian H Chester from 
the National Heart & Lung Institute, Imperial College London was located; they kindly gifted 
us with two cryovials of the HMEC-1 cell line. 
 
Table 2.21. Comparison of endothelial lines for synthetic biology mechanotransduction 
studies 
# 
Cell line 
name 
Organism Tissue Properties 
Flow 
compatible 
Transfection 
efficiencies 
Transgene 
expression 
SV40 large T 
antigen 
expression 
Ref 
PubMed 
hits* 
1 EA.hy926 human HUVEC+A549 cells HUVEC Yes 60% medium No 
[549-
551] 
227 
2 EOMA murine 
Hemangio- 
endothelioma 
microvascular 
endothelial cells 
Yes 65-97% Yes No 
[552-
557] 
18 
3 EJG bovine Adrenal medulla 
capillary 
endothelium 
? ? ? No [558] 4 
4 HUV-EC-C$ human HUVEC HUVEC ? ? ? ? [559] 30 
5 CPA 47 bovine pulmonary artery 
cobblestone 
morphology 
? ? ? No [560] 15 
6 CPAE bovine pulmonary artery ? Up to 25 Pa low Medium, High No 
[561-
564] 
76 
7 
MILE SVEN 1 
(MS1) 
murine pancreatic islet ? ? ? ? Yes [565] 71 
8 MS1 VEGF murine pancreatic islet ? ? ? ? Yes [565] 5 
9 FBHE bovine hearth ? ? ? High No 
[563, 
566, 
567] 
6 
10 Py-4-1 murine hemangioma 
cobblestone 
morphology 
? 
50% 
(Lipofect 
amine 2000) 
High No 
[562, 
568-
570] 
9 
11 bEnd.3 murine 
brain/cerebral 
cortex 
? 2.5 Pa 73% Yes No 
[571] 
[572-
577] 
94 
12 HMEC-1 human 
dermal 
microvascular 
cobblestone 
morphology 
0.4 Pa up to 87% Yes Yes 
[578-
581] 
285 
13 HAEC-hTERT human aorta ? ? ? ? ? 
[582, 
583] 
0 
14 HUV-ST human HUVEC 
cobblestone 
morphology 
? ? ? Yes [584] 1 
15 EVLC2 human HUVEC 
cobblestone 
morphology 
? ? ? Yes [585] 4 
*Number of hits when searched “name + cell line” on PubMed on 31.Jul.2013. 
$
 HU-VE-C have a life expectancy of 50 to 60 population doublings. 
 
Electroporation conditions were optimized by varying the parameters that were known to 
affect transfection efficiencies and cell viabilities [586, 587], such as pulse voltage, pulse 
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duration, number of applied pulses, cell densities, plasmid ratios and cell culturing 
conditions. Electroporation conditions were optimized in accordance with guidelines from the 
transfection system providing company [588]. Electroporation parameters were varied one-
by-one, starting with pulse voltage. After the optimum condition was determined, the 
following parameter, pulse duration, was optimized, and then optimization was continued 
similarly for the remaining parameters sequentially. After the optimal values had been found 
for each parameter individually, the parameter field was again scanned around optimal values 
to determine whether the electroporation outcome could be further improved.  
Instead of using this one-factor-at-a-time method, the more powerful statistics based design 
of experiments (DOE) methodology [589, 590] might have had accelerated the identification 
of optimum input parameter (such as pulse voltage, pulse duration, pulse number, etc.) values 
and ranges which yield the desired output parameters (high transfection efficiency and cell 
viability). Altering multiple factor simultaneously in DOE procedure can also determine 
possible interaction effects between input variables by analyzing the variance [590].  
 
2.4.6 Evaluating the redesigned gene network in the HMEC-1 and MS1 
endothelial cell lines 
After receiving the HMEC-1 cell line, they were expanded to 58 million cells and then frozen 
in 10% DMSO for storage. Next, the electroporation parameters were optimized. For this 
cells were fed or sub-cultured the day before electroporation, such that on the day of the 
electroporation, cells will be 70-90% confluent. Next, 200,000 cells were electroporated per 
reaction with the redesigned gene network encoded on plasmids pZK13 and pZK14 (1:1 
molar ration), systematically varying the pulse voltage. After electroporation, cells were 
seeded in multi-well plates, pre-coated with 1% Gelatine. When delivering pulses above 
1200V, sometimes sparks have been observed in the Neon
TM
 electroporation tip. The 
inefficiently delivered pulses due to the occurrence of these sparks, could be the reason for 
the unexpectedly high cell viabilities and sometimes high total cell numbers at pulses above 
1200 V. 12, 24 and 36 hours post electroporation the gene network was induced with final 
concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt. 24 hour after 
electroporation the culture media was renewed, as usually. 48 hours after electroporation 
HMEC-1 cells were stained with 2 µg/ml Hoechst 33342 and 0.5 µg/ml propidium iodide and 
were imaged. Cells were counted from recorded fluorescent microscopy images using 
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ImageJ. Calculated green fluorescent cell percentages and cell viabilities are plotted on the 
left Y-axis, whereas the total number of cells is plotted on the right Y-axis of Figure 2.38. 
Out of the used pulses, the 1200 V 30 ms double pulse yielded the highest percentage of 
green fluorescent HMEC-1 cells, around 20%. This pulse has a significantly higher voltage 
than the optimal pulse for electroporating EA.hy926 cells and the obtained green fluorescent 
cell percentages are also higher. These results were promising. 
  
 
Figure 2.38. Optimization of electroporation pulse voltages for electroporating HMEC-1 cells 
with the redesigned gene network (pZK13 and pZK14). The gene network was induced with 
bradykinin 12, 24 and 36 hours after electroporation. Cells were stained with Hoechst 33342 
and propidium iodide 48 hours after electroporation and were microscopy imaged. Obtained 
fluorescent images were processed in ImageJ to count cells to determine the percentage of 
green fluorescent cells and cell viabilities, plotted on the left Y-axis of the graph. The number 
of total cells per image is plotted on the secondary, right Y-axis. On the X-axis the 
electroporation pulses are shown. N=2, error bars represent standard deviation. 
 
Next, electroporation conditions were further optimized by finding pulse durations and pulse 
numbers that yield the highest green fluorescent cell percentages. Thus, cells have been 
electroporated with pulses of various lengths and multiplicities, in order to scan the parameter 
space, Figure 2.39. Similarly to the previous pulse voltage optimization experiment cells 
were induced with bradykinin, stained, imaged, counted and cell viabilities and green 
fluorescent cell percentages were determined. The Neon
TM
 pulse generator was not capable 
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of delivering double pulses of above 50 ms when the pulse was 1200 V or higher. By 
lowering the voltage to 1100 V the pulse duration could be increased to a maximum of 60 ms. 
By further lowering the pulse voltage to 1000 and 900 V the pulse duration was increased to 
a maximum of 80 and 100 ms, respectively. When varying the number of 1200 V 30 ms 
pulses, the limit of the pulse generator seemed to be at 5 pulses. When approaching the limit 
of the pulse generator, electrical arching in the form of sparks had occurred. Pulse conditions 
under which it was not possible to deliver any pulse without the occurrence of sparks are 
labelled with “(spark)” on the X-axis of Figure 2.39. A 1200 V 30 ms double pulse has also 
been delivered, the pulse generator was immediately reprogrammed and longer pulse (100 
ms) at lower voltage (400 V) has also been rapidly applied, but without an improvement in 
the obtained green fluorescent cell percentages. Out of the used pulses, the followings 
seemed to deliver the highest percentage of green fluorescent cells: 1200V 50ms 2p, 1200V 
30ms 3p and 1200V 30ms 4p. Green fluorescent cell percentages obtained with these pulses 
show a high standard deviation and subsequent usage of these pulses often yielded sparks. 
Therefore, the more reliable 1200 V, 30 ms double pulse was used, in order to obtain 
reproducible results with low standard deviation. 
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Figure 2.39. Optimization of electroporation pulse duration and multiplicity for 
electroporating HMEC-1 cells with the redesigned gene network (pZK13 and pZK14). The 
gene network was induced with bradykinin 12, 24 and 36 hours after electroporation. Cells 
were stained with 2 µg/ml Hoechst 33342 and 0.5 µg/ml propidium iodide 48 hours after 
electroporation and were microscopy imaged. Obtained fluorescent images were analysed in 
ImageJ to count cells and resulting green fluorescent cell percentages and cell viabilities are 
plotted on the left Y-axis of the graph. The number of total cells per image is plotted on the 
secondary, right Y-axis. On the X-axis the electroporation pulses are shown. N=2, error bars 
represent standard deviation. 
 
The next question became: how leaky the redesigned gene network was in the HMEC-1 cell 
line? To answer this, 200,000 cells per reaction were electroporated with the redesigned gene 
network (1:1 molar ratios of plasmids pZK13 and pZK14). 6, 24 and 36 after electroporation 
final concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt or of 100 
nM HOE 140 were repeatedly added to the culture media, or cell were cultured without 
adding gene network activating or inhibiting compounds, as specified on the X-axis of Figure 
2.40. 48 hours after electroporation cells were stained with Hoechst 33342 and propidium 
iodide, imaged, images processed to determine and plot cell viabilities and green fluorescent 
cell percentages, as previously described. The gene network seemed leaky in HMEC-1 cells, 
the green fluorescent cell percentages in the negative control conditions (HOE 140 and no 
addition) are approximately 50% of the green fluorescent cell percentages in the bradykinin 
activation condition. It came to our knowledge that the door of the cell culture incubator in 
which these cells were placed after electroporation, was opened and shut frequently by other 
lab users, shaking the culture, potentially causing shear stress which might have had activated 
the gene network in the negative control conditions. 
 
 
 
Synthetic gene network for monitoring shear stress sensor activity in endothelial cells 
205 
 
Figure 2.40. Evaluating the leakiness of the redesigned gene network in HMEC-1 cells. Final 
concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt or of 100 nM 
HOE 140 were repeatedly added 6, 24 and 36 hours after electroporation. Alternatively, cells 
were cultured without adding bradykinin or HOE 140. 48 hours after electroporation cells 
were stained with 2 µg/ml Hoechst 33342 and 0.5 µg/ml propidium iodide and were 
microscopy imaged. Obtained fluorescent images were processed in ImageJ to count cells 
and resulting green fluorescent cell percentages and cell viabilities are plotted on the left Y-
axis of the graph. The number of total cells per image is plotted on the secondary, right Y-
axis. The higher-than-expected green fluorescent cell percentages in the negative control 
conditions are most probably due to activation of the gene network by shear stress caused by 
frequent opening and shutting of the incubator door. N=3, error bars represent standard 
deviation. 
 
The above described unsuccessful experimental conditions were repeated alongside with new 
experiments, Figure 2.41. It became of interest to determine whether varying the cell density 
in the Neon
TM
 tip during electroporation, would increase the green fluorescent cell 
percentages. For this, cells were electroporated with 1:1 molar ratios of pZK13 and pZK14 at 
cell densities described on the X-axis of Figure 2.41A. The culture media was supplemented 
with final concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt 6, 24 
and 36 hours after electroporation. In a separate condition, the tetracycline analogue, 
doxycycline, was added at 20 ng/ml final concentration 10 minutes and 12, 24 and 36 hours 
after electroporation to block the transcriptional transactivator, tTA, to transcribe the eGFP 
reporter gene. A second negative control, with non-electroporated cells was also included. 
There wasn’t a large difference between green fluorescent cell percentages of cells 
electroporated at different densities, the 100,000 HMEC-1 per reaction yielding slightly 
higher percentage of green fluorescent cells. The doxycycline negative control yielded a very 
low percentage of green fluorescent cells.  
Knowing that endothelial cells secrete growth factors [591, 592] and signalling molecules 
[593, 594] necessary for cell growth and functioning, the enhancing of post electroporation 
cell viabilities seemed possible by completely or partially replacing the culture medium with 
culture medium collected from healthy cell cultures at 80% confluency. Thus, the first 
condition from the left from Figure 2.41B (“old CM, BD”), contains cells electroporated with 
the redesigned gene network and seeded in 1 day old culture media collected from 80% 
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confluent healthy cell culture. The second condition from the left contains 50% of the same 1 
day old culture medium and 50% fresh culture medium. To these two conditions, final 
concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt were added 6, 24 
and 36 hours after electroporation. In the third condition, cells were electroporated with 
pZK13 and pZK14, plated in fresh culture media which was supplemented with 100 nM HOE 
140 before cell seeding and 6, 24 and 36 hours after cell seeding. Cells from the last two 
conditions, after electroporation with the same plasmids, were seeded in culture media 
supplemented with doxycycline at concentrations indicated on the X-axis. Identical amounts 
of doxycycline were re-added 12, 24 and 36 hours after electroporation. Cells were stained 
with Hoechst 33342 and propidium iodide 48 hours after electroporation and imaged. 
Recorded images were processed in ImageJ and calculated cell viabilities and transfection 
efficiencies are plotted on the Y-axis and the total cell number is plotted on the right Y-axis, 
as usual. Seeding cells in total or partial old media after electroporation does not increase cell 
viabilities or green fluorescent cell percentages. Inhibiting the gene network at the 
transcriptional level with doxycycline seems to be more effective than inhibition at the GPCR 
level with HOE 140. Adding doxycycline before seeding cells, inhibited the reporter eGFP 
transcription most effectively compared to the case when doxycycline was added 10 minutes 
after electroporation. This fact suggests that the expression and activation of a reduced 
number of copies of our gene network happens within 10 minutes after electroporation.   
 
Figure 2.41. Optimizing HMEC-1 cell electroporation densities, culture media and comparing 
negative controls. A. Cells were electroporated with the gene network encoded on plasmid 
pZK13 and pZK14 and densities indicated on the X-axis. The gene network was either 
activated with final concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate 
salt or inhibited at the transcription level by 20 ng/ml doxycycline. 48 hours after 
electroporation cells were stained with 2 µg/ml Hoechst 33342 and 0.5 µg/ml propidium 
iodide and were microscopy imaged. Obtained fluorescent images were processed in ImageJ 
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to count cells and resulting green fluorescent cell percentages and cell viabilities are plotted 
on the left Y-axis of the graph. The number of total cells per image is plotted on the 
secondary, right Y-axis. B. Cells electroporated with the gene network were seeded in 1 day 
old culture media collected from 80% confluent healthy growing cells, in 50% old 50% fresh 
culture media or in fresh culture media. The culture media was supplemented with 2 µM 
[Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt, 100 nM HOE, 10 ng/ml doxycycline or 
20 ng/ml doxycycline. 48 hours after electroporation cells were stained with final 
concentrations of 2 µg/ml Hoechst 33342 and 0.5 µg/ml propidium iodide and were 
microscopy imaged. Obtained fluorescent images were processed in ImageJ to count cells 
and resulting green fluorescent cell percentages and cell viabilities are plotted on the left Y-
axis of the graph. The number of total cells per image is plotted on the secondary, right Y-
axis. N=3, error bars represent standard deviation. 
 
Since green fluorescent cell percentages were not increased above 40% so far by optimizing 
electroporation related parameters, an alternative approach of transfecting the HMEC-1 cell 
line with transfection reagents was considered. No information was available in the literature 
on transfecting HMEC-1 cells with transfection reagents. Our collaborator, Dr. Kimiko 
Yamamoto, from University of Tokyo, recommended to use the Lipofectamine
®
 Plus
TM
 
Reagent from Life Technologies Inc., since this reagent yielded high transfection efficiencies 
in their group when transfecting primary bovine pulmonary endothelial cells. Dr. Kimiko 
Yamamoto also mentioned that electroporation delivers a higher amount of DNA per cell but 
Lipofectamine
®
 delivers DNA to a higher proportion of cells. Dr. Kimiko Yamamoto’s 
transfection protocol was identical with the manufacture’s protocol. Following this protocol, 
cells were seeded the day before transfection so that they become 50-80% confluent at the 
time of transfection. For transfection, the plasmid DNA was pre-complexed with the Plus
TM
 
Reagent, the Lipofectamine
®
 Reagent was added to the pre-complexed DNA–PLUSTM 
Reagent solution, the DNA–PLUSTM–Lipofectamine® Reagent mixture was added to cells. 
Results from this experiment are shown below in Figure 2.42A. Cells were transfected both 
in antibiotic and serum free MCDB 131 medium or in Opti-MEM
®
 I Reduced Serum 
Medium. Three hours after transfection, the culture media was complemented with serum 
containing media, bringing the serum concentration to normal. The DNA–PLUSTM–
Lipofectamine
®
 Reagent mixture was removed 24 hours after transfection when the entire 
culture media was replaced. The gene network was repeatedly induced 12, 24, 36 hours after 
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transfection with final concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin 
acetate salt. Cells were stained with Hoechst 33342 and propidium iodide and were 
microscopy imaged 48 hours after transfection. Cell viabilities and transfection efficiencies 
deduced from recorded microscopy images are shown in Figure 2.42A below. Green 
fluorescent cell percentages were overall low, but it was higher when cells were transfected 
in Opti-MEM
®
 I Reduced Serum Medium. In this experiment cell seeding densities proved to 
be high, cells becoming 90% confluent at the time of transfection. Reducing the 24 hours for 
which DNA–PLUSTM–Lipofectamine® Reagent mixture was incubated with cells to 12 or 3 
hours might yield higher green fluorescent cell percentages. Thus, the experiment was 
repeated, seeding cells at lower densities and reducing the DNA–PLUSTM–Lipofectamine® 
Reagent mixture incubation time. Results from this experiment are shown in Figure 2.42B. 
The green fluorescent cell percentages increased but it did not exceed the 10% obtained by 
electroporation.  
Transfection efficiencies of 40 – 80% have been reported in HEK293 and HeLa cell lines 
using the cationic polymer from Thermo Scientific Inc., TurboFect™ Transfection Reagent 
[595-597]. Since no data were available on transfecting HMEC-1 cells with this TurboFect™ 
and since electroporation did not yield sufficiently high transfection efficiencies, testing the 
TurboFect™ Transfection Reagent on HMEC-1 cells in parallel with testing the 
Lipofectamine
®
 Reagent was carried out. For this, 24 hours prior transfection cells were 
seeded at a density which allowed reaching 70-80% confluency at the time of transfection. 
Various amounts of plasmid DNA were mixed with the transfection reagent and were added 
to the cells. Twelve hours after transfection the culture media was refreshed. The gene 
network was induced with final concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM 
bradykinin acetate salt 12, 24, 36 hours after transfection. Cells were stained with Hoechst 
33342 and propidium iodide and imaged 48 hours after transfection. Calculated cell 
viabilities are shown in Figure 2.42B below. TurboFect did not yield any green fluorescent 
HMEC-1 cells upon transfection with the gene network encoded on pZK13 and pZK14. 
Reagent transfection results were not promising, therefore, these techniques were not to 
employed in the future for the transfection of HMEC-1 cells. 
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Figure 2.42. Reagent transfection of HMEC-1 cells with the gene network encoded on 
plasmid pZK13 and pZK14. Cells were seeded 24 hours prior transfection to reach 70-80% 
confluency at the time of transfection. The transfection reagents were complexed with the 
plasmid DNA and were added to the cell culture. The gene network was activated 12, 24 and 
36 hours after transfection with final concentrations of 2 µM [Hyp
3
]-bradykinin and 2 µM 
bradykinin acetate salt 48 hours after electroporation cells were stained with 2 µg/ml Hoechst 
33342 and 0.5 µg/ml propidium iodide and were microscopy imaged. Obtained fluorescent 
images were processed in ImageJ to count cells and resulting green fluorescent cell 
percentages and cell viabilities are plotted on the left Y-axis of the graph. The number of total 
cells per image is plotted on the secondary, right Y-axis. A. 60,000 HMEC-1 cells seeded per 
wells of 24 well plates 24 hours prior transfection, were either transfected in antibiotic and 
serum free MCDB 131 medium or in Opti-MEM
®
 I Reduced Serum Medium using the 
Lipofectamine
®
 Plus
TM
 Reagent. The DNA–PLUSTM–Lipofectamine® Reagent mixture was 
incubated with the cells for 24 hours. N=4. B. 28,800 or 40,000 HMEC-1 cells seeded 24 
hours prior transfection per well of 24 well plates. Cells were either transfected with 
Lipofectamine
®
 or TurboFect™ transfection reagents. In case of Lipofectamine® transfection, 
the DNA–PLUSTM–Lipofectamine® Reagent mixture was incubated with cells either for 3 or 
12 hours. In case of TurboFect™ transfection, various amounts of plasmid DNA were tried. 
N=2. Based on these results, it has been decided not to continue on using transfection 
reagents for the transfection of HMEC-1 cells since green fluorescent cell percentages 
seemed inferior to those obtained via electroporation. Error bars represent standard deviation. 
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Although the percentage of green fluorescent cells upon electroporating HMEC-1 cells with 
the redesigned gene network was higher than in case of EA.hy926 cells, it wasn’t above 60% 
as it was required in order to reliably study mechanosensing with this shear stress assay. To 
troubleshoot and solve this problem, an experiment was set up for testing components of the 
gene network under various activating and inhibiting conditions. In order to obtain inter-
comparable results, all experimental conditions (such as plasmid molar concentrations, 
plasmid molar ratios, cell densities, pulses, cell handling etc.) were kept identical, except the 
experimental conditions illustrated on the X-axis of Figure 2.43. Six different plasmid sets 
were transfected into cells, out of which four were composed of various combinations of the 
new and old versions of the gene network plasmids. 6, 24 and 36 hours after transfecting cells 
with these four plasmid combinations, the GPCR of the gene network was induced with 2 µM 
[Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt or with shear stress applied by pipetting 
for one minute using a 1,000 µl Eppendorf Research
®
 plus pipette or the GPCR was inhibited 
by 100 nM HOE 140. As negative controls, electroporated cells were also left untreated and 
the transcriptional transactivator (tTA) was inhibited by 20 ng/ml doxycycline added before 
seeding electroporated cells and re-added 24 and 36 hours after electroporation, as well. Non-
electroporated negative control cells were also included, as a base-line. The other two out of 
these six plasmid sets, consisted of the old and new versions of the gene network with the 
reporter plasmids replaced by pZK11 (constitutive phMGFP). 48 hours after electroporation, 
cells were stained with 2 µg/ml Hoechst 33342 and 0.5 µg/ml propidium iodide and imaged 
to determine cell viabilities and transfection efficiencies. These results show that the new 
(redesigned) version of the gene network produces a lower percentage of green fluorescent 
cells than the old version of the gene network (cf. conditions 1–6 vs. conditions 7–12 from 
Figure 2.43). Out of the four gene network plasmid combinations, the redesigned gene 
network (pZK13 and pZK14, conditions 7–12) yielded the lowest overall green fluorescence. 
The pZK9, pZK5, pZK14 plasmid combination (conditions 13–18) showed the second 
highest overall green fluorescent cell percentage. The pZK10, pZK13 combination 
(conditions 19–24) produced the third highest overall green fluorescence, only slightly higher 
than the overall green fluorescence of the redesigned gene network (pZK13 and pZK14). 
Using pZK13 reduces the percentage of green fluorescent cells. This might be due to lower 
transfection efficiencies when transfecting with the large pZK13 plasmid. When using pZK13 
in combination with pZK11 (constitutive phMGFP, condition 26), the green fluorescent cell 
percentage was lower than in case of using pZK11 together with pZK9 and pZK5, again 
showing that the presence of pZK11 reduces the green fluorescence cell percentages. When 
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using pZK13, cell viabilities and the total number of cells seem also to drop. This might also 
due to the fact that larger plasmid are transfected harder, blocking more pores and killing 
more cells. Plasmid pZK14 also yields lower green fluorescent cell percentages compared to 
using its equivalent older version pZK10 (cf. conditions 7–12 vs. conditions 19–24), possibly 
because of the reduced leakiness of pKZ14 (pTRE3G-eGFP) compared to pZK10. Using 
pZK11, conditions 25 and 26, yielded significantly higher green fluorescent cell percentages 
than all the other 4 gene network combinations. This could be due to the combination of the 
following factors: the gene network was not entirely present in cells (only the smaller reporter 
plasmid or pZK11 might have transfected into most cells), expression of the gene network or 
its activation in these cells was not efficient. Another explanation for the lower percentage of 
green fluorescent cells when transfecting with the gene network, might be the necessity of a 
series of events to occur, in order for the green fluorescence to emerge. These events include: 
transfection, expression of the gene network, activation of the gene network by shear stress of 
bradykinin, cleavage of tTA from the GPCR, migration of tTA into the nucleus, activation of 
eGFP transcription by tTA, expression of eGFP. If these events fail to occur or they occur at 
lower efficiencies that overall efficiency will also be reduced. 
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Figure 2.43. Comparing performances of gene circuit components under various activating 
and inhibiting conditions and comparing transfection efficiencies. 100,000 HMEC-1 cells 
were electroporated per reaction using 1200 V 30 ms double pulses with plasmids specified 
in the table below the graph. 6, 24 and 36 hours after transfection, the gene network was 
activated with 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt, with shear stress 
induced by pipetting for 1 minute or it was inhibited with 100 nM HOE 140, or cells were left 
untreated. The gene network was also inhibited with 20 ng/ml doxycycline added before 
seeding electroporated cells and re-added 24 and 36 hours after electroporation. Non-
electroporated cells were also included as an additional negative control condition. Cells were 
stained with Hoechst 33342 and propidium iodide and imaged 48 hours transfection. Images 
were processed in imageJ, determined cell viabilities and transfection efficiencies are plotted 
on the left Y-axis and the total number of cells per image is plotted on the right Y-axis. Error 
bars represent standard deviation, N=4–6. 
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Besides looking at which plasmid combination produces the highest green fluorescent cell 
percentages, it would also be of interest to see how leaky these gene network variants are, and 
to see what is the ratio between activation and inhibition green fluorescence percentage 
values. For this, green fluorescent cell percentages resulting from the no treatment, HOE 140, 
doxycycline and shear stress treatment conditions had been normalized to green fluorescent 
cell percentages from the bradykinin activation condition, using Equation 2.3. Obtained 
results are presented in Table 2.22 below. Rows number 1–3 from this table represent 
leakiness of the gene network version under various inhibitory or no activation conditions. 
The redesigned gene network version (pZK13 and pZK14) has a lower leakiness than the old 
version of the gene network (encoded by pZK9, pZK5 and pZK10). Compared to the 
redesigned gene network, the gene network encoded by pZK9, pZK5 and pZK14 has a lower 
leakiness only in the no treatment condition; under HOE 140 and doxycycline inhibitory 
conditions the leakiness of the pZK9, pZK5 and pZK14 was significantly higher. The gene 
network encoded by plasmids pZK13 and pZK10 has a lower leakiness than the redesigned 
gene network under HOE 140 and doxycycline inhibitory conditions. These results indicate 
that without treatment, the new reporter plasmid pZK14 was less leaky than the old pZK10 
reporter plasmid. Interestingly, plasmid pZK13 seems to produce less leakiness under HOE 
140 and doxycycline inhibitory conditions compared to its old plasmid pZK5 and pZK9 
counterparts. 
The shear stress responsiveness normalized to bradykinin induction seems to be significantly 
higher in case of the redesigned gene network compared to gene network encoded by 
plasmids pZK9, pZK5, pZK14 and to the gene network encoded by plasmids pZK13 and 
pZK10. Looking at both leakiness and shear stress responsiveness, the redesigned gene 
network (encoded by pZK13 and pZK14) seems to perform the best. Therefore, this gene 
network was chosen for further use. The next step would be to increase the green fluorescent 
cell percentages using mammalian antibiotic selection. 
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Table 2.22. Green fluorescent cell percentages from no treatment, HOE 140 treatment, 
doxycycline treatment and shear stress treatment conditions normalized to bradykinin 
treatment green fluorescent cell percentages (values from Figure 2.43).  
No. 
Condition normalized to  
Bradykinin treatment 
Percentages normalized to bradykinin 
treatment 
pZK9, 
pZK5, 
pZK10 
pZK13, 
pZK14 
pZK9, 
pZK5, 
pZK14 
pZK13, 
pZK10 
1 no treatment 74.8% 51.6% 42.9% 71.8% 
2 HOE 140 treatment 84.1% 62.5% 81.5% 43.7% 
3 doxycycline treatment 37.4% 31.9% 71.8% 29.4% 
4 
Shear stress (Pipetting) 
treatment 
96% 95.8% 61.9% 18.3% 
 
In order to determine the Hygromycin B and G 418 antibiotic concentrations required for 
selecting HMEC-1 cells transfected with the gene network, these antibiotics were titrated on 
non-transfected HMEC-1 cells. For this, cells were seeded in 12 well plates pre-coated with 
1% (w/v) gelatine and 24 hours later the culture media was supplemented with Hygromycin 
B and Neomycin (G 418) antibiotics at final concentrations depicted on the X-axis of Figure 
2.44 in each well. Culture media with the corresponding antibiotic concentration was 
refreshed every 2-3 days for a period of 7 days at the end of which cells were stained with 
nuclear stains 2 µg/ml Hoechst 33342 (total cells) and 0.5 µg/ml propidium iodide (dead 
cells) and cells were imaged. Cells were counted and determined cell viabilities are plotted on 
the left Y-axis of Figure 2.44 along with the total number of cells per image plotted on the 
right Y-axis. Cell viabilities do not drop to near zero values; however the numbers of cells 
present was reduced significantly (to values close to zero) at and above 100 µg/ml antibiotic 
concentrations. Cells appeared rounded up and (near) dead but their membranes were not 
permeable for the propidium iodide stain, thus appeared viable when assayed with this 
method. By looking at the total number of cells present per image, HMEC-1 cells seem to die 
at and above 100 µg/ml Hygromycin B and G 418 antibiotic concentrations. Hygromycin B 
seems somewhat more effective in killing HMEC-1 cells compared to G 418. The final 
antibiotic concentrations used for 1 week selection will be in the range of 100–400 µg/ml 
Hygromycin B and 100–400 µg/ml G 418.  
 
Synthetic gene network for monitoring shear stress sensor activity in endothelial cells 
215 
 
 
Figure 2.44. Hygromycin B and G 418 antibiotic titration on HMEC-1 cells for 7 days 
selection. Non-transfected cells were cultured under antibiotic concentrations specified on the 
X-axis for a period of 7 days. Cells were stained with Hoechst 33342 and propidium iodide 
and imaged. Images were processed in ImageJ to determine cell viabilities, plotted on the left 
Y-axis. The total number of cells per image is plotted on the right Y-axis. A. Cell viabilities 
under various Hygromycin B concentrations. B. Cell viabilities in function of G418 
concentrations. Error bars represent standard deviation, N=2. 
 
After the mammalian selection antibiotic concentration range has been determined, HMEC-1 
cells were electroporated with the pZK13, pZK14 at molar ratios of 1:1. Twenty-four hours 
after electroporation final concentrations of 100–400 µg/ml G 418 were added in increments 
of 100 µg/ml. Culture media was renewed every 2-3 days to maintain the selection pressure 
for a period of 7 days. On the last day of selection, the gene network was induced with 
bradykinin, with shear stress applied by pipetting, was inhibited with HOE140 or was left 
unaltered. 24 hours after induction or inhibition of the gene network, cells were stained with 
2 µg/ml Hoechst 33342 and 0.5 µg/ml propidium iodide and were visualized under the 
fluorescent microscope. The percentage of green fluorescent cells was very low, below 2%. 
Next, the selection experiment was repeated but without obtaining any improvement on the 
outcome. Cell viabilities in both experiments were also very low. 
In that period cloning an SV40 origin of replication into plasmid pZK14 was also considered, 
since out of the two plasmids encoding the redesigned gene network, pZK13 and pZK14, 
only pZK13 contains an SV40 origin of replication. This was discussed with the technical 
support team from Clontech Laboratories, Inc. (the company who provided the pZK14 
backbone plasmid, pTRE3G). They recommended not cloning the SV40 origin of replication 
into pZK14 as this might negatively affect the functionality of the plasmid, also significantly 
increasing the background eGFP expression from this plasmid. Thus, pZK14 was left 
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unaltered, without cloning the SV40 origin of replication into it. Since this plasmid did not 
contain an origin of replication, it cannot be used for selection either. Thus, the hygromycin B 
selection cassette was not cloned into this plasmid either.  
This way, cells would only be selected for the presence of pZK13 using the G 418 antibiotic. 
Reducing the G 418 selection time to two days to shorten the time of experiments was also 
considered. For this, G 418 was titrated for a two day selection on HMEC-1 cells using the 
same experimental approach as previously described. Results from this titration experiment 
are shown in Figure 2.45 below. At G 418 concentration of above 200 µg/ml, the cell 
morphology changed, cells started to look elongated and rounded up, indicating that their 
viability became reduced. 
 
 
 
Figure 2.45. G 418 antibiotic titration on HMEC-1 cells for 2 days selection. Non-transfected 
cells were seeded in 24 well plates coated with 1% gelatine. Twenty-four hours after seeding, 
wells of the 24 well plates were supplemented with antibiotic concentrations specified on the 
X-axis and incubated for a period of 2 days. A. Cell viabilities in function of G418 
concentrations. Cells were stained with Hoechst 33342 and propidium iodide, and imaged. 
Images were processed in ImageJ to determine cell viabilities, plotted on the left Y-axis. The 
total number of cells per image is plotted on the right Y-axis. Error bars represent standard 
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deviation, N=2. B. Phase contrast microscopy images showing cell morphologies and the 
proportion of adherently growing cells, as an indicator of cell viability. According to these 
images cell viability decreased at G418 concentrations of above 200 µg/ml.  
 
Next, a selection experiment was carried out; where HMEC-1 cells have been electroporated 
with the gene network using 1200 V 30 ms double pulses. Twenty four hours after 
electroporation the culture media was supplemented with 400 µg/ml G 418 antibiotic and 
selection was carried out for a period of two days. At the end of the selection period the 
culture media was replaced with G 418 antibiotic free media and the gene network was 
induced with 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt. Cell were stained 
with Hoechst 33342 and propidium iodide 24 hours after induction and imaged. Results from 
cell counts from microscopy images are shown in  
Figure 2.46. Green fluorescent cell percentages did not increase to the desired values in this 
selection experiment. 
  
 
Figure 2.46. Selection of HMEC-1 cells electroporated with the gene network. HMEC-1 cells 
were electroporated with 1:1 molar ratio of pZK13 and pZK14 (redesigned gene network), 
using 1200 V 30 ms double pulses. 24 hours after electroporation, the culture media was 
supplemented with 400 µg/ml G 418 antibiotic and selection was carried out for two day, at 
the of which the gene network was induced with 2 µM [Hyp
3
]-bradykinin and 2 µM 
bradykinin acetate salt. 24 hours after induction cells were stained with Hoechst 33342 and 
propidium iodide and cells were imaged. Recorded images were processed in imageJ to 
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determine cell viabilities and transfection efficiencies. Error bars represent standard 
deviation, N=4. 
 
In parallel, electroporation conditions were being optimized for the MS1 endothelial cell line 
as well and the G 418 selection antibiotic was also titrated in order to determine the G 418 
concentration for selection. The MS1 cell line was viable at G 418 concentration as high as 
2,000–10,000 µg/ml. Since MS1 cells were not selectable with G 418 this cell line was not 
used further in this project.  
Green fluorescent HMEC-1 cell percentages did not increase in the experiment described at  
Figure 2.46, thus a strategy of electroporating solely with pZK13, then selecting cells that 
contain this plasmid, then electroporate selected cells with pZK14, and then activate the gene 
network, was designed. Therefore, HMEC-1 cells were electroporated with pZK13, seeded in 
T75 flasks and 24 hours after electroporation selection was started by replacing the culture 
media and supplementing with the fresh media with 200 and 400 µg/ml G 418 in separate 
T75 flasks. Selection was carried out for two days at the end of which the culture media was 
renewed with G 418 free media. Twenty-four hours after stopping the selection cells were re-
electroporated with pZK14. To induce the gene network, final concentrations of 2 µM 
[Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt were added 6 and 24 hours after 
electroporation with pZK14. To inhibit the gene network, following the second 
electroporation, cells were seeded in culture media containing final concentrations of 20 
ng/ml doxycycline and doxycycline was re-added 24 hours after electroporation. Cell staining 
with final concentrations of 2 µg/ml Hoechst 33342 and 0.5 µg/ml propidium iodide and 
imaging took place 48 hours after electroporation with pZK14. Resulting images were 
processed in ImageJ to count total, dead and reporter gene expressing cells. Derived cell 
viabilities and green fluorescent cell percentages are plotted on the left Y-axis, whereas the 
total number of cells per image is shown on the right Y-axis of  
Figure 2.47. Treatment conditions are shown on the X-axis of  
Figure 2.47. As this figure shows, green fluorescent cell percentages of HMEC-1 selected 
with 200 µg/ml G 418 and induced with bradykinin average 67.1%. HMEC-1 cells selected 
with 400 µg/ml G 418 and induced with bradykinin yielded only 25.7% green fluorescent 
cells with a large standard deviation (35.9%). Only 4.4% of cells became green fluorescent 
when selected with 200 µg/ml G 418 and inhibited with 20 ng/ml doxycycline. Cell 
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viabilities and total cell numbers per image are lower in the 400 µg/ml G 418 selection 
condition, compared to the 200 µg/ml G 418 selection condition, as expected. This 
experimental procedure finally yielded high enough green fluorescent cell percentages in 
order to apply the gene network for mechanosensing studies. 
 
 
Figure 2.47. Selection of HMEC-1 cells electroporated with pZK13 followed by a second 
electroporation and induction. HMEC-1 cells were electroporated with pZK13. Twenty-four 
hours after electroporation the culture media was supplemented with 200 and 400 µg/ml G 
418 and cells were incubated for two days at the end of which the culture media was replaced 
with G 418 media. Twenty-four hours after ending the selection cells were electroporated 
with pZK14. Six and twenty-four hours after the second electroporation cells were induced 
with 2 µM [Hyp
3
]-bradykinin and 2 µM bradykinin acetate salt. As negative control, cells 
electroporated with pZK14 were seeded in culture media containing 20 ng/ml doxycycline, 
the same amount of doxycycline being added 24 hours after the second electroporation. Cells 
were stained with Hoechst 33342 and propidium iodide and were imaged 48 hours after the 
second electroporation. Recorded images were processed in imageJ to determine cell 
viabilities and transfection efficiencies, plotted on the left Y-axis alongside total cell numbers 
per images on the right Y-axis. Treatment conditions are shown on the X-axis. Error bars 
represent standard deviation, N=3. 
     
After obtaining green fluorescent cell percentages of above 60% using the electroporation–
selection–electroporation–induction method, testing HMEC-1 cells under 1.5–2 Pa shear 
stress became the next aim, since no evidence proving that these cells could withstand shear 
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stresses of above 0.3 Pa was available. A flow experiment was set up where non-transfected 
HMEC-1 cells were seeded in three different flow channels from ibidi: µ-Slide I 
0.2
 Luer, µ-
Slide I 
0.4
 Luer, and µ-Slide I 
0.8
 Luer, with heights of 200, 400 and 800 µm, respectively. 
Prior to cell seeding all flow channels have been coated with 1 mg/ml fibronectin. Twenty-
four hours after cell seeding, the three ibidi flow channels were connected to the flow setup, 
connecting the 800 µm high channel first, the 400 µm high channel seconds and the 200 µm 
high channel third. Besides the flow channels, the flow setup consisted of a Cobe precision 
peristaltic pump, a bubble catcher media reservoir, and platinum-cured silicone tubing. The 
rotational speed of the peristaltic pump (measured in rotations per minute, RPM) was 
correlated flow rate (in ml/min) by measuring how much water was the pump pushing 
through per minute at various pump rotational speeds, the resulting plot is shown in 
Appendix 9. A pump rotational speed of 3 RPM produces 3.2, 0.8 and 0.2 Pa shear stress in 
the µ-Slide I 
0.2
 Luer, µ-Slide I 
0.4
 Luer, and µ-Slide I 
0.8
 Luer flow channels, respectively. 
Thus, the pump was employed at 3 RPM during the flow experiment. In the first two hours of 
the experiment, the pump was set to 1 RPM to yield 1.5, 0.4 and 0.1 Pa shear stress value in 
the µ-Slide I 
0.2
 Luer, µ-Slide I 
0.4
 Luer, and µ-Slide I 
0.8
 Luer flow channels, respectively, in 
order to allow the cells to adapt to the flow conditions. Phase contrast microscopy images of 
cells from all 3 ibidi channels recorded before the flow experiment, 24 hours into the flow 
experiment and after 48 of flow exposure are shown below in Figure 2.48. Before the flow 
experiment the cells are growing in a monolayer, after 24 hours of flow cells were still 
present at all 3 shear stress values. Interestingly, cells appeared to align perpendicularly to the 
flow direction, especially at 0.8 Pa shear stress. Cells were still present after 48 hours of flow 
exposure, however at 3.2 Pa there was no continuous cell layer. At 0.8 Pa shear stress, the 
perpendicular cell alignment was still predominant after 48 hours of flow. Cells exposed to 
0.2 Pa of shear stress for 48 hours seemed to take the cobblestone morphology. These results 
confirmed that HMEC-1 cells can withstand shear stresses of up to 3.2 Pa for a period of 24 
hours, thus they are suitable for our applications also from the point view of flow 
experiments.  
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Figure 2.48. Flow experiment on non-transfected HMEC-1 cells. HMEC-1 cells were seeded 
in µ-Slide I 
0.2
 Luer, µ-Slide I 
0.4
 Luer, and µ-Slide I 
0.8
 Luer flow channels pre-coated with 
1% fibronectin. After a priming period of 2 hours at low flow rate, the flow was increased to 
3 ml/min, which yielded 3.2, 0.8 and 0.2 Pa shear stress in the µ-Slide I 
0.2
 Luer, µ-Slide I 
0.4
 
Luer, and µ-Slide I 
0.8
 Luer flow channels, respectively. This flow rate was maintained for 48 
hours. Images were recoded before starting the flow and after 24 and 48 hours of flow 
exposure using the 10x objective. 
 
After having set up a method for obtaining high green fluorescent cell percentages using 
selection and after knowing that these cells can withstand shear stress values of interest, the 
goal was to study the response of the gene network to a large range of shear stress values. In 
order to expose cells to a range of lineally increasing shear stress values, a flow channel was 
designed in which the height of the channel decreases along the flow axis to yield linearly 
increasing shear stress along the flow axis at the bottom of the channel. This in-house 
developed flow setup is described in detail in Chapter 3. The flow experiment procedure was 
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initially optimized in our in-house designed flow device for HMEC-1 cells. Thus, non-
electroporated cells were seeded on the glass slide which was part of the cell seeding well. 
Twenty-four hours after cell seeding, the glass slide with cells was dis-assembled from the 
well and the bottomless flow channel was placed on top of the glass slide. This way, the glass 
slide on which cells were seeded, constituted the bottom of the flow channel which was filled 
with culture media and was connected to the tubing of the flow setup. In the initial 1 hour of 
the flow experiment, the Cobe peristaltic pump was operated at 2 RPM, to yield 3 ml/min 
flow rate, allowing the cells to adjust to the flow condition. During the course of the 
following two hours the rotational speed of the pump was gradually increased to 12 RPM and 
this 12 RPM, which yielded 28 ml/min flow rate, was maintained for a period of 24 hours. 
Cells were then stained with final concentrations of 2 µg/ml Hoechst 33342 and 0.5 µg/ml 
propidium iodide and then fixed with 4% (v/v) paraformaldehyde in PBS. Subsequently, 
fixed cells were inspected under the microscope. In the initial 3 trials, cells were not present 
after the 24 hour flow experiment even if a confluent monolayer was visible before starting 
the flow. By replacing the bottomless PDMS flow channel with a new channel of the same 
type, the cell monolayer was present after the 24 hours of flow. The reason for this could be 
that during an initial experiment, cells were stained and fixed in the assembled flow channel, 
and stains and paraformaldehyde might have had gotten absorbed by the PDMS of the flow 
channel. These stains and paraformaldehyde diffusing out of the PDMS might have caused 
the cells to die in subsequent flow experiments. In subsequent experiments, after finishing the 
flow experiment, the flow setup was completely disassembled and cells were stained and 
fixed on the glass slide, avoiding the contact of stains and fixing agents with the rest of the 
flow setup. 
Once flow experiments were successfully carried out with non-electroporated HMEC-1 cells 
in our in-house designed flow channel, HMEC-1 cells were electroporated with the gene 
network (encoded on pZK13 and pZK14) and then seeded on the glass slide, in the seeding 
well. Twenty-four hours after electroporation, the flow setup was assembled by replacing the 
seeding well with the bottomless flow channel. Cells were primed for 1 hour at 3 ml/min flow 
rate, followed by 2 hours of gradually increasing flow rate up to 28 ml/min which was then 
maintained for a period of further 24 hours. At the end of the flow experiment, the setup was 
disassembled and cells on the slide were stained with 2 µg/ml Hoechst 33342 and 0.5 µg/ml 
propidium iodide and then fixed with 4% (v/v) paraformaldehyde. The entire cell monolayer 
was imaged by programming the stage of the microscope for tile acquisition. The X and Y 
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Cartesian coordinates of the recorded images were correlated with shear stress values 
knowing that shear stress increases linearly from 0 to 5 Pa along the flow axis at the flow rate 
of 28 ml/min. From images recorded at locations where shear stress values were 0.2, 0.5, 1, 
1.5, 2, 2.5, 3.0, 3.5, 4.0, 4.5, and 5 Pa, cells have been counted to determine the percentage of 
green fluorescent cells. The resulting green fluorescence values have been plotted in function 
of the shear stress in Figure 2.49 below. Interestingly, the percentage of green fluorescent 
cells increases with shear stress up to approximately 3 Pa shear stress values and then 
decreases as the shear stress increases. 
 
 
Figure 2.49. Activation of the gene network by shear stress in the linear shear stress inducing 
flow channel. HMEC-1 cells were electroporated with 1:1 molar ration of pZK13 and pZK14 
and seeded in the seeding well of the flow setup. Twenty-four hours after cell seeding, the 
well was replaced with the bottomless flow channel and following a 3 hours priming period 
at low flow rates, cells have been exposed to 24 hours of 28 ml/min flow which yielded a 
shear stress increasing from 0 to 5 Pa along the flow axis of the in-house designed flow 
channel. Cells on the glass slide were stained with 2 µg/ml Hoechst 33342 and 0.5 µg/ml 
propidium iodide and then fixed with 4% (v/v) paraformaldehyde. The slide was imaged 
using tile acquisition and cells were counted from images where cells have been exposed to 
shear stress values of 0.2, 0.5, 1, 1.5, 2, 2.5, 3.0, 3.5, 4.0, 4.5, and 5 Pa. Resulting green 
fluorescent cell percentages were plotted against shear stress. Error bars represent standard 
deviation, N=2. 
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In order to evaluate the activation of the gene network by shear stress at higher green 
fluorescent cell percentages, HMEC-1 cells were electroporated with pZK13, seeded cells in 
T75 flasks and 24 hours later started selecting cells with final concentrations of 200 µg/ml of 
G 418 for a period of 48 hours. At the end of the selection period, the culture media was 
replaced with fresh, G 418 free medium and 24 hours later cells were electroporated with 
pZK14 and seeded in the seeding well of the in-house designed flow channel. Twenty-four 
hours after seeding, the flow experiment was started with an initial 3 hours priming period as 
previously described, and the experimental 28 ml/min flow rate was maintained for a period 
of 24 hours. As described in the previous experiment, cells were stained, fixed and imaged; 
calculated green fluorescent cell percentages were plotted against shear stress to obtain the 
graph from Figure 2.50. By increasing the shear stress, the percentage of green fluorescent 
cells increased up to 4.5 Pa. When gene network containing HMEC-1 cells were selected 
using G 418 antibiotic, the percentage of green fluorescent cells did not decrease at shear 
stress values of above 3 Pa, as in case of experiment without antibiotic selection presented in 
Figure 2.49. The major difference between experiments summarized in Figure 2.49 and 
Figure 2.50 is the selection of pZK13 using G 418. Therefore, the difference in green 
fluorescent cell percentages at high shear stress values could be attributed to G 418 selection. 
An explanation for selection causing a difference between green fluorescent cell percentages 
at high shear stress values would be the following. High shear stress values represent non-
optimal growth condition for HMEC-1 cells, about 50% of them were washed away by 3.2 Pa 
shear stress applied for 48 hours, as shown in Figure 2.48. Under these non-optimal growth 
conditions, cells might shut down gene expression (including eGFP expression), thus the 
percentage of green fluorescent cells decreased. On the other hand, when applying selection 
pressure with 200 µg/ml of G 418, the survival of cells depended on expressing the neomycin 
resistance gene from the plasmid, thus gene expression from plasmid remained high levels 
under non-optimal selection conditions. When a subsequent non-optimal growth condition 
was applied, this time by high shear stress, cells kept on maintaining high expression levels 
from the plasmid from which expression assured their survival earlier on.  
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Figure 2.50. Activation of the gene network in antibiotic selected HMEC-1 cells by shear 
stress in the linear shear stress inducing device. HMEC-1 cells were electroporated with 
pZK13 and 24 hours later, selection with 200 µg/ml of G 418 was started and was carried out 
for a period of 48 hours. 24 hours after stopping the selection, cells were electroporated with 
pZK14 and seeded in the in-house designed flow device. Twenty-four hours after cell seeding 
cells were primed at low flow rates for 3 hours and then exposed to 24 hours of 28 ml/min 
flow which yielded a shear stress increasing from 0 to 5 Pa along the flow axis of the in-
house designed flow channel. Cells on the glass slide were stained with 2 µg/ml Hoechst 
33342 and 0.5 µg/ml propidium iodide and then fixed with 4% (v/v) paraformaldehyde. The 
slide was imaged using tile acquisition and cells were counted from images where cells have 
been exposed to shear stress values of 0.2, 0.5, 1, 1.5, 2, 2.5, 3.0, 3.5, 4.0, 4.5, and 5 Pa. 
Resulting green fluorescent cell percentages were plotted against shear stress. Error bars 
represent standard deviation, N=3 for data points at 0.2 and 0.5 Pa and N=5 for all other data 
points. 
 
It could be hypothesized that the increase in fluorescent cell numbers along flow axis might 
be due to excretion of signalling molecules by cells upstream, which then activates the gene 
network in cells downstream. To tackle this paracrine signalling question, the direction of 
flow was reversed in our flow channel and the decrease in green fluorescent cell percentages 
in function of decreasing shear stress along the flow axis was monitored. Thus, this 
experiment was identical with the experiment described at Figure 2.50, with the exception 
that the flow entered the flow chamber in the high shear stress (low channel height) region, 
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flowed through the channel and exited at the low shear stress (high channel height) end of the 
flow channel. Results from this pilot experiment are summarized in Figure 2.51 below. High 
to low shear stress flow caused an overall lower cell count in the flow chamber, but overall 
the percentage of eGFP expressing cells in function of shear stress remained similar to the 
regular (low to high shear stress) flow experiment. In reverse flow experiments, it was 
frequently found that less than 10 cells were found per images between 0.2 – 1 Pa. This could 
well be due to debris from upstream impacting with downstream cells and dislodging them. 
Cells that remained often showed anomalously high eGFP expression, which did not correlate 
with viable cell counts observed in the Hoechst channel. For this reason, images from 0 – 1 
Pa were not included in the graph. Figure 2.51 shows a high number of green fluorescent 
cells emerges when the flow enters at the high shear stress end of the channel, without 
activation from cells upstream in the flow, thus without activation by paracrine signalling. 
Additionally, along the flow path, as shear stress decreases, the number of green fluorescent 
cells was also decreasing. This further shows that activation of the gene network by cell to 
cell signalling does not occur. Therefore, these data indicates that shear stress activates the 
gene network in each cell individually. 
 
Figure 2.51. Pilot flow experiment with reversed flow direction (high shear to low shear). 
HMEC-1 cells were electroporated with pZK13 and 24 hours later, selection with 200 μg/ml 
of G 418 was started and was carried out for a period of 48 hours. 24 hours after stopping the 
selection, cells were electroporated with pZK14 and seeded in the in-house designed flow 
device. Twenty-four hours after cell seeding, the flow experiment was set up by flowing the 
culture media in the reversed direction in the flow channel: flow entering at high shear stress 
and exiting at low shear stress. In the initial phase, cells were primed at low flow rates for 4 
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hours and then exposed to 24 hours of 28 ml/min flow which yielded a shear stress 
decreasing from 5 to 0 Pa along the flow axis of the in-house designed flow channel. Cells on 
the glass slide were stained with 2 μg/ml Hoechst 33342 and 0.5 μg/ml propidium iodide and 
then fixed with 4% (v/v) paraformaldehyde. The slide was imaged using tile acquisition and cells 
were counted from images where cells have been exposed to shear stress values of 1, 1.5, 2, 2.5, 
3.0, 3.5, 4.0, 4.5, and 5 Pa. Resulting green fluorescent cell percentages were plotted against 
shear stress. Error bars represent standard deviation. N=1, number of technical replicates equals 4 
since 4 images were recorded at each shear stress value within one experiment. 
Results presented in this chapter showed that a synthetic gene network is capable of 
monitoring the mechanosensor activity of the B2 Bradykinin GPCR. These findings initiate 
further studies in the field of synthetic mechanobiology, as presented in the 2.5.2 Future work 
section. 
 SUMMARY AND FUTURE WORK 2.5
2.5.1 Summary 
Our synthetic gene network for monitoring shear stress sensor activity in endothelial cells has 
been constructed at the plasmid level. The synthetic gene network consists of a shear stress 
sensor, a reporter gene (eGFP), and a cascade which signals from the sensor to the reporter 
gene. The synthetic gene network was proven functional in HeLa cells by bradykinin 
activation. Next, electroporation conditions were optimized for transfecting the gene network 
into the EA.hy926 endothelial cell line. The gene network was transfected into EA.hy926 
cells and the activity of the network was confirmed by bradykinin. Subsequently, EA.hy926 
cells were seeded in flow chambers and it was shown that the gene network was activated by 
1.5-2 Pa shear stress, by 24 hours flow exposure. Out of the total cells, only around up to 
12% became green fluorescent upon transfection with the gene network followed by the 
activation of the gene network. This proportion of cells wasn’t high enough for reliably 
studying shear stress sensing in endothelial cells using this gene circuit. This low percentage 
of functional gene network containing cells was attributed to inefficient transfection, since 
transfecting cells with 3 plasmids at the same time is difficult. In order to increase the 
percentage of cells with a responsive gene network, the plasmids encoding the gene network 
were re-configured, reducing their number from 3 to 2 and mammalian antibiotic selection 
markers for selecting cells that contain the gene network were also included. Following this, 
the electroporation parameters were again optimized for transfecting EA.hy926 endothelial 
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cells with the redesigned gene network encoded on two plasmids. The redesigned gene 
network was inserted into the EA.hy926 endothelial cells and mammalian antibiotic selection 
was carried out in order to enrich the cell population in cells that contain the gene network. 
The selection of EA.hy926 cells containing the gene network was not successful, most 
probably due to the incapability of EA.hy926 cells to replicate plasmids and plasmids 
degraded during the selection process. In order to allow plasmids replication, the HMEC-1 
cell line was employed, which was capable of replicating plasmids using the Simian virus 40 
replication system. Electroporation conditions were optimized for transfecting HMEC-1 cells 
with the redesigned gene network. Next, the antibiotic selection procedure was optimized and 
cells were selected using the G 418 antibiotic for 2 days. The flow experiment was also 
optimized to expose HMEC-1 cells to linearly increasing shear stress, along the flow axis at 
the channel floor of our in-house designed flow chamber. Following this, HMEC-1 cells were 
electroporated with the plasmid encoding the gene network (without the reporter gene), 
selected for two days, electroporated with the reporter gene plasmid of the gene network, 
seeded in our in-house designed flow channel and exposed to linearly increasing shear stress 
along the channel floor, in the range of 0–5 Pa for 24 hours. The percentage of green 
fluorescent cells increased exponentially with shear stress, plateauing at 2 – 3 Pa, as 
expected. Our results showed that a synthetic gene network is capable of monitoring 
mechanosensor activity. This new assay enables to screen for compounds that modify the 
response of mechanosensors to shear stress. 
2.5.2 Future work 
We have considered 6 different directions for continuing my project. The first one is to create 
similar gene networks with different GPCRs, expanding the assay. Furthermore, designing 
similar gene networks but for shear stress sensors from other protein families (such as 
receptor tyrosine kinase, ion channels, NADPH oxidases, PECAM-1, integrins etc.) would 
also be of great relevance. For example, the Tango Assay for Receptor Tyrosine Kinases 
[247] could be employed to monitor the activation of shear stress sensitive Receptor Tyrosine 
Kinases in endothelial cells exposed to shear stress. 
The second future direction of this project would be to identify novel shear stress sensors. For 
this application, the shear stress sensor in our gene network could be replaced with another 
GPCR which is specific to endothelial cells but which is not known to be shear stress 
responsive. If the gene network containing this endothelial specific GPCR becomes activated 
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under flow conditions, without activation under static condition, this would indicate that the 
GPCR in question is responsive to shear stress. If gene networks will be developed to monitor 
the activation of other families of trans-membrane proteins, a similar approach could be 
undertaken to identify shear stress sensors from these other trans-membrane protein families. 
A third future direction would be to examine the behaviour of these gene networks under 
various shear stress regimes, including constant (uniform) shear stress, pulsatile shear stress 
and oscillatory shear stress. This would reveal whether these shear stress sensors behave 
differently under various shear stress regimes.   
The fourth future direction would be to study the activation of shear stress sensors by pulling 
them with magnetic tweezers. For this, magnetic micro-beads coated with ligands that bind to 
the shear stress sensors will be pulled by the electromagnet. This direction is already 
undertaken by an M.Res. student who is co-supervised by Dr. Armando Del Rio Hernandez 
and Prof. Rob Krams. 
The fifth direction is to screen for compounds that are modifying the ability of the shear 
stress sensors to sense atherogenic shear stress. More specifically, in case of the bradykinin 
B2 GPCR, it would be of interest to find compounds that are activating shear stress sensors at 
low and/or oscillatory shear stress values. For this, cells containing the gene network should 
be seeded in flow channels and exposed to shear stress in the presence of potential bradykinin 
B2 GPCR activators in the flown culture media. The compound which activates the shear 
stress sensor at low shear stress levels, without modifying its activity at high shear stress 
would be a good candidate for consideration for future studies in mice fed with a high fat diet 
and with a shear stress modifying cuff placed around their coronary arteries [30, 598]; in 
order to see whether the occurrence of plaques would be reduced by the bradykinin B2 GPCR 
activator compound. Once other gene networks containing other shear stress sensors will be 
available, compounds that modify the activation of those shear stress sensors can be screened 
for as well, and subsequently those compounds can be subjected for studies in mice as 
previously described.  
The sixth direction is to couple the gene network to endogenous genes and to regulate the 
expression of these genes by the activation or inhibition of the gene network. This would 
open avenues for conditional gene therapy, whereby the expression of atheroprotective or 
therapeutic genes would be controlled by the gene network that can be switched on by 
atherogenic or other disease promoting conditions. To this end, the eGFP reporter gene has 
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been replaced with the endogenous KLF2 gene, thus upon activating the gene network, the 
atheroprotective KLF2 is being expressed.  
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 ABSTRACT 3.1
In order to effectively study the effect of shear stress caused by fluid flow on the 
endothelium, a flow chamber in which shear stress at the channel floor varies linearly along 
the axis of flow, without inducing shear stress variation across the width of the channel floor, 
is required. This flow channel also allows the growth of endothelial cells on the channels 
floor under sterile conditions, their exposure to 0-10 Pa range of linearly increasing shear 
stress along the flow axis and imaging by fluorescent microscopy. In this project, such a 
novel flow chamber was developed. 
A 3-Dimensional Computer Aided Design (3D CAD) model of the flow channel was 
constructed in SolidWorks. The resulting model was tested by computation fluid dynamics, 
calculating the shear stress at the channel floor, using the Flow Simulation package in 
SolidWorks. The bottom-less channel was manufactured by casting Polydimethylsiloxane 
(PDMS) on metal mould patterns. A PDMS cell seeding well was also manufactured by 
casting. Complementary multifunctional clamp-microscope holder metal parts were also 
fabricated. The geometry of the manufactured PDMS bottomless flow channel was verified 
with a confocal laser surface profiler. Primary endothelial cells were seeded, exposed to flow 
and imaged in this channel in order to validate the design for experiments with cells. 
The channel geometry, with a height decreasing following a square root function along the 
flow axis, was generated. Fluid dynamics flow simulations showed that the shear stress at the 
channel floor varies linearly along the axis of flow and remains constant across the width of 
the channel floor. The PDMS bottomless flow channels were manufactured along with 
PDMS seeding wells. Cells were seeded on a glass slide in the PDMS seeding well. Twenty-
four hours after cell seeding, the PDMS seeding well was replaced by the bottomless flow 
channel. The cell monolayer on the glass slide, inside the flow channel, was exposed to 
linearly increasing shear stress along flow axis for 24 hours. Next, cells were visualized by 
microscopy to confirm their presence; rendering the in-house designed flow device adequate 
for biomechanical in vitro cell experiments. 
The flow device was designed, manufactured and showed to be suitable for biomechanical 
studies on primary vascular cells. 
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 INTRODUCTION 3.2
3.2.1 Atherosclerosis and shear stress 
The second tool that was develop is a height-variance flow chamber which aids the exposure 
of vascular cells to linearly increasing shear stress along the length of the channel floor for in 
vitro cellular biomechanical studies. 
Such a device is needed because atherosclerosis has been observed to occur at specific, well 
defined sites in the arterial system: at bifurcations, side branches and curved vessel segments 
[15] and because at these areas, the blood flow patterns are irregular compared to straight 
vessel segments. More specifically, the shear stress exerted by the flow of blood on the inner 
lining (endothelium) of blood vessels is low or oscillatory low, compared to endothelial shear 
stress values from straight arterial segments of identical diameter [17, 21, 51, 599]. 
Therefore, low and oscillatory low shear stress is correlated with the development of 
atherosclerosis [21, 30].  
Numerous studies have been carried out to investigate the effect of atherogenic shear stress 
regimes on the cellular and molecular level (for a review cf. [18]). To simplify the study of 
shear stress at the cellular and molecular level, vascular cells have been isolated from 
mammalian organisms and cultured in vitro, reducing interference and effects from other cell 
types, from tissues and from paracrine and endocrine signalling molecules from the 
respective mammalian organism. In vitro cultured cells are either primary cells isolated from 
mammalian organisms or immortalized vascular cell lines.  
3.2.2 Shear stress generating flow devices 
In order to expose in vitro cultured cells to fluid flow, mimicking the physiological blood 
flow conditions, several techniques and devices have been developed which move the cell 
culture medium in contact with the relatively static vascular cell monolayer. This way, the 
flow of liquid exerts shear stress on cultured vascular cells, with magnitudes similar to the 
shear stress generated by the flow of blood in in vivo blood vessels. The techniques 
developed for exposing cultured cells to flow environments can be classified into the 
following main categories: parallel–plate flow chambers, orbitally shaken dishes, cone–plate 
viscometers, parallel disk apparatuses, radial flow devices, cylindrical tubes, annular flow 
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chambers, flow chambers with variable degrees of stenosis and linear shear-stress flow 
chambers. In the following paragraphs, these flow devoices will be briefly presented. 
The majority of studies that involve flow experiments on vascular cells utilize parallel–plate 
flow chambers [600-606]. As the name suggests, the liquid flows between two parallel plates 
and cells are seeded usually on the bottom plate, in contact with the liquid. In order to 
maintain uniform shear stress across the width of parallel plate flow channels, the height of 
the flow channel should be much smaller than the width and length of the channel, in practice 
a height : width ratio of at least 1 : 50 is used [606-608]. Parallel–plate flow chambers have 
the advantage of, firstly, being capable of delivering well-defined and constant shear-stress 
on cells over a defined time period. Secondly, parallel–plate flow chambers are relatively 
simple in design, assembly and operation. Thirdly, during the flow experiment, cells can be 
visualised under a microscope or visualised in real time, utilizing video microscopy (also 
known as live cell imaging). Fourthly, it permits continuous sampling of the culture medium 
for secreted metabolites [603, 606]. A disadvantage of parallel-plate flow channels is that it 
cannot be applied to study the effect of shear stress on cells that grow in suspension [606]. 
Parallel-plate flow channels are readily available from companies such as ibidi GmbH., 
Martinsried, Germany and CytoDyne, La Jolla, CA, USA.  
Endothelial cells have also been subjected to shear stress by culturing them in multi-well 
plates and by simply placing this endothelial cell containing multi well plate onto an orbital 
shaker [609-613]. By orbitally shaking the multi-well plate, the culture media waves around 
the wells [614, 615], exposing cells to shear stress which varies spatially across the bottom of 
the wells. The main advantage of exposing cells to shear stress using this approach is the 
simplicity of the method, without the requirement for sophisticated equipment. Orbitally 
shaken dishes have the disadvantages of not being capable of applying as well defined shear 
stress regimes as parallel plate flow channels and are not applicable for live cell imaging. 
Cone–plate viscometers [616-619] can be used to apply shear stress both to cells that grow in 
suspension and to cells that grow adhering to surfaces [606]. This device consists of a non-
moving bottom plate, on which cells growing on cover slips can be placed, and a cone which 
is placed above the plate. In between the plate and the cone, culture medium is inserted. 
Shear stress is applied to cells on the coverslip by spinning the cone, which in turn moves the 
liquid in between the plate and cone. By choosing a small cone angle (0.5–3 degrees) and by 
applying a constant, low rotational speed, the shear stress is nearly uniform across the bottom 
plate [620]. This apparatus is capable of producing laminar shear stress between 10
-3
 and 10 
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Pa and turbulent shear stress from 0.2 to 20 Pa [620]. The main advantages of cone-plate 
viscometers are, first, that there are no entrance and exit length, unlike in case of parallel-
plate flow chambers. Secondly, small changes in dimensions of the device do not lead to 
large changes in wall shear stress. Thirdly, several coverslips can be exposed to shear stress 
in one experiment. Fourthly, the operating fluid volume is relatively small [620]. Among the 
disadvantages of this apparatus are that it does not permit continuous sampling of the culture 
medium during the experiment, has significant medium evaporation, thus refiling with fresh 
medium during the experiment is required, and it is not compatible with live cell imaging 
[603, 607, 608]. Some of these disadvantages has been later overcome by modifying the 
design of the apparatus [621]. 
Parallel disk apparatuses are similar in construction and operation to cone–plate viscometers, 
with the difference that the cone is replaced with another disk, as the name indicates. By 
rotating the top disk, shear stress gradients can be applied to adherent cells across the surface 
of the bottom plate, if flow patterns are well defined [608, 622, 623]. The maximum reported 
wall shear stress that endothelial cells can be exposed to, using this device, is between 0.7–
1.5 Pa [623]. Parallel disk devices are not widely employed, because they present similar 
experimental problems to cone–plate viscometers [608]. Additionally, the device cannot be 
used to effectively expose endothelial cells to pathophysiological levels of shear stress [608, 
615]. By reducing the gap size in between the two plates, shear stress can be increased, 
however, with small gap sizes, cell viability have been observed to decrease, most probably 
because nutrients cannot reach the cells [623].  
Radial flow devices yield a spatially varying shear stress within the device during the same 
experiment at constant operating conditions [624, 625]. Radial flow devices were designed to 
solve some of the mechanical problems that were encountered with the spinning disk and 
cone systems [624]. These devices consist of two parallel stationary disks with a narrow 
spacing in between them. The bottom disk contains an inlet pipe in the centre where the 
tissue culture medium enters at a constant flow rate, flows radially out to a collection 
chamber and shears the cells seeded on the surface of the top disk [624, 626]. To allow 
visualization of cells under a microscope, transparent disk can also be used [625]. The flow 
of fluid in the radial direction produces a shear stress gradient across the top surface with 
shear stress decreasing with distance from the central inlet hole [624]. This device has been 
shown to produce shear stress in between 0 and 7 Pa [625, 626]. Radial flow devices have 
been mostly applyied to investiate adhesion and detachment of cells to and from surfaces, and 
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also to study ligand-receptor binding affinity [625-629]. An advantge of this system, 
compared to rotating cone and plate devices, is that parts are not moving, thus the frequency 
of sterility related problems is reduced and continous visulaization of the cells is easily 
achievable [624]. A common disadvantage of radial flow devices is that turbulent flow occurs 
at the central area, due to the inlet flow stream, thus shear stress is high and hard to predict in 
this area [624]. The area and pattern of turbulence can be manipulated by modifying the 
geometry of the inlet pipe and plate or by adjusting the volumetric flow rate [606, 624]. 
Another approach for exposing cells to shear stress is to seed cells in a cylindrical tube and to 
flow the culture medium across the tube using a pumping system [608, 630]. In case of fully 
developed, laminar, viscous flow inside cylindrical tube flow devices, the velocity profile is 
parabolic, and shear stress is zero along the centreline and highest at the walls [606]. 
Cylindrical tube flow devices, in general, produce higher shear stress compared to parallel 
plate flow chambers, but the tube must also be longer than the parallel plates [608]. 
Cylindrical tube flow devices have similar advantages and disadvantages as parallel plate 
flow chambers. An added disadvantage of the tube system is the difficulty in microscopic 
imaging, because the curved surface of the tube causes optical distortions [608]. Additionally, 
seeding cells in a monolayer on the inner wall on the tube is more difficult than seeding cells 
on a flat surface, especially when the inner diameter of the tube is small. Small variation in 
the radius of the cylindrical tube produces large changes in shear stress, since shear stress 
varies with the cube of the radius [608]. Based on the principle of cylindrical tube flow 
devices, several tubular perfusion systems have been developed [630-632].  
In annular flow chambers, blood vessel segments are exposed to flowing fluid (usually blood) 
[633-635]. For this, the vessel segment is turned inside out and wrapped around a rod. Thus, 
the endothelial cell layer covers the outside of the vessel, which covers the rod. The vessel-
covered rod is then placed inside a tube and fluid streams along the rod, forming an annulus. 
The main disadvantage of this technique is the difficulty in microscopy imaging. Moreover, 
only vessel of certain dimensions can be used and it is rather difficult to adopt this method for 
non-vascular materials [606].  
In order to study the effect of local flow disturbances on vascular cells, flow chambers with 
variable degrees of stenosis or expansion have been developed [636-640]. These flow devices 
are modifications of parallel plate flow chambers or cylindrical tube flow devices, and 
contain a recess or expansion in the flow channel [606]. A disadvantage of flow chambers 
with variable degrees of stenosis or expansion is that the flow patterns in the stenosis or 
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expansion area are complex and usually difficult to predict [606]. In one of these flow 
devices, peak shear stress values of 8 Pa and shear stress gradients of 250 Pa were produced 
[638]. Another group developed a parallel-plate perfusion chamber device to study thrombus 
formation at the "apex" of eccentric stenoses [640]. In this device the stenosis was formed by 
a gradual, rather than step, variation in the cross sectional area of the flow chamber [640]. 
The parallel plate flow chamber with divergent entrance and convergent exits has also been 
developed to generate spatially varying shear stress within the flow chamber [641].  
Finally, a linear shear stress flow chamber has also been designed to expose cells to linearly 
increasing shear stress along the centre line of the channel length, at constant flow rate, 
constant channel height, within the same flow field [642], [643]. This linear shear stress or 
tapered plate flow chamber is a modification of the parallel plate flow channel, in which the 
channel width varies along the channel length. At the bottom wall and near the channel 
outlet, shear stress does decrease linearly with distance from the inlet of the channel [606]. 
Using this width variance linear shear stress flow chamber, shear stress values of up to 4.5 Pa 
were achieved by Usami et al. [642] and Tsou et al., who adapted the same channel designed, 
generated shear stress of up to 2.5 Pa using their linear shear stress flow chamber [643].  
3.2.3 Need for an effective linear shear stress inducing flow channel 
In order to efficiently study the effect of shear stress caused by fluid flow on the endothelium, 
a flow chamber in which shear stress at the channel floor varies linearly along the axis of 
flow, without inducing shear stress variation across the width of the channel floor, is 
required. This flow channel should also allow the culture of endothelial cells on the channels 
floor under sterile conditions, their exposure to 0–10 Pa range of linearly increasing shear 
stress along the flow axis and imaging by fluorescent microscopy. To fulfil the need for such 
a flow chamber, the aim of the project presented in this third chapter is to design a flow 
channel which generates linearly increasing shear stress along the length of the channel floor 
in the range of 0–10 Pa. Additionally, this channel should also provide a large sampling area 
due to constant shear stress across the channel width, sterile operation and compatibility with 
standard light microscopes.  
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 MATERIALS AND METHODS 3.3
3.3.1 Design of linearly increasing shear stress inducing flow channel and 
validation by computational fluid dynamics 
A 3-Dimensional Computer Aided Design (3D CAD) model of a 0.5 cm wide, 5 cm long 
flow channel with a height varying along the channel length described by a square root 
function, was generated in SolidWorks 2012 version 20.0. The shear stress at the bottom wall 
of the channel (channel floor) in the resulting model was calculated using the Flow 
Simulation 2012 Computational Fluid Dynamics package in SolidWorks. For the flow 
simulation, the interior of the channel was selected as the computational flow domain. For 
boundary conditions, in the channel model there was one inlet, one outlet and all other 
boundaries were considered to be rigid and impermeable walls. The inlet flow rate was set to 
5 ml/min and at the outlet standard atmospheric pressure (1 atm = 101325 Pa) was modelled. 
Water at 20.05°C was used as the computational fluid; water was a close approximation of 
mammalian cell culture medium that was used in flow experiments in the actual experimental 
setup. For meshing, advanced geometry resolution and result resolution of 6 (out of 8, default 
value being 3) was used. Mesh refinement was automatically done by SolidWorks Flow 
Simulation package by dividing the computational domain into elementary rectangular 
volumes and subdividing these volumes into further elementary rectangular volumes in 
accordance with the results and geometry resolution settings. For validation, obtained flow 
velocities were compared to analytically calculated flow velocities. 
3.3.2 Manufacturing of linearly increasing shear stress inducing flow 
channel 
To manufacture the bottomless flow channel with the desired geometry, both 3D printing 
(also known as rapid prototyping) and casting were employed. Rapid prototyping and 
manufacturing of metal parts was carried out at the Mechanical Instrumentation Workshop, 
Department of Physics, Imperial College London. For 3D printing, FullCure720 rapid 
prototype resin was printed using an Objet Eden250 Professional 3D Printer in high quality 
printing mode which yields a resolution of 16 µm for the height of flow channel. For casting, 
both polydimethylsiloxane (PDMS) and thermosetting polyester (TPE) were separately 
poured onto metal mould patterns contained inside a petri dish. The fabrication of the metal 
mould parts is described in the section below. To cast the PDMS, first the elastomer 
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(monomer, base) was mixed with the curing agent at a 10:1 volumetric ratio. This solution 
was poured on top of the mould and was degassed in a vacuum chamber to remove air 
bubbles. Next, the degassed PDMS was cured at 60°C for 3 hours in an FMA-275 Grieve 
oven. After curing, the PDMS was detached from the metal mould to obtain the bottomless 
flow channel. The geometry of obtained flow channels was verified with a Xyris 4000 
Confocal Laser Surface Profiler from Taicaan Technologies. For TPE casting, 1 part of 
Methyl ethyl ketone peroxide catalyst was added to 100 parts of polyester resin, was mixed 
and briefly degased under vacuum and was cured at room temperature for 36 hours. After 
curing, the TPE was removed from the metal mould to obtain the bottomless flow channel. 
Fullcure720 (RGD720) rapid prototype resin was acquired from Stratasys Ltd., Edina, MN, 
USA. SYLGARD
®
 184 silicone elastomer PDMS kit was supplied by Dow Corning 
Corporation (MI, USA). Water clear casting TPE resin was provided by CFSNET Ltd. 
Redruth, Cornwall, UK. 
3.3.3 Manufacturing of metal mould parts for casting the linearly 
increasing shear stress inducing flow channel 
The curved channel height profile of the metal wedge mould was generated by high precision 
wire-cut electric discharge machining (EDM) using a Fanuc Robocut α-oic wire-cut electric 
discharge machine. At both ends of this wedge, round holes were drilled using a Bridgeport 
EZ vertical milling machine. Into these holes long cylinders were fixed using epoxy glue, to 
obtain inlets and outlets for flow in the casted channel. These long cylinders were cut using 
an Emcomat 14-D Lathe machine. The wedge with cylinders attached was then fitted into a 
base part into a rectangular hole cut with wire-cut EDM using the Fanuc Robocut α-oic 
machine. Exterior sides of this base part were cut using a Bridgeport EZ vertical milling 
machine. The material of metal parts was H30 6082T651 aluminium alloy acquired from 
Smiths Metal Centres Ltd., Biggleswade, UK. For metal-to-metal gluing, Loctite
®
 Epoxy 
Metal from Loctite
®
 Düsseldorf, Germany was used. 
3.3.4 Manufacturing of the cell seeding well 
To facilitate cell seeding a well was also created. The bottom of the well consisted of a 7.5 x 
2.5 cm standard plain microscopy glass slide. The 5.5 x 0.5 cm rectangular well was cut into 
the centre of a 7.2 cm long, 2.3 cm wide and 1 cm thick PDMS cuboid plate. By placing this 
PDMS piece on top of the glass slide, a 0.5 cm deep, 5.5 x 0.5 cm rectangular well was 
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obtained. This PDMS part was obtained by casting PDMS on a metal mould. The metal 
mould consisted of the wedge described in the section above, without placing this wedge into 
the 0.5 cm thick base part. This wedge was placed on the centre of a 7.5 x 2.5 cm standard 
plain microscopy glass inside a petri dish. For casting, first 9 volume parts of the monomer 
base were mixed with 1 volume part of the curing agent. This solution was poured onto the 
metal wedge mould inside the petri dish and PDMS was degassed in a vacuum chamber to 
remove air bubbles. Next, the degassed PDMS was cured at 60°C for 3 hours in an FMA-275 
Grieve oven. After curing, the PDMS was detached from the metal mould and exterior of the 
PDMS well part was cut and rectified with a SM0510 surgical scalpel blade from Swann-
Morton Ltd., Sheffield, UK. Shandon™ 1.0-1.2 mm thick, 76 x 26 mm plain microscopy 
glass slides (6776111) were purchased from Thermo Fisher Scientific Inc. Corning
®
 plain 
microscope glass slides (CLS294775X25-72EA) were ordered from Sigma-Aldrich Corp. 
3.3.5 Manufacturing of commentary equipment for the flow device 
Complementary metal parts for clamping the bottomless flow channel or seeding well to the 
glass slide, and for visualizing cells, cultured on the glass, under standard microscopes, were 
cut using the Bridgeport EZ vertical milling machine. To clamp the metal plates together with 
the bottomless flow channel and glass slide in between, standard metric M4 steel screws with 
M4 steel washers were screwed from the top of the device into the base plate. Holes for 
screws were drilled using the Bridgeport EZ vertical milling machine and the screw threads 
in the base plate were generated using a M4 x 0.70 threading and drilling hand-tool from 
Wiseman Threading Tools Ltd., Redditch, UK. The material of all generated metal parts 
except the screws and washers was H30 6082T651 aluminium alloy provided by Smiths 
Metal Centres Ltd., Biggleswade, UK. Standard metric M4 coarse thread high tensile steel 
screws and M4 stainless steel washers were provided by TR Fastenings Ltd., Uckfield, UK. 
3.3.6 Validation of the flow device by micro particle image velocimetry 
To experimentally measure flow velocities in our in-house designed flow channel, micro 
particle image velocimetry (µPIV) was used. For this, flow experiments were carried out 
under a Zeiss Axiovert 200 inverted microscope with a fully motorised stage, controlled by 
C-Imaging Simple-PCI acquisition software. The SJ-1220 Atto Bioinstrument peristaltic 
pump was circulating the liquid at the lowest operational flow rate, at 0.292 ml/min, in the 
linear shear stress inducing channel. The liquid in the flow setup was water, containing latex 
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beads of mean particle diameter of 1.0 μm and of a 1.0500 g/cm3 density and a 0.0025% 
(w/v) concentration. While running the flow, videos were recorded of flowing latex beads at 
locations 5 mm apart along the channel length at a height that corresponded to the middle of 
the channel in the lowest height area. In the last 5 mm in high shear stress region on the 
channel videos were recorded at locations at 1 mm increments. For video recording the 
Hamamatsu EM-CCD C9100-02 camera with a clock rate of 35 MHz per pixel and the 10X 
EC Plan-Neofluar 0.30 M27 objective was used on the bright field channel of the microscope. 
In order to increase the number of frames that can be recorded each second, the field of view 
was reduced to 500×125 µm. The highest frame rate that could be obtained was between 70-
80 frames per second. Recorder videos were analysed in Fiji v1.47f [644, 645] with the PIV 
analyser PlugIn [646]. Carboxylate-modified polystyrene latex beads (L4655) were supplied 
by Sigma-Aldrich Corp. 
3.3.7 Mammalian cell culture 
Primary porcine aortic endothelial cells (PAECs) were isolated and cultured as described in 
the Materials and Methods section of Chapter 4. For this project, PAECs at passage 3 have 
been thawed from frozen liquid nitrogen stocks as described in the Materials and Methods 
section of Chapter 2. 
3.3.8 Operation of the linearly increasing shear stress inducing 
microfluidics device 
The flow setup was similar to the one described in the Materials and Methods section of 
Chapter 2, with the exception of the flow channel and the complementary clamp-microscope 
holder. The PDMS flow channel, the PDMS seeding well, the complementary clamp-
microscope holder with screws (Figure 3.13), the bubble catcher media reservoir and 
platinum-cured silicone tubing was sterilized by autoclaving at 135 °C for 5 minutes in a 
MLS-3751L Sanyo autoclave. On the 7.5 x 2.5 cm standard plain microscopy glass slide, a 
7.5 x 2.5 cm layer of acrylic adhesive film was placed with a 0.5 x 6 cm well cut into its 
centre. The glass slide with the acrylic adhesive film on top was sterilized with 254 nm UV 
light for 4 hours. Working under sterile conditions, the glass slide with the acrylic adhesive 
film was placed in the metal holder, the PDMS seeding well was placed on top of the glass 
slide, aligning the well of the adhesive film with the well of the PDMS, the top metal slide 
was placed over the PDMS well and the two metal parts was screwed together applying even 
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torque. 150 µl of 1 mg/ml fibronectin solution was added to the obtained seeding well. The 
device was placed in a 1000 µl pipette tip box modified to accommodate the device and this 
box was placed in the cell culture incubator at 37 °C for 1 hour. After coating, the fibronectin 
solution was removed and PAECs were seeded at 40.000 cells/cm
2
 density in 500 µl of 
culture media. Twenty-four hours after cell seeding, the device was disassembled and the 
PDMS seeding well was replaced by the bottomless PDMS flow channel, screws being again 
evenly torqued. In order to account for the extra height (250 µm) introduced by the acrylic 
adhesive film, the PDMS bottomless flow channel had height by 250 µm less than it would 
have without the presence of the acrylic adhesive film. The culture media for flow 
experiments was pre-equilibrated in the cell culture incubator for 2 hours to temperature and 
gas concentrations required for cell growth. The tubing of the media reservoir, containing the 
pre-equilibrated media was connected to the cell containing flow channel, avoiding air 
bubbles. The flow setup was placed in the cell culture incubator and the pump head tubing 
was connected to the peristaltic pump. The Cobe precision peristaltic pump remained outside 
the incubator. 
The flow experiment was started by priming cells for 1 hour at 0 – 0.5 Pa shear stress, then 
the flow rate was gradually increased to yield the experimental 0.2 – 10 Pa shear over the 
following 2 hours and then maintained at the experimental level for 24, 36 or 48 hours.  
In all flow experiments the culture media was flowing from the media reservoir, through the 
flow channel to the pump and back to the media reservoir. At the end of the flow experiment, 
the pump was stopped, the pump was separated from the rest of the flow setup, the flow 
channel was dismounted and the slide was visualised under a microscope. The acrylic 
adhesive film (AB-0558) was purchased from Thermo Fisher Scientific Inc. 
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 RESULTS AND DISCUSSION 3.4
3.4.1 Design of linearly increasing shear stress inducing microfluidics 
device 
In order to efficiently study mechanosensing in endothelial cells, a flow channel in which 
shear stress increases linearly from near 0 to 10 Pa along the flow path is needed. To our 
knowledge, only the parallel plate flow channel designed by Usami et. al. [642] was built to 
satisfy this requirement. However, our flow simulations showed that the lower range on the 
shear stress does not come close to 0 and the shear stress range along the channel length is 
not wide enough, Figure 3.2. Furthermore, shear stress values are not uniform across the 
width of the channel, higher shear stress occurs in the width-wise centre of the channel. 
Because of this non-uniformity of shear stress across the channel width, the sampling area is 
reduced. Due to these, this parallel plate flow channel was not suitable for our applications. 
Thus, designing a flow channel to fulfil the need for a linear shear stress inducing flow 
channel was aimed in this chapter. 
To design our flow channel, instead of modifying the width of the channel, the channel height 
was intended to be altered. For this, the mathematical formula derived from the Navier–
Stokes equations by Usami et. al. [642] was applied, in order to relate shear stress values to 
the geometry of the channel, Equation 3.1. 
𝜏 =
6µ𝑄
ℎ2𝑤
(1 −
𝑧
𝐿
) 
 
Equation 3.1. Mathematical formula derived by Usami et. al. [642] to determine shear stress 
in function of channel geometry.  
Where:  
τ: shear stress along the centre line of the channel floor [dyn/cm2] 
 µ: dynamic viscosity of the fluid [dyn·s/cm
2
] 
 Q: volumetric flow rate [cm
3
/s] 
 h: height of the channel [cm] 
 w: width of the channel [cm] 
z: arbitrary position along the channel length measured from the channel entrance,               
    where L=0 [cm] 
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 L: total length of the channel [cm]. 
 
From Equation 3.1, the channel height was expressed in function of channel length-wise 
position, with position zero coinciding to L=0 cm where shear stress was also 0 dyn/cm
2
. 
This way, Equation 3.2 was obtained. 
ℎ =  √
ℎ1
2𝐿
𝐿 − 𝑧
 
Equation 3.2. Mathematical formula for channel height variation which yields linearly 
varying shear stress along the length of the channel floor. 
Where: 
h: is the height of the channel at an arbitrary position channel length-wise 
h1: is the lowest height of the channel, or exit height, where shear stress is maximum 
L: total length of the channel [cm] 
z: arbitrary position along the channel length measured from the channel entrance,               
    where L=0 [cm]. 
  
Using Equation 3.2 to generate the height profile of the channel, 4 different channels with 
lowest channel heights of 50, 100, 200 and 400 µm height were designed in SolidWorks. The 
channel with the 200 µm minimum height is shown in Figure 3.1 below.  
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Figure 3.1. The geometry of the flow channel for inducting linearly increasing shear stress, 
designed in SolidWorks. The lowest height of this channel (in the high shear stress region) is 
200 µm. 
 
The geometry presented in Figure 3.1 was obtained by optimizing the geometry and flow 
inlet and outlet angles based on flow simulations results, in an iterative manner. Table 3.1 
shows the relevant geometries for the channels with 200 and 400 µm minimum height in the 
high shear region. 
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Table 3.1. Characteristic geometries of the 200 and 400 µm minimum height flow channels 
Channel 
Channel 
length 
[cm] 
Channel 
width 
[cm] 
Maximum 
channel height 
[mm] 
Minimum 
channel height 
[µm] 
I/O 
angle* 
200 µm 
minimum height 
6 0.5 6.32 200 µm 90° 
400 µm 
minimum height 
6 0.5 12.65 400 µm 90° 
*the angle between the axis of the inlet or outlet ports and the channel floor. 
3.4.2 Validation of the flow chamber by flow simulations 
In order to evaluate the performance of flow channels, computational fluid dynamics was 
employed using the Flow Simulation package in SolidWorks 2012. First, the performance of 
the parallel plate flow channel designed by Usami et. al. was evaluated. As described in the 
previous section, results from this simulation were unsatisfactory, see Figure 3.2 below.  
 
 
Figure 3.2. Performance of the flow channel designed by Usami et. al. [642]. A. Illustration 
of the parallel plate flow channel. The width of the flow channel varies in order to modify 
flow velocities and consequently shear stress values. B. Variation of the shear stress along the 
length of the channel, in the width-wise middle of the channel floor. Flow simulation results 
obtained in SolidWorks at 5 ml/min flow rate. C. Variation of shear stress across the width of 
the channel, in the length-wise middle of the channel. Flow simulation results obtained in 
SolidWorks at 5 ml/min flow rate. 
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As part of the design cycle, fluid dynamics calculations were performed using SolidWorks’ 
Flow Simulation package in order to determine the shear stress on the channel floor, where 
cells are intended to be seeded. The interior of the channel (volume marked in red in Figure 
3.1) was selected as the computational flow domain. The hole at the maximum height area of 
the channel was set as the fluid inlet. The hole in the area where the height is minimal was set 
as the outlet. At the inlet, volumetric flow rate was varied between 1–100 ml/min and at the 
outlet standard atmospheric pressure (101325 Pa) was computed. Figure 3.3 below shows the 
shear stress map at the channel floor in the channel with 200 µm height in the high shear 
stress area. Here, it can be seen that the shear stress increased along the length of the channel 
and remained fairly uniform across the width of the channel.  
 
Figure 3.3. Shear stress map at the floor of the flow channel with 200 µm minimal height 
computed using SolidWorks Flow Simulation Package. The flow entered with a flow rate of 
10 ml/min at the high height end of the channel and the flow exited at the low height end of 
the channel. 
 
In order to more accurately show the shear stress at the channel floor, shear stress was plotted 
along a straight line drawn along the length of the channel floor, in the width-wise centre of 
the channel floor. Additionally, shear stress was also plotted on lines drawn across the 
channel width on the channel floor, in the length-wise centre of the channel floor. These 
plots, showing shear stress at the channel floor along the length of the channel and across the 
width of the channel are shown for 3 different flow rates in Figure 3.4 below for the channel 
with 200 µm minimal height. By varying the flow rate, the range of the shear stress varies, 
the shear stress in the low end of the range tends to zero whereas the shear stress at high end 
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of the range varies proportionally with the flow rate. In other words, by varying the flow rate, 
the low end of the shear stress range remains fixed at zero but the slope of the line on the 
shear stress versus channel length plot changes, modifying the high end of the shear stress 
range. The magnitude of shear stress always varied linearly along the length on the channel 
floor at these flow rates. Along the length, in the width-wise centre of the channel floor, shear 
stress peaks prominently at 5.5 cm, as visible in Figure 3.4A, C, E. This shear stress peak at 
5.5 cm channel length was caused by the increased flow velocity, due to the narrowing of the 
channel at the outlet hole, as shown in the channel geometry in Figure 3.1. Shear stress 
remains uniform across the width of the channel, giving a high sampling area in 
biomechanical cell experiments. Thus, our channel yielded linearly increasing shear stress 
along the length of the channel and uniform shear stress across the width of the channel, 
outperforming the previous design by Usami et. al. [642]. Shear stress varies linearly from 
zero up to a value dependent on the flow rate, making our channel suitable for shear stress 
biology studies at a range of shear stress chosen by the future user of this device in the range 
of 0–10 Pa.  
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Figure 3.4. Shear stress computed in SolidWorks along the length and across the width of the 
floor of the channel with 200 µm minimal height, at 3 flow rates. A. Variation of shear stress 
along the length of the channel floor, in the width-wise centre of the channel floor, at 5 
ml/min flow rate. B. Shear stress across the width of the channel floor, in the length-wise 
middle of the channel floor, at 5 ml/min flow rate. C. Shear stress along the length of the 
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channel floor, in the width-wise centre of the channel floor, at 10 ml/min flow rate. D. Shear 
stress calculation across the width of the channel floor, in the length-wise centre of the 
channel floor, at 5 ml/min flow rate. E. Evolution of shear stress along the length of the 
channel floor, in the width-wise centre of the channel floor, at 20 ml/min flow rate. F. Shear 
stress across the channel floor width, in the length-wise centre of the channel floor, at 20 
ml/min flow rate. 
 
Similarly to the computational fluid dynamics results presented in Figure 3.3 and Figure 3.4, 
flow simulations were also performed on the channel with 400 µm minimum height. The 
shear stress map at the floor of this channel is shown in Figure 3.5 below. This shear stress 
map shows that shear stress increased along the length of the channel and remained fairly 
uniform across the width of the channel. 
 
 
Figure 3.5. Shear stress mapped in SolidWorks at the channel floor of the flow channel with 
400 µm minimal height. The fluid flowed in at a rate of 40 ml/min at the high end of the 
channel and the fluid exited at the low end of the channel. 
 
As in case of the simulation from which results are presented in Figure 3.4, shear stress was 
computed along the length of the channel floor, in the width-wise centre of the channel floor 
for the flow channel with 400 µm minimal height. Shear stress was also calculated across the 
channel width, in the length-wise centre of the floor of the channel with 400 µm minimal 
height. Results are plotted in Figure 3.6 below at 3 different flow rates. Similarly to the 200 
Linearly increasing shear stress inducing flow device for in vitro cellular biomechanical studies 
251 
 
µm minimal height channel, in the 400 µm minimal height channel, shear stress also 
increases linearly along the channel length. The low end of the shear stress range tends to 
zero in the tested 10-100 ml/min flow rate range. Shear stress at the high shear region of the 
channel varies proportionally to the flow rate. Thus, by modifying the flow rate the 
experimenter can choose a shear stress range suitable for her or his purposes. Shear stress 
across the width of the channel floor remains uniform in the tested 10-100 ml/min flow rate 
range. In Figure 3.6, irregularities can be observed in the linearity of shear stress in function 
of channel length line. These irregularities were not visible in Figure 3.4 in case of the 200 
µm minimal height channel. There are two potential causes for these irregularities in Figure 
3.6. First, the channel might not produce the desired shear stress profile, due to the height of 
the channel. Second, these irregularities might be due to errors in the computational flow 
simulations, more specifically the meshing along the channel floor might not be optimal. 
However, these irregularities are insignificantly small and even if the shear stress profile of 
the channel is in fact as it is shown in Figure 3.6, the channel still fits our purposes. For these 
reasons, the cause of these irregularities was not further investigated. 
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Figure 3.6. Shear stress plotted along the length and across the width of the floor of the 400 
µm minimal height channel at 3 flow rates. A. Shear stress along the length of the channel 
floor, in the width-wise centre of the channel floor, at 20 ml/min flow rate. B. Shear stress 
across the width of the channel floor, in the length-wise middle of the channel floor, at 20 
ml/min flow rate. C. Shear stress along the length of the channel floor, in the width-wise 
centre of the channel floor, at 40 ml/min flow rate. D. Shear stress computed across the width 
of the channel floor, in the length-wise centre of the channel floor, at 40 ml/min flow rate. E. 
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Shear stress in function of the length of the channel floor, in the width-wise centre of the 
channel floor, at 80 ml/min flow rate. F. Shear stress across the channel floor width, in the 
length-wise centre of the channel floor, at 80 ml/min flow rate. 
 
It would be interesting to see whether the same shear stress profile is obtained when the flow 
direction is reversed in our channels. For this, similar fluid dynamics simulations were 
carried out in SolidWorks, with the difference of setting the flow inlet at the low height (high 
shear) end of our channels and applying atmospheric pressure at the outlet, at the high height 
(low shear) end of the channel. Figure 3.7 below shows the shear stress map obtained at the 
channel floor of the channel with 200 µm height in the high shear stress area, when the flow 
direction was reversed. This map revealed that shear stress decreased along the length of the 
channel and remained fairly uniform across the width of the channel, similarly to the case 
when the liquid was flowing in the opposite direction. 
 
 
Figure 3.7. Shear stress map at the floor of the flow channel with 200 µm minimal height, 
reversed flow direction. The fluid flowed in with a rate of 10 ml/min at the low height end of 
the channel and the fluid exited at the high height end of the channel, where standard 
atmospheric pressure (101325 Pa) was applied. 
 
As previously described in Figure 3.4, shear stress was plotted in function of channel length, 
at the width-wise centre of the channel floor for the flow channel with 200 µm minimal 
height, when the flow entered at the low height end of the channel and exited at the low 
height end of the channel; reverse flow direction compared to Figure 3.4. Shear stress was 
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also calculated across the channel width, in the length-wise centre of the floor of the channel 
with 200 µm minimal height. Resulting plots are shown below in Figure 3.8 at 3 different 
flow rates. Thus, when reversing the flow direction, the linearity of the shear stress along the 
channel length was maintained in the 5–20 ml/min flow rate range. The low end of the shear 
stress range was still tending to zero. The slope of shear stress plotted against the channel 
length and high end of the shear stress range were varying proportionally with the flow rate. 
Shear stress across the width of the channel floor remained uniform in the tested 5–20 ml/min 
flow rate range. These results show that the flow direction can be reversed in our channel 
with 200 µm minimal height, without modifications in the shear stress profile. 
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Figure 3.8. Shear stress plotted along the length and across the width of the floor of the 200 
µm minimal height channel at 3 flow rates, when the flow entered at the high height end and 
exited at the low height end of the channel. A. Shear stress along the length of the channel 
floor, in the width-wise centre of the channel floor, at 5 ml/min flow rate. B. Shear stress 
across the width of the channel floor, in the length-wise middle of the channel floor, at 5 
ml/min flow rate. C. Shear stress along the length of the channel floor, in the width-wise 
centre of the channel floor, at 10 ml/min flow rate. D. Shear stress computed across the width 
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of the channel floor, in the length-wise centre of the channel floor, at 10 ml/min flow rate. E. 
Shear stress in function of the length of the channel floor, in the width-wise centre of the 
channel floor, at 20 ml/min flow rate. F. Shear stress across the channel floor width, in the 
length-wise centre of the channel floor, at 20 ml/min flow rate. 
 
Part of this systematic process of characterizing channels with 200 and 400 µm minimum 
height for both direct and reverse flow direction, flow simulation were also carried out in 
order to map the shear stress at the floor of the 400 µm minimum height channel when the 
flow entered at the low height end and exited at the high height end of the channel. The shear 
stress map resulting from this fluid dynamics computation in SolidWorks is shown in Figure 
3.9 below. 
 
Figure 3.9. Shear stress map at the channel floor of the flow channel with 400 µm minimal 
height, reversed flow direction. The fluid flowed in with a rate of 40 ml/min at the low height 
end of the channel and the fluid exited at the high height end of the channel, where standard 
atmospheric pressure (101325 Pa) was considered. 
 
Next, shear stress was plotted against channel length, on the width-wise centre line of the 
channel floor in the channel with 400 µm minimal height when the flow was entering at the 
low height end of the channel and was exiting at the high height end of the channel. Shear 
stress was also plotted across the width of the same channel under identical flow conditions, 
in the length-wise centre of the channel. Results are shown in Figure 3.10 below. These plots 
show that, when reversing the flow direction in the 400 µm minimal height channel, the 
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linearity of the shear stress in function of channel length was maintained in the 20–80 ml/min 
flow rate range. The low end of the shear stress range was still tending to zero. The slope of 
shear stress plotted against the channel length and high end of the shear stress range were 
varying proportionally with the flow rate. Shear stress across the width of the channel floor 
remains uniform in the tested 20–80 ml/min flow rate range. As the flow rate increases, a 
spike was appearing at the high shear stress end on the shear stress vs channel length plot. 
This high shear stress spike appears at the flow inlet, where flow enters the channel 
perpendicularly; the 90° change in flow direction and the narrow channel geometry was most 
probably responsible for this high shear stress spike. However, the linearity of shear stress in 
function of channel length was fairly well maintained in the sampling area (channel floor in 
between the inlet and outlet hole) of the channel. Additionally, it is worth noticing that shear 
stress does not reach the 10 Pa value in the reverse flow simulation at 80 ml/min flow rate as 
it does in the direct flow scenario (Figure 3.6) at the same flow rate. In order to reach the 10 
Pa shear stress value in case of reversed flow, the flow rate should be slightly increased. 
These results show that the flow direction can be reversed in our channel with 400 µm 
minimal height, without significant modifications in the shear stress profile. 
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Figure 3.10. Shear stress plotted along the length and across the width of the floor of the 400 
µm minimal height channel at 3 flow rates, when the flow entered at the high height end and 
exited at the low height end of the channel. A. Shear stress along the length of the channel 
floor, in the width-wise centre of the channel floor, at 20 ml/min flow rate. B. Shear stress 
across the width of the channel floor, in the length-wise middle of the channel floor, at 20 
ml/min flow rate. C. Shear stress along the length of the channel floor, in the width-wise 
centre of the channel floor, at 40 ml/min flow rate. D. Shear stress computed across the width 
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of the channel floor, in the length-wise centre of the channel floor, at 40 ml/min flow rate. E. 
Shear stress in function of the length of the channel floor, in the width-wise centre of the 
channel floor, at 80 ml/min flow rate. F. Shear stress across the channel floor width, in the 
length-wise centre of the channel floor, at 80 ml/min flow rate. 
 
Fluid dynamics flow simulations were performed in SolidWorks on channels with height in 
high shear region (lowest channel height) of 50, 100 µm heights and similar results were 
obtained. These fluid dynamics simulations showed that our channels with minimum heights 
ranging from 50 to 400 µm, yield linearly increasing shear stress along the length of the 
channel floor, maintaining uniformity of shear stress across the width of the channel floor, 
both for direct and reverse flow directions. Thus, our height-varied design outperformed 
existing width-varied channel designs. 
3.4.3 Manufacturing of linearly increasing shear stress inducing 
microfluidics device 
Once our design was validated by flow simulations in SolidWorks, options to manufacture a 
prototype of our channel were considered. First, it has been decided to generate a channel 
which can be assembled from two components: a bottomless flow channel and a glass slide. 
The bottomless channel with varying channel height mounted on top of a glass would form 
the closed channel. Microscopy glass slides were readily available. To manufacture the 
bottomless channel two different techniques were employed: 3 dimensional (D) printing (also 
known as rapid prototyping) and casting. For 3D printing, the channel geometry generated in 
SolidWorks was printed out on an Objet Eden250 Professional 3D Printer using FullCure720 
rapid prototype resin. An image of the manufactured channel is shown below in Figure 3.11. 
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Figure 3.11. Image of the 100 µm minimal height channel manufactured by 3 dimensional 
(D) printing (also known as rapid prototyping), using FullCure720 rapid prototype resin 
printed out on an Objet Eden250 Professional 3D Printer. 
 
To cast the channel, negative mould patterns were first manufactured from aluminium as 
illustrated in Figure 3.12 below. First, a wedge was cut out from a 0.5 cm thick aluminium 
plate (W1), as shown in the upper part of Figure 3.12 in blue. The wedge was flipped 90° as 
shown in the transition from W1 to W3. At both ends of the W1 part, round holes were 
drilled into which long cylinders were glued (W4) to obtain flow inlets and outlets in the 
casted channel. Next, a rectangular hole was cut into an aluminium plate (B1) to obtain the 
base part (B2) shown in the bottom left part of Figure 3.12 in yellow. Finally, the base part 
(B2) was assembled with the wedge (W4), as illustrated in the bottom right corner of Figure 
3.12, in the transition from M1 to M2. This way the negative mould was obtained to cast the 
channel with varying height and 0.5 cm constant width. The height of the mould that casts the 
minimum height of the channel was verified with a Xyris 4000 Confocal Laser Surface 
Profiler. 
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Figure 3.12. Manufacturing of the negative mould for casting the bottomless channel. Top: a 
0.5 cm thick aluminium plate (W1) was cut to obtain the a wedge part (W2), which was then 
flipped 90° (W3), holes were drilled at its both ends into which aluminium cylinders were 
glued (W4). Bottom left: a 0.5 cm thick aluminium plate (B1) was cut a rectangular hole into 
to obtain the base part (B2). Bottom right: the wedged (W4) was assembled (M1 → M2) with 
the base part (B2), to obtain the final mould (M2) for casting.   
The obtained mould (M2) was placed into a well (or a Petri dish), on top of glass slide, the 
casting material was prepared and was poured on top of the mould. The casting material was 
cured in the oven after which it was separated from the mould to obtain the bottomless flow 
channel. When necessary, the outer edges of the channel were trimmed. Two different casting 
materials were used and evaluated: polydimethylsiloxane (PDMS) and thermosetting 
polyester (TPE).  
Table 3.2 below shows relevant manufacturing parameters and properties of the channels 
obtained with three different manufacturing methods. Manufacturing time, cost and accuracy 
is superior in case of the casting process compared to 3D printing. Out of the 3 channels, only 
the PDMS one was sterilizable by autoclaving. When the 3D printed channel was autoclaved 
the channel changed shape, and TPE melted under autoclaving conditions. Ethanol 
sterilization proved applicable for the 3D printed channel, however, TPE dissolved when 
submerged in 70% ethanol. The smoothness of the channel ceiling (surface finish) in case of 
casting depends on the negative mould. Casting yielded a smoother surface finish compared 
to rapid prototyping. Since cells in these channels would be imaged under the fluorescent 
microscope, the autofluorescent properties of these channels were also examined. For this, 
channels were looked at under the fluorescent microscope, using the three filters that would 
be used in experiments: GFP, DAPI and DsRED. The FullCure720 rapid prototype resin of 
the 3D printed channels emitted bright (white) light under all three fluorescent filters, 
showing a strong autofluorescence, rendering the channel unsuitable for imaging under the 
fluorescent microscope. The TPE channel yielded weak autofluorescence under the DAPI 
filter and strong autofluorescence under the DsRED filter. Out of the 3 channels, only the 
PDMS channel was suitable for fluorescent imaging using all three fluorescent filters. Based 
on the comparison of relevant properties of the 3 manufacturing procedures and of the 
resulting channels, PDMS casting yielded the best outcome: low manufacturing cost and 
time, high manufacturing accuracy and surface finish and very low autofluorescence. 
Therefore, proceeding with manufacturing the channels by casting in PDMS has been 
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decided. Channels with heights in the high shear stress region (lowest channel height) of 50, 
100, 200 and 400 µm were manufactured. 
  
Table 3.2. Comparison of relevant properties of channels obtained with 3 manufacturing 
methods. 
 Rapid Prototyping PDMS casting TPE casting 
Manufacturing 
Cost 
£90 per channel £5–7 per channel* <£1 per channel* 
Manufacturing 
Time 
1–2 days 3–4hrs* 1–2hrs* 
Manufacturing 
Accuracy 
42 µm in X axis 
84 µm in Y axis 
16 µm in Z axis 
Subject to mould  
(<5 µm) 
Subject to mould  
(<5 µm) 
Autoclavability No (Warping) Yes No 
Surface Finish 
(low shear 
region) $ 
   
Surface Finish 
(medium shear 
region) $ 
   
Surface Finish 
(high shear 
region) $ 
   
Autofluorescence 
GFP filter,  
4900 ms 
exposure time ¥ 
   
Autofluorescence 
DAPI filter,  
200 ms exposure 
time ¥ 
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Autofluorescence 
DsRED filter, 
4100 ms 
exposure time ¥  
   
    * referring exclusively to the casting procedure, without considering the manufacturing of         
       the negative mould. 
    
$
 10X objective used for imaging, surface finish on the channel ceiling is shown. 
      ¥  
5X objective used for imaging. 
3.4.4 Design and manufacturing of commentary equipment for the flow 
device 
To assemble the bottomless channel to the glass slide, complementary clamping–holding 
equipment was designed and manufactured by cutting from aluminium. The complementary 
equipment and the assembly of the channel are shown below in Figure 3.13. As illustrated in 
Figure 3.13A, the complementary equipment consists of two metal plates which hold the 
glass slide together with the bottomless flow channel. The bottom metal plate has the 
dimensions of a standard multi well plate, 127.8×85.5 mm, thus conveniently fitting into 
standard microscope stage holders. In the centre, it contains a 77×27 mm slot where standard 
75×25 mm microscopy slides were placed. The corners of this slot are extended to facilitate 
easy handling of the glass slide. To allow visualising under the microscope, a 68×8 mm hole 
was cut into the centre of the glass slide fitting slot. This base plate also contains screw 
threaded holes, into which standard metric M4 steel screws, passing through the top plate, 
were fastened. On top of this aluminium bottom plate, inside the slot, the standard 75×25 mm 
microscopy slide was placed. On top of the glass slide, the bottomless flow channel was 
mounted. The top aluminium plate was positioned above of the bottomless flow channel and 
6 standard metric M4 steel screws went through the top aluminium plate and screwed into the 
bottom plate to seal the channel. Edges of both the bottom and top aluminium plates were 
rounded to minimize scratch and prick related injuries. The manufactured and assembled 
device is shown in Figure 3.13B. 
In order to facilitate the seeding of cells on the glass slide, during the cell seeding process, a 
PDMS cell seeding well was used, with geometry similar to part B2 from Figure 3.12. This 
PDMS seeding well was used instead of the bottomless channel to obtain uniform cell 
seeding densities along the surface of the cell seeding area. Cell seeding in the bottomless 
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channel, would have had yielded high cell densities in the high channel height region, where 
the height of the cell suspension volume is high, and low cell densities in the low channel 
region, where a lower cell suspension volume and cell amount would be present per unit area. 
Twenty-four hours after cell seeding, this cell seeding well was replaced with the bottomless 
flow channel. Cell seeding was not possible directly in the channel since the varying height 
would have yielded non-uniform cell seeding densities along the length of the channel, high 
cell densities in the low shear region and low cell densities in the high shear region, would 
have had been obtained. 
 
A 
B 
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Figure 3.13. Complementary equipment and the assembly of the flow device. A. Illustration 
of the device parts. From the bottom: microscope holder and bottom clamp plate; microscopy 
glass slide on which cell are seeded and which constitutes the bottom of the flow channel; 
bottomless flow channel; top clamp plate; screws which fit into the bottom plate. B. The 
manufactured and assembled flow device. 
3.4.5 Validation of the flow device by flow experiments 
After the flow device has been designed and manufactured, it was tested for leakiness by 
connecting the channel to the media reservoir and Cobe precision peristaltic pump through 
tubing. In the media reservoir, 60 ml of 0.01% (w/v) trypan blue solution was placed. This 
blue coloured solution was circulated in the flow setup by running the pump at 10–50 ml/min 
flow rates for 6 hours. The flow setup, except the pump, was placed inside the incubator and 
a white paper tissue was placed beneath the flow channel to blot and observe any blue trypan 
blue solution that would leak out of the channel. After circulating the liquid through the setup 
for 6 hours, no leakage of the trypan blue solution could be observed.  
We have tried carrying out micro particle image velocimetry (µPIV) in order to determine the 
flow velocities in different parts of the channel and determine whether these experimentally 
determined flow velocities differ from flow velocities obtained by fluid dynamics 
computations in SolidWorks. Based on experimentally determined flow velocities, shear 
stress could be calculated at regularly selected locations along the length of the channel floor 
and compare these with shear stress values predicted by flow simulations in SolidWorks. 
Thus, a flow experiment was set up under a light microscope that was equipped with the 
fastest camera that was accessible. The highest framerate of the camera was unknown prior to 
starting the µPIV experiments, since the framerate could be increased by decreasing the field 
of view. Thus, the camera was tested under our experimental conditions. In the flow fluid, 1 
µm diameter latex beads were suspended. The smaller and slower Atto peristaltic pump was 
run at the lowest possible flow rate. Unfortunately, even at this low flow rate, the frame rate 
of the fastest accessible camera proved to be low for tracking the movement of individual 
particles. The highest frame rate that the camera could achieve was 70–80 frames per second 
and approximately 200 frames per second frame rate would have had been required for our 
application. Particle velocities from recorded videos were analysed in Fiji with PIV PlugIn, 
without success, due to the low frame rate of the camera. Thus, it has been decided not to 
invest more time and effort into validating our flow channel using µPIV. 
Linearly increasing shear stress inducing flow device for in vitro cellular biomechanical studies 
266 
 
Next, flow experiments were carried out using Porcine Aortic Endothelial cells (PAECs) at 
passage 3 in the flow device to determine whether the flow device was suitable for cell 
experiments. The main concern was whether cells will be present without contamination after 
24 or 48 hours of flow exposure in our in-house developed device. For this, cells were 
cultured in the seeding well which was pre-coated with 1 mg/ml fibronectin solution. 
Twenty-four hours after seeding, the PDMS well was replaced with the PDMS bottomless 
channel and the flow channel was connected to the rest of the flow setup, avoiding air 
bubbles. The flow experiment was started by running the pump at 2–3 ml/min flow rate in the 
first hour of the experiment to allow the cells to adjust to the flow condition. Over the course 
of the following two hours, the flow rate was gradually increased to reach the value which 
yielded 0–10 Pa shear stress along the length of the channel floor. After a period of twenty 
four hours of flow exposure, the pump was stopped, the setup was disassembled and cells 
were imaged. Recorded microscopy images are shown below in Figure 3.14. It can be seen 
that cells were present after 24 hours of flow exposure in our in-house build device. Below 
1.5–2 Pa shear stress, cells were not aligned to the flow direction, however above 1.5–2 Pa 
shear stress cells started to align and cells showed flow alignment up to shear stress values of 
8 Pa. Above 8 Pa of shear stress, cells started to detach from the glass slide and washed away. 
The flow alignment and cell detachment at high shear stress occurred at the expected shear 
stress values, additionally indicating that our flow device delivers the computed shear stress 
values.    
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Figure 3.14. Phase contrast microscopic images of PAECs exposed to linearly increasing 
shear stress along the length of the channel floor in our in-house designed flow device. Cells 
were seeded in the PDMS seeding well coated with 1 mg/ml fibronectin. 24 hours after 
seeding, the PDMS seeding well was detached from the glass slide and was replaced with the 
PDMS bottomless flow channel. Next, the flow experiment was started with lower flow rate 
in the initial two hours and maintained at 0–10 Pa yielding flow rate thereafter for 24 hours. 
The presence of cells and flow alignment starting above 1.5 Pa confirmed the success of our 
in-house designed channel.     
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 SUMMARY AND FUTURE WORK 3.5
3.5.1 Summary 
The 3D CAD model of the flow channel with 0.5 cm width, 5 cm length and with height 
varying along the channel length described by a square root function, was generated in 
SolidWorks. Shear stress at the bottom wall (channel floor), computed in SolidWorks’ Flow 
Simulation Package, was linearly increasing along the channel length and shear stress was 
uniform across the width of the channel. By modifying the flow rate, the linearity of shear 
stress increase along the channel length was maintained. The shear stress in the low shear 
(high channel height) area tended to zero in the tested 1–10m ml/min flow rate range, while 
the shear stress in the high shear stress (low channel height) area varied proportionally with 
the flow rate. Therefore, cells can be exposed to linearly increasing shear stress along the 
channel length and the obtained sampling area is high, due to the uniformity of shear stress 
across the channel width. Channels with heights in the high shear stress region ranging from 
50 to 400 µm were designed and validated by flow simulations. 
To obtain the physical flow channel with this rather complex geometry, two separate, 
assemblable parts were used: a glass slide on which cells were seeded and a bottomless flow 
channel. Two different manufacturing methods, 3D printing and casting, were employed in 
order to identify the bottomless channel fabrication process that yielded the most ideal 
outcome. Casting was performed using two different materials: polydimethylsiloxane 
(PDMS) and thermosetting polyester (TPE). Casting in PDMS yielded the channel with the 
best properties (low manufacturing cost and time, high manufacturing accuracy and surface 
finish and very low autofluorescence). Channels with heights in the high shear stress region 
ranging from 50 to 400 µm were manufactured. A PDMS part which forms a well when 
mounted on the glass slide was also designed and manufactured in order to facilitate the 
seeding of cells on the glass slide. After cell seeding, the PDMS well part could be replaced 
with the bottomless flow channel to expose cells to shear stress.  
Complementary equipment that clamps the bottomless channel to the glass slide and 
facilitates visualization under conventional microscopes was designed in SolidWorks and was 
manufactured. The complementary equipment consisted of two metal plates in between 
which the bottomless flow channel is mounted on top of the glass slide and the two metal 
plates were held together by screws. Both metal plates contained an opening in the channel 
Linearly increasing shear stress inducing flow device for in vitro cellular biomechanical studies 
269 
 
area to allow light to pass through the equipment for visualization of cells under microscopes. 
The bottom metal plate was designed to fit into the stage of conventional microscopes. These 
two metal plates were designed by cutting from aluminium.    
After the flow channel and complementary equipment was manufactured, the setup was first 
tested for leakiness and no leakiness was observed. Next, cells were seeded in the PDMS 
seeding well mounted on the glass slide with the aid of the complementary clamping 
equipment. Twenty four hours after cell seeding, the PDMS seeding well was replaced with 
the bottomless flow channel and cells were exposed to shear stress ranging 0–10 Pa along the 
channel length. After 24 hours of flow exposure, cells were imaged under a phase contrast 
microscope. The presence of contamination-free cells up to 8 Pa of shear stress, and their 
alignment to the flow direction above 1.5 Pa confirmed the applicability of the in-house 
designed setup for flow experiments on mammalian vascular cells. 
3.5.2 Future Work 
In order to faster and more conveniently assemble and disassemble of the flow device, a lever 
based clamping system could be designed and implemented. The clamp could be tightened by 
pushing the lever downwards towards the bottom plate and the clamp could be loosened and 
disassembled by lifting the lever up. By replacing the screw based clamping system with the 
lever based one, clamping could be performed considerable faster, thus, decreasing cell death 
rate during this process.   
If a microscopy camera capable of capturing at least 200 frames per second becomes 
available, micro particle image velocimetry could be carried out in order to determine how 
well do the computationally predicted flow velocities compare to the experimentally 
determined flow velocities. 
If PDMS bottomless flow channels of different designs are needed to be manufactured in the 
future, the negative mould could be printed out using a 3D printer. The entire negative mould 
could be printed out as one piece, without the need of subsequently assembling the mould 
from parts as it was done in case of the negative metal moulds. In order to smoothen the 
surface of the 3D printed mould, polishing, abrasion or grinding could be applied. The 
geometry of the smoothened 3D printed mould, could be verified by the optical profiler. This 
way, the casted PDMS parts will become smooth and will properly adhere to the glass slide, 
preventing leakage. 
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Oxygen plasma treatment of PDMS and glass slide could result in sealing the PDMS 
bottomless flow channel to the glass slide [647] without using the complementary clamping 
system. During oxygen plasma treatment, the methyl groups (–CH3) of PDMS are converted 
into hydroxyl groups (–OH) [647]. The resulting silanol (Si–OH) coated surface is 
hydrophilic and siloxane (Si–O–Si) bonds form in between plasma treated PDMS and glass, 
with the loss of a water molecule (dehydration synthesis) [647]. Oxygen plasma treatment 
levels (mainly plasma intensity and exposure time) could be optimized in order to reduce the 
proportion of silanol (Si–OH) groups which in order to reversibly bind the PDMS cell 
seeding well part to the glass slide. Thus, after cell seeding, this PDMS seeding well could be 
replaced with the PDMS bottomless flow channel.  
In order to carry out a large number of flow experiments in parallel, tens of narrow PDMS 
flow channels with height variance that yields linearly increasing shear stress along the 
channel length, could be fitted onto a single glass slide. This would considerably increase the 
throughput of the experiments, when for example compounds that modify the activity of 
shear stress sensors would be screened for. However, this task remains challenging, since in 
flow experiments the culture media recirculates and separate media circuits would be 
necessary for each flow channel in order to avoid mixing of compounds. Furthermore, 
ideally, each circuit would need a separate pump-head, increasing the number of necessary 
pumps. Without recirculation, large media volumes (in the order of litres) would be required 
with larger compound quantities to carry out a 24 hour flow experiment, whereas such 
compounds are usually available at low quantities at high prices. For this application, a 
possible solution would be to use the commercially available BioFlux multiwell plate based 
microfluidics device with flow channels at the bottom of the plate in between wells, from 
Fluxion Biosciences, San Francisco, CA, USA. This device, however, would not be capable 
of delivering linearly increasing shear stress along the channel length. Further work is needed 
to design and manufacture such a high-throughput linear shear stress inducing microfluidics 
device. 
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 ABSTRACT 4.1
Shear stress and other biochemical signals are mediated and processed by complex and 
interconnected signal-transduction pathways, which are not fully understood. To characterize 
these extremely complex signalling pathways, high throughput systems are required that can 
add functions (gain-of-function) and delete functions (loss-of-function) from primary cells by 
inserting cDNA and/or siRNA, respectively. Furthermore, in order to mimic physiologically 
relevant conditions, such as blood flow, cells need to be exposed to biomechanical stimulus. 
Thus, the project presented in this chapter aims to design and evaluate a device for 
electroporation transfection and for applying biomechanical stimulus in the form of fluid 
shear stress to primary adherent cells. 
Primary mammalian endothelial cells were electroporated in adherent state with siRNA using 
in-house designed electroporation devices. Following electroporation with fluorescently 
labelled siRNA, cells were imaged with fluorescent microscopy. After transfection with anti-
KLF2 (necessary for flow alignment) siRNA (siKLF2), cells were exposed to 1.5-2 Pa shear 
stress for up to 48 hours and cell morphology changes caused by electroporation and fluid 
flow were monitored using phase contrast microscopy and quantified by image analysis. 
KLF2 mRNA levels were quantified by reverse transcription real-time polymerase chain 
reaction (qPCR). 
Electroporation with our device of hard-to-transfect endothelial cells yields siRNA 
transfection efficiencies of 70%, while keeping cell viability above 95%. Electroporation 
with siKLF2 and exposure to physiological levels (1.5-2 Pa) of shear stress for 24 hours 
followed by quantitative image analysis of microscopic images, showed the loss of cell 
alignment in endothelial cells. Furthermore, quantification of mRNA by qPCR revealed a 
52% KLF2 down-regulation in siKLF2 electroporated sheared cells compared to non-
electroporated sheared cells. 
This novel electroporator yielded high transfection efficiencies for hard-to-transfect seeded 
primary cardiac cells, being able to deliver siRNAs that deleted the flow alignment function 
from primary endothelial cells. The electroporator was shown to be flow-compatible, opening 
avenues for signalling pathways studies in cardiac cells under physiologically relevant 
mechanical and flow conditions as well as in complex chemical environments. 
 
In-situ electroporation and flow device for mechanotransduction systems biology studies 
273 
 
 INTRODUCTION 4.2
4.2.1 Signal transduction 
The third tool that was developed is an electroporation and flow device, which facilitates the 
study of cardiovascular signal transduction pathways. 
In fact, besides cardiovascular signal transduction, the ability of cells in general to receive 
and respond to external chemical and physical signals is fundamental to all three domains of 
life (Archaea, Bacteria and Eukaryota). Chemical signals consist of molecules or atoms, both 
with electrical charge (ions) and without electrical charge, which either bind to 
transmembrane proteins embedded in the plasma membrane or enter the intracellular space 
by directly traversing the plasma membrane. In the first case, the binding of extracellular 
molecules or atoms (extracellular ligands) triggers a conformational change of the 
transmembrane proteins, which can subsequently activate a cascade of protein interactions 
within the cell. This intracellular signal transduction couples to gene expression regulators 
and eventually gene activity is modified, by up- or down-regulating gene expression. Upon 
ligand binding, some transmembrane proteins can also fold into a channel conformation, 
allowing atoms and molecules to pass through this channel, in addition to other molecules 
that diffuse through the lipid bilayer. In the second case, when signalling molecules enter the 
intracellular space by traversing the plasma membrane (either by passing the lipid bilayer or 
transmembrane protein channels), chemical signals are directly transduced to intracellular 
proteins that directly or indirectly (through other intermediates) modify gene activity. Thus, 
chemical signals are mediated by signal-transduction pathways which modify gene 
expression to govern cellular functions.  
Similarly, physical signals can also couple to molecular circuits that detect, amplify and 
integrate diverse external signals and modify gene expression patterns. The physical signals 
that cells sense and respond to include temperature, electromagnetic radiation (e.g. visible 
light), electrical potential, magnetism, and mechanical factors (pressure, force, strain and 
shear stress). The important role of mechanical factors on cellular and molecular processes is 
increasingly being recognized, and has led to the emerging field of mechanobiology. 
Mechanical stimulus is mediated by signal-transduction pathways to control functions such as 
cellular cell division, gene expression, cell migration, morphogenesis, cell adhesion, fluid 
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homeostasis, ion channel gating, vesicular transport [648-650], and a variety of diseases, 
including hypertension and atherosclerosis [651]. 
4.2.2 Bio-mechanical factors and atherosclerosis 
The crucial importance of identifying (mechanical) factors in the development and 
progression of atherosclerosis is of particular interest due to the extremely high human 
mortality rates caused by this condition. Atherosclerosis is, by far, the most important 
contributor to cardiovascular diseases, and cardiovascular diseases are the leading cause of 
death globally [6-8]. Atherosclerosis occurs in blood vessels (arteries) that transport 
oxygenated blood and nutrients (including lipids) from the heart towards the tissues and 
organs of the body, and causes sclerosis (or hardening) of the arterial wall, hence its name. 
Atherosclerosis is a lipid driven, chronic inflammatory disease leading to plaque formation 
and through plaque rupture, can cause heart attack, stroke, gangrene and loss of function in 
the extremities [652]. The progression of atherosclerosis has been associated with certain risk 
factors, including: hypercholesterolemia, hypertension, diabetes, obesity, cigarette smoking, 
inflammatory biomarkers, and others [14]; these risk factors also guide the diagnosis and 
treatment of the disease. In spite of the fact that the above mentioned risk factors are 
omnipresent in the entire arterial system, atherosclerosis evolves at well-defined sites such as 
curved vessel segments, bifurcation and side branching points [653-655]. 
It has been postulated that disturbances of the blood flow pattern at or near these 
atherosclerosis predilection sites play a crucial role in the initiation and progression of 
atherosclerosis (for reviews see [18, 402, 656]). While early studies [657, 658] focused on the 
role of blood flow in the initiation of the disease, recent studies also suggests an important 
role of blood flow in advanced stages of atherosclerosis [659], the formation of vulnerable 
plaques [30, 659-661], in-stent restenosis [662, 663], and inflammation and plaque formation 
[30, 664, 665]. As a consequence, the theory relating bloody flow patterns with disease 
formation is of great interest to clinical diagnosis with a number of clinical validation studies 
being carried out [659, 664]. However, despite compelling evidence of blood flow playing a 
key role in all stages of atherosclerotic diseases, the exact interaction between the above 
mentioned risk factors and blood flow patterns is largely unknown.  
The field of mechanobiology studies blood flow quantitatively, while bringing together 
engineering knowledge with cellular and molecular biology. The interior of blood vessels 
(including arteries) are lined with a layer of endothelial cells, which are in direct contact with 
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blood. The flow of blood exerts a friction force on the endothelial surface, acting in the plane 
of the endothelium, and its magnitude scales with the velocity of the blood. This force acting 
per unit area is termed shear stress (also referred to as hemodynamic shear stress), and it is 
measured in dyne/cm
2
 or Newton/m
2
 (N/m
2
) or Pascal (Pa). Endothelial shear stress values in 
healthy human arteries range from 10-70 dyne/cm
2 
[21];
 
corresponding to 1-7 Pa.  
4.2.3 The complexity of cardiovascular mechanotransduction  
At a molecular level, numerous molecules and cellular microdomains from the basal (at the 
interface of the endothelium with the rest of the arterial wall), junctional (between 
neighbouring endothelial cells) and luminal (at the blood-endothelium interface) surfaces of 
endothelial cells have been found to detect and respond to shear stress. These include: ion 
channels [666], receptor tyrosine kinases [423], the apical glycocalyx [266-268], primary 
cilia [442], heterotrimeric G proteins and G protein coupled receptors [667], xanthine oxidase 
[257], growth factor receptors [668], nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase [669], caveolae [429, 666], cell membrane phospholipid bilayer [670], platelet EC-
adhesion molecule (PECAM-1) [259], vascular endothelial (VE)-cadherin [260], focal 
adhesion sites [21, 671], and the cytoskeleton [269]; (for a review see [18, 450, 672-675]). 
The understanding of the dynamics of individual mechanosensors is currently emerging, but 
their integration, and consequently, the mechanism by which endothelial cells sense 
hemodynamic shear stress is not fully understood. After stimulation by shear stress an 
(unknown) combination of these receptors is activated, which then activate 6-8 downstream 
signalling pathways, eventually leading to changes in gene expression patterns. These 6-8 
mechano-transduction pathways regulate 8 acknowledged transcription factors, which leads 
to a total of ~2,000 genes responsible for the response to shear stress [402, 600, 656, 664, 
676].  
The immense complexity that results from the interactions of these high number of gene 
products (proteins, small interfering RNAs, microRNA) prohibits an intuitive and coherent 
understanding of the processes involved. Mathematical modelling is often used to study these 
large networks, and computational modelling has indeed been able to predict new signalling 
pathway dynamics (for reviews see [67, 677]). Also, new emerging properties have been 
identified for several shear-sensitive pathways; these new properties include oscillatory 
behaviour (IP3-pathway, MAPK-pathway, NF-κB-pathway), bi-stability (MAPK-pathway) 
and memory (MAPK-pathway). However, despite these early successes, the failure of 
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computational modelling methods to accurately represent reality became apparent. One of the 
most important reasons for this failure in computational modelling is the high dimensionality, 
complexity and inter-connectedness of the signalling pathways which are not fully mapped 
out. In addition, there is a lack of sufficient experimental data for modelling and model 
validation. For instance, the MAPK-pathway has been modelled with >100 coupled ordinary 
differential equations including over a hundred of kinetic parameters. The actual values of 
these parameters are often derived from several unrelated literature sources based on different 
cell types and/or different organisms making the prediction of these models rather unrealistic. 
Other theoretical methods, such as parameter estimation techniques, suffer from finding non-
unique solutions in this high-dimensional parameter space and cannot be solved due to the 
lack of quantitative information of kinetic constants. The understanding, modelling and 
prediction of behaviours of mechano-transduction signalling pathways under mechanical 
stimulation is proven to be even more difficult due to relatively scarce qualitative data 
available in literature. Without a systematic way of generating large amounts of experimental 
data for characterizing mechanotransduction signalling pathways, there is little hope for 
unravelling the cause of atherosclerosis risk factor advancement at molecular level, and using 
this information to aid clinical decision that will eventually lead to disease prevention and 
improved patient recovery. 
4.2.4 RNA interference and currently available electroporators 
The solution that was proposed to fully characterize these complex cardiovascular mechano-
transduction pathways, typically containing thousands of interacting elements, was the 
development of high-throughput systems that can add functions (gain-of-function) or inhibit 
functions (loss-of-function) in cardiac cells by inserting cDNA or siRNA, respectively. At the 
same time, our platform should also be able to mimic physiologically relevant conditions, 
such as the exposure to shear stress in our in vitro cell culture. Thus, our platform consists of 
a device capable of transfecting primary cardiac cells and a microfluidics flow channel for 
exposing cells to controlled levels of shear stress. For high-throughput, mammalian gene 
expression loss-of-function data collection, RNA interference could be employed. RNA 
interference is a powerful and reliable tool for studies into these signalling pathways, and 
involves the insertion (also referred to as transfection) of short (20-25 bp) double stranded 
small interfering RNA (siRNA) molecules into cultured mammalian cells. Once inside the 
cells, these siRNA molecules take advantage of the cell’s natural machinery to effectively 
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knock down expression of the target gene (at the mRNA level) to which that particular 
siRNA anneals to due to Watson-Crick base pairs complementarity. Our platform would also 
allow monitoring gene interactions using a reversed engineering approach. For this, gene 
encoding cDNA will be inserted into endothelial cells, and these cDNAs will be silenced by 
inserting siRNAs into the same cells.  
Transfection of primary cells is notoriously difficult, but recent reports indicate that this can 
be reliably achieved with membrane electroporation [678]. Electroporation may be defined as 
the application of electric pulses causing temporary pores on the cell membrane allowing 
membrane impermeable substances (e.g. DNA, RNA, proteins) to enter the cell. 
Electroporation was chosen because it is simple, high-throughput, adaptable, and gives good 
transfection yields for a variety of primary cell types. In order to achieve spatial and temporal 
control of the transfection process, primary endothelial cells were electroporated in their 
natural surface adherent state, also minimizing the disruption of their cell division cycle 
during detachment while exposed to trypsin [679-681]. To functionally characterize gene 
networks in cardiac cells, physiologically complex mechanical and chemical environment 
should be mimicked. Hence, the incorporation of an electroporator in a flow channel seems 
an efficient way to carry out mechano-sensitive pathway studies effectively. Out of the 
existing adherent mammalian cell electroporation techniques (summarized in Table 4.1), 
none is readily compatible with systems that expose cardiac cells to physiologically-relevant 
mechanical and chemical conditions. Thus, a platform has been developed which allows 
electroporation of hard-to-transfect adherent primary cardiac cells as well as the 
incorporation of a microfluidics device that recreates physiologically relevant fluid flow and 
chemical conditions. The construction and operation of the device relies on commercially-
available components; the protocols presented here are thus readily reproducible by interested 
researchers. The operation of the device is validated by flow experiments following the 
electroporation of a siRNA knock down of a flow-response target gene (Krüppel-like factor 
2, KLF2) [682] on primary Porcine Aortic Endothelial Cells (PAEC). Phenotypes of the cell 
culture as well as qPCR results confirm the successful knock down of the target gene. 
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Table 4.1. Summary of electroporation techniques for adherent mammalian cells 
No. Cell type 
Flow 
compatibility 
High-throughput 
Transfection 
efficiency+ 
Survival 
rate+ 
Reference 
1 Cell lines No No - - [683] 
2 Cell lines No No - - [684] 
3 Cell lines No No - - [685] 
4 Cell lines No No - - [686] 
5 
Cell lines and primary 
aortic smooth muscle 
cells 
No No 43% 60% [687] 
6 Cell lines No No - - [688] 
7 
Cell lines and 
progenitor 
hippocampus cells 
No No Not specified 
Not 
specified 
[689] 
8 
Cell lines and 
hippocampal cultures 
No No 92% 92% [690] 
9 
Primary neurons and 
glia 
No No 92% 
Not 
specified 
[691] 
10 
Cell lines and 
HUVEC 
No No 13-36% 
Greater than 
31% 
[692] 
11 
Cell lines and 
HUVEC 
No No Not specified 
Not 
specified 
[693] 
12 
Cell lines and primary 
neurons and 
embryonic fibroblasts 
No No 25%,40% 90% [694] 
13 Cell lines No No - - [695] 
14 Cell lines No No - - [696] 
15 Cell lines No No - - [697] 
16 Cell lines No No - - [698] 
17 Cell lines No No - - [699] 
18 Cell lines No No - - [700] 
19 Cell lines No No - - [701] 
20 Cell lines No Yes - - [702] 
21 Cell lines No No - - [703] 
22 
Cell lines and primary 
neurons 
No No Not specified 
Not 
specified 
[704] 
23 
Cell lines and primary 
macrophages 
No No 99% (PI)& 93% [705] 
24 Primary chondrocytes No No 
30%, nearly 
100% 
Not 
specified 
[706] 
25 
Cell lines and 
HUVEC 
No Yes Not specified 
Not 
specified 
[707] 
26 Cell lines and primary No Yes 60% Not [708] 
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macrophages specified 
+ Transfection efficiencies and survivor rates are shown for primary cells only. 
& Primary macrophages mice were electroporated with propidium iodide (PI)  
 
 
 MATERIALS AND METHODS 4.3
4.3.1 Primary cell isolation and culturing 
Thoracic aorta segments of 10-15 cm obtained from approximately 6 month old domestic 
pigs (Sus scrofa domesticus) were obtained within 24 hours of the death of the animal. The 
aorta segments were stored in Hank’s Balanced Salt Solution (HBSS) supplemented with 200 
U/ml Penicillin, 200 µg/ml Streptomycin, 100 µg/ml Gentamycin and 100 µg/ml 
Amphotericin. Aorta segments and cells were handled in Euroclone Bioair Top Safe 1.5 and 
Euroclone Bioair Top Safe 1.2 Class II safety cabinets. Intercostal arteries of aorta segments 
were ligated and the lumen was subsequently rinsed with phosphate buffered saline (PBS) 
supplemented with 100 U/ml Penicillin, 100 µg/ml Streptomycin, 50 µg/ml Gentamycin and 
50 µg/ml Amphotericin to remove red blood cells. Next, one end of the vessel was clamped 
and the lumen was filled with serum-free Dulbecco's Modified Eagle's Medium (DMEM) 
containing 0.2 mg/ml collagenase, 200 U/ml Penicillin, 200 µg/ml Streptomycin, 100 µg/ml 
Gentamycin and 100 µg/ml Amphotericin. The other vessel end was also clamped and the 
collagenase filled vessel was then incubated at 37°C for 15 minutes. The detached endothelial 
cells (EC) were collected and the lumen was flushed with PBS supplemented with 100 U/ml 
Penicillin, 100 µg/ml Streptomycin, 50 µg/ml Gentamycin and 50 µg/ml Amphotericin. The 
collected ECs were pelleted by centrifuging at 200 g for 5 minutes, re-suspended and placed 
in culture flasks. The culture medium consisted of DMEM supplemented with 5 mM L-
Glutamine, 5 µg/ml EC growth factors, 90 µg/ml heparin and 10% (v/v) foetal calf serum 
(FCS). Primary pig aortic ECs (PAECs) were cultured for up to 5 passages at 37°C, saturated 
humidity and 5% (v/v) CO2 in MCO-18M, MCO-18AC or MCO-18AIC Sanyo incubators. 
Cells were grown in polystyrene Corning
®
 cell culture flasks with 25 cm
2
 (430639) or 75 cm
2
 
(430641) cell growth area treated for optimal cell attachment, with canted neck and with 
vented cap from Corning Inc. Prior passaging, the culture media, 1 x PBS and trypsin-EDTA 
solution was pre-warmed to 37°C in a Fisher Scientific DMU19 Water Bath. For passaging, 
cells were washed twice with 1 ml of 1 x PBS solution per 10 cm
2
 growth area and detached 
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by incubating at 37°C for 5-6 minutes in 0.4 ml of 0.1% (w/v) trypsin, 0.02% EDTA solution 
per 10 cm
2
 of cell growth area. Cell-trypsin solution was transferred to 15 or 50 ml conical 
polypropylene CentriStar™ centrifuge tubes containing 10 ml of culture medium with serum 
and centrifuged for 5 minutes at 150 g in a MSE Mistral 2000 centrifuge. The cell pellet was 
re-suspended in fresh culture media, transferred to new cell culture flasks and placed back in 
the cell culture incubator. Integra Pipetboys with 5 ml (734-1737), 10 ml (734-1738) and 25 
ml (734-1739) polystyrene Stripettes
®
 attachments were used to handle liquid volumes in the 
order of millilitres. Microliter volumes were measured using 10 µl (S1120-3810), 200 µl 
(S1120-8810), 1,000 µl (S1126-7810) StartLab TipOne
®
 Filter Tips connected onto 
Eppendorf Research
®
 plus, adjustable-volume, single channel pipettes. For liquid disposal, a 
vacuum line was used which consisted of autoclaved glass Pasteur pipettes (612-1701, VWR) 
and C-Flex tubing (190-947-001, Cole-Parmer), a Büchner flask containing Klorsept 87 
solution (CLE1490, Scientific Laboratory Supplies Ltd.), a Whatman™ Vacu-Guard Filters 
(09-744-75, Thermo Fisher Scientific Inc.) and a central vacuum pump. Seventy percent 
ethanol was used to sterilize surfaces. Conical 15 ml (734-1867) or conical-skirted 50 ml 
(734-1876) polypropylene CentriStar™ tubes with high-density polyethylene caps were 
purchased from VWR. DMEM (D5546), L-Glutamine (G8540), EC growth factors (E2759), 
heparin (H0777), FCS (F7524), collagenase (C9891), gentamycin (G3632), amphotericin 
(A9528), HBSS (H9269), Penicillin-Streptomycin (P4333) and Trypsin-EDTA solution 
(T4049) were supplied by Sigma-Aldrich Corp. Dulbecco's phosphate buffered saline 10x 
(D1408) from Sigma-Aldrich Corp. was diluted 1:10 (v/v) in autoclaved Milli-Q water to 
obtain 1xPBS. Ethanol (20821.321) was ordered from VWR BDH Prolabo. 
4.3.2 Electroporation setup 
For in-situ electroporation, cells were seeded on a 5 x 5 cm Indium Tin Oxide coated 
electrically conductive and transparent glass slide (GTO-5051) from UQG Ltd, Cambridge, 
UK. This glass slide/electrode was mounted on a Petri dish (101R20) from Sterilin Ltd., 
Newport, UK) to aid the sterilization/incubation process. Next, small wells (0.5cm x 0.5cm) 
were cut into PCR tape (AB-0558) from Thermo Fisher Scientific Inc. Gold plated metal 
components (546-3276) from RS Components Ltd., Corby, UK were used as the top 
(positive) electrode. The distance between the two electrodes was approximately 500 µm. 
Metal tags were glued to the conductive ITO glass slide using CW2000 nickel conductive 
glue-pen form Circuit Works. Electrically conductive wires were soldered to metal tags and 
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were connected to the negative outlet of an Agilent 33220A 20 MHz Function/Arbitrary 
Waveform Generator which was programmed with Visual Basic scripts. This way, the ITO 
conductive glass slide became the negative electrode. Delivered square pulses were 
monitored with an Agilent DSO3062A Digital Storage Oscilloscope. During the optimisation 
process, duration and voltage of square electrical pulses varied from 1ms to 1 s and 0.1 to 12 
V, respectively. Double, triple and multiple pulses with variable duration and voltage were 
also used. To facilitate convenient optimization for electroporation parameters, multiple wells 
of 0.5 cm x 0.5 cm were used with top electrodes ordered from RS Components Ltd. The 
final chambers for the combined electroporation and flow experiments are of 0.5 mm x 0.5 
cm x 5 cm (H*W*L) and the top electrode consisted of 0.5 x 0.5 x 0.8 cm solid aluminium 
blocks plated with gold at the London & Brighton Plating Company Ltd., Brighton, UK. 
4.3.3 Electroporation procedure 
For the optimisation of the electroporation protocol, electroporation wells (contained in a 
petri dish) were sterilized with 254 nm UV light for 4 hours and each of the 0.5 x 0.5 cm 
wells were coated with 15 µl of fibronectin solution (1 mg/ml) by incubation at 37°C for one 
hour; fibronectin (33010-018) was acquired from Life Technologies Inc., Carlsbad, CA, 
USA. Cells were seeded in each well at an initial density of 38,000 cells/cm
2
 and 12-24 hours 
after seeding the confluent adhering cell monolayer in each of these wells were washed with 
30 µl PBS to remove debris and dead cells. 15 µl fluorescent siRNA (1-20 µM) dissolved in 
PBS was pipetted into each electroporation well after which an electrical square pulse train 
was applied between the top gold plated electrode (+) and conductive glass substrate (‒). The 
following fluorescent siRNAs were used: AllStars Negative Control siRNA Alexa Fluor 488 
conjugate (1027284) from Qiagen N.V.; Silencer
®
 Cy™3 labelled Negative Control No. 1 
siRNA (AM4621) and Silencer
®
 FAM labelled Negative Control No. 1 siRNA (AM4620) 
from Invitrogen Corp., Carlsbad, CA, USA. After electroporation with fluorescently labelled 
siRNA, cells were visualized with either a Leica TCS SP5 DMI6000 confocal microscope or 
a Zeiss Axiovert 200 inverted fluorescent microscope.  
For the electroporation/flow devices, the incubation chambers (0.5mm x 0.5cm x 5cm) were 
coated with 150 µl fibronectin solution (1 mg/ml) in preparation for cell culture. After 
reaching confluency cells were washed with 250 µl PBS immediately before the adherent 
monolayer was electroporated with 150 µl, 33 µM siRNA solution that silences the 
expression of Krüppel-like factor 2 (KLF2; Dharmacon). 
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4.3.4 Flow experiments 
The flow setup consisted of a flow channel, a peristaltic pump, platinum-cured silicone 
tubing and a bubble catcher media reservoir. The flow channel was created by mounting a 
bottomless self-adhesive flow chamber (IB-80168) from ibidi GmbH, Munich, Germany, on 
top of the electroporation-flow chamber (See Figure 4.1), 4 and 24 hours after electroporation 
of the confluent adherent cells. Flow channels were connected to each other and to a 
peristaltic pump using platinum-cured silicone tubing (WZ-95802-03) of 2.29 mm inner 
diameter and 4 mm outer diameter from Cole Parmer to carry out multiple experiments 
simultaneously. The Cobe precision blood pump (03600-001) from Cobe, Lakewoor, CO. 
USA was used to suck liquid from the medium reservoir, through the flow channels; 
recycling media to the medium reservoir (see Figure 4.1.C). For the pump head, a 36 cm long 
platinum-cured silicone tubing (WZ-95802-04) of 3 mm inner diameter and 4.8 mm outer 
diameter from Cole Parmer was used. The pump head tubing was connected to the rest of the 
tubing using straight through connectors with classic series barbs with 3.2 mm inner diameter 
from The West Group Ltd. Two kinds of inert, high temperature resistant media reservoirs 
were used. The first one was a 150 ml glass chamber with a loosely fitted lid containing a 
media inlet and with an outlet at the bottom of the chamber. The second reservoir was a 500 
mL Schott glass bottle with a screw-on polypropylene cap perforated to fit three tubes: media 
inlet, media outlet and gas exchange (fitted with a 0.22 μm hydrophobic filter). The flow 
setup was sterilized at 135 °C for 5 minutes in a MLS-3751L Sanyo autoclave. Prior the flow 
experiment, 60-80 ml of culture media was added to the media reservoir and the flow setup 
was placed in a cell culture incubator for 2 hours to equilibrate the temperature and gas 
content. Then the flow channel was connected to the pre-equilibrated flow setup through Luer 
to 200 series barb elbow connectors with 3.2 mm inner diameter from The West Group Ltd., 
Waterlooville, UK. The pump generated pulsatile flow and the flow rate was gradually 
increased during the initial two hours of the experiment up to a flow rate of 45-50 ml/min, 
which yielded a shear stress of 1.5-2 Pa in the 50x5x0.75 mm flow channel. This 
physiological shear stress was maintained for 24 hours at 37°C in humidified air that 
contained 5% CO2. After the experiment, cell phenotypes were observed under the Leica DM 
IL LED–DFC290 phase contrast microscope using the 10X objective, for further quantitative 
analysis (see below).  
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Figure 4.1. Scheme of the electroporation-flow device. A. Construction of the device. First an 
indium tin oxide (ITO) coated transparent and electrically conductive glass slide was placed 
in a Petri dish, and metal wires were soldered to metal connectors glued to corners of the 
glass slide, using electrically conductive glue. Next, the cell accommodating chamber was 
created by placing adhesive PCR tape double layer on top of the glass slide. After 
sterilization with UV light and coating with fibronectin, cells were seeded, left to reach 
confluence and electroporated in the chamber. Flow chambers were created by placing a 
bottomless flow channel on top of the cell containing chamber. B. Electroporation procedure. 
The glass slide on which cells adhered was connected to the negative outlet of the electrical 
pulse generator by wires. A gold plated solid aluminium block was wired to the positive 
outlet of the same pulse generator. The metal block came on top of the adherent cell 
monolayer in contact with the electroporation solution, and the pulse was delivered. C. Flow 
experiment procedure. Following electroporation the wires and the top electrode were 
removed, and a bottomless self-adhesive ibidi flow channel was placed on top of the cell 
containing well. The obtained flow chamber was connected by tubes to the culture medium 
reservoir and the peristaltic pump, facilitating the suction of liquid from the reservoir through 
the flow chamber into the pump, and pushing the liquid back into the reservoir. 
4.3.5 Cellular viability tests 
Viability of PAECs was assessed using the trypan blue dye exclusion test as described before 
[19]. For this procedure, cells in each of the 0.5 x 0.5 cm wells were washed twice with 30 + 
30 µl of PBS pre-warmed to 37°C. Subsequently, 15 µl of 0.4% (w/v) trypan blue solution 
was added to cells, and incubated 3 minutes at room temperature. Hereafter, cells in each well 
were washed twice with 30-30 µl of PBS pre-warmed to 37°C and visualized under a Leica 
DM IL LED–DFC 290 phase contrast microscope. Non-viable cells were stained in blue. 
Post-electroporation cellular viability was also determined using propidium iodide (PI) [20]. 
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Cells with 0.5 µg/ml of PI in culture media were incubated at 37°C for 10-30 minutes and 
visualised under a Zeiss Axiovert 200 fluorescent microscope. Trypan blue (SV30084.01) 
was obtained from Thermo Fisher Scientific Inc. HyClone and PI (81845) was purchased 
from Sigma-Aldrich Corp. 
4.3.6 mRNA quantification using (real-time) qPCR 
Immediately after completion of the flow experiment, the total RNA was isolated using the 
RNeasy Mini Kit (74106) from Qiagen N.V. For this, cells were lysed under high salt 
conditions, in the highly denaturing guanidine-thiocyanate–containing buffer to inactivate 
RNases, ensuring the purification of intact RNA molecules. To provide appropriate binding 
conditions ethanol was added and the samples were applied to RNeasy Mini spin columns. 
Impurities were washed away and the RNA was eluted from the silica-based membrane using 
50 μl water.  
The concentration, purity and integrity of RNA was checked with a NanoDrop
TM
 2000c 
Spectrophotometer. 
Next, the total RNA was converted into cDNA with the High Capacity RNA-to-cDNA Kit 
(4387406) from Applied Biosystems, Foster City, CA, United States. For this, the reverse 
transcription (RT) mixture was prepared as shown in Table 4.2. 
Table 4.2. Composition of the reverse transcription mix 
Component Volume [µl] 
2X RT Buffer 10 10 
20X RT Enzyme 
Mix 
1 - 
Sample up to 9 µl up to 9 µl 
Nuclease-free H2O up to 20 µl up to 20 µl 
 
Next, the 96-well plate which contained the mixture was briefly centrifuge to spin down the 
contents and to eliminate air bubbles. The reverse transcription reaction was then carried out 
in a Labnet MultiGene™ Gradient PCR Thermal Cycler following the program from Table 
4.3 below. 
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Table 4.3. Temperature program for the reverse transcription reaction 
Step 1 2 2 
Temperature 
[°C] 
37 95 4 
Time [min] 60 5 ∞ 
 
Levels of KLF2 cDNA were quantified by real-time polymerase chain reaction (qPCR) using 
SYBR Fast SYBR
®
 Green Master Mix Real-Time PCR Master Mix (4385616) from Applied 
Biosciences in 20 μL reactions, in an Eppendorf realplex4 epgradient S qPCR Mastercycler® 
with KLF2 specific primers following the thermal cycling program shown in Table 4.4. DNA 
primers (KLF2_Forward: AGACCACGATCCTCCTTGAC, KLF2_Reverse: 
AAGCCTCGATCCTCTAGTGTAG) for qPCR were synthesized at Invitrogen Corp. and 
used at the final concentration of 300 nM. Five μL of cDNA sample was added per reaction 
to the master mix to obtain a total volume of 15 µl. Reactions were carried out in triplicates 
and two negative controls (without primer or without template) were added to each 
experiment. 
Table 4.4. Thermal cycling program for qPCR. 
Step Temp 
[°C] 
Time  
Initial 
Denaturation  
95  45 s 
45 Cycles  95 
58 
15 s 
30 s 
Gradient*  65-95 20 min  
Hold  4  ∞ 
* Melting curve produced for quality control to  
monitor specificity of the amplification reaction. 
4.3.7 Quantitative analysis of cell alignment 
Angles of endothelial cells with respect to the flow direction were calculated from phase 
contrast images, applying a phase quadrature technique. Effectively, this method spatially 
convolves the phase-contrast image field with spatially oriented complex filters to obtain the 
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dominant direction, independent of image intensity. The resulting histogram of angles was 
normalised and compared to a uniform or a single angle distribution applying the Kullback-
Leibler divergence, or relative entropy. A value of zero indicates a uniform distribution of 
angles (‘absence of cell alignment’) and a value >0 indicates degree of cell alignment.  
 
 
 RESULTS AND DISCUSSION 4.4
4.4.1 Design and operation of the electroporation-flow device 
An overview of the platform is shown in Figure 4.1. A glass slide coated with indium tin 
oxide (ITO) was fitted inside a 90 mm diameter circular Petri dish, to aid the 
sterilization/incubation process. The ITO coated glass slide was electrically conductive and 
optically transparent, allowing electroporation and subsequent visualization by visible light 
and fluorescent microscopy. Furthermore, ITO is very durable, inert and non-toxic to cells, 
promoting excellent cell adhesion and growth [683]. The corners of the glass slide were 
soldered to electrically conductive wires that connect to the negative outlet of the electrical 
pulse generator. Subsequently, walls of small culturing chambers were created, consisting of 
a double layer of electronically isolating PCR tape that was stacked on top of the glass slide. 
The size of the electroporation-flow channel that was cut out in the PCR tape was 0.5 cm X 5 
cm with a height of 500 µm. For electroporation, a gold plated solid aluminium block was 
connected to the positive outlet of the electric pulse generator, and was placed on top of the 
cell monolayer creating a chamber with a height of 500 µm. This way, the positive electrode 
was in direct contact with the electrically isolating plate through electroporation solution that 
covered the cells, (Figure 4.1). Electrical pulses for electroporation were generated using an 
Agilent 33220A 20 MHz Function/Arbitrary Waveform Generator programmed with Visual 
Basic scripts. Delivered square pulses were monitored with an Agilent DSO3062A Digital 
Storage Oscilloscope. To facilitate convenient optimization for electroporation parameters, 
multiple smaller wells with a size of 0.5 cm X 0.5 cm and a height of 500 µm, were used. 
After the electrical pulse was delivered, the top metal electrode and wires were removed, and 
cells were examined under the microscope. Next, a flow channel was created by placing a 
bottomless self-adhesive flow chamber from Ibidi on top of the electroporation-flow chamber 
(Figure 4.1.C). Cells can be subjected to shear stress at any time between 4 and 24 hours after 
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electroporation of the confluent adherent cells. Flow channels were connected to each other, 
and to a Cobe precision peristaltic blood pump using platinum-cured silicone tubing to carry 
out multiple experiments simultaneously. The Cobe precision blood pump was used to suck 
liquid from the flow channels, through a medium container, where the medium was recycled 
(Figure 4.1.C). The pump generated pulsatile flow, and the flow rate was gradually increased 
during the initial two hours of the experiment up to a flow rate of 45-50 mL/min, which 
yielded a shear stress of 1.5–2 Pa in the 50 x 5 x 0.75 mm flow channel. This physiological 
shear stress was maintained for 24 hours at 37°C in humidified air that contained 5% CO2. 
After the experiment, cell phenotypes were observed under the Leica DM IL LED–DFC290 
phase contrast microscope using the 10X objective. 
4.4.2 In-situ electroporation of adherent primary cells with fluorescently 
labelled siRNAs 
Before knock-down effects on mechanotransduction pathways can be investigated, the 
electroporation parameters must be optimized for the target cell type. For the optimization of 
the electroporation protocol, electroporation wells (contained in a Petri dish) were sterilized 
with 254 nm UV light for 4 hours, and each of the 0.5 X 0.5 cm wells were coated with 15 
µL of fibronectin solution (1 mg/mL) by incubation at 37°C for one hour. Cells were seeded 
in each well at an initial density of 38,000 cells/cm
2
, and 12-24 hours after seeding the 
confluent adhering cell monolayer in each of these wells were washed with PBS to remove 
debris and dead cells. 15 µL fluorescent siRNA (1-20 µM) dissolved in PBS was pipetted 
into each electroporation well after which an electrical pulse train was applied between the 
top gold plated electrode (+) and conductive glass substrate (-). The following fluorescent 
siRNAs were used: AllStars Negative Control siRNA Alexa Fluor 488 conjugate from 
Qiagen; Silencer
®
 Cy™3 labelled Negative Control No. 1 siRNA and Silencer® FAM 
labelled Negative Control No. 1 siRNA from Invitrogen. After electroporation with 
fluorescently-labelled siRNA, cells were visualized with either a Leica TCS SP5 DMI6000 
confocal microscope or a Zeiss Axiovert 200 inverted fluorescent microscope.  
A series of electroporation parameters and conditions were systematically changed, aiming to 
increase transfection efficiencies while keeping cell death to a minimum for primary PAECs. 
Fluorescently-labelled siRNA (Alexa Fluor 488) that does not target any known DNA or 
RNA sequence in mammalian cells had been used for this purpose. The optimal concentration 
of the fluorescently-labelled siRNA was determined to be 5 µM for transfection. It has also 
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been observed that transfection efficiencies appeared to be significantly higher when the 
bottom glass slide acted as the negative electrode and the top metal electrode was positive 
(configuration I) compared to the reverse case when the glass slide was positive and the top 
metal was the negative electrode (configuration II). Using configuration I, a variety of square 
electrical pulses were systematically tested (i.e. single, double, triple, and multiple pulses), 
modifying the pulse duration from 1 to 1000 milliseconds (ms), modifying the electrical 
potential difference (or voltage) from 1 to 12 Volts (V), and also varying the number of 
pulses from 1 to 100. Square pulses used during this optimization phase are represented in 
Figure 4.2. Out of these pulses, the 3V pulse of 5 ms duration pulse yielded maximal cell 
viability and transfection efficiencies. 
 
Figure 4.2. Electrical square pulses applied for optimizing the electroporation parameters. A. 
Single pulses with magnitudes between 1 and 12 Volts (V), and with durations of 1ms to 1 s. 
B. Double pulses of 1 to 12 V lasting between 1 ms and 1 s, with a gap of 1 to 100 ms in 
between pulses. C. Triple pulses with magnitudes between 1 and 12 V, with duration of 1 ms 
to 1 s and with pauses of 1 to 100 ms in between pulses. D. Multiple (4 to 100) pulses of 2 to 
10 V with a duration of 1 to 80 ms and with gaps of 1 to 20 ms in between pulses. Out of 
these pulses the 3 V 5 ms pulses gave the highest transfection efficiencies with high cell 
viabilities. 
 
Transfection results produced using the 3V pulse of 5 ms are shown in Figure 4.3. 
Approximately 70% of cells electroporated with green fluorescently-labelled siRNA (Alexa 
Fluor 488) appeared green upon excitation with ~488 nm wavelength light. Viability of 
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PAECs after electroporation was assessed using the trypan blue dye exclusion test as 
described before [709]. For this procedure, cells in each of the 0.5 X 0.5 cm wells were 
washed twice with PBS pre-warmed to 37°C. Subsequently, 15 µL of 0.4% (w/v) trypan blue 
solution was added to cells, and incubated 3 minutes at room temperature. Hereafter, cells in 
each well were washed twice with PBS pre-warmed to 37°C, and visualized under a Leica 
DM IL LED–DFC 290 phase contrast microscope. Non-viable cells were stained in blue. 
Post-electroporation cellular viability was also determined using propidium iodide (PI) [710]. 
Cells with 0.5 µg/mL of PI in culture media were incubated at 37°C for 10-30 minutes, and 
visualized under a Zeiss Axiovert 200 fluorescent microscope. Non-viable cells are red 
fluorescent due to propidium iodide uptake. Cell viability (100 minus number of red 
fluorescent cells divided by total number of cells present after electroporation) was >95%. 
 
 
Figure 4.3. Pictures of adherent primary Porcine Aortic Endothelial Cells (PAECs) post 
electroporation. PAECs were isolated from thoracic aorta segments domestic pigs (Sus scrofa 
domesticus), and cultured for up to a maximum of 5 passages at 37°C, saturated humidity and 
5% (v/v) CO2 in DMEM supplemented with 5 mM L-Glutamine, 5 µg/ml EC growth factors, 
90 µg/ml heparin, and 10% (v/v) foetal calf serum (FCS). From left to right: phase contrast 
(all cells), green fluorescent (cells electroporated with Alexa Fluor 488 siRNA), red 
fluorescent (non-viable cells stained with propidium iodide), and combined microscopy 
images taken 30 minutes after electroporation are shown. The transfection efficiency was 
70% and cell viability was >95%. 
 
 
In-situ electroporation and flow device for mechanotransduction systems biology studies 
290 
 
4.4.3 Primary cell mechanotransduction pathway studies 
The aim of our device is to facilitate the study of mechanotransduction pathways in primary 
cells. This was carried out in the framework of RNA interference. Therefore, it must provide 
reliable siRNA transfection through electroporation, facilitate the application of well 
controlled shear stress on seeded cells, and allow convenient readout such as microscopy. For 
the electroporation-flow devices, the incubation chambers (0.5mm X 0.5cm X 5cm) were 
coated with 150 µL fibronectin solution (1 mg/mL) for cell adhesion. After reaching 
confluency, cells were washed with PBS immediately before the adherent monolayer was 
electroporated with 150 µL siRNA (33 µM) solution that silences the expression of Krüppel-
like factor 2. For the application of shear stress, a bottomless self-adhesive microfluidics flow 
channel was placed on top of the electroporation well, and the resulting flow channel was 
connected to a peristaltic pump. Phase contrast light microscopy images of cells after flow 
experiments are shown in Figure 4.4.  
Endothelial cells cultured under static conditions have a cobblestone like appearance. 
Whereas cells subjected to shear stress (2 Pa for 24 hours) stimulus appears elongated and 
aligns with the direction of the liquid flow. This has been confirmed with our setup, and 
cobblestone and flow-elongated morphologies were obtained as shown in columns A and B 
of Figure 4.4, respectively. On the other hand, cells electroporated with KLF2 targeting 
siRNA molecules (siKLF2) and sheared with 2 Pa for 24 hours lost their ability to align to the 
direction of fluid flow a property attributed to the transcription factor KLF2 [711]. This was 
verified with our system where 24 hours of continuous flow was applied to cells transfected 
with siKLF2 (see Figure 4.4.C), providing evidence that our system was capable of delivering 
siRNAs to primary endothelial cells as well as inducing an appropriate amount of shear stress 
for mechanotransduction experiments. 
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Figure 4.4. The novel electroporator is flow compatible and capable of delivering siRNA that 
modifies functions (alignment to flow) from primary endothelial cells. Phase contrast 
microscopy images of PAECs (top row) and orientation histograms (bottom row) showing the 
amount (fraction) of cells in function of orientation angle for the images above. The 
histograms are normalised, so that the vertical axis represents Probability Density Functions 
(PDF) over angle, θ. A. Static (e.g. non-electroporated cells cultured under static conditions); 
B. No electroporation, sheared 24 h (cells not electroporated but sheared with 1.5–2 Pa for 24 
hours); C. Electroporation with KLF2 siRNA, sheared 24 h (cells electroporated with 33 µM 
siKLF2 and exposed to 1.5–2 Pa of shear stress for of 24 hours). 
 
Images were analysed in order to quantify cellular alignment to the direction of flow by 
determining the number of cells in each orientation angle. For this, angles of endothelial cells 
with respect to the flow direction were calculated from phase contrast images, applying a 
phase quadrature technique. Effectively, this method spatially convolves the phase-contrast 
image field with spatially-oriented complex filters to obtain the dominant direction, 
independent of image intensity. The resulting histogram of angles was normalized, and 
compared to a uniform or a single angle distribution applying the Kullback-Leibler 
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divergence, or relative entropy. Obtained orientation histograms are shown below microscopy 
images in Figure 4.4. Histograms A and C show a relatively even distribution of cells by 
orientation angles whereas in case of histogram B a significant majority of cells are oriented 
at an angle of 15 degrees, ± 10 degrees. These histograms confirm that siKLF2 
electroporated, sheared cells (similarly to the static control) are less aligned than non-
electroporated sheared cells. Entropy values show a similar trend, with low entropy (low 
degree of disorder) for shear exposed cells without siKLF2 electroporation, and high entropy 
(high degree of disorder) for siKLF2 electroporated and sheared cell as well as for the static 
control. 
In order to further quantify the knockdown of the gene that caused loss of flow alignment in 
endothelial cells, the mRNA levels of KLF2 were quantified from 10 electroporation 
experiments using qPCR (see Figure 4.5 for details). Thus, immediately after completion of 
the flow experiment, cells were lysed and the total RNA was isolated using RNeasy Mini Kit 
from Qiagen. Next, the total RNA was converted into cDNA with the High Capacity RNA-
to-cDNA Kit from Applied Biosystems. Levels of KLF2 cDNA were quantified by real-time 
polymerase chain reaction (qPCR) using KLF2 specific primers. mRNA levels in non-
electroporated, sheared endothelial cells was considered as 100%, and electroporation with 
siKLF2 yielded 52% KLF2 mRNA down-regulation, a reduction comparable to those 
reported in literature [712]. 
 
Figure 4.5. Quantification of KLF2 mRNA down-regulation by qPCR. KLF2 mRNA levels 
from “static” (PAECs from static culture); “non-electroporated, sheared 24 h” (cells exposed 
to 1.5–2 Pa shear stress for 24 hours without prior electroporation); “siKLF2 electroporated, 
sheared 24 h” (PAECs electroporated with 33 µM siKLF2 and exposed to 1.5–2 Pa shear 
stress for 24 hours). Considering “non-electroporated, sheared 24 h” as 100%, siKLF2 
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electroporation yielded 52% KLF2 mRNA down-regulation. mRNA levels were normalized 
to the enzyme HPRT1. 
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 SUMMARY AND FUTURE WORK 4.5
4.5.1 Summary 
The electroporation-flow device was designed and developed. The electroporation protocol 
was optimized using siRNA molecules labelled with fluorescent dyes. The electroporation-
flow device consisted of an electrically conductive ITO coated glass slide, onto which a cell 
seeding and electroporation well was created, by sticking an adhesive tape with a rectangular 
hole was cut in the centre. The ITO coating of the glass slide onto which the cells were 
seeded acted as the negative electrode and a gold plated metal block placed above the well 
constituted the positive electrode for electroporation. To obtain the flow channel, an ibidi 
bottomless self-adhesive flow chamber was mounted on top of the well, aligning the cell 
seeding and electroporation well with the channel of the flow chamber.  
It was shown that our electroporation device was capable of transfecting primary PAECs 
while these cells remain adhered to surfaces, with transfection efficiencies of up to 70% and 
cell survival rate >95%. We have demonstrated that we were able to suppress one of the most 
important mechano-sensitive signalling pathways, and showed a consequent misalignment of 
endothelial cells. Electroporation with KLF2 targeting siRNAs resulted in inhibition of the 
inherent flow induced alignment of primary endothelial cells, and in an approximate halving 
of the expected KLF2 mRNA expression, as determined by qPCR. In summary, our platform 
was capable of delivering cell membrane impermeable substances into hard-to-transfect 
primary endothelial cells allowing biomechanical studies under physiologically relevant 
complex flow and chemical conditions. 
The work presented in this chapter was published as a book chapter entitled “An in-situ 
electroporation and flow device for mechanotransduction studies” (pages 49-68) in the book 
with the title “Microarrays: Principles, Applications and Technologies” edited by J. V. 
Rogers at Nova Science Publishers, New York (ISBN: 978-1-62948-669-7). Based on the 
results presented in this chapter, a grant application to the Government of the Swiss 
Confederation was submitted. This funding was subsequently granted and a research 
associate was employed to continue this project.  
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4.5.2 Future work 
The research associate who continues this project is currently making substantial progress in 
increasing the throughput of this system. The siRNA platform that she develops is highly 
modular and uses ultra-high parallelisation gene knockdown and monitoring techniques to 
characterize complex signal transduction cascades in primary mammalian cells.  
The platform consists of the following custom-made components: highly efficient 
electroporator for mammalian cells, ultra-high precision robot dispenser, and a modular 
parallel plate chamber for experimental interventions. These components were designed to 
yield optimal performance for a series of procedures such as dispensing, bespoke cell 
seeding, transfection and imaging. Each step of the process has been carefully evaluated. A 
“reversed” transfection technique of cells is being adapted. For this, siRNA or cDNA is 
deposited using a GeSIM robotic Nano-Plotter
TM
 NP2.1 system with a piezoelectric Pico-Tip 
J on a glass slide before seeding cells for electroporation.  
The strengths of this siRNA platform resides in its high precision (<2%) and accuracy 
(<0.05%), its ultra-high parallelisation (500-2000 experiments), the presence of a bespoke 
electroporator which guarantees a high transfection efficiency in primary mammalian cells 
and its modularity which makes it possible to test for chemical, biological and mechanical 
intervention and adapt it to perform integrative experiments. All components are compatible 
with standard microscopes, enabling to perform automatic screening and high resolution 
imaging at singe cell level. The tests that were already performed are: 1) dispensing accuracy 
and precision; 2) cell viability, transfection efficiency and cross contamination and 3) 
functional inhibition. 
The above mentioned research associate collaborates with a Ph.D. student to develop 
computational techniques for network inference in order to decipher the topology of these 
complex signalling networks. This novel logic-based network inference approach was already 
shown to infer >85% of networks from datasets provided by the DREAM consortium, even if 
the network motifs are complex.  
The data that will be generated by the high-throughput siRNA platform will be fed into this 
computational network inference algorithm to characterize complex and interconnected 
biomechanical and biochemical signal transduction pathways.  
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5 General conclusions 
 
Cardiovascular diseases develop due to multiple factors, including biomechanical factors, 
such as shear stress generated by the flow of blood. In order to tackle this serious life-
threatening condition, synthetic and systems biology tools for investigating and obviating the 
effect of atherogenic blood flow on vascular cells have been developed. Three different 
synthetic and systems biology tools were presented in Chapters 2, 3 and 4 of this thesis. 
In Chapter 2, a synthetic biology based gene network for monitoring shear stress sensor 
activity in endothelial cells was designed and implemented to determine the dose response of 
the gene network to shear stress. In order to develop this gene network, an iterative cycle of 
DNA construction and evaluation of DNA construct function in mammalian cells was carried 
out. The major problem that was need to be solved was the difficulty of inserting large DNA 
constructs into a large proportion of the hard-to-transfect endothelial cell line population. To 
solve this problem, several options had been considered and cells that contain the DNA 
plasmids of interested were selected using mammalian selection antibiotics. Plasmids were 
engineered having this antibiotic selection criterion in mind and an endothelial cell line 
capable of replicating plasmids was also employed. After establishing a procedure where 
cells were electroporated with one of the two plasmids, selected with antibiotics for two days, 
electroporated with the second plasmid and induced with bradykinin, 67% of cells contained 
the inducible gene network. Next, flow experiments were carried out in the in-house designed 
linear shear stress inducing flow setup. In the end, a logarithmic dose response curve to shear 
stress has been obtained on antibiotic selected gene network containing HMEC-1 cells. 
In the project presented in Chapter 2, difficulties were also faced during plasmid 
construction. It is worth noting, that the Gibson Assembly kit, used for the first time in our 
group by me, failed to successfully assemble 4 linear DNA fragments with overlapping ends 
into one circular DNA plasmid. Besides setting up the Gibson Assembly technique, I was the 
first person in the group to: (1) order de novo synthesis of DNA from a company, (2) 
electroporate EA.hy926 and HMEC-1 endothelial cell lines with DNA plasmids, (3) to carry 
out successful flow experiment using the large pump that sits outside of the cell culture 
incubator with the used flow setup, (4) to carry out antibiotic titration and selection 
experiments and (5) to transfect EA.hy926 and HMEC-1 using transfection reagents. Bearing 
in mind that I was the first person to enter the field of synthetic biology in our group and that 
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numerous techniques were set up by me, I consider that substantial progress was made due to 
my hard work and dedication.  
Our Chapter 2 results show – for the first time – that a synthetic gene network is capable of 
monitoring mechanosensor activity. This new assay enables to screen for compounds that 
modify the response of mechanosensors to shear stress and facilitates future application 
described in the Future work subsection (2.5.2) of Chapter 2. 
Chapter 3 describes the design, manufacture and evaluation of a flow chamber which enables 
exposure of endothelial cells to linearly increasing shear stress along the length of the channel 
floor for in vitro cellular biomechanical studies. The first challenge in this project was to 
design a channel geometry which yielded spatially, linearly varying shear stress in the range 
of 0–10 Pa in computational flow simulations. The linearity of the shear stress needed to be 
maintained independently of the flow rate and the low end of the shear stress range was 
required to tend to zero independently of the flow rate while high end of the shear stress 
range was required to vary proportionally with shear stress. After trying several channel 
geometries, the height variance channel model presented in the Results and Discussion 
section of Chapter 3 was seen to yield the most ideal outcome in computational flow 
simulations. The next challenge was to manufacture this flow chamber with complex height 
variance geometry keeping in mind the goal of applying this channel for experiments on 
vascular cells. Several manufacturing methods were considered and evaluated; moulding in 
PDMS seemed the most suitable for our purposes (for details c.f. Results and Discussion 
section of Chapter 3). To seal the channel and to allow visualization under microscopes, 
complementary clamping equipment was also designed and manufactured. Finally, the 
operation of this channel for flow experiments on endothelial cells was optimized and our 
channel was proven functional for this purpose.  
The flow device presented in Chapter 3 outperforms currently available width variance linear 
shear stress inducing devices in terms of the extent of shear stress range, controllable by flow 
rate, linearity of shear stress along the channel length, and the large sampling area granted by 
the uniformity of shear stress across the channel width. Considering that no member of our 
group has previously designed a flow chamber, the development and implementation of this 
device constitutes a significant success. 
In Chapter 4, a device that is capable of electroporating primary vascular cells in their 
adherent state and allows the exposure of these cells to fluid flow to mimic physiological 
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conditions was developed. This device was proven capable of down-regulating the expression 
of genes targeted with siRNA molecules. The major challenge in this project was to deliver 
fluorescently labelled siRNA molecules into hard-to-transfect primary endothelial cells with 
high efficiencies while keeping cell viabilities high. This was achieved by systematically 
varying the electroporation parameters and the configuration of the electrodes. Next, 
electroporated cells were coupled to flow setup to expose the cell layer to well-controlled 
levels of shear stress. To our knowledge, this is the first device capable of electroporating 
adherent primary endothelial cells at high efficiencies and which is also connectable to a flow 
setup for mimicking physiological flow conditions. 
In conclusion, my contribution to science through my PhD was the development of tools, 
technologies that are valuable for atherosclerosis research and have the potential to contribute 
to the treatment of this lethal disease. 
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7 Appendices 
 
 Appendix 1 7.1
> α2A-AR-AVPR2tail-TCS-tTA expected sequence 
ATGTTCCGCCAGGAGCAGCCGTTGGCCGAGGGCAGCTTTGCGCCCATGGGCTCCCTGCAG
CCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGGGGCGGCGCCCGGG
CCACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCCGGCCTGCTCATGC
TGCTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACGAGCCGCGCGCTCA
AGGCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATCCTGGTGGCCACGC
TCGTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTACTTCGGCAAGGCTT
GGTGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCCATCGTGCACCTGT
GCGCCATCAGCCTGGACCGCTACTGGTCCATCACACAGGCCATCGAGTACAACCTGAAG
CGCACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATCTCGGCCGTCATC
TCCTTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGCCCGCAGCCGGC
CGAGCCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCGTGCATCGGCT
CCTTCTTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTACCAGATCGCCAA
GCGTCGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCCGCGCCGCCGG
GGGGCACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGCCCGGGGGG
CGCAGAGGCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCCGCGCCGG
CCGGGCCGCGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGACCACGCC
GAGCGGCCTCCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAAGGCCC
GAGCGAGCCAGGTGAAGCCGGGCGACAGCCTGCCGCGGCGCGGGCCGGGGGCGACGGG
GATCGGGACGCCGGCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGGCGTCG
CGCTGGCGCGGGCGGCAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTGGTCAT
CGGAGTGTTCGTGGTGTGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCGTCGGG
TGCTCCGTGCCACGCACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAGCTCGT
TGAACCCGGTCATCTACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAAGATCC
TCTGTCGGGGGGACAGGAAGCGGATCGTGTGAGCCCGGGGACGCACCCCACCCAGCCTG
GGTCCCCAAGATGAGTCCTGCACCACCGCCAGCTCCTCCCTGGCCAAGGACACTTCATCG
GGATCCGAGAACCTGTACTTCCAGCTAAGATTAGATAAAAGTAAAGTGATTAACAGCGC
ATTAGAGCTGCTTAATGAGGTCGGAATCGAAGGTTTAACAACCCGTAAACTCGCCCAGA
AGCTAGGTGTAGAGCAGCCTACATTGTATTGGCATGTAAAAAATAAGCGGGCTTTGCTCG
ACGCCTTAGCCATTGAGATGTTAGATAGGCACCATACTCACTTTTGCCCTTTAGAAGGGG
AAAGCTGGCAAGATTTTTTACGTAATAACGCTAAAAGTTTTAGATGTGCTTTACTAAGTC
ATCGCGATGGAGCAAAAGTACATTTAGGTACACGGCCTACAGAAAAACAGTATGAAACT
CTCGAAAATCAATTAGCCTTTTTATGCCAACAAGGTTTTTCACTAGAGAATGCATTATAT
GCACTCAGCGCTGTGGGGCATTTTACTTTAGGTTGCGTATTGGAAGATCAAGAGCATCAA
GTCGCTAAAGAAGAAAGGGAAACACCTACTACTGATAGTATGCCGCCATTATTACGACA
AGCTATCGAATTATTTGATCACCAAGGTGCAGAGCCAGCCTTCTTATTCGGCCTTGAATT
GATCATATGCGGATTAGAAAAACAACTTAAATGTGAAAGTGGGTCCGCGTACAGCCGCG
CGCGTACGAAAAACAATTACGGGTCTACCATCGAGGGCCTGCTCGATCTCCCGGACGAC
GACGCCCCCGAAGAGGCGGGGCTGGCGGCTCCGCGCCTGTCCTTTCTCCCCGCGGGACA
CACGCGCAGACTGTCGACGGCCCCCCCGACCGATGTCAGCCTGGGGGACGAGCTCCACT
TAGACGGCGAGGACGTGGCGATGGCGCATGCCGACGCGCTAGACGATTTCGATCTGGAC
ATGTTGGGGGACGGGGATTCCCCGGGTCCGGGATTTACCCCCCACGACTCCGCCCCCTAC
GGCGCTCTGGATATGGCCGACTTCGAGTTTGAGCAGATGTTTACCGATGCCCTTGGAATT
GACGAGTACGGTGGGTAG 
 
Homo sapiens adrenoceptor alpha 2A (Alpha2A-AR) coding sequence; GenBank: NM_000681.3  
Web page: http://www.ncbi.nlm.nih.gov/nuccore/NM_000681.3  date last accessed: 24.May.2012 
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Arginine vasopressin receptor 2, last 29 aa (AVPR2tail); GenBank: Z11687.1 
Web page: http://www.ncbi.nlm.nih.gov/nuccore/Z11687 date last accessed: 24.May.2012 
Tobacco etch virus protease (TEV) cleavage site (TCS); DNA sequence that encodes the SENLYFQL 
amino acid sequence  
Transcription factor (tTA) first two codons replaced 
http://www.ncbi.nlm.nih.gov/nuccore/EU908848 date last accessed: 24.May.2012 
 
> βArrestin2-TEV expected sequence 
CGTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAG
TTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTG
GGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATAT
AAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGT
AAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCC
TTGAATTACTTCCACGCCCCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGG
AAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGT
TGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTG
TCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTT
TTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTT
TTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGG
GGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGC
TCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCG
GTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCT
CAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAA
AAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTC
CAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGG
GTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTG
GCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCA
AGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGAATGGGCGAAA
AACCGGGCACCCGCGTGTTTAAAAAAAGCAGCCCGAACTGCAAACTGACCGTGTATCTG
GGCAAACGCGATTTTGTGGATCATCTGGATAAAGTGGATCCGGTGGATGGCGTGGTGCT
GGTGGATCCGGATTATCTGAAAGATCGCAAAGTGTTTGTGACCCTGACCTGCGCGTTTCG
CTATGGCCGCGAAGATCTGGATGTGCTGGGCCTGAGCTTTCGCAAAGATCTGTTTATTGC
GACCTATCAGGCGTTTCCGCCGGTGCCGAACCCGCCGCGCCCGCCGACCCGCCTGCAGG
ATCGCCTGCTGCGCAAACTGGGCCAGCATGCGCATCCGTTTTTTTTTACCATTCCGCAGA
ACCTGCCGTGCAGCGTGACCCTGCAGCCGGGCCCGGAAGATACCGGCAAAGCGTGCGGC
GTGGATTTTGAAATTCGCGCGTTTTGCGCGAAAAGCCTGGAAGAAAAAAGCCATAAACG
CAACAGCGTGCGCCTGGTGATTCGCAAAGTGCAGTTTGCGCCGGAAAAACCGGGCCCGC
AGCCGAGCGCGGAAACCACCCGCCATTTTCTGATGAGCGATCGCAGCCTGCATCTGGAA
GCGAGCCTGGATAAAGAACTGTATTATCATGGCGAACCGCTGAACGTGAACGTGCATGT
GACCAACAACAGCACCAAAACCGTGAAAAAAATTAAAGTGAGCGTGCGCCAGTATGCG
GATATTTGCCTGTTTAGCACCGCGCAGTATAAATGCCCGGTGGCGCAGCTGGAACAGGAT
GATCAGGTGAGCCCGAGCAGCACCTTTTGCAAAGTGTATACCATTACCCCGCTGCTGAGC
GATAACCGCGAAAAACGCGGCCTGGCGCTGGATGGCAAACTGAAACATGAAGATACCA
ACCTGGCGAGCAGCACCATTGTGAAAGAAGGCGCGAACAAAGAAGTGCTGGGCATTCTG
GTGAGCTATCGCGTGAAAGTGAAACTGGTGGTGAGCCGCGGCGGCGATGTGAGCGTGGA
ACTGCCGTTTGTGCTGATGCATCCGAAACCGCATGATCATATTCCGCTGCCGCGCCCGCA
GAGCGCGGCGCCGGAAACCGATGTGCCGGTGGATACCAACCTGATTGAATTTGATACCA
ACTATGCGACCGATGATGATATTGTGTTTGAAGATTTTGCGCGCCTGCGCCTGAAAGGCA
TGAAAGATGATGATTATGATGATCAGCTGTGCGGATCTAGCCTGTTTAAAGGCCCGCGCG
ATTATAACCCGATTAGCAGCACCATTTGCCATCTGACCAACGAAAGCGATGGCCATACCA
CCAGCCTGTATGGCATTGGCTTTGGCCCGTTTATTATTACCAACAAACATCTGTTTCGCCG
CAACAACGGCACCCTGCTGGTGCAGAGCCTGCATGGCGTGTTTAAAGTGAAAAACACCA
CCACCCTGCAGCAGCATCTGATTGATGGCCGCGATATGATTATTATTCGCATGCCGAAAG
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ATTTTCCGCCGTTTCCGCAGAAACTGAAATTTCGCGAACCGCAGCGCGAAGAACGCATTT
GCCTGGTGACCACCAACTTTCAGACCAAAAGCATGAGCAGCATGGTGAGCGATACCAGC
TGCACCTTTCCGAGCAGCGATGGCATTTTTTGGAAACATTGGATTCAGACCAAAGATGGC
CAGTGCGGCAGCCCGCTGGTGAGCACCCGCGATGGCTTTATTGTGGGCATTCATAGCGCG
AGCAACTTTACCAACACCAACAACTATTTTACCAGCGTGCCGAAAAACTTTATGGAACTG
CTGACCAACCAGGAAGCGCAGCAGTGGGTGAGCGGCTGGCGCCTGAACGCGGATAGCGT
GCTGTGGGGCGGCCATAAAGTGTTTATGAGCAAACCGGAAGAACCGTTTCAGCCGGTGA
AAGAAGCGACCCAGCTGATGAACGAACTGGTGTATAGCCAGATGTACCCATACGATGTT
CCAGATTACGCT 
 
EF1a promoter; Web pages: http://www.ncbi.nlm.nih.gov/gene/1915 http://www.addgene.org/11154/  
date last accessed: 24.May.2012 
βArrestin2 ; NCBI Reference Sequence: NM_004313.3 
Web page: http://www.ncbi.nlm.nih.gov/nuccore/NM_004313 date last accessed: 24.May.2012 
BamHI restriction endonuclease site 
Tobacco etch virus (TEV) protease; GenBank: M15239.1   
Web page: http://www.ncbi.nlm.nih.gov/nuccore/M15239 date last accessed: 24.May.2012 
HA epitope 
Web page: http://www.clontech.com/images/pt/PT3283-SEQ.txt date last accessed: 08.April.2011 
 
> Luciferase expected sequence 
ATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTATCCTCTAGAGGATGG
AACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGCCCTGGTTCCTGGAACAA
TTGCTTTTACAGATGCACATATCGAGGTGAACATCACGTACGCGGAATACTTCGAAATGT
CCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCTGAATACAAATCACAGAATCGTC
GTATGCAGTGAAAACTCTCTTCAATTCTTTATGCCGGTGTTGGGCGCGTTATTTATCGGAG
TTGCAGTTGCGCCCGCGAACGACATTTATAATGAACGTGAATTGCTCAACAGTATGAACA
TTTCGCAGCCTACCGTAGTGTTTGTTTCCAAAAAGGGGTTGCAAAAAATTTTGAACGTGC
AAAAAAAATTACCAATAATCCAGAAAATTATTATCATGGATTCTAAAACGGATTACCAG
GGATTTCAGTCGA 
TGTACACGTTCGTCACATCTCATCTACCTCCCGGTTTTAATGAATACGATTTTGTACCAGA
GTCCTTTGATCGTGACAAAACAATTGCACTGATAATGAATTCCTCTGGATCTACTGGGTT
ACCTAAGGGTGTGGCCCTTCCGCATAGAACTGCCTGCGTCAGATTCTCGCATGCCAGAGA
TCCTATTTTTGGCAATCAAATCATTCCGGATACTGCGATTTTAAGTGTTGTTCCATTCCAT
CACGGTTTTGGAATGTTTACTACACTCGGATATTTGATATGTGGATTTCGAGTCGTCTTAA
TGTATAGATTTGAAGAAGAGCTGTTTTTACGATCCCTTCAGGATTACAAAATTCAAAGTG
CGTTGCTAGTACCAACCCTATTTTCATTCTTCGCCAAAAGCACTCTGATTGACAAATACG
ATTTATCTAATTTACACGAAATTGCTTCTGGGGGCGCACCTCTTTCGAAAGAAGTCGGGG
AAGCGGTTGCAAAACGCTTCCATCTTCCAGGGATACGACAAGGATATGGGCTCACTGAG
ACTACATCAGCTATTCTGATTACACCCGAGGGGGATGATAAACCGGGCGCGGTCGGTAA
AGTTGTTCCATTTTTTGAAGCGAAGGTTGTGGATCTGGATACCGGGAAAACGCTGGGCGT
TAATCAGAGAGGCGAATTATGTGTCAGAGGACCTATGATTATGTCCGGTTATGTAAACAA
TCCGGAAGCGACCAACGCCTTGATTGACAAGGATGGATGGCTACATTCTGGAGACATAG
CTTACTGGGACGAAGACGAACACTTCTTCATAGTTGACCGCTTGAAGTCTTTAATTAAAT
ACAAAGGATATCAGGTGGCCCCCGCTGAATTGGAATCGATATTGTTACAACACCCCAAC
ATCTTCGACGCGGGCGTGGCAGGTCTTCCCGACGATGACGCCGGTGAACTTCCCGCCGCC
GTTGTTGTTTTGGAGCACGGAAAGACGATGACGGAAAAAGAGATCGTGGATTACGTCGC
CAGTCAAGTAACAACCGCGAAAAAGTTGCGCGGAGGAGTTGTGTTTGTGGACGAAGTAC
CGAAAGGTCTTACCGGAAAACTCGACGCAAGAAAAATCAGAGAGATCCTCATAAAGGCC
AAGAAGGGCGGAAAGTCCAAATTGTAA 
 
Firefly luciferase coding sequence 
Web page: http://www.ncbi.nlm.nih.gov/nuccore/M15077.1 date last accessed: 24.May.2012 
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 Appendix 2 7.2
> pZK1 (α2A-AR-AVPR2tail-TCS-tTA) sequence obtained by DNA sequencing 
CCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTT
GGCAGTACATCAAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTa
AAATGGCCCGCCTGGCATTATGCCCAGTACATGAMCTTACgGGgACTTTCCTACTTGGCA
GTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAA
TGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA
TGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAATAACCCCGC
CCCGTTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTC
GTTTAGTGAACCGTCAGATCACTAGAAGCTTTATTGCGGTAGTTTATCACAGTTAAATTG
CTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGAAGTTGGTCGT
GAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAA
ACTGGGCTTGTCGAGACAGAGAAGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTAC
TGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCAATTACAGCTCTTAA
GGCTAGAGTACTTAATACGACTCACTATAGGCTAGAGCGGCCGCGGAATtCACCATGGGC
TCCCTGCAGCCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGGGGCG
GCGCCCGGGCCACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCCGGCC
TGCTCATGCTGCTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACGAGCC
GCGCGCTCAAGGCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATCCTGG
TGGCCACGCTCGTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTACTTCG
GCAAGGCTTGGTGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCCATCG
TGCACCTGTGCGCCATCAGCCTGGACCGCTACTGgTCCATCACACAGGCCATCGAGTACA
ACCTGAAGCGCACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATCTCGG
CCGTCATCTCCTTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGCCCGC
AGCCGGCCGAGCCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCGTGC
ATCGGCTCCTTCTTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTACCAGA
TCGCCAAGCGTCGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCCGCG
CCGCCGGGGGGCACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGCCC
GGGGGGCGCAGAGGCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCCG
CGCCGGCCGGGCCACGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGAC
CACGCCGAGCGGCCTCCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAA
GGCCCGAGCGAGCCAGGTGAAGCCGGGCGACAGCCTGCCGCGGCGCGGGCCGGGGGCG
ACGGGGATCGGGACGCCGGCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGG
CGTCGCGCTGGCGCGGGCGGCAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTG
GTCATCGGAGTGTTCGTGGTGTGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCG
TCGGGTGCTCCGTGCCACGCACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAG
CTCGTTGAACCCGGTCATCTACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAA
GATCCTCTGTCGGGGGGACAGGAAGTCTAGAACCCCACCCAGCCTGGGTCCCCAAGATG
AGTCCTGCACCACCGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGGGATCCGAGAACC
TGTACTTCCAGCTAAGATTAGATAAAAGTAAAGTGATTaACAGCGCATTAGAGCTGCTTA
ATGAGGTCGGAATCGAAGGTTTAACAACCCGTAAACTCGCCCAGAAGCTAGGTGTAGAG
CAGCCTACATTGTATTGGCATGTAAAAAATAAGCGGGCTTTGCTCGACGCCTTAGCCATT
GAGATGTTAGATAGGCACCATACTCACTTTTGCCCTTTAGAAGGGGAAAGCTGGCAAGA
TTTTTTACGTAATAACGCTAAAAGTTTTAGATGTGCTTTACTAAGTCATCGCGATGGAGC
AAAAGTACATTTAGGTACACGGCCTACAGAAAAACAGTATGAAACTCTCGAAAATCAAT
TAGCCTTTTTATGCCAACAAGGTTTTTCACTAGAGAATGCATTATATGCACTCAGCGCTGT
GGGGCATTTTACTTTAGGTTGCGTATTGGAAGATCAAGAGCATCAAGTCGCTAAAGAAG
AAAGGGAAACACCTACTACTGATAGTATGCCGCCATTATTACGACAAGCTATCGAATTAT
TTGATCACCAAGGTGCAGAGCCAGCCTTCTTATTCGGCCTTGAATTGATCATATGCGGAT
TAGAAAAACAACTTAAATGTGAAAGTGGGTCCGCGTACAGCCGCGCGCGTACGAAAAAC
AATTACGGGTCTACCATCGAGGGCCTGCTCGATCTCCCGGACGACGACGCCCCCGAAGA
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GGCGGGGCTGGCGGCTCCGCGCCTGTCCTTTCTCCCCGCGGGACACACGCGCAGACTGTC
GACGGCCCCCCCGACCGATGTCAGCCTGGGGGACGAGCTCCACTTAGACGGCGAGGACG
TGGCGATGGCGCATGCCGACGCGCTAGACGATTTCGATCTGGACATGTTGGGGGACGGG
GATTCCCCGGGTCCGGGATTTACCCCCCACGACTCCGCCCCCTACGGCGCTCTGGATATG
GCCGACTTCGAGTTTGAGCAGATGTTTACCGATGCCCTTGGAATTGACGAGTACGGTGGG
TAGGGGGCGCGAGGATCTCTCGAGGGCCGCTTCGAGCAGACATGATAAGATACATTGAT
GAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGT
GATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAAT
TGCATTCATTTTATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTAAAGCAAGTAA
AACCTCTACAAATGTGGTAAAATCGATAAGGATCGATCCGGGCTGGCGTAATAGCGAAG
AGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGACGCGC
CCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACA
CTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGC
CGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTA
CGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCC
TGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGT
TCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTT
GCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTT
TAACAAAATATTAACGCTTACAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCG
GTATTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAA
GCCAGCCCCGACACCCGCCAACACCCGCTGACGSGCCTTGACGGGCTTGTCTGCTCCCGG
GATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAAAGGTTTTCAC
CGTCTTCCC 
 
 
> pZK1 complete sequence (α2A-AR-AVPR2tail-TCS-tTA in pCI) 
TCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTAT
TGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCCAA
TATGACCGCCATGTTGGCATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGT
CATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGC
CTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAG
TAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCC
ACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACG
GTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGC
AGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCA
ATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCA
ATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAATAACCCCG
CCCCGTTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCT
CGTTTAGTGAACCGTCAGATCACTAGAAGCTTTATTGCGGTAGTTTATCACAGTTAAATT
GCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGAAGTTGGTCG
TGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAA
ACTGGGCTTGTCGAGACAGAGAAGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTAC
TGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCAATTACAGCTCTTAA
GGCTAGAGTACTTAATACGACTCACTATAGGCTAGAGCGGCCGCGGAATtCACCATGGGC
TCCCTGCAGCCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGGGGCG
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GCGCCCGGGCCACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCCGGCC
TGCTCATGCTGCTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACGAGCC
GCGCGCTCAAGGCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATCCTGG
TGGCCACGCTCGTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTACTTCG
GCAAGGCTTGGTGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCCATCG
TGCACCTGTGCGCCATCAGCCTGGACCGCTACTGgTCCATCACACAGGCCATCGAGTACA
ACCTGAAGCGCACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATCTCGG
CCGTCATCTCCTTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGCCCGC
AGCCGGCCGAGCCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCGTGC
ATCGGCTCCTTCTTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTACCAGA
TCGCCAAGCGTCGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCCGCG
CCGCCGGGGGGCACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGCCC
GGGGGGCGCAGAGGCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCCG
CGCCGGCCGGGCCACGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGAC
CACGCCGAGCGGCCTCCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAA
GGCCCGAGCGAGCCAGGTGAAGCCGGGCGACAGCCTGCCGCGGCGCGGGCCGGGGGCG
ACGGGGATCGGGACGCCGGCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGG
CGTCGCGCTGGCGCGGGCGGCAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTG
GTCATCGGAGTGTTCGTGGTGTGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCG
TCGGGTGCTCCGTGCCACGCACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAG
CTCGTTGAACCCGGTCATCTACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAA
GATCCTCTGTCGGGGGGACAGGAAGTCTAGAACCCCACCCAGCCTGGGTCCCCAAGATG
AGTCCTGCACCACCGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGGGATCCGAGAACC
TGTACTTCCAGCTAAGATTAGATAAAAGTAAAGTGATTaACAGCGCATTAGAGCTGCTTA
ATGAGGTCGGAATCGAAGGTTTAACAACCCGTAAACTCGCCCAGAAGCTAGGTGTAGAG
CAGCCTACATTGTATTGGCATGTAAAAAATAAGCGGGCTTTGCTCGACGCCTTAGCCATT
GAGATGTTAGATAGGCACCATACTCACTTTTGCCCTTTAGAAGGGGAAAGCTGGCAAGA
TTTTTTACGTAATAACGCTAAAAGTTTTAGATGTGCTTTACTAAGTCATCGCGATGGAGC
AAAAGTACATTTAGGTACACGGCCTACAGAAAAACAGTATGAAACTCTCGAAAATCAAT
TAGCCTTTTTATGCCAACAAGGTTTTTCACTAGAGAATGCATTATATGCACTCAGCGCTGT
GGGGCATTTTACTTTAGGTTGCGTATTGGAAGATCAAGAGCATCAAGTCGCTAAAGAAG
AAAGGGAAACACCTACTACTGATAGTATGCCGCCATTATTACGACAAGCTATCGAATTAT
TTGATCACCAAGGTGCAGAGCCAGCCTTCTTATTCGGCCTTGAATTGATCATATGCGGAT
TAGAAAAACAACTTAAATGTGAAAGTGGGTCCGCGTACAGCCGCGCGCGTACGAAAAAC
AATTACGGGTCTACCATCGAGGGCCTGCTCGATCTCCCGGACGACGACGCCCCCGAAGA
GGCGGGGCTGGCGGCTCCGCGCCTGTCCTTTCTCCCCGCGGGACACACGCGCAGACTGTC
GACGGCCCCCCCGACCGATGTCAGCCTGGGGGACGAGCTCCACTTAGACGGCGAGGACG
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TGGCGATGGCGCATGCCGACGCGCTAGACGATTTCGATCTGGACATGTTGGGGGACGGG
GATTCCCCGGGTCCGGGATTTACCCCCCACGACTCCGCCCCCTACGGCGCTCTGGATATG
GCCGACTTCGAGTTTGAGCAGATGTTTACCGATGCCCTTGGAATTGACGAGTACGGTGGG
TAGGGGGCGCGAGGATCTCTCGAGGGCCGCTTCGAGCAGACATGATAAGATACATTGAT
GAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGT
GATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAAT
TGCATTCATTTTATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTAAAGCAAGTAA
AACCTCTACAAATGTGGTAAAATCGATAAGGATCCGGGCTGGCGTAATAGCGAAGAGGC
CCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGT
AGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGC
CAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGC
TTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGC
ACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGAT
AGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCA
AACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCG
ATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAAC
AAAATATTAACGCTTACAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTAT
TTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCA
GCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATC
CGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTC
ATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGT
CATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAAC
CCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCC
TGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTC
GCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGT
GAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATC
TCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCA
CTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAAC
TCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAA
AGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGT
GATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGC
TTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAA
TGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGT
TGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACT
GGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGT
TTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGG
GGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACT
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ATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTA
ACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTT
AAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAG
TTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCT
TTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTT
TGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCG
CAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCT
GTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGC
GATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCG
GTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCG
AACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAG
GCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTC
CAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGC
GTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCG
GCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGGCTCGACAGATCT 
 
ATGGGCTCCCTGCA – α2A-AR-AVPR2tail-TCS-tTA coding sequence, open reading frame 
ATGGGCTCCCTGCA – α2A-AR GPCR coding sequence 
CCAATAGGGACTTT – obtained by DNA sequencing, sequencing read 
TCAATATTGGCCATT – pCI sequence taken from Promega website 
http://www.promega.co.uk/products/vectors/mammalian-expression-vectors/pci-mammalian-
expression-
vector/?origUrl=http%3a%2f%2fwww.promega.com%2fproducts%2fvectors%2fmammalian-
expression-vectors%2fpci-mammalian-expression-vector%2f 
 
 
 
 
> pZK5 (βArrestin2-TEV) sequence obtained by DNA sequencing 
ATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTA
CTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGT
ACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTG
ACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACA
ACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGC
AGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACT
CACTATAGGGAGACCCAAGCTTGGTACCGAGCTCGGATcCACTAGTAACGGCCGCCAGTG
TGCTGGAATTCGATTCAGGATCCTCTGGAATGGGGGAGAAACCCGGGACCAGGGTCTTC
AAGAAGTCGAGCCCTAACTGCAAGCTCACCGTGTACTTGGGCAAGCGGgACTTCGTAGAT
CACCTGGACAAAGTGGACCCTGTAGATGGCGTGGTGCTTGTGGACCCTGACTACCTGAA
GGACCGCAAAGTGTTTGTGACCCTCACCTGCGCCTTCCGCTATGGCCGTGAAGACCTGGA
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TGTGCTGGGCTTGTCCTTCCGCAAAGACCTGTTCATCGCCACCTACCAGGCCTTCCCCCCG
GTGCCCAACCCACCCCGGCCCCCCACCCGCCTGCAGGACCGGCTGCTGAGGAAGCTGGG
CCAGCATGCCCACCCCTTCTTCTTCACCATACCCCAGAATCTTCCATGCTCCGTCACACTG
CAGCCAGGCCCAGAGGATACAGGAAAGGcCTGCGGCGTAGACTTTGAGATTCGAGCCTT
CTGTGCTAAATCACTAGAAGAGAAAAGCCACAAAAGGAACTCTGTGCGGCTGGTGATCC
GAAAGGTGCAGTTCGCCCCGGAGAAACCCGGCCCCCAGCCTTCAGCCGAAACCACACGC
CACTTCCTCATGTCTGACCGGTCCCTGCACCTCGAGGCTTCCCTGGACAAGGAGCTGTAC
TACCATGGGGAGCCCCTCAATGTAAATGTCCACGTCACCAACAACTCCACCAAGACCGTC
AAGAAGATCAAAGTCTCTGTGAGACAGTACGCCGACATCTGCCTCTTCAGCACCGCCCA
GTACAAGTGTCCTGTGGCTCAACTCGAACAAGATGACCAGGTATCTCCCAGCTCCACATT
CTGTAAGGTGTACACCATAACCCCACTGCTCAGTGACAACCGGGAGAAGCGGGGTCTCG
CCCTGGATGGGAAACTCAAGCACGAGGACACCAACCTGgCTTCCAGCACCATCGTGAAG
GAGGGTGCCAACAAGGAGGTGCTGGGAATCCTGGTGTCCTACAGGGTCAAGGTGAAGCT
GGTGGTGTCTCGAGGCGGGGATGTCTCTGTGGAGCTGCCTTTTGTTCTTATGCACCCCAA
GCCCCACGACCACATCCCCcTCCCcAGACCCCAGTCAGCCGCTCCGGAGACAGATGTCCC
TGTGGACACCAACCTCATTGAATTTGATACCAACTATGCCACAGATGATGACATTGTGTT
TGAGGACTTTGCCCGGCTTCGGCTGAAGGGGATGAAGGATGACGACTATGATGATCAAC
TCTGCGGATCTAGCTTGTTTAAGGGACCACGTGATTACAACCCGATATCGAGCAcCATTT
GTCATTTGACGAATGAATCTGATGGGCACACAACATCGTTGTATGGTATTGGATTTGGTC
CCTTCATCATTACAAACAAGCACTTGTTTAGAAGAAATAATGGAACACTGTTGGTCCAAT
CACTACATGGTGTATTCAAGGTCAAGAACACCACGACTTTGCAACAACACCTCATTGATG
GGAGGGACATGATAATTATTCGCATGCCTAAGGATTTCCCACCATTTCCTCAAAAGCTGA
AATTTAGAGAGCCACAAAGGGAAGAGCGCATATGTCTTGTGACAACCAACTTCCAAACT
AAGAGCATGTCTAGCATGGTGTCAGACACTAGTTGCACATTCCCTTCATCTGATGGCATA
TTCTGGAAGCATTGGATTCAAACCAAGGATGGGCAGTGTGGCAGTCCATTAGTATCAACT
AGAGATGGGTTCATTGTTGGTATACACTCAGCATCGAATTTCACCAACACAAACAATTAT
TTCACAAGCGTGCCGAAAAACTTCATGGAATTGTTGACAAGTCAGGAGGCGCAGCAGTG
GGTTAGTGGTTGGCGATTAAATGCTGACTCAGTATTGTGGGGGGGCCATAAAGTTTTCAT
GAGCAAACCTGAAGAGCCTTTTCAGCCAGTTAAGGAAGCGACTCAACTCATGAATGAAT
TGGTGTACTCGTACCCATATGATGTTCCAGATTACGCTTGAGCGGCCGCTCGAGCATGCA
TCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGAC
TGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTG
GAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTG
AGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTG
GGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAA
GAACCAGCTGGGGCTCTAGGGGGTAT 
 
> pZK5 (βArrestin2-TEV) complete sequence in pcDNA3 
GACGGATCGGGAGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATG
CCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCG
CGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTG
CTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACAT
TGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATAT
ATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGAC
CCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTC
CATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTG
TATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCAT
TATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCA
TCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTG
Appendices 
347 
 
ACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACC
AAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGC
GGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACC
CACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTTGGTA
CCGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATTCGATTCAGGATCCTCT
GGAATGGGGGAGAAACCCGGGACCAGGGTCTTCAAGAAGTCGAGCCCTAACTGCAAGCT
CACCGTGTACTTGGGCAAGCGGgACTTCGTAGATCACCTGGACAAAGTGGACCCTGTAGA
TGGCGTGGTGCTTGTGGACCCTGACTACCTGAAGGACCGCAAAGTGTTTGTGACCCTCAC
CTGCGCCTTCCGCTATGGCCGTGAAGACCTGGATGTGCTGGGCTTGTCCTTCCGCAAAGA
CCTGTTCATCGCCACCTACCAGGCCTTCCCCCCGGTGCCCAACCCACCCCGGCCCCCCAC
CCGCCTGCAGGACCGGCTGCTGAGGAAGCTGGGCCAGCATGCCCACCCCTTCTTCTTCAC
CATACCCCAGAATCTTCCATGCTCCGTCACACTGCAGCCAGGCCCAGAGGATACAGGAA
AGGcCTGCGGCGTAGACTTTGAGATTCGAGCCTTCTGTGCTAAATCACTAGAAGAGAAAA
GCCACAAAAGGAACTCTGTGCGGCTGGTGATCCGAAAGGTGCAGTTCGCCCCGGAGAAA
CCCGGCCCCCAGCCTTCAGCCGAAACCACACGCCACTTCCTCATGTCTGACCGGTCCCTG
CACCTCGAGGCTTCCCTGGACAAGGAGCTGTACTACCATGGGGAGCCCCTCAATGTAAAT
GTCCACGTCACCAACAACTCCACCAAGACCGTCAAGAAGATCAAAGTCTCTGTGAGACA
GTACGCCGACATCTGCCTCTTCAGCACCGCCCAGTACAAGTGTCCTGTGGCTCAACTCGA
ACAAGATGACCAGGTATCTCCCAGCTCCACATTCTGTAAGGTGTACACCATAACCCCACT
GCTCAGTGACAACCGGGAGAAGCGGGGTCTCGCCCTGGATGGGAAACTCAAGCACGAGG
ACACCAACCTGgCTTCCAGCACCATCGTGAAGGAGGGTGCCAACAAGGAGGTGCTGGGA
ATCCTGGTGTCCTACAGGGTCAAGGTGAAGCTGGTGGTGTCTCGAGGCGGGGATGTCTCT
GTGGAGCTGCCTTTTGTTCTTATGCACCCCAAGCCCCACGACCACATCCCCcTCCCcAGAC
CCCAGTCAGCCGCTCCGGAGACAGATGTCCCTGTGGACACCAACCTCATTGAATTTGATA
CCAACTATGCCACAGATGATGACATTGTGTTTGAGGACTTTGCCCGGCTTCGGCTGAAGG
GGATGAAGGATGACGACTATGATGATCAACTCTGCGGATCTAGCTTGTTTAAGGGACCA
CGTGATTACAACCCGATATCGAGCAcCATTTGTCATTTGACGAATGAATCTGATGGGCAC
ACAACATCGTTGTATGGTATTGGATTTGGTCCCTTCATCATTACAAACAAGCACTTGTTTA
GAAGAAATAATGGAACACTGTTGGTCCAATCACTACATGGTGTATTCAAGGTCAAGAAC
ACCACGACTTTGCAACAACACCTCATTGATGGGAGGGACATGATAATTATTCGCATGCCT
AAGGATTTCCCACCATTTCCTCAAAAGCTGAAATTTAGAGAGCCACAAAGGGAAGAGCG
CATATGTCTTGTGACAACCAACTTCCAAACTAAGAGCATGTCTAGCATGGTGTCAGACAC
TAGTTGCACATTCCCTTCATCTGATGGCATATTCTGGAAGCATTGGATTCAAACCAAGGA
TGGGCAGTGTGGCAGTCCATTAGTATCAACTAGAGATGGGTTCATTGTTGGTATACACTC
AGCATCGAATTTCACCAACACAAACAATTATTTCACAAGCGTGCCGAAAAACTTCATGG
AATTGTTGACAAGTCAGGAGGCGCAGCAGTGGGTTAGTGGTTGGCGATTAAATGCTGAC
TCAGTATTGTGGGGGGGCCATAAAGTTTTCATGAGCAAACCTGAAGAGCCTTTTCAGCCA
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GTTAAGGAAGCGACTCAACTCATGAATGAATTGGTGTACTCGTACCCATATGATGTTCCA
GATTACGCTTGAGCGGCCGCTCGAGCATGCATCTAGAGGGCCCTATTCTATAGTGTCACC
TAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGT
TTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAA
TAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGG
GTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATG
CGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCC
CACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGAC
CGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCC
ACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGCATCCCTTTAGGGTTCCGATTTA
GTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGC
CATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGG
ACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAA
GGGATTTTGGGGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAAC
GCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAG
GCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTC
CCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCA
TAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCC
GCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAG
CTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCG
GGAGCTTGTATATCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATG
ATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGG
CTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGC
GCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCA
GGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGC
TCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAG
GATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATG
CGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGC
ATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGA
AGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCG
ACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAA
AATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAG
GACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCG
CTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTT
CTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCC
AACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGA
ATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTC
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TTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATC
ACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCA
TCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATG
GTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGC
CGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTG
CGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAA
TCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCA
CTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGG
TAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGG
CCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCC
GCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACA
GGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCG
ACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTC
AATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTG
TGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGT
CCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGC
AGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTA
CACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAG
AGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTG
CAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTA
CGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTAT
CAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAA
GTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCT
CAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTAC
GATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCT
CACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGT
GGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTA
AGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTG
TCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTT
ACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTC
AGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTT
ACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCT
GAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACC
GCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAA
ACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAA
CTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCA
AAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCC
Appendices 
350 
 
TTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGA
ATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC
CTGACGTC 
 
ATGGGGGAGAAACC – βArrestin2-TEV coding sequence, open reading frame 
CCTGCTTGTGTGT – obtained by DNA sequencing, sequencing read 
GACGGATCGGGAGAT – pcDNA3 sequence taken from lablife website 
https://www.lablife.org/g?a=seqa&id=vdb_g2.9Qyh_n9D3As.29eaY9eZRAcswvk-
_sequence_50b40aa1a5822687e7e39d8c4eacc28ff7a6099b_10 
 
 
> pZK6 (Luciferase) sequence obtained by DNA sequencing 
TCGATTCTAGAATTCGCTGTCTGCGAGGGCCAGCTGTTGGGGTGAGTACTCCCTCTCAAA
AGCGGGCATGACTTCTGCGCTAAGATTGTCAGTTTCCAAAAACGAGGAGGATTTGATATT
CACCTGGCCCGCGGTGATGCCTTTGAGGGTGGCCGCGTCCATCTGGTCAGAAAAGACAA
TCTTTTTGTTGTCAAGCTTGAGGTGTGGCAGGCTTGAGATCTGGCCATACACTTGAGTGA
CAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACTGCAGCCC
AAGCGGATCCTGCGGATTTAATTAACCCGGGTACCGAGCTCGAATTCCAGCTTGGCATTC
CGGTACTGTTGGTAAAATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCT
ATCCTCTAGAGGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGCC
CTGGTTCCTGGAACAATTGCTTTTACAGATGCACATATCGAGGTGAACATCACGTACGCG
GAATACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCTGAATAC
AAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTTTATGCCGGTGTTGGG
CGCGTTATTTATCGGAGTTGCAGTTGCGCCCGCGAACGACATTTATAATGAACGTGAATT
GCTCAACAGTATGAACATTTCGCAGCCTACCGTAGTGTTTGTTTCCAAAAAGGGGTTGCA
AAAAATTTTGAACGTGCAAAAAAAATTACCAATAATCCAGAAAATTATTATCATGGATTC
TAAAACGGATTACCAGGGATTTCAGTCGATGTACACGTTCGTCACATCTCATCTACCTCC
CGGTTTTAATGAATACGATTTTGTACCAGAGTCCTTTGATCGTGACAAAACAATTGCACT
GATAATGAATTCCTCTGGATCTACTGGGTTACCTAAGGGTGTGGCCCTTCCGCATAGAAC
TGCCTGCGTCAGATTCTCGCATGCCAGAGATCCTATTTTTGGCAATCAAATCATTCCGGA
TACTGCGATTTTAAGTGTTGTTCCATTCCATCACGGTTTTGGAATGTTTACTACACTCGGA
TATTTGATATGTGGATTTCGAGTCGTCTTAATGTATAGATTTGAAGAAGAGCTGTTTTTAC
GATCCCTTCAGGATTACAAAATTCAAAGTGCGTTGCTAGTACCAACCCTATTTTCATTCTT
CGCCAAAAGCACTCTGATTGACAAATACGATTTATCTAATTTACACGAAATTGCTTCTGG
GGGCGCACCTCTTTCGAAAGAAGTCGGGGAAGCGGTTGCAAAACGCTTCCATCTTCCAG
GGATACGACAAGGATATGGGCTCACTGAGACTACATCAGCTATTCTGATTACACCCGAG
GGGGATGATAAACCGGGCGCGGTCGGTAAAGTTGTTCCATTTTTTGAAGCGAAGGTTGTG
GATCTGGATACCGGGAAAACGCTGGGCGTTAATCAGAGAGGCGAATTATGTGTCAGAGG
ACCTATGATTATGTCCGGTTATGTAAACAATCCGGAAGCGACCAACGCCTTGATTGACAA
GGATGGATGGCTACATTCTGGAGACATAGCTTACTGGGACGAAGACGAACACTTCTTCAT
AGTTGACCGCTTGAAGTCTTTAATTAAATACAAAGGATATCAGGTGGCCCCCGCTGAATT
GGAATCGATATTGTTACAACACCCCAACATCTTCGACGCGGGCGTGGCAGGTCTTCCCGA
CGATGACGCCGGTGAACTTCCCGCCGCCGTTGTTGTTTTGGAGCACGGAAAGACGATGAC
GGAAAAAGAGATCGTGGATTACGTCGCCAGTCAAGTAACAACCGCGAAAAAGTTGCGCG
GAGGAGTTGTGTTTGTGGACGAAGTACCGAAAGGTCTTACCGGAAAACTCGACGCAAGA
AAAATCAGAGAGATCCTCATAAAGGCCAAGAAGGGCGGAAAGTCCAAATTGTAAAATGT
AACTGTATTCAGCGATGACGAAATTCTTAGCTATTGTAATACTCTAGAGGATCTTTGTGA
Appendices 
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AGGAACCTTACTTCTGTGGTGTGACATAATTGGACAAACTACCTACAGAGATTTAAAGCT
CTAAGGTAAATATAAAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTAATTGTTTG
TGTATTTTAGATTCCAACCTATGGAACTGATGAATGGGAGCAGTGGTGGAATGCCTTTAA
TGAGGAAAACCTGTTTTGCTCAGAAGAAATGCCATCTAGTGATGATGAGGCTACTGCTGA
CTCTCAACATTCTACTCCTCCAAAAAAGAAGAGAAAGGTAGAAGACCCCAAGGACTTTC
CTTCAGAATTGCTAAGTTTTTTGAGTCATGCTGTGTTTAGTAATAGAACTCTTGCTTGCTT
TGCTATTTACACCACAAAGGAAAAAGCTGCACTGCTATACAAGAAAATTATGGAAAAAT
ATTCTGTAACCTTTATAAGTAGGCATAACAGTTATAATCATAACATACTGTTTTTTCTTAC
TCCACACAGGCATAGAGTGTCTGCTATTAATAACTATGCTCAAAAATTGTGTACCTTTAG
CTTTTTAATTTGTAAAGGGGTTAATAAGGAATATTTGATGTATAGTGCCTTGACTAGAGA
TCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCT
CCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGC
TTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTC
ACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGATCCCC
AGGAAGCTCCTCTGTGTCTCATACTCTCGAGTTTACCACTCCCTATCAGTGATAGAGAAA
AGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTA
CCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGAT
AGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTC
GAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTAT
CAGTGATAGAGAAAAGTGAAAGTCGAGCTCGGTACCCGGGTCGAGGTAGGCGTGTACGG
TGGGAGGCCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCA
TCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCCCGA
ATTCACCACGTGGCCGCATCGATTCTAGAATTCGCTGTCTGCGAGGGCCAGCTGTTGGGG
TGAGTACTCCCTCTCAAAAGCGGGCATGACTTCTGCGCTAAGATTGTCAGTTTCCAAAAA
CGAGGAGGATTTGATATTCACCTGGCCCGCGGTGATGCCTTTGAGGGTGGCCGCGTCCAT
CTGGTCAGAAAAGACAATCTTTTTGTTGTCAAGCTTGAGGTGTGGCAGGCTTGAGATCTG
GCCATACACTTGAGTGACAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCC
AGGTCCAACTGCAGCCCAAGCGGATCCTGCGGATTTAATTAACCCGGGTACCGAGCTCG
AATTCCAGCTTGGCATTCCGGTACTGTTGGTAAAATGGAAGACGCCAAAAACATAAAGA
AAGGCCCGGCGCCATTCTATCCTCTAGAGGATGGAACCGCTGGAGAGC 
 
ATGGAAGACGC – Luciferase sequence 
CTGCAG—PstI 
 
> pZK6 (Luciferase) sequence obtained by DNA sequencing, incomplete sequence 
TCGATTCTAGAATTCGCTGTCTGCGAGGGCCAGCTGTTGGGGTGAGTACTCCCTCTCAAA
AGCGGGCATGACTTCTGCGCTAAGATTGTCAGTTTCCAAAAACGAGGAGGATTTGATATT
CACCTGGCCCGCGGTGATGCCTTTGAGGGTGGCCGCGTCCATCTGGTCAGAAAAGACAA
TCTTTTTGTTGTCAAGCTTGAGGTGTGGCAGGCTTGAGATCTGGCCATACACTTGAGTGA
CAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACTGCAGCCC
AAGCGGATCCTGCGGATTTAATTAACCCGGGTACCGAGCTCGAATTCCAGCTTGGCATTC
CGGTACTGTTGGTAAAATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCT
ATCCTCTAGAGGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGCC
CTGGTTCCTGGAACAATTGCTTTTACAGATGCACATATCGAGGTGAACATCACGTACGCG
GAATACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCTGAATAC
AAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTTTATGCCGGTGTTGGG
CGCGTTATTTATCGGAGTTGCAGTTGCGCCCGCGAACGACATTTATAATGAACGTGAATT
GCTCAACAGTATGAACATTTCGCAGCCTACCGTAGTGTTTGTTTCCAAAAAGGGGTTGCA
AAAAATTTTGAACGTGCAAAAAAAATTACCAATAATCCAGAAAATTATTATCATGGATTC
TAAAACGGATTACCAGGGATTTCAGTCGATGTACACGTTCGTCACATCTCATCTACCTCC
CGGTTTTAATGAATACGATTTTGTACCAGAGTCCTTTGATCGTGACAAAACAATTGCACT
GATAATGAATTCCTCTGGATCTACTGGGTTACCTAAGGGTGTGGCCCTTCCGCATAGAAC
TGCCTGCGTCAGATTCTCGCATGCCAGAGATCCTATTTTTGGCAATCAAATCATTCCGGA
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TACTGCGATTTTAAGTGTTGTTCCATTCCATCACGGTTTTGGAATGTTTACTACACTCGGA
TATTTGATATGTGGATTTCGAGTCGTCTTAATGTATAGATTTGAAGAAGAGCTGTTTTTAC
GATCCCTTCAGGATTACAAAATTCAAAGTGCGTTGCTAGTACCAACCCTATTTTCATTCTT
CGCCAAAAGCACTCTGATTGACAAATACGATTTATCTAATTTACACGAAATTGCTTCTGG
GGGCGCACCTCTTTCGAAAGAAGTCGGGGAAGCGGTTGCAAAACGCTTCCATCTTCCAG
GGATACGACAAGGATATGGGCTCACTGAGACTACATCAGCTATTCTGATTACACCCGAG
GGGGATGATAAACCGGGCGCGGTCGGTAAAGTTGTTCCATTTTTTGAAGCGAAGGTTGTG
GATCTGGATACCGGGAAAACGCTGGGCGTTAATCAGAGAGGCGAATTATGTGTCAGAGG
ACCTATGATTATGTCCGGTTATGTAAACAATCCGGAAGCGACCAACGCCTTGATTGACAA
GGATGGATGGCTACATTCTGGAGACATAGCTTACTGGGACGAAGACGAACACTTCTTCAT
AGTTGACCGCTTGAAGTCTTTAATTAAATACAAAGGATATCAGGTGGCCCCCGCTGAATT
GGAATCGATATTGTTACAACACCCCAACATCTTCGACGCGGGCGTGGCAGGTCTTCCCGA
CGATGACGCCGGTGAACTTCCCGCCGCCGTTGTTGTTTTGGAGCACGGAAAGACGATGAC
GGAAAAAGAGATCGTGGATTACGTCGCCAGTCAAGTAACAACCGCGAAAAAGTTGCGCG
GAGGAGTTGTGTTTGTGGACGAAGTACCGAAAGGTCTTACCGGAAAACTCGACGCAAGA
AAAATCAGAGAGATCCTCATAAAGGCCAAGAAGGGCGGAAAGTCCAAATTGTAAAATGT
AACTGTATTCAGCGATGACGAAATTCTTAGCTATTGTAATACTCTAGAGGATCTTTGTGA
AGGAACCTTACTTCTGTGGTGTGACATAATTGGACAAACTACCTACAGAGATTTAAAGCT
CTAAGGTAAATATAAAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTAATTGTTTG
TGTATTTTAGATTCCAACCTATGGAACTGATGAATGGGAGCAGTGGTGGAATGCCTTTAA
TGAGGAAAACCTGTTTTGCTCAGAAGAAATGCCATCTAGTGATGATGAGGCTACTGCTGA
CTCTCAACATTCTACTCCTCCAAAAAAGAAGAGAAAGGTAGAAGACCCCAAGGACTTTC
CTTCAGAATTGCTAAGTTTTTTGAGTCATGCTGTGTTTAGTAATAGAACTCTTGCTTGCTT
TGCTATTTACACCACAAAGGAAAAAGCTGCACTGCTATACAAGAAAATTATGGAAAAAT
ATTCTGTAACCTTTATAAGTAGGCATAACAGTTATAATCATAACATACTGTTTTTTCTTAC
TCCACACAGGCATAGAGTGTCTGCTATTAATAACTATGCTCAAAAATTGTGTACCTTTAG
CTTTTTAATTTGTAAAGGGGTTAATAAGGAATATTTGATGTATAGTGCCTTGACTAGAGA
TCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCT
CCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGC
TTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTC
ACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGATCCCC
AGGAAGCTCCTCTGTGTCTCATACTCTCGAGTTTACCACTCCCTATCAGTGATAGAGAAA
AGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTA
CCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGAT
AGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTC
GAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTAT
CAGTGATAGAGAAAAGTGAAAGTCGAGCTCGGTACCCGGGTCGAGGTAGGCGTGTACGG
TGGGAGGCCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCA
TCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCCCGA
ATTCACCACGTGGCCGCA 
 
ATGGAAGACGC – Luciferase sequence 
CTGCAG—PstI 
 
>pZK6 (Luciferase) complete (pUHC 13-3 based) 11Oct2013 
 
5’-
GAATTCCTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACC
ACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAG
AGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGA
GTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCA
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GTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGA
AAGTCGAGCTCGGTACCCGGGTCGAGGTAGGCGTGTACGGTGGGAGGCCTATATAAGCA
GAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCC
ATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCCCGAATTCACCACGTGGCCGCAT
CGATTCTAGAATTCGCTGTCTGCGAGGGCCAGCTGTTGGGGTGAGTACTCCCTCTCAAAA
GCGGGCATGACTTCTGCGCTAAGATTGTCAGTTTCCAAAAACGAGGAGGATTTGATATTC
ACCTGGCCCGCGGTGATGCCTTTGAGGGTGGCCGCGTCCATCTGGTCAGAAAAGACAAT
CTTTTTGTTGTCAAGCTTGAGGTGTGGCAGGCTTGAGATCTGGCCATACACTTGAGTGAC
AATGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACTGCAGCCC
AAGCGGATCCTGCGGATTTAATTAACCCGGGTACCGAGCTCGAATTCCAGCTTGGCATTC
CGGTACTGTTGGTAAAATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCT
ATCCTCTAGAGGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGATACGCC
CTGGTTCCTGGAACAATTGCTTTTACAGATGCACATATCGAGGTGAACATCACGTACGCG
GAATACTTCGAAATGTCCGTTCGGTTGGCAGAAGCTATGAAACGATATGGGCTGAATAC
AAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTTTATGCCGGTGTTGGG
CGCGTTATTTATCGGAGTTGCAGTTGCGCCCGCGAACGACATTTATAATGAACGTGAATT
GCTCAACAGTATGAACATTTCGCAGCCTACCGTAGTGTTTGTTTCCAAAAAGGGGTTGCA
AAAAATTTTGAACGTGCAAAAAAAATTACCAATAATCCAGAAAATTATTATCATGGATTC
TAAAACGGATTACCAGGGATTTCAGTCGATGTACACGTTCGTCACATCTCATCTACCTCC
CGGTTTTAATGAATACGATTTTGTACCAGAGTCCTTTGATCGTGACAAAACAATTGCACT
GATAATGAATTCCTCTGGATCTACTGGGTTACCTAAGGGTGTGGCCCTTCCGCATAGAAC
TGCCTGCGTCAGATTCTCGCATGCCAGAGATCCTATTTTTGGCAATCAAATCATTCCGGA
TACTGCGATTTTAAGTGTTGTTCCATTCCATCACGGTTTTGGAATGTTTACTACACTCGGA
TATTTGATATGTGGATTTCGAGTCGTCTTAATGTATAGATTTGAAGAAGAGCTGTTTTTAC
GATCCCTTCAGGATTACAAAATTCAAAGTGCGTTGCTAGTACCAACCCTATTTTCATTCTT
CGCCAAAAGCACTCTGATTGACAAATACGATTTATCTAATTTACACGAAATTGCTTCTGG
GGGCGCACCTCTTTCGAAAGAAGTCGGGGAAGCGGTTGCAAAACGCTTCCATCTTCCAG
GGATACGACAAGGATATGGGCTCACTGAGACTACATCAGCTATTCTGATTACACCCGAG
GGGGATGATAAACCGGGCGCGGTCGGTAAAGTTGTTCCATTTTTTGAAGCGAAGGTTGTG
GATCTGGATACCGGGAAAACGCTGGGCGTTAATCAGAGAGGCGAATTATGTGTCAGAGG
ACCTATGATTATGTCCGGTTATGTAAACAATCCGGAAGCGACCAACGCCTTGATTGACAA
GGATGGATGGCTACATTCTGGAGACATAGCTTACTGGGACGAAGACGAACACTTCTTCAT
AGTTGACCGCTTGAAGTCTTTAATTAAATACAAAGGATATCAGGTGGCCCCCGCTGAATT
GGAATCGATATTGTTACAACACCCCAACATCTTCGACGCGGGCGTGGCAGGTCTTCCCGA
CGATGACGCCGGTGAACTTCCCGCCGCCGTTGTTGTTTTGGAGCACGGAAAGACGATGAC
GGAAAAAGAGATCGTGGATTACGTCGCCAGTCAAGTAACAACCGCGAAAAAGTTGCGCG
GAGGAGTTGTGTTTGTGGACGAAGTACCGAAAGGTCTTACCGGAAAACTCGACGCAAGA
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AAAATCAGAGAGATCCTCATAAAGGCCAAGAAGGGCGGAAAGTCCAAATTGTAAAATGT
AACTGTATTCAGCGATGACGAAATTCTTAGCTATTGTAATACTCTAGAGGATCTTTGTGA
AGGAACCTTACTTCTGTGGTGTGACATAATTGGACAAACTACCTACAGAGATTTAAAGCT
CTAAGGTAAATATAAAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTAATTGTTTG
TGTATTTTAGATTCCAACCTATGGAACTGATGAATGGGAGCAGTGGTGGAATGCCTTTAA
TGAGGAAAACCTGTTTTGCTCAGAAGAAATGCCATCTAGTGATGATGAGGCTACTGCTGA
CTCTCAACATTCTACTCCTCCAAAAAAGAAGAGAAAGGTAGAAGACCCCAAGGACTTTC
CTTCAGAATTGCTAAGTTTTTTGAGTCATGCTGTGTTTAGTAATAGAACTCTTGCTTGCTT
TGCTATTTACACCACAAAGGAAAAAGCTGCACTGCTATACAAGAAAATTATGGAAAAAT
ATTCTGTAACCTTTATAAGTAGGCATAACAGTTATAATCATAACATACTGTTTTTTCTTAC
TCCACACAGGCATAGAGTGTCTGCTATTAATAACTATGCTCAAAAATTGTGTACCTTTAG
CTTTTTAATTTGTAAAGGGGTTAATAAGGAATATTTGATGTATAGTGCCTTGACTAGAGA
TCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCT
CCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGC
TTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTC
ACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGCCTCTAG
AGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCT
TCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCA
GCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAA
CATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCG
TTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGG
TGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGT
GCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGA
AGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCT
CCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTA
ACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTG
GTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGG
CCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTT
ACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGG
TGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCC
TTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTT
GGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTT
TAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAG
TGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTC
GTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACC
GCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGG
CCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCC
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GGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTA
CAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAAC
GATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTC
CTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCAC
TGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTC
AACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAAT
ACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTT
CTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCA
CTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAA
AACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATA
CTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCG
GATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCC
GAAAAGTGCCACCTGACGTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAA
AAATAGGCGTATCACGAGGCCCTTTCGTCTTCAA-3’ 
ATGGAAGACGC – Luciferase sequence 
TCGATTCTA—sequence obtained by DNA sequencing 
 
 Appendix 3 7.3
> human bradykinin receptor B2 (BDK-B2) coding sequence, gene synthesis order 
GAATTCACCATGCTCAATGTCACCTTGCAAGGGCCCACTCTTAACGGGACCTTTGCCCAG
AGCAAATGCCCCCAAGTGGAGTGGCTGGGCTGGCTCAACACCATCCAGCCCCCCTTCCTC
TGGGTGCTGTTCGTGCTGGCCACCCTAGAGAACATCTTTGTCCTCAGCGTCTTCTGCCTGC
ACAAGAGCAGCTGCACGGTGGCAGAGATCTACCTGGGGAACCTGGCCGCAGCAGACCTG
ATCCTGGCCTGCGGGCTGCCCTTCTGGGCCATCACCATCTCCAACAACTTCGACTGGCTC
TTTGGGGAGACGCTCTGCCGCGTGGTGAATGCCATTATCTCCATGAACCTGTACAGCAGC
ATCTGTTTCCTGATGCTGGTGAGCATCGACCGCTACCTGGCCCTGGTGAAAACCATGTCC
ATGGGCCGGATGCGCGGCGTGCGCTGGGCCAAGCTCTACAGCTTGGTGATCTGGGGGTG
TACGCTGCTCCTGAGCTCACCCATGCTGGTGTTCCGGACCATGAAGGAGTACAGCGATGA
GGGCCACAACGTCACCGCTTGTGTCATCAGCTACCCATCCCTCATCTGGGAAGTGTTCAC
CAACATGCTCCTGAATGTCGTGGGCTTCCTGCTGCCCCTGAGTGTCATCACCTTCTGCACG
ATGCAGATCATGCAGGTGCTGCGGAACAACGAGATGCAGAAGTTCAAGGAGATCCAGAC
GGAGAGGAGGGCCACGGTGCTAGTCCTGGTTGTGCTGCTGCTATTCATCATCTGCTGGCT
GCCCTTCCAGATCAGCACCTTCCTGGATACGCTGCATCGCCTCGGCATCCTCTCCAGCTG
CCAGGACGAGCGCATCATCGATGTAATCACACAGATCGCCTCCTTCATGGCCTACAGCAA
CAGCTGCCTCAACCCACTGGTGTACGTGATCGTGGGCAAGCGCTTCCGAAAGAAGTCTTG
GGAGGTGTACCAGGGAGTGTGCCAGAAAGGGGGCTGCAGGTCAGAACCCATTCAGATGG
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AGAACTCCATGGGCACACTGCGGACCTCCATCTCCGTGGAACGCCAGATTCACAAACTG
CAGGACTGGGCAGGGAGCAGACAGTCTAGA 
 
> pZK7 complete sequence, BDK-B2 in pBlueScript II SK(+) 
CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCA
TTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGA
GATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTC
CAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCAC
CCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGG
AGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGA
AGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGT
AACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCATTCGCCATTCAG
GCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGC
GAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCAC
GACGTTGTAAAACGACGGCCAGTGAGCGCGCGTAATACGACTCACTATAGGGCGAATTG
GGTACCGGGCCCCCCCTCGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCCTGCAG
CCCGAATTCACCATGCTCAATGTCACCTTGCAAGGGCCCACTCTTAACGGGACCTTTGCC
CAGAGCAAATGCCCCCAAGTGGAGTGGCTGGGCTGGCTCAACACCATCCAGCCCCCCTT
CCTCTGGGTGCTGTTCGTGCTGGCCACCCTAGAGAACATCTTTGTCCTCAGCGTCTTCTGC
CTGCACAAGAGCAGCTGCACGGTGGCAGAGATCTACCTGGGGAACCTGGCCGCAGCAGA
CCTGATCCTGGCCTGCGGGCTGCCCTTCTGGGCCATCACCATCTCCAACAACTTCGACTG
GCTCTTTGGGGAGACGCTCTGCCGCGTGGTGAATGCCATTATCTCCATGAACCTGTACAG
CAGCATCTGTTTCCTGATGCTGGTGAGCATCGACCGCTACCTGGCCCTGGTGAAAACCAT
GTCCATGGGCCGGATGCGCGGCGTGCGCTGGGCCAAGCTCTACAGCTTGGTGATCTGGG
GGTGTACGCTGCTCCTGAGCTCACCCATGCTGGTGTTCCGGACCATGAAGGAGTACAGCG
ATGAGGGCCACAACGTCACCGCTTGTGTCATCAGCTACCCATCCCTCATCTGGGAAGTGT
TCACCAACATGCTCCTGAATGTCGTGGGCTTCCTGCTGCCCCTGAGTGTCATCACCTTCTG
CACGATGCAGATCATGCAGGTGCTGCGGAACAACGAGATGCAGAAGTTCAAGGAGATCC
AGACGGAGAGGAGGGCCACGGTGCTAGTCCTGGTTGTGCTGCTGCTATTCATCATCTGCT
GGCTGCCCTTCCAGATCAGCACCTTCCTGGATACGCTGCATCGCCTCGGCATCCTCTCCA
GCTGCCAGGACGAGCGCATCATCGATGTAATCACACAGATCGCCTCCTTCATGGCCTACA
GCAACAGCTGCCTCAACCCACTGGTGTACGTGATCGTGGGCAAGCGCTTCCGAAAGAAG
TCTTGGGAGGTGTACCAGGGAGTGTGCCAGAAAGGGGGCTGCAGGTCAGAACCCATTCA
GATGGAGAACTCCATGGGCACACTGCGGACCTCCATCTCCGTGGAACGCCAGATTCACA
AACTGCAGGACTGGGCAGGGAGCAGACAGTCTAGAGGGGGATCCACTAGTTCTAGAGCG
GCCGCCACCGCGGTGGAGCTCCAGCTTTTGTTCCCTTTAGTGAGGGTTAATTGCGCGCTT
Appendices 
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GGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACAC
AACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACT
CACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCT
GCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCG
CTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTC
ACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATG
TGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTT
CCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGC
GAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCT
CTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGT
GGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAA
GCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTA
TCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAA
CAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTA
ACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCT
TCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGT
TTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTG
ATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTC
ATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAA
TCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAG
GCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGT
AGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGA
GACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGA
GCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGA
AGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGG
CATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCA
AGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCG
ATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCAT
AATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCA
AGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGG
ATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGG
GGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTG
CACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAG
GAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCAT
ACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATAC
ATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAA
GTGCCAC 
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GAATTCACCA – Gene synthesis ordered from Eurofins, checked by DNA sequencing 
CTAAATTGTA – pBlueScript II SK(+) backbone from: 
https://www.addgene.org/browse/sequence_vdb/1946/ 
 
 
> enhanced green fluorescent protein (eGFP) coding sequence, gene synthesis order 
CTGCAGCCCAAGCGGATCCTGCGGATTTAATTAACCCGGGTACCGAGCTCGAATTCCAGC
TTGGCATTCCGGTACTGTTGGTAAAATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG
TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCC
GGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCAC
CGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTG
CTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGA
AGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCG
CCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGAC
TTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAA
CGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCC
ACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATC
GGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAG
CAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCG
GGATCACTCTCGGCATGGACGAGCTGTACAAGTAAGATATC 
 
>pZK8 complete sequence, pCR2.1, 3929 bp + eGFP gene (expected) 
AGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTT 
TCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAG 
GCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAA 
ACAGCTATGACCATGATTACGCCAAGCTTGGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGC 
TGGAATTCGCCCTTCTGCAGCCCAAGCGGATCCTGCGGATTTAATTAACCCGGGTACCGAGCTC
GAATTCCAGCTTGGCATTCCGGTACTGTTGGTAAAATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGT
GGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCT
ACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTAC
GGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACC
GCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAC
GTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCA
GCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGT
CCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
ATGGACGAGCTGTACAAGTAAGATATCAAGGGCGAATTCTGCAGATATCCATCACACTGGCGGCCGCTCGAGCATGCATCT
AGAGGGCCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGG
CGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTT
CCCAACAGTTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCA
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GCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTT
CCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTA
GGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTG
GACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCC
TATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATTCAGGGCGCAAGGGCTGCTAAAGGAAG
CGGAACACGTAGAAAGCCAGTCCGCAGAAACGGTGCTGACCCCGGATGAATGTCAGCTACTGGGCTATCTGGACAAGGGAAAA
CGCAAGCGCAAAGAGAAAGCAGGTAGCTTGCAGTGGGCTTACATGGCGATAGCTAGACTGGGCGGTTTTATGGACAGCAAGCG
AACCGGAATTGCCAGCTGGGGCGCCCTCTGGTAAGGTTGGGAAGCCCTGCAAAGTAAACTGGATGGCTTTCTTGCCGCCAAGG
ATCTGATGGCGCAGGGGATCAAGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGC
AGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGT
TCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCA
GCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCT
GCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCCCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAA
TGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGG
ATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAA
GGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCT
TTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAA
GAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCG
CCTTCTTGACGAGTTCTTCTGAATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGC
GGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGG
GTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTT
AAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAA
TGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAA
CCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATG
GGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCC
TGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGA
TGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGT
GAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAG
TCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAG
TTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTC
ATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCC
TTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTAC
CAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCAC
CACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTC
GTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGC
CCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGA
AAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCT
TTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAA
ACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGAT
TCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAG
CGAGGAAGCGGAAG 
CTGCAG—PstI 
eGFP Coding sequence 
 
GATATC-EcoRV 
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 Appendix 4 7.4
> pZK7 (human bradykinin receptor B2 (BDK-B2)) synthesized, sequence confirmed 
GGGTAACGGCCGTCAAAGGCCAAAGTTTCCCTTAGAATTCACCcATGCTCAATGTCACCT
TGCAAGGGCCCACTCTTAACGGGACCTTTGCCCAGAGCAAATGCCCCCAAGTGGAGTGG
CTGGGCTGGCTCAACACCATCCAGCCCCCCTTCCTCTGGGTGCTGTTCGTGCTGGCCACC
CTAGAGAACATCTTTGTCCTCAGCGTCTTCTGCCTGCACAAGAGCAGCTGCACGGTGGCA
GAGATCTACCTGGGGAACCTGGCCGCAGCAGACCTGATCCTGGCCTGCGGGCTGCCCTTC
TGGGCCATCACCATCTCCAACAACTTCGACTGGCTCTTTGGGGAGACGCTCTGCCGCGTG
GTGAATGCCATTATCTCCATGAACCTGTACAGCAGCATCTGTTTCCTGATGCTGGTGAGC
ATCGACCGCTACCTGGCCCTGGTGAAAACCATGTCCATGGGCCGGATGCGCGGCGTGCG
CTGGGCCAAGCTCTACAGCTTGGTGATCTGGGGGTGTACGCTGCTCCTGAGCTCACCCAT
GCTGGTGTTCCGGACCATGAAGGAGTACAGCGATGAGGGCCACAACGTCACCGCTTGTG
TCATCAGCTACCCATCCCTCATCTGGGAAGTGTTCACCAACATGCTCCTGAATGTCGTGG
GCTTCCTGCTGCCCCTGAGTGTCATCACCTTCTGCACGATGCAGATCATGCAGGTGCTGC
GGAACAACGAGATGCAGAAGTTCAAGGAGATCCAGACGGAGAGGAGGGCCACGGTGCT
AGTCCTGGTTGTGCTGCTGCTATTCATCATCTGCTGGCTGCCCTTCCAGATCAGCACCTTC
CTGGATACGCTGCATCGCCTCGGCATCCTCTCCAGCTGCCAGGACGAGCGCATCATCGAT
GTAATCACACAGATCGCCTCCTTCATGGCCTACAGCAACAGCTGCCTCAACCCACTGGTG
TACGTGATCGTGGGCAAGCGCTTCCGAAAGAAGTCTTGGGAGGTGTACCAGGGAGTGTG
CCAGAAAGGGGGCTGCAGGTCAGAACCCATTCAGATGGAGAACTCCATGGGCACACTGC
GGACCTCCATCTCCGTGGAACGCCAGATTCACAAACTGSAGGACTGGGCAGGGAGCAGA
CAGTCTAGATAAGGGATATCACGTGAAGCTTGCAAG 
 
> pZK8 (enhanced green fluorescent protein (eGFP)) synthesized, sequence confirmed 
ACGGCCGCCAGTGTGCTGGAATTCGCCCTTATTGAAGACTTAWGCCTGCAGCCCAAGCG
GATCCTGCGGATTTAATTAACCCGGGTACCGAGCTCGAATTCCAGCTTGGCATTCCGGTA
CTGTTGGTAAAATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTG
GTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGG
CGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGT
GCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCC
CGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGG
AGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTC
GAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGG
CAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGG
CCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGAC
GGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGT
GCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACG
AGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGC
ATGGACGAGCTGTACAAGTAAGATATCACCAAGGGCGAATTCTGCAGATATCCATCACA
CTGGCGGCCGCTCGAGCATGCATCTAGAGGGCCCAATTCGCCCTATAGTGAGTCGTATTA
CAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACT
TAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCAC
CGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGTARCGGC
GCATTAAGCGCGGCGGGTGTGGgTGGTTACGCGCAGCGTGACCGCTACMYTTGCCAGCG
CCCTAaGCGCCCGCTCCTTTtCGCTTTCTTCCYTTCCTTTtCTCgCCACGTTtCGCCGGStTTTC
CCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACC
TCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGA
CGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAAC
TGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATT
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TCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAA
ATTCAGGGCGCAAGGGCTGCTAAAGGAAGCGGAACACGTAGAAAGCCAGTCCGCAGAA
ACGGTGCTGACCCCGGATGAATGTCAGCTACTGGGCTATCTGGACAAGGGAAAACGCAA
GCGCAAAGAGAAAGCAGGTAGCTTGCAGTGGGCTTACATGGCGATAGCTAGACTGGGCG
GTTTTATGGACAGCAAGCGAACCGGAATTGCCAGCTGGGGCGCCCTCTGGTAAGGTTGG
GAAGCCCTGCAAAGTAAACTGGATGGCTTTCTTGCCGCCAAGGATCTGATGGCGCAGGG
GATCAAGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGA
TTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAA
CAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTT
CTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCG
GCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGA
AGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCCC
ACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGC
TTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGT
ACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCT
CGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCG
TCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTG
GATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTA
CCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACG
GTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTG
AATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTG
CGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTG
AAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATC
CTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTAT
GTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACT
ATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCA
TGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAAC
TTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGG
GATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGA
CGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTG
GCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAA
GTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTG
GAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCC
TCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAG
ACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTA
CTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAG
ATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGT
CAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCT
GCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAG
CTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTT
CTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATAC
CTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACC
GGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGG
TTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGC
GTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTA
AGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGT
ATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTC
GTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGG
CCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAAC
CGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAG
CGAGTCAGTGAGCGAGGAAGCGGAAG 
 
 
 
Appendices 
362 
 
 Appendix 5 7.5
> pZK9 (BDK-B2-AVPR2tail-TCS-tTA) plasmid construction sequence confirmation 
ACTCACGGGGATTTcCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCA
AAATCAACGGGACTTTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAAATGGGCG
GTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATC
ACTAGAAGCTTTATTGCGGTAGTTTATCACAGTTAAATTGCTAACGCAGTCAGTGCTTCT
GACACAACAGTCTCGAACTTAAGCTGCAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAG
TATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGA
GAAGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCT
CTCCACAGGTGTCCACTCCCAGTTCAATTACAGCTCTTAAGGCTAGAGTACTTAATACGA
CTCACTATAGGCTAGAGCGGCCGCGGAATTCACCATGCTCAATGTCACCTTGCAAGGGCC
CACTCTTAACGGGACCTTTGCCCAGAGCAAATGCCCCCAAGTGGAGTGGCTGGGCTGGCT
CAACACCATCCAGCCCCCCTTCCTCTGGGTGCTGTTCGTGCTGGCCACCCtAGAGAACATC
TTTGTCCTCAGCGTCTTCTGCCTGCACAAGAGCAGCTGCACGGTGGCAGAGATCTACCTG
GGGAACCTGGCCGCAGCAGACCTGATCCTGGCCTGCGGGCTGCCCTTCTGGGCCATCACC
ATCTCCAACAACTTCGACTGGCTCTTTGGGGAGACGCTCTGCCGCGTGGTGAATGCCATT
ATCTCCATGAACCTGTACAGCAGCATCTGTTTCCTGATGCTGGTGAGCATCGACCGCTAC
CTGGCCCTGGTGAAAACCATGTCCATGGGCCGGATGCGCGGCGTGCGCTGGGCCAAGCT
CTACAGCTTGGTGATCTGGGGGTGTACGCTGCTCCTGAGCTCACCCATGCTGGTGTTCCG
GACCATGAAGGAGTACAGCGATGAGGGCCACAACGTCACCGCTTGTGTCATCAGCTACC
CATCCCTCATCTGGGAAGTGTTCACCAACATGCTCCTGAATGTCGTGGGCTTCCTGCTGC
CCCTGAGTGTCATCACCTTCTGCACGATGCAGATCATGCAGGTGCTGCGGAACAACGAG
ATGCAGAAGTTCAAGGAGATCCAGACGGAGAGGAGGGCCACGGTGCTAGTCCTGGTTGT
GCTGCTGCTATTCATCATCTGCTGGCTGCCCTTCCAGATCAGCACCTTCCTGGATACGCTG
CATCGCCTCGGCATCCTCTCCAGCTGCCAGGACGAGCGCATCATCGATGTAATCACACAG
ATCGCCTCCTTCATGGCCTACAGCAACAGCTGCCTCAACCCACTGGTGTACGTGATCGTG
GGCAAGCGCTTCCGAAAGAAGTCTTGGGAGGTGTACCAGGGAGTGTGCCAGAAAGGGG
GCTGCAGGTCAGAACCCATTCAGATGGAGAACTCCATGGGCACACTGCGGACCTCCATC
TCCGTGGAACGCCAGATTCACAAACTGCAGGACTGGGCAGGGAGCAGACAGTCTAGAAC
CCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCACCGCCAGCTCCTCCCTGGCCAA
GGACACTTCATCGGGATCCGAGAACCTGTACTTCCAGCTAAGATTAGATAAAAGTAAAG
TGATTAACAGCGCATTAGAGCTGCTTAATGAGGTCGGAATCGAAGGTTTAACAACCCGT
AAACTCGCCCAGAAGCTAGGTGTAGAGCAGCCTACATTGTATTGGCATGTAAAAAATAA
GCGGGCTTTGCTCGACGCCTTAGCCATTGAGATGTTAGATAGGCACCATACTCACTTTTG
CCCTTTAGAAGGGGAAAGCTGGCAAGATTTTTTACGTAATAACGCTAAAAGTTTTAGATG
TGCTTTACTAAGTCATCGCGATGGAGCAAAAGTACATTTAGGTACACGGCCTACAGAAA
AACAGTATGAAACTCTCGAAAATCAATTAGCCTTTTTATGCCAACAAGGTTTTTCACTAG
AGAATGCATTATATGCACTCAGCGCTGTGGGGCATTTTACTTTAGGTTGCGTATTGGAAG
ATCAAGAGCATCAAG 
 
> pZK9 complete sequence (BDK-B2-AVPR2tail-TCS-tTA in pCI) 
TCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTAT
TGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCCAA
TATGACCGCCATGTTGGCATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGT
CATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGC
CTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAG
TAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCC
ACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACG
GTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGC
Appendices 
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AGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCA
ATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCA
ATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAATAACCCCG
CCCCGTTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCT
CGTTTAGTGAACCGTCAGATCACTAGAAGCTTTATTGCGGTAGTTTATCACAGTTAAATT
GCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGAAGTTGGTCG
TGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAA
ACTGGGCTTGTCGAGACAGAGAAGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTAC
TGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCAATTACAGCTCTTAA
GGCTAGAGTACTTAATACGACTCACTATAGGCTAGAGCGGCCGCGGAATtCACCATGCTC
AATGTCACCTTGCAAGGGCCCACTCTTAACGGGACCTTTGCCCAGAGCAAATGCCCCCAA
GTGGAGTGGCTGGGCTGGCTCAACACCATCCAGCCCCCCTTCCTCTGGGTGCTGTTCGTG
CTGGCCACCCTAGAGAACATCTTTGTCCTCAGCGTCTTCTGCCTGCACAAGAGCAGCTGC
ACGGTGGCAGAGATCTACCTGGGGAACCTGGCCGCAGCAGACCTGATCCTGGCCTGCGG
GCTGCCCTTCTGGGCCATCACCATCTCCAACAACTTCGACTGGCTCTTTGGGGAGACGCT
CTGCCGCGTGGTGAATGCCATTATCTCCATGAACCTGTACAGCAGCATCTGTTTCCTGAT
GCTGGTGAGCATCGACCGCTACCTGGCCCTGGTGAAAACCATGTCCATGGGCCGGATGC
GCGGCGTGCGCTGGGCCAAGCTCTACAGCTTGGTGATCTGGGGGTGTACGCTGCTCCTGA
GCTCACCCATGCTGGTGTTCCGGACCATGAAGGAGTACAGCGATGAGGGCCACAACGTC
ACCGCTTGTGTCATCAGCTACCCATCCCTCATCTGGGAAGTGTTCACCAACATGCTCCTG
AATGTCGTGGGCTTCCTGCTGCCCCTGAGTGTCATCACCTTCTGCACGATGCAGATCATG
CAGGTGCTGCGGAACAACGAGATGCAGAAGTTCAAGGAGATCCAGACGGAGAGGAGGG
CCACGGTGCTAGTCCTGGTTGTGCTGCTGCTATTCATCATCTGCTGGCTGCCCTTCCAGAT
CAGCACCTTCCTGGATACGCTGCATCGCCTCGGCATCCTCTCCAGCTGCCAGGACGAGCG
CATCATCGATGTAATCACACAGATCGCCTCCTTCATGGCCTACAGCAACAGCTGCCTCAA
CCCACTGGTGTACGTGATCGTGGGCAAGCGCTTCCGAAAGAAGTCTTGGGAGGTGTACC
AGGGAGTGTGCCAGAAAGGGGGCTGCAGGTCAGAACCCATTCAGATGGAGAACTCCATG
GGCACACTGCGGACCTCCATCTCCGTGGAACGCCAGATTCACAAACTGCAGGACTGGGC
AGGGAGCAGACAGTCTAGAACCCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCA
CCGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGGGATCCGAGAACCTGTACTTCCAGC
TAAGATTAGATAAAAGTAAAGTGATTAACAGCGCATTAGAGCTGCTTAATGAGGTCGGA
ATCGAAGGTTTAACAACCCGTAAACTCGCCCAGAAGCTAGGTGTAGAGCAGCCTACATT
GTATTGGCATGTAAAAAATAAGCGGGCTTTGCTCGACGCCTTAGCCATTGAGATGTTAGA
TAGGCACCATACTCACTTTTGCCCTTTAGAAGGGGAAAGCTGGCAAGATTTTTTACGTAA
TAACGCTAAAAGTTTTAGATGTGCTTTACTAAGTCATCGCGATGGAGCAAAAGTACATTT
AGGTACACGGCCTACAGAAAAACAGTATGAAACTCTCGAAAATCAATTAGCCTTTTTATG
CCAACAAGGTTTTTCACTAGAGAATGCATTATATGCACTCAGCGCTGTGGGGCATTTTAC
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TTTAGGTTGCGTATTGGAAGATCAAGAGCATCAAGTCGCTAAAGAAGAAAGGGAAACAC
CTACTACTGATAGTATGCCGCCATTATTACGACAAGCTATCGAATTATTTGATCACCAAG
GTGCAGAGCCAGCCTTCTTATTCGGCCTTGAATTGATCATATGCGGATTAGAAAAACAAC
TTAAATGTGAAAGTGGGTCCGCGTACAGCCGCGCGCGTACGAAAAACAATTACGGGTCT
ACCATCGAGGGCCTGCTCGATCTCCCGGACGACGACGCCCCCGAAGAGGCGGGGCTGGC
GGCTCCGCGCCTGTCCTTTCTCCCCGCGGGACACACGCGCAGACTGTCGACGGCCCCCCC
GACCGATGTCAGCCTGGGGGACGAGCTCCACTTAGACGGCGAGGACGTGGCGATGGCGC
ATGCCGACGCGCTAGACGATTTCGATCTGGACATGTTGGGGGACGGGGATTCCCCGGGT
CCGGGATTTACCCCCCACGACTCCGCCCCCTACGGCGCTCTGGATATGGCCGACTTCGAG
TTTGAGCAGATGTTTACCGATGCCCTTGGAATTGACGAGTACGGTGGGTAGGGGGCGCG
AGGATCTCTCGAGGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACA
AACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGC
TTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTT
TATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAA
ATGTGGTAAAATCGATAAGGATCCGGGCTGGCGTAATAGCGAAGAGGCCCGCACCGATC
GCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATT
AAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAG
CGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAA
GCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCC
AAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTT
CGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACA
ACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCT
ATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAA
CGCTTACAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGC
ATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACAC
CCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGA
CAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAA
CGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATA
ATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGT
TTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATG
CTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATT
CCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAA
AAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGC
GGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAA
GTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGC
CGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTT
ACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACAC
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TGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCA
CAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCA
TACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAA
CTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAG
GCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCT
GATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGA
TGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA
ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAG
ACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGAT
CTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTC
CACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTG
CGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCG
GATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCA
AATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCG
CCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCG
TGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTG
AACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGAT
ACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAG
GTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGA
AACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTT
TGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTA
CGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGGCTCGACAGATCT 
 
ATGCTCAATGTCACC – BDK-B2-AVPR2tail-TCS-tTAcoding sequence, open reading frame 
 ATGCTCAATGTCACC – BDK-B2 GPCR coding sequence 
ACTTTCCTACTTGGCAG – obtained by DNA sequencing, sequencing read 
TCAATATTGGCCATT – pCI sequence taken from Promega website 
http://www.promega.co.uk/products/vectors/mammalian-expression-vectors/pci-mammalian-
expression-
vector/?origUrl=http%3a%2f%2fwww.promega.com%2fproducts%2fvectors%2fmammalian-
expression-vectors%2fpci-mammalian-expression-vector%2f 
 
 
>pZK10 (eGFP tango reporter) plasmid construction sequence confirmation 
ATTCACCACGTGGCCGCATCGATTCTAGAATTCGCTGTCTGCGAGGGCCAGCTGTTGGGG
TGAGTACTCCCTCTCAAAAGCGGGCATGACTTCTGCGCTAAGATTGTCAGTTTCCAAAAA
Appendices 
366 
 
CGAGGAGGATTTGATATTCACCTGGCCCGCGGTGATGCCTTTGAGGGTGGCCGCGTCCAT
CTGGTCAGAAAAGACAATCTTTTTGTTGTCAAGCTTGAGGTGTGGCAGGCTTGAGATCTG
GCCATACACTTGAGTGACAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCC
AGGTCCAACTGCAGCCCAAGCGGATCCTGCGGATTTAATTAACCCGGGTACCGAGCTCG
AATTCCAGCTTGGCATTCCGGTACTGTTGGTAAAATGGTGAGCAAGGGCGAGGAGCTGTT
CACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCA
GCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATC
TGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGC
GTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCC
ATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAA
GACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGG
GCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAAC
AGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAA
GATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACA
CCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCG
CCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACC
GCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAGATATCAGGTGGCCCCC
GCTGAATTGGAATCGATATTGTTACAACACCCCAACATCTTCGACGCGGGCGTGGCAGGT
CTTCCCGACGATGACGCCGGTGAACTTCCCGCCGCCGTTGTTGTTTTGGAGCACGGAAAG
ACGATGACGGAtAAAAGAGATCGTGGATTACGTCGCCAGTCAAGTAACAACCGC 
 
>pZK10 complete (pUHC 13-3 based) 11Oct2013 
5’-
GAATTCCTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACC
ACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAG
AGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGA
GTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCA
GTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGA
AAGTCGAGCTCGGTACCCGGGTCGAGGTAGGCGTGTACGGTGGGAGGCCTATATAAGCA
GAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCC
ATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCCCGAATTCACCACGTGGCCGCAT
CGATTCTAGAATTCGCTGTCTGCGAGGGCCAGCTGTTGGGGTGAGTACTCCCTCTCAAAA
GCGGGCATGACTTCTGCGCTAAGATTGTCAGTTTCCAAAAACGAGGAGGATTTGATATTC
ACCTGGCCCGCGGTGATGCCTTTGAGGGTGGCCGCGTCCATCTGGTCAGAAAAGACAAT
CTTTTTGTTGTCAAGCTTGAGGTGTGGCAGGCTTGAGATCTGGCCATACACTTGAGTGAC
AATGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACTGCAGCCC
Appendices 
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AAGCGGATCCTGCGGATTTAATTAACCCGGGTACCGAGCTCGAATTCCAGCTTGGCATTC
CGGTACTGTTGGTAAAATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCA
TCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGC
GAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCT
GCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCG
CTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGT
CCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGA
AGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAG
GACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATAT
CATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGC
CCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCC
AACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCT
CGGCATGGACGAGCTGTACAAGTAAGATATCAGGTGGCCCCCGCTGAATTGGAATCGAT
ATTGTTACAACACCCCAACATCTTCGACGCGGGCGTGGCAGGTCTTCCCGACGATGACGC
CGGTGAACTTCCCGCCGCCGTTGTTGTTTTGGAGCACGGAAAGACGATGACGGAAAAAG
AGATCGTGGATTACGTCGCCAGTCAAGTAACAACCGCGAAAAAGTTGCGCGGAGGAGTT
GTGTTTGTGGACGAAGTACCGAAAGGTCTTACCGGAAAACTCGACGCAAGAAAAATCAG
AGAGATCCTCATAAAGGCCAAGAAGGGCGGAAAGTCCAAATTGTAAAATGTAACTGTAT
TCAGCGATGACGAAATTCTTAGCTATTGTAATACTCTAGAGGATCTTTGTGAAGGAACCT
TACTTCTGTGGTGTGACATAATTGGACAAACTACCTACAGAGATTTAAAGCTCTAAGGTA
AATATAAAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTAATTGTTTGTGTATTTT
AGATTCCAACCTATGGAACTGATGAATGGGAGCAGTGGTGGAATGCCTTTAATGAGGAA
AACCTGTTTTGCTCAGAAGAAATGCCATCTAGTGATGATGAGGCTACTGCTGACTCTCAA
CATTCTACTCCTCCAAAAAAGAAGAGAAAGGTAGAAGACCCCAAGGACTTTCCTTCAGA
ATTGCTAAGTTTTTTGAGTCATGCTGTGTTTAGTAATAGAACTCTTGCTTGCTTTGCTATTT
ACACCACAAAGGAAAAAGCTGCACTGCTATACAAGAAAATTATGGAAAAATATTCTGTA
ACCTTTATAAGTAGGCATAACAGTTATAATCATAACATACTGTTTTTTCTTACTCCACACA
GGCATAGAGTGTCTGCTATTAATAACTATGCTCAAAAATTGTGTACCTTTAGCTTTTTAAT
TTGTAAAGGGGTTAATAAGGAATATTTGATGTATAGTGCCTTGACTAGAGATCATAATCA
GCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGA
ACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATG
GTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATT
CTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGCCTCTAGAGCTGCAT
TAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCC
TCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCA
AAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAG
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CAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCAT
AGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAA
CCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCC
TGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCG
CTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGG
GCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTC
TTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGG
ATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTA
CGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGG
AAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTT
TGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCT
TTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGA
GATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAA
TCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCAC
CTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGAT
AACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACC
CACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGC
AGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCT
AGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATC
GTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGG
CGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATC
GTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAAT
TCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGT
CATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATA
ATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGC
GAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCAC
CCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAA
GGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTC
TTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATAT
TTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTG
CCACCTGACGTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGC
GTATCACGAGGCCCTTTCGTCTTCAA-3’ 
 
ATGGTGAGCA – eGFP coding sequence 
CTCGAGTTTACCA – obtained from DNA sequencing 
Appendices 
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GAATTC - pUHC 13-3 sequence, http://www.zmbh.uni-heidelberg.de/bujard/reporter/pUHC13-
3.html 
 
 Appendix 6 7.6
> pZK9 (BDK-B2-AVPR2tail-TCS-tTA) endotoxin-free plasmid production, sequence confirmation 
GTAcACcAaTGGGCGTGGAtAGCGGTTTGACTCACGGGGATTTCCaAGTCTCCACCCCATTG
ACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAATA
ACCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGC
AGAGCTCGTTTAGTGAACCGTCAGATCACTAGAAGCTTTATTGCGGTAGTTTATCACAGT
TAAATTGCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGAAGT
TGGTCGTGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCA
ATAGAAACTGGGCTTGTCGAGACAGAGAAGACTCTTGCGTTTCTGATAGGCACCTATTGG
TCTTACTGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCAATTACAGC
TCTTAAGGCTAGAGTACTTAATACGACTCACTATAGGCTAGAGCGGCCGCGGAATTCACC
ATGCTCAATGTCACCTTGCAAGGGCCCACTCTTAACGGGACCTTTGCCCAGAGCAAATGC
CCCCAAGTGGAGTGGCTGGGCTGGCTCAACACCATCCAGCCCCCCTTCCTCTGGGTGCTG
TTCGTGCTGGCCACCCTAGAGAACATCTTTGTCCTCAGCGTCTTCTGCCTGCACAAGAGC
AGCTGCACGGTGGCAGAGATCTACCTGGGGAACCTGGCCGCAGCAGACCTGATCCTGGC
CTGCGGGCTGCCCTTCTGGGCCATCACCATCTCCAACAACTTCGACTGGCTCTTTGGGGA
GACGCTCTGCCGCGTGGTGAATGCCATTATCTCCATGAACCTGTACAGCAGCATCTGTTT
CCTGATGCTGGTGAGCATCGACCGCTACCTGGCCCTGGTGAAAACCATGTCCATGGGCCG
GATGCGCGGCGTGCGCTGGGCCAAGCTCTACAGCTTGGTGATCTGGGGGTGTACGCTGCT
CCTGAGCTCACCCATGCTGGTGTTCCGGACCATGAAGGAGTACAGCGATGAGGGCCACA
ACGTCACCGCTTGTGTCATCAGCTACCCATCCCTCATCTGGGAAGTGTTCACCAACATGC
TCCTGAATGTCGTGGGCTTCCTGCTGCCCCTGAGTGTCATCACCTTCTGCACGATGCAGAT
CATGCAGGTGCTGCGGAACAACGAGATGCAGAAGTTCAAGGAGATCCAGACGGAGAGG
AGGGCCACGGTGCTAGTCCTGGTTGTGCTGCTGCTATTCATCATCTGCTGGCTGCCCTTCC
AGATCAGCACCTTCCTGGATACGCTGCATCGCCTCGGCATCCTCTCCAGCTGCCAGGACG
AGCGCATCATCGATGTAATCACACAGATCGCCTCCTTCATGGCCTACAGCAACAGCTGCC
TCAACCCACTGGTGTACGTGATCGTGGGCAAGCGCTTCCGAAAGAAGTCTTGGGAGGTG
TACCAGGGAGTGTGCCAGAAAGGGGGCTGCAGGTCAGAACCCATTCAGATGGAGAACTC
CATGGGCACACTGCGGACCTCCATCTCCGTGGAACGCCAGATTCACAAACTGCAGGACT
GGGCAGGGAGCAGACAGTCTAGAACCCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGC
ACCACCGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGGGATCCGAGAACCTGTACTTC
CAGCTAAGATTAGATAAAAGTAAAGTGATTAACAGCGCATTAGAGCTGCTTAATGAGGT
CGGAATCGAAGGTTTAACAACCCGTAAACTCGCCCAGAAGCTAGGTGTAGAGCAGCCTA
CATTGTATTGGCATGTAAAAAATAAGCGGGCTTTGCTCGACGCCTTAGCCATTGAGATGT
TAGATAGGCACCATACTCACTTTTGCCCTTTAGAAGGGGAAAGCTGGCAAGATTTTTTAC
GTAATAACGCTAAAAGTTTTAGATGTGCTTTACTAAGTCATCGCGATGGAGCAAAAGTAC
ATTTAGGTACACGGCCTACAGAAAAACAGTATGAAACTCTCGAAAATCAATTAGCCTTTT
TATGCCAACAAGGTTTTTCACTAGAGAATGCATTATATGCACTCAGCGCTGTGGGGCATT
TTACTTTAGGTTGCGTATTGGAAGATCAAGAGCATCAAGTCGCTAAAGAaGAAAGG 
 
> pZK5 (βArrestin2-TEV) endotoxin-free plasmid production, sequence confirmation 
CCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAACAAG
GCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCT
TCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTA
ATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTAC
GGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGA
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CGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATT
TACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTA
TTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGG
ACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTT
TTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCA
CCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATG
TCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCT
ATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTA
ATACGACTCACTATAGGGAGACCCAAGCTTGGTACCGAGCTCGGATCCACTAGTAACGG
CCGCCAGTGTGCTGGAATTCGATTCAGGATCCTCTGGAATGGGGGAGAAACCCGGGACC
AGGGTCTTCAAGAAGTCGAGCCCTAACTGCAAGCTCACCGTGTACTTGGGCAAGCGGGA
CTTCGTAGATCACCTGGACAAAGTGGACCCTGTAGATGGCGTGGTGCTTGTGGACCCTGA
CTACCTGAAGGACCGCAAAGTGTTTGTGACCCTCACCTGCGCCTTCCGCTATGGCCGTGA
AGACCTGGATGTGCTGGGCTTGTCCTTCCGCAAAGACCTGTTCATCGCCACCTACCAGGC
CTTCCCCCCGGTGCCCAACCCACCCCGGCCCCCCACCCGCCTGCAGGACCGGCTGCTGAG
GAAGCTGGGCCAGCATGCCCACCCCTTCTTCTTCACCATACCCCAGAATCTTCCATGCTC
CGTCACACTGCAGCCAGGCCCAGAGGATACAGGAAAGGCCTGCGGCGTAGACTTTGAGA
TTCGAGCCTTCTGTGCTAAATCACTAGAAGAGAAAAGCCACAAAAGGAACTCTGTGCGG
CTGGTGATCCGAAAGGTGCAGTTCGCCCCGGAGAAACCCGGCCCCCAGCCTTCAGCCGA
AACCACACGCCACTTCCTCATGTCTGACCGGTCCCTGCACCTCGAGGCTTCCCTGGACAA
GGAGCTGTACTACCATGGGGAGCCCCTCAATGTAAATGTCCACGTCACCAACAACTCCAC
CAAGACCGTCAAGAAGATCAAAGTCTCTGTGAGACAGTACGCCGACATCTGCCTCTTCA
GCACCGCCCAGTACAAGTGTCCTGTGGCTCAACTCGAACAAGATGACCAGGTATCTCCCA
GCTCCACATTCTGTAAGGTGTACACCATAACCCCACTGCTCAGTGACAACCGGGAGAAG
CGGGGTCTCGCCCTGGATGGGAAACTCAAGCACGAGGACACCAACCTGGCTTCCAGCAC
CATCGTGAAGGAGGGTGCCAACAAGGAGGTGCTGGGAATCCTGGTGTCCTACAGGGTCA
AGGTGAAGCTGGTGGTGTCTCGAGGCGGGGATGTCTCTGTGGAGCTGCCTTTTGTTCTTA
TGCACCCCAAGCCCCACGACCACATCCCCCTCCCCAGACCCCAGTCAGCCGCTCCGGAGA
CAGATGTCCCTGTGGACACCAACCTCATTGAATTTGATACCAACTATGCCACAGATGATG
ACATTGTGTTTGAGGACTTTGCCCGGCTTCGGCTGAAGGGGATGAAGGATGACGACTATG
ATGATCAACTCTGCGGATCTAGCTTGTTTAAGGGACCACGTGATTACAACCCGATATCGA
GCACCATTTGTCATTTGACGAATGAATCTGATGGGCACACAACATCGTTGTATGGTATTG
GATTTGGTCCCTTCATCATTACAAACAAGCACTTGTTTAGAAGAAATAATGGAACACTGT
TGGTCCAATCACTACATGGTGTATTCAAGGTCAAGAACACCACGACTTTGCAACAACACC
TCATTGATGGGAGGGACATGATAATTATTCGCATGCCTAAGGATTTCCCACCATTTCCTC
AAAAGCTGAAATTTAGAGAGCCACAAAGGGAAGAGCGCATATGTCTTGTGACAACCAAC
TTCCAAACTAAGAGCATGTCTAGCATGGTGTCAGACACTAGTTGCACATTCCCTTCATCT
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GATGGCATATTCTGGAAGCATTGGATTCAAACCAAGGATGGGCAGTGTGGCAGTCCATT
AGTATCAACTAGAGATGGGTTCATTgTTGGTATACACTcAGCATCGAATTTCACCAACACA
AACAATTATTTCACAAGCGTGCCGAAAAACTTCATGGAATTGTTGACAAGTCAGGAGGC
GCAGCAGTGGGTTAGTGGTTGGCGATTAAATGCTGACTCAGTATTGTGGGGGGGCCATA
AAGTTTTCATGAGCAAACCTGAAGAGCCTTTTCAGCCAGTTAAGGAAGCGACTCAACTCA
TGAATGAATTGGTGTACTCGTACCCATATGATGTTCCAGATTACGCTTGAGCGGCCGCTC
GAGCATGCATCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATC
AGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCC
TTGACCCTGGAAGgTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCG
CATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGG
GGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGT 
>pZK10 (eGFP tango reporter) endotoxin-free plasmid production, sequence confirmation 
CGTGGCCGCATCGATTCTAGAATTCGCTGTCTGCGAGGGCCAGCTGcTTGGGGTGAGTAC
TCCCTCTCAAAAGCGGGCATGACTTCTGCGCTAAGATTGTCAGTTTCCAAAAACGAGGAG
GATTTGATATTCACCTGGCCCGCGGTGATGCCTTTGAGGGTGGCCGCGTCCATCTGGTCA
GAAAAGACAATCTTTTTGTTGTCAAGCTTGAGGTGTGGCAGGCTTGAGATCTGGCCATAC
ACTTGAGTGACAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGGTCCA
ACTGCAGCCCAAGCGGATCCTGCGGATTTAATTAACCCGGGTACCGAGCTCGAATTCCAG
CTTGGCATTCCGGTACTGTTGGTAAAATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGG
GTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTC
CGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCA
CCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGT
GCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGC
GCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGA
CTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACA
ACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGC
CACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCAT
CGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGA
GCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
GGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAGATATCAGGTGGCCCCCGCTGAA
TTGGAATCGATATTGTTACAACACCCCAACATCTTCGACGCGGGCGTGGCAGGTCTTCCC
GACGATGaCGCCGGTGAACTTCCCGCCGCCGTTGTTGTTTTGGAGCACGGAAAGACGATG
ACGGAAAAAGAGATCGTGGATTACGTCGCCAGTCAAGTAACAACCGCGAAAAAGTtGCG
CGgAGGAGTTGTGTTTGTGGACGAAGTACCGAAAGGTCTTACCGGAAAACTCGACGCAA
GAAAAATCAGAGAGATCCTCATAAAGGCCAAGAAGGGCGGAAAGTCCAAATTGTAAAA
TGTAACTGTATTCAGCGATGACGAAATTCTTAGCTATTGTAATACTCTAGAGGATCTTTGT
GAAGGAACCTTACTTCTGTGGTGTGACATAATTGGACAAACTACCTACAGAGATTTAAAG
CTCTAAGGTAAATATAAAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTAATTGTT
TGTGTATTTTAGATTCCAACCTATGGAACTGATGAATGGGAGCAGTGGTGGAATGCCTTT
AATGAGGAAAACCTGTTTTGCTCAGAAGAAATGCCATCTAGTGATGATGAGGCTACTGCT
GACTCTCAACATTCTACTCCTCCAAAAAAGAAGAGAAAGGTAGAAGACCCCAAGGACTT
TCCTTCAGAATTGCTAAGTTTTTTGAGTCATGCTGTGTTTAGTAATAGAACTCTTGCTTGC
TTTGCTATTTACACCACAAAGGAAAAAGCTGCACTGCTATACAAGAAAATTATGGAAAA
ATATTCTGTAACCTTTATAAGTAGGCATAACAGTTATAATCATAACATACTGTTTTTTCTT
ACTCCACACAGGCATAGAGTGTCTGCTATTAATAACTATGCTCAAAAATTGTGTACCTTT
AGCTTTTTAATTTGTAAAGGGGTTAATAAGGAATATTTGATGTATAGTGCCTTGACTAGA
GATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACA
CCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCA
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GCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTT
TCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCA 
 
>pZK11 (constitutive Monster GFP, positive control) endotoxin-free plasmid production, sequence 
confirmation 
GATCAAGCTGCGGATGGAGGGCGCCGTGAACGGCCACWWATTCGTGATCGAGGGCGAC
GGGAAAGGCAAGCCCTTTGAGGGTAAGCAGACTATGGACCTGACCGTGATCGAGGGCGC
CCCCCTGCCCTTCGCTTATGACATTCTCACCACCGTGTTCGACTACGGTAACCGTGTCTTC
GCCAAGTACCCCAAGGACATCCCTGACTACTTCAAGCAGACCTTCCCCGAGGGCTACTCG
TGGGAGCGAAGCATGACATACGAGGACCAGGGAATCTGTATCGCTACAAACGACATCAC
CATGATGAAGGGTGTGGACGACTGCTTCGTGTACAAAATCCGCTTCGACGGGGTCAACTT
CCCTGCTAATGGCCCGGTGATGCAGCGCAAGACCCTAAAGTGGGAGCCCAGTACCGAGA
AGATGTACGTGCGGGACGGCGTACTGAAGGGCGATGTTAATATGGCACTGCTCTTGGAG
GGAGGCGGCCACTACCGCTGCGACTTCAAGACCACCTACAAAGCCAAGAAGGTGGTGCA
GCTTCCCGACTACCACTTCGTGGACCACCGCATCGAGATCGTGAGCCACGACAAGGACT
ACAACAAAGTCAAGCTGTACGAGCACGCCGAAGCCCACAGCGGACTACCCCGCCAGGCC
GGCTAATAGTTCTAGAGCGGCCGCTTCCCTTTAGTGAGGGTTAATGCTTCGAGCAGACAT
GATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTG 
 
>pZK11 complete sequence 
TCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTAT
TGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCCAA
TATGACCGCCATGTTGGCATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGT
CATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGC
CTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAG
TAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCC
ACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACG
GTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGC
AGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCA
ATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCA
ATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAATAACCCCG
CCCCGTTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCT
CGTTTAGTGAACCGTCAGATCACTAGAAGCTTTATTGCGGTAGTTTATCACAGTTAAATT
GCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGAAGTTGGTCG
TGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAA
ACTGGGCTTGTCGAGACAGAGAAGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTAC
TGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAGTTCAATTACAGCTCTTAA
GGCTAGAGTACTTAATACGACTCACTATAGGCTAGCCCCGGGGATATCGCCACCATGGG
CGTGATCAAGCCCGACATGAAGATCAAGCTGCGGATGGAGGGCGCCGTGAACGGCCACA
AATTCGTGATCGAGGGCGACGGGAAAGGCAAGCCCTTTGAGGGTAAGCAGACTATGGAC
CTGACCGTGATCGAGGGCGCCCCCCTGCCCTTCGCTTATGACATTCTCACCACCGTGTTC
GACTACGGTAACCGTGTCTTCGCCAAGTACCCCAAGGACATCCCTGACTACTTCAAGCAG
ACCTTCCCCGAGGGCTACTCGTGGGAGCGAAGCATGACATACGAGGACCAGGGAATCTG
TATCGCTACAAACGACATCACCATGATGAAGGGTGTGGACGACTGCTTCGTGTACAAAA
TCCGCTTCGACGGGGTCAACTTCCCTGCTAATGGCCCGGTGATGCAGCGCAAGACCCTAA
AGTGGGAGCCCAGTACCGAGAAGATGTACGTGCGGGACGGCGTACTGAAGGGCGATGTT
AATATGGCACTGCTCTTGGAGGGAGGCGGCCACTACCGCTGCGACTTCAAGACCACCTA
CAAAGCCAAGAAGGTGGTGCAGCTTCCCGACTACCACTTCGTGGACCACCGCATCGAGA
TCGTGAGCCACGACAAGGACTACAACAAAGTCAAGCTGTACGAGCACGCCGAAGCCCAC
AGCGGACTACCCCGCCAGGCCGGCTAATAGTTCTAGAGCGGCCGCTTCCCTTTAGTGAGG
GTTAATGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTA
GAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAAC
CATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGT
TCAGGGGGAGATGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAAAA
TCCGATAAGGATCGATCCGGGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTT
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CCCAACAGTTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAAGCG
CGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCC
GCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCGGGCTTTCCCCGTCAAGCTCT
AAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAA
ACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCC
TTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACT
CAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGG
TTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTT
ACAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATG
GTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCC
AACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGC
TGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGC
GAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGT
TTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTT
TTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAA
TAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTT
TTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATG
CTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAG
ATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTG
CTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATA
CACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGAT
GGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGC
CAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACAT
GGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAA
ACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTA
ACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGAT
AAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAA
TCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA
GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAA
ATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAA
GTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGG
TGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTG
AGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGT
AATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCA
AGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATAC
TGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTAC
ATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTT
ACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGG
GGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTAC
AGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCC
GGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCC
TGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGAT
GCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTC
CTGGCCTTTTGCTGGCCTTTTGCTCACATGGCTCGACAGATCT 
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Figure Appendix 7. Circular map of plasmid pZK12 (pIRES). 
 
 
>pIRES sequencing results of MCS A, IRES, and MCS B 
TTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAGACTCTTGCGTTTCTGAT
AGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCA
GTTCAATTACAGCTCTTAAGGCTAGAGTACTTAATACGACTCACTATAGGCTAGCCTCGA
GAATTCACGCGTCGAGCATGCATCTAGGGCGGCCAATTCCGCCCCTCTCCCCCCCCCCCC
TCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCG
TTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAAC
CTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGC
AAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACA
ACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGC
GGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCACGT
TGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGG
GGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTCGGTGC
ACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACCACGGG
GACGTGGTTTTCCTTtGAAAAACACGATGATAAGCTtGCCACAACCCGGGATCCTCTAGAG
TCGACCCGGGCGGCCGCTTCCCTTTAGTGAGGGTTAATGCTTCGAGCAGACATGATAAGA
TACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGT
GAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAAC
AACAACAA 
 
 Appendix 8 7.8
>pZK12 complete sequence  
TCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTAT
TGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCCAA
TATGACCGCCATGTTGGCATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGT
CATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGC
CTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAG
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TAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCC
ACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACG
GTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGC
AGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCA
ATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCA
ATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTGCG
ATCGCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAA
GCAGAGCTCGTTTAGTGAACCGTCAGATCACTAGAAGCTTTATTGCGGTAGTTTATCACA
GTTAAATTGCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGTG
ACTCTCTTAAGGTAGCCTTGCAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAA
GGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAGAC
TCTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCAC
AGGTGTCCACTCCCAGTTCAATTACAGCTCTTAAGGCTAGAGTACTTAATACGACTCACT
ATAGGCTAGCCTCGAGAATTCACGCGTCGAGCATGCATCTAGGGCGGCCAATTCCGCCCC
TCTCCCCCCCCCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAAT
AAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGT
GAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCT
CGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTT
CTTGAAGACAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGGC
GACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACA
ACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAG
CGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATC
TGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCC
CCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAAGCTTGCCACAACC
CGGGATCCTCTAGAGTCGACCCGGGCGGCCGCTTCCCTTTAGTGAGGGTTAATGCTTCGA
GCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAA
AAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGC
AATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGATG
TGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAAAATCCGATAAGGATC
GATCCGGGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCG
CAGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGT
GGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTT
CTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTC
CCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGT
GATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAG
TCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCG
GTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGC
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TGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTCCTGAT
GCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATACGCGGATCTGCGCA
GCACCATGGCCTGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTACCTTCTGAGGCGG
AAAGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAG
CAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCC
CCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAT
AGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCG
CCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAG
CTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTGAT
TCTTCTGACACAACAGTCTCGAACTTAAGGCTAGAGCCACCATGATTGAACAAGATGGAT
TGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAAC
AGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTC
TTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGG
CTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAA
GCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCA
CCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCT
TGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTA
CTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTC
GCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGT
CGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGG
ATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTAC
CCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGG
TATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGA
GCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGATGG
CCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGATA
GCGATAAGGATCCGCGTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTA
AGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCG
GCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCA
CCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTT
AATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGC
GGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAAT
AACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCC
GTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACG
CTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACT
GGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGAT
GAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGA
GCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCAC
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AGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCA
TGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTA
ACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAG
CTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAAC
AACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAAT
AGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTG
GCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAG
CACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAG
GCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCA
TTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTT
TAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAA
CGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGA
GATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCG
GTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGC
AGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAG
AACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCC
AGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGC
GCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCT
ACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGG
AGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGG
AGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGAC
TTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGC
AACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGGCTCGACAGA
TCT 
 
>pZK13 complete sequence 
TCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTAT
TGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCCAA
TATGACCGCCATGTTGGCATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGT
CATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGC
CTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAG
TAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCC
ACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACG
GTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGC
AGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCA
ATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCA
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ATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTGCG
ATCGCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAA
GCAGAGCTCGTTTAGTGAACCGTCAGATCACTAGAAGCTTTATTGCGGTAGTTTATCACA
GTTAAATTGCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGTG
ACTCTCTTAAGGTAGCCTTGCAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAA
GGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAGAC
TCTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCAC
AGGTGTCCACTCCCAGTTCAATTACAGCTCTTAAGGCTAGAGTACTTAATACGACTCACT
ATAGGCTAGCCTCGAGATGCTCAATGTCACCTTGCAAGGGCCCACTCTTAACGGGACCTT
TGCCCAGAGCAAATGCCCCCAAGTGGAGTGGCTGGGCTGGCTCAACACCATCCAGCCCC
CCTTCCTCTGGGTGCTGTTCGTGCTGGCCACCCTAGAGAACATCTTTGTCCTCAGCGTCTT
CTGCCTGCACAAGAGCAGCTGCACGGTGGCAGAGATCTACCTGGGGAACCTGGCCGCAG
CAGACCTGATCCTGGCCTGCGGGCTGCCCTTCTGGGCCATCACCATCTCCAACAACTTCG
ACTGGCTCTTTGGGGAGACGCTCTGCCGCGTGGTGAATGCCATTATCTCCATGAACCTGT
ACAGCAGCATCTGTTTCCTGATGCTGGTGAGCATCGACCGCTACCTGGCCCTGGTGAAAA
CCATGTCCATGGGCCGGATGCGCGGCGTGCGCTGGGCCAAGCTCTACAGCTTGGTGATCT
GGGGGTGTACGCTGCTCCTGAGCTCACCCATGCTGGTGTTCCGGACCATGAAGGAGTACA
GCGATGAGGGCCACAACGTCACCGCTTGTGTCATCAGCTACCCATCCCTCATCTGGGAAG
TGTTCACCAACATGCTCCTGAATGTCGTGGGCTTCCTGCTGCCCCTGAGTGTCATCACCTT
CTGCACGATGCAGATCATGCAGGTGCTGCGGAACAACGAGATGCAGAAGTTCAAGGAGA
TCCAGACGGAGAGGAGGGCCACGGTGCTAGTCCTGGTTGTGCTGCTGCTATTCATCATCT
GCTGGCTGCCCTTCCAGATCAGCACCTTCCTGGATACGCTGCATCGCCTCGGCATCCTCTC
CAGCTGCCAGGACGAGCGCATCATCGATGTAATCACACAGATCGCCTCCTTCATGGCCTA
CAGCAACAGCTGCCTCAACCCACTGGTGTACGTGATCGTGGGCAAGCGCTTCCGAAAGA
AGTCTTGGGAGGTGTACCAGGGAGTGTGCCAGAAAGGGGGCTGCAGGTCAGAACCCATT
CAGATGGAGAACTCCATGGGCACACTGCGGACCTCCATCTCCGTGGAACGCCAGATTCA
CAAACTGCAGGACTGGGCAGGGAGCAGACAGTCTAGAACCCCACCCAGCCTGGGTCCCC
AAGATGAGTCCTGCACCACCGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGGGATCCG
AGAACCTGTACTTCCAGCTAAGATTAGATAAAAGTAAAGTGATTAACAGCGCATTAGAG
CTGCTTAATGAGGTCGGAATCGAAGGTTTAACAACCCGTAAACTCGCCCAGAAGCTAGG
TGTAGAGCAGCCTACATTGTATTGGCATGTAAAAAATAAGCGGGCTTTGCTCGACGCCTT
AGCCATTGAGATGTTAGATAGGCACCATACTCACTTTTGCCCTTTAGAAGGGGAAAGCTG
GCAAGATTTTTTACGTAATAACGCTAAAAGTTTTAGATGTGCTTTACTAAGTCATCGCGA
TGGAGCAAAAGTACATTTAGGTACACGGCCTACAGAAAAACAGTATGAAACTCTCGAAA
ATCAATTAGCCTTTTTATGCCAACAAGGTTTTTCACTAGAGAATGCATTATATGCACTCA
GCGCTGTGGGGCATTTTACTTTAGGTTGCGTATTGGAAGATCAAGAGCATCAAGTCGCTA
AAGAAGAAAGGGAAACACCTACTACTGATAGTATGCCGCCATTATTACGACAAGCTATC
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GAATTATTTGATCACCAAGGTGCAGAGCCAGCCTTCTTATTCGGCCTTGAATTGATCATA
TGCGGATTAGAAAAACAACTTAAATGTGAAAGTGGGTCCGCGTACAGCCGCGCGCGTAC
GAAAAACAATTACGGGTCTACCATCGAGGGCCTGCTCGATCTCCCGGACGACGACGCCC
CCGAAGAGGCGGGGCTGGCGGCTCCGCGCCTGTCCTTTCTCCCCGCGGGACACACGCGC
AGACTGTCGACGGCCCCCCCGACCGATGTCAGCCTGGGGGACGAGCTCCACTTAGACGG
CGAGGACGTGGCGATGGCGCATGCCGACGCGCTAGACGATTTCGATCTGGACATGTTGG
GGGACGGGGATTCCCCGGGTCCGGGATTTACCCCCCACGACTCCGCCCCCTACGGCGCTC
TGGATATGGCCGACTTCGAGTTTGAGCAGATGTTTACCGATGCCCTTGGAATTGACGAGT
ACGGTGGGTAGCACGCGTCGAGCATGCATCTAGGGCGGCCAATTCCGCCCCTCTCCCCCC
CCCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGG
TGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCC
GGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAG
GAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGAC
AAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGC
CTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTG
CCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAA
CAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTC
GGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACC
ACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAAGCTTGCCACAACCCGGAATTCT
ATGGGGGAGAAACCCGGGACCAGGGTCTTCAAGAAGTCGAGCCCTAACTGCAAGCTCAC
CGTGTACTTGGGCAAGCGGGACTTCGTAGATCACCTGGACAAAGTGGACCCTGTAGATG
GCGTGGTGCTTGTGGACCCTGACTACCTGAAGGACCGCAAAGTGTTTGTGACCCTCACCT
GCGCCTTCCGCTATGGCCGTGAAGACCTGGATGTGCTGGGCTTGTCCTTCCGCAAAGACC
TGTTCATCGCCACCTACCAGGCCTTCCCCCCGGTGCCCAACCCACCCCGGCCCCCCACCC
GCCTGCAGGACCGGCTGCTGAGGAAGCTGGGCCAGCATGCCCACCCCTTCTTCTTCACCA
TACCCCAGAATCTTCCATGCTCCGTCACACTGCAGCCAGGCCCAGAGGATACAGGAAAG
GCCTGCGGCGTAGACTTTGAGATTCGAGCCTTCTGTGCTAAATCACTAGAAGAGAAAAG
CCACAAAAGGAACTCTGTGCGGCTGGTGATCCGAAAGGTGCAGTTCGCCCCGGAGAAAC
CCGGCCCCCAGCCTTCAGCCGAAACCACACGCCACTTCCTCATGTCTGACCGGTCCCTGC
ACCTCGAGGCTTCCCTGGACAAGGAGCTGTACTACCATGGGGAGCCCCTCAATGTAAAT
GTCCACGTCACCAACAACTCCACCAAGACCGTCAAGAAGATCAAAGTCTCTGTGAGACA
GTACGCCGACATCTGCCTCTTCAGCACCGCCCAGTACAAGTGTCCTGTGGCTCAACTCGA
ACAAGATGACCAGGTATCTCCCAGCTCCACATTCTGTAAGGTGTACACCATAACCCCACT
GCTCAGTGACAACCGGGAGAAGCGGGGTCTCGCCCTGGATGGGAAACTCAAGCACGAGG
ACACCAACCTGGCTTCCAGCACCATCGTGAAGGAGGGTGCCAACAAGGAGGTGCTGGGA
ATCCTGGTGTCCTACAGGGTCAAGGTGAAGCTGGTGGTGTCTCGAGGCGGGGATGTCTCT
GTGGAGCTGCCTTTTGTTCTTATGCACCCCAAGCCCCACGACCACATCCCCCTCCCCAGA
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CCCCAGTCAGCCGCTCCGGAGACAGATGTCCCTGTGGACACCAACCTCATTGAATTTGAT
ACCAACTATGCCACAGATGATGACATTGTGTTTGAGGACTTTGCCCGGCTTCGGCTGAAG
GGGATGAAGGATGACGACTATGATGATCAACTCTGCGGATCTAGCTTGTTTAAGGGACC
ACGTGATTACAACCCGATATCGAGCACCATTTGTCATTTGACGAATGAATCTGATGGGCA
CACAACATCGTTGTATGGTATTGGATTTGGTCCCTTCATCATTACAAACAAGCACTTGTTT
AGAAGAAATAATGGAACACTGTTGGTCCAATCACTACATGGTGTATTCAAGGTCAAGAA
CACCACGACTTTGCAACAACACCTCATTGATGGGAGGGACATGATAATTATTCGCATGCC
TAAGGATTTCCCACCATTTCCTCAAAAGCTGAAATTTAGAGAGCCACAAAGGGAAGAGC
GCATATGTCTTGTGACAACCAACTTCCAAACTAAGAGCATGTCTAGCATGGTGTCAGACA
CTAGTTGCACATTCCCTTCATCTGATGGCATATTCTGGAAGCATTGGATTCAAACCAAGG
ATGGGCAGTGTGGCAGTCCATTAGTATCAACTAGAGATGGGTTCATTgTTGGTATACACTc
AGCATCGAATTTCACCAACACAAACAATTATTTCACAAGCGTGCCGAAAAACTTCATGG
AATTGTTGACAAGTCAGGAGGCGCAGCAGTGGGTTAGTGGTTGGCGATTAAATGCTGAC
TCAGTATTGTGGGGGGGCCATAAAGTTTTCATGAGCAAACCTGAAGAGCCTTTTCAGCCA
GTTAAGGAAGCGACTCAACTCATGAATGAATTGGTGTACTCGTACCCATATGATGTTCCA
GATTACGCTTGAAGTCGACCCGGGCGGCCGCTTCCCTTTAGTGAGGGTTAATGCTTCGAG
CAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAA
AAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCA
ATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGATGT
GGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAAAATCCGATAAGGATCG
ATCCGGGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGC
AGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTG
GTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCT
TCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCC
TTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGA
TGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTC
CACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGT
CTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTG
ATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTCCTGATGC
GGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATACGCGGATCTGCGCAGC
ACCATGGCCTGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGAA
AGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCA
GGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCC
AGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAG
TCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCC
CCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCT
ATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTGATTC
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TTCTGACACAACAGTCTCGAACTTAAGGCTAGAGCCACCATGATTGAACAAGATGGATT
GCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAAC
AGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTC
TTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGG
CTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAA
GCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCA
CCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCT
TGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTA
CTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTC
GCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGT
CGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGG
ATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTAC
CCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGG
TATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGA
GCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGATGG
CCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGATA
GCGATAAGGATCCGCGTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTA
AGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCG
GCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCA
CCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTT
AATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGC
GGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAAT
AACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCC
GTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACG
CTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACT
GGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGAT
GAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGA
GCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCAC
AGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCA
TGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTA
ACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAG
CTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAAC
AACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAAT
AGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTG
GCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAG
CACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAG
GCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCA
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TTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTT
TAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAA
CGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGA
GATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCG
GTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGC
AGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAG
AACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCC
AGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGC
GCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCT
ACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGG
AGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGG
AGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGAC
TTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGC
AACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGGCTCGACAGA
TCT 
 
CTCGAACTTAAGCTGCAGT – pIRES sequence 
 
GAATTC – EcoRI 
ACTCGCCCAGAAGCTAGGTGTAGAG – gene construct 1 (BDK-B2-AVPR-TCS-tTA) 
 
TCTAGA – XbaI 
GGGTCTTCAAGAAGTCGAGCCCTA – gene construct 2 (BetaArrestin-TEV) 
 
>pZK14 complete sequence (pTRE3G-EGFP) 
CTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGAAGAGTTTACTCCCTATCAGTGA
TAGAGAACGTATGCAGACTTTACTCCCTATCAGTGATAGAGAACGTATAAGGAGTTTACT
CCCTATCAGTGATAGAGAACGTATGACCAGTTTACTCCCTATCAGTGATAGAGAACGTAT
CTACAGTTTACTCCCTATCAGTGATAGAGAACGTATATCCAGTTTACTCCCTATCAGTGAT
AGAGAACGTATAAGCTTTAGGCGTGTACGGTGGGCGCCTATAAAAGCAGAGCTCGTTTA
GTGAACCGTCAGATCGCCTGGAGCAATTCCACAACACTTTTGTCTTATACCAACTTTCCG
TACCACTTCCTACCCTCGTAAAGTCGACAACGCCACCATGGTGAGCAAGGGCGAGGAGC
TGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAG
TTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTT
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CATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTA
CGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTC
CGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACT
ACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTG
AAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTA
CAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACT
TCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAG
AACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCA
GTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCG
TGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTCCGGACTCAGATCTC
GAGCTCAAGCTTCGAATTCTAAGGATCCAATGTAACTGTATTCAGCGATGACGAAATTCT
TAGCTATTGTAATACTCTAGAGGATCTTTGTGAAGGAACCTTACTTCTGTGGTGTGACAT
AATTGGACAAACTACCTACAGAGATTTAAAGCTCTAAGGTAAATATAAAATTTTTAAGTG
TATAATGTGTTAAACTACTGATTCTAATTGTTTGTGTATTTTAGATTCCAACCTATGGAAC
TGATGAATGGGAGCAGTGGTGGAATGCCTTTAATGAGGAAAACCTGTTTTGCTCAGAAG
AAATGCCATCTAGTGATGATGAGGCTACTGCTGACTCTCAACATTCTACTCCTCCAAAAA
AGAAGAGAAAGGTAGAAGACCCCAAGGACTTTCCTTCAGAATTGCTAAGTTTTTTGAGTC
ATGCTGTGTTTAGTAATAGAACTCTTGCTTGCTTTGCTATTTACACCACAAAGGAAAAAG
CTGCACTGCTATACAAGAAAATTATGGAAAAATATTCTGTAACCTTTATAAGTAGGCATA
ACAGTTATAATCATAACATACTGTTTTTTCTTACTCCACACAGGCATAGAGTGTCTGCTAT
TAATAACTATGCTCAAAAATTGTGTACCTTTAGCTTTTTAATTTGTAAAGGGGTTAATAA
GGAATATTTGATGTATAGTGCCTTGACTAGAGATCATAATCAGCCATACCACATTTGTAG
AGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGA
ATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATA
GCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAA
ACTCATCAATGTATCTTATCATGTCTGCGGCTCTAGAGCTGCATTAATGAATCGGCCAAC
GCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGC
TGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGT
TATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAA
GGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGA
CGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAA
GATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCT
TACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGC
TGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCC
CCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTA
AGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTA
TGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAA
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CAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCT
CTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGA
TTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACG
CTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATC
TTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAG
TAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGT
CTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAG
GGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCA
GATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAAC
TTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCC
AGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTC
GTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCC
CATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTT
GGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCC
ATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTG
TATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAG
CAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGAT
CTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGC
ATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAA
AAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATT
ATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGA
AAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAA
GAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGT
CTTCAAGAATTC 
 
CTCGAGTTTACTCCC – pTRE3G backbone sequence 
GTCGACAACGCCACC – part of the multiple cloning site sequence from pEGFP-C1 
ATGGTGAGCAA – eGFP sequence 
 
The coding sequence from pZK14 was converted into amino acid sequence and this amino acid 
sequence (labelled as “our”) was aligned with other eGFP amino acid sequences from the NCBI 
database. The sequence identity between our sequences and sequences from the database was 99%, 
rending our amino acid sequence as eGFP.  
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 Appendix 9 7.9
 
 
Calibration of the Cobe peristaltic pump. 
 
 Appendix 10 7.10
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Dear Dr. Kis, 
 
Good day. Thank you for your email message. Yes, this is satisfactory. 
 
 
Sincerely, 
Stella Rosa 
 
Administrative Assistant to Nadya Gotsiridze-Columbus 
Nova Science Publishers, Inc. 
400 Oser Avenue, Suite 1600 
Hauppauge, NY 11788 USA 
Tel: 631- 231-7269, Fax: 631-231-8175 
Nova.Main@novapublishers.com 
 
At 11:54 AM 3/17/2015, Kis, Zoltán wrote: 
>Dear Ms. Stella Rosa, 
> 
>Thank you for granting permission to re-use the content from this  
>book chapter in my PhD thesis. 
> 
>Credit to Nova Science Publishers, Inc. will be given and the  
>following text will be included in my thesis. 
> 
>[Content from Chapter 4 "In-situ electroporation and flow device for  
>mechanotransduction systems biology studies" of this PhD thesis was  
>previously published as a chapter in a book. 
> 
>The copyright holder of this book, Nova Science Publishers, Inc.,  
>granted permission to use this book chapter in this PhD thesis. 
> 
>Content from Chapter 4 "In-situ electroporation and flow device for  
>mechanotransduction systems biology studies" of this PhD thesis was  
>reprinted from: the book entitled "Microarrays: Principles,  
>Applications and Technologies", editor: J. V. Rogers, Chapter IV "An  
>in-situ electroporation and flow device for mechanotransduction  
>studies", pages 49-68, © Copyright 2014 Nova Science Publishers,  
>Inc., authors: Zoltán Kis, Leila Towhidi, Henry Ip, Emmanuel  
>Drakakis, Anil Bharath, Rob Krams. ISBN: 978-1-62948-713-7. 2014.] 
> 
>Could you please confirm whether this satisfies Nova Science  
>Publishers, Inc.'s requirements. 
> 
>Best wishes, 
>Zoltan 
> 
>________________________________________ 
>From: Nova Science Publishers, Inc. [Nova.Main@novapublishers.com] 
>Sent: 17 March 2015 14:24 
>To: Kis, Zoltán 
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>Subject: Publication Cooperation 
> 
>Dear Dr. Kis, 
> 
>Good day. Thank you for your email message. We are happy to grant  
>you permission to use the chapter free of charge in your PhD thesis  
>provided a credit to Nova is given. 
> 
>Nova Science Publishers Credit Line Information 
> 
>  [Reprinted from: publication, title, vol. number, title of  
> article/chapter, page numbers, copyright (year) and author(s). The  
> statement, with permission from Nova Science Publishers, Inc.  
> should also be noted]. 
> 
> 
>Sincerely, 
>Stella Rosa 
> 
>Administrative Assistant to Nadya Gotsiridze-Columbus 
>Nova Science Publishers, Inc. 
>400 Oser Avenue, Suite 1600 
>Hauppauge, NY 11788 USA 
>Tel: 631- 231-7269, Fax: 631-231-8175 
>Nova.Main@novapublishers.com]” 
7.10.2 Royal Society Publishing – Licence and copyright  
Content presented in section 2.2.1 Mammalian synthetic biology was submitted for 
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The Royal Society Publishing does not claim copyright for publications in their journals. The 
copyright remains with the authors of journal articles. 
Below are the licence and copyright terms from the Royal Society Publishing. 
 
“5. You retain copyright in the Article. However, You authorise Us to act on Your behalf to 
defend Your copyright in the Article should anyone infringe it, and to retain half of any 
damages awarded after deducting Our costs. 
 
6. You retain the right to use the Article in the following ways, provided that you 
acknowledge the Definitive Published Version of the article by placing the full bibliographic 
reference and URL of the relevant journal homepage close to the title of the Article: 
 
a) In relation to the Preprint, Author Generated Postprint and Definitive Published Version of 
the Article, You are free to: make copies for Your own personal use; use the Article for the 
internal teaching purposes of Your own institution or company; and make and distribute 
copies (including through e-mail) of the Article to research colleagues, for personal use by 
such colleagues on a non-commercial, non-systematic basis. 
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b) In relation to the Preprint version only, You are free to post it on web sites, including 
electronic preprint servers. 
 
When the Definitive Published Version of the article is published the Author must 
acknowledges it by placing the full bibliographic reference and URL of the relevant journal 
homepage close to the title of the Article. 
 
c) In relation to the Author Generated Postprint only, You are free to: post it on Your 
personal or institutional web site and load it onto an institutional or not for profit repository 
no earlier than 12 months from the date of first publication of the Definitive Published 
Version provided that a link to the Definitive Published Version is included; use it in printed 
compilations of Your work subsequent to publication of the Definitive Published Version of 
the Article, expand the Article into book-length form, and/or otherwise re-use portions of the 
Author Generated Postprint of the Article in other works. You are also free to present the 
Article at a meeting or conference and to disseminate copies of such Article to the delegates 
attending such meeting or conference and/or to use the Author Generated Postprint in a thesis 
or dissertation (provided that this is not to be published commercially).” 
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